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ABSTRACT 
Parasitic nematode infections remain a serious global public health threat to humans 
and animals. These infections cause debilitating conditions in humans and significant 
economic losses through infection of livestock and crop damage. Control of parasitic 
nematode diseases has continued to rely on use of anthelmintic drugs as there is presently no 
effective vaccine for the majority of these infections. Over the years, anthelmintic drug 
discovery has been very slow, and the majority of anthelmintic drugs used in human 
medicine today were initially developed for animal use as those affected live in the world’s 
poorest nations that lack the financial means to afford conventional drugs. However, 
resistance to all the major anthelmintic drug classes has been reported in numerous veterinary 
parasite species and there are increasing concerns of resistance development in human 
parasite species. The emergence of widespread resistance therefore underscores the urgent 
need for the search of new targets, leads and strategies for anthelmintic drug discovery and 
development. 
We have identified the nicotinic acetylcholine receptor (nAChR) subunit ACR-16 
from Ascaris suum and showed that ACR-16 forms a functional homopentameric nAChR 
when expressed in Xenopus oocytes. A. suum is a gastrointestinal (GI) tract parasitic 
nematode of pigs that is very closely related to the human equivalent A. lumbricoides. ACR-
16 is not activated by cholinergic anthelmintics and, although ACR-16 is most closely related 
to vertebrate 7 receptors based on amino acid sequence alignment, it has some marked 
pharmacological differences from vertebrate 7 receptors. As opposed to vertebrate 7 
receptors, ACR-16 was insensitive to -bungarotoxin and the effects of ivermectin, genistein 
and PNU120596 on ACR-16 were inhibitory rather than potentiating. The relative calcium 
xii 
 
permeability ratio for ACR-16 was about 50x lower than that for vertebrate 7 receptors. We 
have showed using reverse transcription polymerase chain reaction (RT-PCR) that mRNA 
for ACR-16 is widely distributed throughout Ascaris tissues; suggesting ACR-16 may have 
functions other than neurotransmission. Our results showed, for the first time, the 
characterization of the pharmacology of ACR-16 from a parasitic nematode. Based on the 
pharmacology and expression pattern of ACR-16 in different tissues of the parasite, we 
suggest ACR-16 is an attractive new anthelmintic drug target with ‘resistance-busting’ 
properties that should be further exploited for therapeutic drug development. 
Secondly, we have showed that the plants Daniellia oliveri and Psorospermum 
febrifugum have potential as sources of lead compounds for the development of the much-
needed filaricidal drugs to treat onchocerciasis (river blindness) and lymphatic filariasis 
(elephantiasis). We prepared extracts of different polarities from D. oliveri and P. febrifugum 
and showed these extracts to be active against Onchocerca ochengi microfilariae and adults, 
and against adult Brugia pahangi based on visual motility scoring, MTT/formazan assay and 
the Worminator motility measurement system. Importantly, some extracts with O. ochengi 
microfilariae activity were also active on the adult worm. These extracts also showed activity 
against adult B. pahangi. We further fractionated the active extracts using Sep-Pak cartridges 
and High Performance Liquid Chromatography (HPLC) and showed some of these fractions 
retained activity against adult B. pahangi. We recommend that the active HPLC fractions be 
further purified to allow for the isolation of the bioactive compounds. This could 
significantly contribute to chemotherapeutic control of filarial infections currently hampered 
by the lack of macrofilaricides (adulticides). 
xiii 
 
Lastly, we have demonstrated that use of combination therapy over single drug 
therapy is a potentially useful tool for increasing efficacy, spectrum of action and reducing 
the likelihood of resistance development. We showed the combination of derquantel and 
abamectin to produce a greater inhibition of acetylcholine and pyrantel responses of 
expressed pyrantel/tribendimidine nAChRs from Oesophagostomum dentatum than 
derquantel or abamectin used alone. These nAChRs comprise of UNC-29, UNC-63 and 
UNC-38 subunits. Our results also showed abamectin acts on nAChRs, in addition to its 
known effects on glutamate-gated chloride channels (GluCls), implying abamectin has 
multiple targets. We further showed the action of abamectin on the expressed O. dentatum 
pyrantel/tribendimidine nAChRs to be bi-phasic, suggesting two allosteric sites of action: a 
high affinity negative allosteric modulation (NAM) site causing antagonism at lower 
concentrations (≤0.1 µM) and a lower affinity positive allosteric modulation (PAM) site 
causing a reduction in the antagonism at higher concentrations (0.3 µM). 
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CHAPTER 1. GENERAL INTRODUCTION 
1.1 Introduction 
Parasitic nematodes are a significant threat to both animals and humans, particularly 
in tropical and subtropical regions of the world. Parasitic nematodes also cause economic 
losses through infection of livestock and crop damage. In humans and animals, control of 
infections caused by parasitic nematodes relies mainly on the use of anthelmintic drugs, of 
which there are a limited number, and the majority of these act on ion channels. Anthelmintic 
drugs are grouped into different classes based on chemical structure and mode of action. The 
three major classes are the benzimidazoles (BZs), imidazothiazoles/tetrahydropyrimidines 
and macrocyclic lactones (MLs). The benzimidazoles (e.g thiabendazole, mebendazole, 
albendazole, flubendazole) target -tubulin, an important protein in maintaining parasite cell 
structure. Imidazothiazoles/tetrahydropyrimidines (e.g levamisole, pyrantel, oxantel, 
morantel) act on nicotinic acetylcholine receptors (nAChRs), which are prototypical ligand-
gated ion channels (LGICs) that mediate fast signal transmission at parasite neuromuscular 
and nerve-nerve junctions. Macrocyclic lactones (e.g ivermectin, abamectin, moxidectin) act 
on glutamate-gated chloride channels (GluCls). More recent anthelmintic drug classes 
include the amino-acetonitrile derivatives (AADs) (e.g monepantel), spiroindoles (e.g 
derquantel) and cyclooctadepsipeptides (e.g emodepside). Monepantel acts on the DEG-3-
type nAChRs: ACR-20, ACR-23 and MPTL-1. Derquantel acts as an antagonist of several 
nAChR types. Emodepside acts on both SLO-1 potassium channels and latrophilin receptors. 
The recently introduced anthelmintic drug, tribendimidine, targets nAChRs just as 
imidazothiazoles/tetrahydopyrimidines, and is approved for human use in China. 
Anthelmintic drugs exhibit their effects by interfering with locomotion, feeding, egg laying 
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or growth. Regrettably, resistance has been reported for all three major anthelmintic drug 
classes, as well as the AAD monepantel, thus, underscoring the pressing need for strategies 
to slow down or overcome resistance. Therefore, these PhD studies seek to address three 
main strategies by which anthelmintic resistance can be overcome. The first aim was to 
characterize the pharmacology of a new nAChR drug target, ACR-16, from the pig parasite, 
Ascaris suum, a good laboratory model for the human parasite, A. lumbricoides. The second 
aim was to demonstrate that plant natural products may serve as potential sources for new 
anthelmintics by investigating the efficacy and cytotoxicity of extracts from traditional 
medicinal plants against Onchocerca ochengi, the best-known laboratory model for the 
human equivalent, O. volvulus, and against Brugia pahangi, a good model for B. malayi. The 
third aim was to investigate interactions between derquantel, abamectin and expressed 
nAChRs from Oesophagostomum dentatum to gain mechanistic insight into this recently 
developed combination therapy. 
1.2 Thesis Organization 
In this thesis, a general introduction is provided about parasitic nematodes and the 
target sites of anthelmintic drugs used to treat nematode infections. Ion channels are 
highlighted as targets for the majority of available anthelmintic drugs and an emphasis is 
placed on anthelmintic drug resistance and the need to overcome drug resistance. Three 
strategies are proposed as ways of overcoming drug resistance and these are: the 
characterization of new drug targets, the development of new drugs from plant natural 
products and the use of combination therapy. In chapter 2, I have reviewed the literature 
relating to parasitic nematodes particularly Ascaris suum, Onchocerca volvulus and Brugia 
malayi, nicotinic acetylcholine receptors (nAChRs) of parasitic nematodes, and the medicinal 
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plants, Daniellia oliveri and Psorospermum febrifugum. In chapters 3, 4 and 5, I present 
research work done by myself and collaborators that has been published (chapters 3 and 5) or 
in preparation for publication (chapter 4). Chapter 3 describes the cloning and 
pharmacological characterization of a new homomeric nicotinic acetylcholine receptor ACR-
16 from Ascaris suum (Asu-ACR-16). ACR-16 may serve as a potential target for the 
development of new ‘resistance-busting’ anthelmintic drugs. I did all the work outlined in 
this paper, except Asu-acr-16 cloning which was done by our collaborators at Institut 
National de la Recherche Agronomique (INRA-Nouzilly) in France and isolation of 
cytoplasm for single-cell PCR which was done in our lab. Chapter 4 shows the efficacy of 
extracts of Daniellia oliveri and Psorospermum febrifugum against Onchocerca ochengi and 
Brugia pahangi, bioassay-guided fractionation and cytotoxicity of active extracts of D. 
oliveri and P. febrifugum. All the work in this chapter was done by me, with significant input 
from our collaborators at the University of Buea, Cameroon, University of California San 
Francisco and Iowa State University. Chapter 5 describes the effects of the recently 
developed derquantel and abamectin combination on expressed pyrantel/tribendimidine 
nAChRs from Oesophagostomum dentatum. I did all the work presented in this paper, except 
the cloning of the receptor subunits which was done by a former graduate student in our lab. 
Chapter 6 is a general discussion and conclusions of my PhD research and suggestions for 
future work. Appendix A is a research paper on acetylcholine receptor diversity in 
Oesophagostomum dentatum. Appendix B is an invited review on advances in anthelmintic 
drug development. Appendix C is a research paper on modeling the Ascaris suum ACR-16 
receptor. Appendix D is a research paper on the mode of action of the cholinomimetic 
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morantel on the Ascaris suum ACR-16 receptor. Lastly, Appendix E is a list of all conference 
abstracts, awards and funding obtained. 
  
5 
 
CHAPTER 2. LITERATURE REVIEW 
2.1 Parasitic Nematodes 
Parasites are organisms that live on or in another organism known as the host, and 
benefit at the expense of the host. Parasites are harmful to the host and may even cause death. 
Most generally, the host-parasite relationship is such that the host does not benefit from the 
relationship and stressors associated with harboring parasites can be deleterious. Parasites are 
classified as ectoparasites if the parasites live outside the body, and as endoparasites if they 
live inside the body. In animals, ectoparasites live on the skin and can cause itching and 
rashes, while endoparasites may live in the blood, muscles, liver, brain or digestive tract 
(Hopla et al., 1994). 
Nematodes (or roundworms) belong to the phylum Nematoda. There are over 25,000 
known nematode species, of which more than 50% are parasitic (Zhang, 2013). These 
include the soil-transmitted helminths (STHs) and filarial worms. Parasitic nematode 
infections are a global public health problem. These infections include four of the seventeen 
diseases that are classified as “Neglected Tropical Diseases” (NTDs) by the World Health 
Organization (WHO). The seventeen NTDs are Buruli ulcer, Chagas disease, Dengue and 
Chikungunya, Dracunculiasis (guinea-worm disease), Echinococcosis, Foodborne 
trematodiases, Human African trypanosomiasis (sleeping sickness), Leishmaniasis, Leprosy 
(Hansen’s disease), Lymphatic filariasis, Onchocerciasis (river blindness), Rabies, 
Schistosomiasis, Soil-transmitted helminthiases, Taeniasis/Cysticercosis, Trachoma and 
Yaws (Endemic treponematoses) (Johnston et al., 2014). Of these seventeen NTDs, thirteen 
have been identified as core (Table 2.0), (Feasey et al., 2010). Among the core NTDs are the  
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Table 2.0 The thirteen core NTDs. (Modified from Feasey et al., 2010, pp. 182-183) 
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nematode infections: soil-transmitted helminthiases caused by intestinal parasitic worms and 
filariases (lymphatic filariaisis and onchocerciasis) caused by filarial worms. Over 3 billion 
people, primarily in developing countries with poor sanitation and lack of health education 
programs are infected with parasitic nematodes (Chan, 1997). Parasitic nematode infections 
do not only cause debilitating conditions in humans but also cause serious problems in 
livestock production worldwide. They cause significant economic losses and are a threat to 
food security (Fitzpatrick, 2013; Hotez et al., 2009; Hotez & Kamath, 2009). As a result, 
affected communities are constantly trapped in a cycle of poverty and disease. 
2.1.1 Soil-transmitted helminthiases 
2.1.1.1 Ascariasis.  Soil-transmitted helminthiases (STHs) are a group of NTDs 
caused by roundworms (Ascaris lumbricoides), hookworms (Ancylostoma duodenale and 
Necator americanus) and whipworms (Trichuris trichuria) (Bethony et al., 2006). STHs are 
a public health concern in Africa, Latin America, Middle East and Asia (Figure 2.0) (Savioli 
& Albonico, 2004). Ascariasis is commonly seen in tropical and subtropical areas around the 
world where the infection has been strongly associated with poor hygiene, poor sanitation 
and use of human feces as fertilizers. Over 1 billion people worldwide are infected with A. 
lumbricoides (Crompton, 1988; de Silva et al., 2003). The infection is most prevalent among 
school-aged children in rural areas (Fernandez et al., 2002; Luong, 2003; Rayan et al., 2010). 
The life cycle of Ascaris lumbricoides requires only humans as the definitive host; 
there is no intermediate host (Figure 2.1). Adult female worms are larger (20 – 35 cm) than 
males (15 – 30 cm). The worms live in the lumen of the small intestine of infected persons. 
Eggs are passed in the feces and the infection is passed from one person to another by 
ingestion of soil that is contaminated with feces from infected persons. This can occur by 
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Source: Savioli & Albonico, 2004, p. 618. 
 
Figure 2.0 Global distribution of soil-transmitted helminthiases (STHs). STHs are a major 
public health problem in Africa, Latin America, Middle East and Asia. Transmission of 
STHs also occurs in Australia and a few European countries, although not a major public 
health concern in these areas.  
 
 
putting hands that have come in contact with contaminated soil in the mouth or by 
consuming improperly washed or peeled vegetables or fruits. An adult female produces up to 
200,000 eggs per day which may be fertilized or unfertilized. Only fertilized eggs become 
infective while unfertilized eggs do not. Depending on environmental conditions, the 
fertilized eggs become infective after 18 days to several weeks after they embryonate. Moist, 
warm, shaded soil provides optimum conditions for this to occur. Once swallowed, the larvae 
hatch, invade the intestinal mucosa and are transported via the portal and systemic circulation 
to the lungs. While in the lungs, the larvae further mature in about 10 to 14 days and then 
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Source: Accessed on 03-19-17 at 11:45PM CST, from 
https://www.cdc.gov/parasites/images/ascariasis/ascariasis_lifecycle.gif 
 
Figure 2.1 Life cycle of Ascaris lumbricoides. 
 
penetrate the alveolar walls and ascend the bronchial tree to the throat and are swallowed. Once 
they reach the small intestine, they develop into adults which typically live for up to 1 – 2 
years. 
Infected persons are often asymptomatic. When symptoms occur, they range from 
light, such as abdominal discomfort to heavy, such as anemia, malnutrition, intestinal 
blockage and impaired physical and mental growth in children (Bethony et al., 2006; 
Gyorkos et al., 2011; Hughes et al., 2004). Cough may occur as a result of migration of the 
worms through the (Hoenigl et al., 2010). Irrespective of age, the prevalence of ascariasis is 
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higher among females than males (Elkins et al., 1986; Elkins et al., 1988; Haswell-Elkins et 
al., 1989). Ascaris infection is diagnosed by microscopic examination of stool for the 
presence of eggs. A single dose of albendazole (400 mg) or mebendazole (500 mg) is 
effective in treating Ascaris infections (Albonico et al., 1994; Norhayati et al., 1997).   
2.1.2 Filariases 
2.1.2.1 Onchocerciasis (River blindness).  Onchocerca is a genus of filarial 
nematodes of the order Spirurida, family Onchocercidea. Of the various Onchocerca species, 
only one, O. volvulus infects humans (Krueger et al., 2007; Morales-Hojas et al., 2006). O. 
volvulus is the causative agent of human onchocerciasis or river blindness, and is transmitted 
by the blackfly, Simulium damnosum (Nelson, 1970; Sharp, 1927). The disease is called river 
blindness because the blackfly vector breeds along fast flowing rivers (Winthrop et al., 
2011). Consequently, the disease is most prevalent around these rivers. These areas usually 
constitute fertile farmlands which are often abandoned for less fertile areas as an escape 
strategy from the bite of the blackfly and hence, transmission of onchocerciasis. Most of the 
endemic areas are often inhabited by peasant farmers, therefore, migration from fertile to 
infertile lands causes agricultural and economic losses (Bradley, 1976; Stingl, 1987). The 
scientific literature on onchocerciasis dates as far back as 1875 when O’Neill first detected 
O. volvulus microfilariae in the skin of patients with “craw-craw” in Ghana. In 1893, O. 
volvulus adult worms were described by Leuckart from subcutaneous nodules collected from 
patients in Ghana, and in the 1920s, Blacklock in Sierra Leone identified the blackfly S. 
damnosum as the disease vector. Hissette and Robles in the Congo and Guatemala 
respectively, associated blindness with onchocerciasis (Burnham, 1998; Cupp et al., 2011; 
Nelson, 1991). Globally, onchocerciasis is endemic in 36 countries of sub-Saharan Africa, 
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the Yemen and Latin America, 30 of which are in Africa (Figure 2.2). An estimated 37 
million people suffer from onchocerciasis, with 99% of infected persons living in Africa. 
Another 120 million people worldwide are at risk of contracting the disease, of which 90 
million live in Africa (Basanez et al., 2006; Gustavsen et al., 2011). Onchocerciasis is the 
world’s second leading infectious cause of blindness after trachoma (Thylefors et al., 1995). 
About 1 million of infected persons have ocular onchocerciasis, with an estimated 500,000 
having impaired vision and 270,000 blinded as a result of the infection (Boatin & Richards, 
2006). In hyperendemic areas, infection rates can be as high as 100%, with about 50% of the 
population blinded as a result of onchocerciasis (Etya'ale, 2002; Taylor, 1990). Eye and skin 
lesions and severe itching produced by the microfilariae are the greatest burdens of 
onchocerciasis (Kale, 1998). Blindness and skin disease due to onchocerciasis have been 
associated with reduced life expectancy, poverty, decreased productivity, poor academic 
performance, higher rates of school dropout of children (predominantly females) of infected 
parents and social stigmatization, particularly among women (Benton, 1998; Brieger et al., 
1998; Malatt & Taylor, 1992; Vlassoff et al., 2000). 
Onchocerciasis is a chronic infection. Clinical manifestations develop years after 
infection. The most common early symptom of infection with onchocerciasis is pruritis 
which is as a result of localized host inflammatory responses to dead and dying microfilariae 
in the skin (Somorin, 1983; Udall, 2007). Other symptoms include disfiguring dermatitis or 
leopard skin, onchocercomata (subcutaneous nodules), lymphadenopathies and ocular lesions 
(Browne, 1960; Connor & Palmieri, 1985; Enk et al., 2003; Okulicz et al., 2004). Ocular 
lesions constitute the most serious of these clinical manifestations as they can progress to 
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Source: Accessed on 02-22-17 at 12:00AM CST, from: 
http://www.who.int/entity/mediacentre/factsheets/Onchocerciasis_2015_310_px.png 
 
Figure 2.2 Global distribution of onchocerciasis 
 
blindness. It is thought that antigens of Wolbachia endobacteria which live in a symbiotic 
relationship with O. volvulus greatly contribute to the pathological reactions associated with 
onchocerciasis (Brattig, 2004; Saint Andre et al., 2002). Presumptive diagnosis of 
onchocerciasis in endemic areas is therefore based on physical examination of these clinical 
manifestations. Nonetheless, it is important to differentiate clinical manifestations associated 
with onchocerciasis from those due to other skin infections such as scabies and contact 
dermatitis. For this reason, definitive methods ranging from use of microscopy to detect 
microfilariae through detection of O. volvulus specific antigens and antibodies to DNA 
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probes have been developed for diagnosis of onchocerciasis (Boatin et al., 1998; Bradley & 
Unnasch, 1996; Harnett, 2002; Zimmerman et al., 1994). 
The life cycle of O. volvulus involves the blackfly and human stages (Figure 2.3). 
Adult female worms, during a blood meal, inject infective third stage (L3) larvae into the 
human host via the bite wound. Next, the L3 larvae develop into adults in subcutaneous 
nodules. Nodules typically contain on average 2 – 3 female worms and 1 – 2 adult male 
worms. Females are usually confined to nodules while males can migrate from nodule to 
nodule, perhaps in search of females (Schulz-Key & Karam, 1986). Adult female worms are 
generally larger, and measure 270 – 400 m in diameter and 33 – 50 cm in length, compared 
to the adult male worms which measure 130 – 210 m in diameter and 1.9 – 4.2 cm in 
length. Adult worms have a life span of up to 15 years. After mating, females produce 
hundreds of unsheathed microfilariae daily which are typically found in the skin and 
lymphatics of connective tissues, but sometimes in peripheral blood, urine, sputum and the 
eyes (Anderson et al., 1975a; Anderson et al., 1975b; Schulz-Key, 1990). Female worms are 
capable of producing microfilariae for up to 9 years. The microfilariae measure 5 – 9 m in 
diameter and 220 – 360 m in length and have a life span of up to 2 years. The blackfly 
during another blood meal from an infected person ingests microfilariae which migrate from 
the blackfly’s gut to thoracic muscles where they moult into the first larval stage (L1). L1 
larvae subsequently develop into L3 larvae which eventually migrate to the blackfly’s head 
region and proboscis, ready to be injected into a human host during the next blood meal. 
Control against onchocerciasis includes measures directed against the blackfly vector 
and the parasites by use of insecticides and chemotherapeutic agents respectively. Vector 
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Source: Accessed on 02-21-17 at 08:38PM CST, from 
https://www.cdc.gov/dpdx/onchocerciasis/modules/o_volvulus_lifecycle.gif 
 
Figure 2.3 Life cycle of Onchocerca volvulus. 
 
control though successful to an extent, has some limitations; it is costly and also the thick 
canopies of the tropical forests prevent insecticides from reaching the breeding sites. Vector 
control is further limited by increasing resistance of the blackfly to insecticides (Davies, 
1994). Therefore, chemotherapy remains the most efficient method of controlling 
onchocerciasis. Ivermectin, administered at a dose of 150 g/kg, is the sole drug of choice 
for the control of onchocerciasis. Although ivermectin effectively kills microfilariae 
produced by adult worms (macrofilariae), it has little or no effects on the adults which may 
live for up to 15 years in human hosts (Duke, 1972). Hence, parasite control is hindered by 
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the lack of an effective adulticide (macrofilaricide) (Hopkins, 2005). There are also concerns 
about the development of resistance to ivermectin owing to its large scale repeated use (Osei-
Atweneboana et al., 2011; Richards et al., 2001). Additionally, ivermectin can provoke 
severe life-threatening adverse reactions including encephalopathy, coma and death in 
patients heavily infected with the filarial parasite, Loa loa (eye worm) (Boussinesq et al., 
2003; Gardon et al., 1997; Mackenzie et al., 2007). These adverse reactions produced by the 
death of L. loa microfilariae greatly hinder use of ivermectin for treatment of onchocerciasis 
in areas of co-endemicity with loiasis. Studies have shown that targeting the endosymbiotic 
bacteria Wolbachia with the antibiotic, doxycycline for 4 to 6 weeks causes adult female 
worm sterility and a reduction in worm viability, development, embryogenesis and survival 
(Hoerauf et al., 2002; Hoerauf et al., 2008; Hoerauf et al., 2009; Taylor et al., 2000; Turner 
et al., 2010). Treatment of onchocerciasis with doxycycline is also advantageous in patients 
co-infected with L. loa because of its lack of activity against L. loa microfilariae or adult 
worms (Wanji et al., 2009). Although antibiotics have demonstrated activity against adult 
worms, the long treatment regimes required with antibiotic treatment present logistical 
problems for mass drug administration. Another limitation is contraindication of antibiotics 
in pregnant women and children under the age of 8 (Tamarozzi et al., 2011). Ultimately, new 
drugs are needed for the effective control and elimination of onchocerciasis (Hotez, 2007). 
Due to ethical constraints obtaining O. volvulus and difficulty maintaining O. 
volvulus under experimental conditions, other appropriate animal equivalents have been 
explored for studies on chemotherapy, host-parasite relationships and immunology of 
onchocerciasis. In this regard, the bovine O. ochengi has been identified as the closest 
relative to human O. volvulus (Makepeace & Tanya, 2016; Trees et al., 1998). Both O. 
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ochengi and O. volvulus share the same Simulium vectors (Wahl et al., 1998a). For this 
reason, a reduction in the vector biting rate for humans and hence a reduction in the 
transmission of human onchocerciasis has been observed in regions where there is a high 
bovine population and for which bovine and human onchocerciasis are endemic (Eisenbarth 
et al., 2016; Wahl et al., 1998b). O. ochengi and O. volvulus also demonstrate comparable 
drug sensitivities (Trees et al., 2000). These similarities, along with the relative availability 
and low cost of obtaining O. ochengi make O. ochengi the best laboratory model for anti-
Onchocerca drug screens and the study of host-parasite interplay in human onchocerciasis.    
2.1.2.2 Lymphatic filariasis (Elephantiasis).  Lymphatic filariasis (LF), commonly 
known as elephantiasis is a neglected tropical disease that is caused by filarial nematodes of 
the family Filariodidea. These include Wuchereria bancrofti, Brugia malayi and Brugia 
timori. W. bancrofti accounts for 90% of LF cases, while B. malayi and B. timori account for 
the remaining 10% (Palumbo, 2008). Bancroftian filariasis occurs in both urban and rural 
areas, while Brugian filariasis occurs mainly in rural areas. The parasites that cause LF are 
transmitted to humans by mosquitoes of the genera Culex, Anopheles, Mansonia and Aedes. 
Culex mosquitoes are found across urban and semi-urban areas, Anopheles are found mainly 
in rural areas, and Aedes are found mainly in endemic islands in the Pacific. Urban W. 
bancrofti is primarily transmitted by Culex quinquefasciatus, whereas Anopheles and Aedes 
spp mosquitoes are typical vectors of rural W. bancrofti. Brugian filariasis is mainly 
transmitted by Mansonia, Anopheles and Aedes spp mosquitoes (Mak, 1987). LF can lead to 
an altered lymphatic system and abnormal swelling of body parts, causing pain and severe 
disability, ranking as the second leading cause of permanent disability worldwide after 
mental illness (Noordin, 2007; Wynd et al., 2007). Globally, over 120 million people are 
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infected with LF, with another 1.2 billion at risk and about 40 million disfigured and 
incapacitated as a result of the disease (Fenwick, 2012; Nutman, 2013). The majority of LF 
cases are seen in Africa (Figure 2.4). 
The majority of infected persons are asymptomatic, but can show acute symptoms 
such as inflammation of the skin, lymph nodes and lymphatic vessels which often progress to 
chronic conditions like lymphedema (tissue swelling) or elephantiasis (tissue/skin 
thickening) of limbs and hydrocele (scrotal swelling) (Babu & Nutman, 2012; Shenoy, 
2008). 
Of these symptoms, elephantiasis is the most chronic and obvious, occurring in about 
10% of LF cases. Chronic LF has serious mental, social and economic effects which include 
stigma and poor economic output, hence, poverty. The role of gender in social stigmatization 
due to chronic LF has been reported, with the burden falling more on women 
(Bandyopadhyay, 1996; Coreil et al., 1998; Gyapong et al., 1996). The conventional method 
 
 
Source:  Accessed on 03-20-17 at 04:15PM CST, from 
https://www.cdc.gov/parasites/images/lymphaticfilariasis/lf_geo_distrib.jpg 
 
Figure 2.4 Global distribution of lymphatic filariasis indicated in red. 
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of diagnosing LF is microscopic detection of microfilariae in blood smears. Blood samples 
for microfilariae detection are usually collected at night because during the day, microfilariae 
hide in blood capillaries of internal organs. However, this conventional method has low 
sensitivity, leading to the development of more sensitive PCR-based methods, 
immunological and serological techniques (Melrose et al., 2004; Weil & Ramzy, 2007). 
These methods also allow for blood samples to be collected from patients at anytime of the 
day.  
 The life cycle of parasites that cause LF is similar to that of O. volvulus, involving 
mosquito and human stages (Figure 2.5). Infected mosquitoes during a blood meal introduce 
L3 larvae into the body of a human host which migrate to the lymphatic vessels and develop 
into adult worms. Adult B. malayi females are larger (measuring 43 – 55 mm in length by 
130 – 170 m in width) than adult males (measuring 13 – 23 mm in length by 70 – 80 m in 
width). Adult W. bancrofti are similar to adult B. malayi except both sexes are larger. Adult 
worms produce sheathed microfilariae (measuring 177 – 230 m in length by 5 – 7 m in 
width) which typically enter the bloodstream and are ready to be ingested by the mosquito 
during another blood meal. As with O. volvulus, once ingested by the arthropod vector, 
microfilariae shed their sheaths and migrate to mosquito’s thoracic muscles via midgut where 
they moult into L1 larvae and subsequently develop into L3. L3 larvae then migrate to the 
mosquito’s head and proboscis, ready to infect another human, thus continuing the 
transmission cycle. 
Chemotherapy is the most cost-effective tool to control LF. This is achieved by mass 
treatment with a combination of albendazole (200 mg) with either ivermectin (150 – 200  
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Source: Accessed on 03-05-17 at 02:08AM CST, from 
https://www.cdc.gov/parasites/images/lymphaticfilariasis/b_malayi_lifecycle.gif 
 
Figure 2.5 Life cycle of Brugia malayi. 
 
g/kg) or diethylcarbamazine (DEC) (6 mg/kg) (Karam & Ottesen, 2000; Ottesen et al., 
1997). However, these drugs are only microfilaricidal, with limited activity against adult 
worms which can live for an average of 5 – 10 years and will continue to produce 
microfilariae. Clearly, new drugs effective against adult worms are needed. DEC is further 
contraindicated in onchocerciasis due to the possibility for the occurrence of severe treatment 
adverse reactions involving the skin and eye (Mazzotti reaction) (Awadzi & Gilles, 1992). 
Ideally, LF patients who are co-infected with onchocerciasis should be treated with the 
albendazole and ivermectin combination. Recently, the combination of DEC, albendazole 
and ivermectin was demonstrated to be more efficient than the DEC and albendazole 
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combination for the treatment of Bancroftian filariasis. Twelve patients who received a single 
dose of the DEC, albendazole and ivermectin combination tested negative for microfilariae at 
12 and 24 months after treatment, suggesting adult worm death or sterility (Thomsen et al., 
2016). However, more studies are needed to ascertain the safety of this triple drug therapy, 
particularly in individuals who are co-infected with onchocerciasis and loiasis. Studies have 
also shown that targeting the Wolbachia endosymbiont with doxycycline (200 mg for 4 – 6 
weeks) can result in adult worm sterility (Hoerauf et al., 2003). 
Due to the constraints in obtaining large numbers of B. malayi for drug screens, B. 
pahangi which naturally infects cats and wild animals is used. Cats respond to B. pahangi in 
a similar manner as humans respond to B. malayi and W. bancrofti (Denham & Fletcher, 
1987). Likewise, B. pahangi is equally susceptible to drugs that act on B. malayi. Also, given 
the relatively high costs of maintaining cats, the gerbil-B. pahangi system is used as a 
suitable model for drug screens and host-parasite studies (Bulman et al., 2015). 
2.2 Nematode Neuromuscular System 
Here we focus on the neuromuscular system of Ascaris lumbricoides var. suum. The 
neuromuscular system of Ascaris spp is the earliest and well-studied nematode 
neuromuscular system. The nematode neuromuscular system is unique in several ways. For 
instance, projections are sent from muscle cells to nerves as opposed to from nerves to 
muscle cells in vertebrates. Like other nematodes, Ascaris spp has a fixed number of cells 
and cell divisions. Other unique features are the small and constant number of neurons (ca 
250) in the nervous system and the large cells which make up the musculature (del Castillo et 
al., 1989). 
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2.2.1 Nervous System 
The nervous system of Ascaris is made up of three components namely: (i) nerve ring 
and associated ganglia in the anterior region, (ii) major dorsal and ventral nerve cords and 
smaller subdorsal and subventral nerve cords, and (iii) a smaller set of ganglia in the 
posterior region. The motor nervous system (remaining region of the nervous system in a 
decapitated and tailless Ascaris that can still control movement) of Ascaris is composed of 
five repeating units or segments. Each unit or segment contains eleven motoneurons which 
based on morphology were classified into seven types with all their somata positioned in the 
ventral nerve cord (Stretton et al., 1978). Three of the seven types namely; DI, DE2 and DE3 
occur only once in each segment whereas the other four types namely; DE1, VI, V1 and V2 
occur twice. Of these seven types, two (V1 and V2) are confined to the ventral nerve cord 
while the other five have processes in both dorsal and ventral nerve cords. The processes in 
dorsal and nerve cords of these motoneurons are linked by lateral processes known as 
commissures. Additionally, there are six non-segmental interneurons, three right-hand 
commissures and one left-hand commissure in each segment (Figure 2.6) (Martin, 1997; 
Martin et al., 1991; Stretton et al., 1978). The six non-segmental interneurons are located in 
the ventral nerve cord with their somata in the head or tail segments. 
2.2.2 Muscular System 
Transversely, the anterior portion of Ascaris body (from outside to inside, Figure 
2.7A) shows the body to be composed of three concentric rings of cuticle, hypodermis and 
somatic muscle layer which surrounds the perienteric cavity containing the gut (Martin, 
1997; Martin et al., 1991). Two fields (dorsal and ventral) of mononucleated muscle cells (5 
x 104 in number) which form the somatic muscle layer are separated by the two lateral lines  
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Source:  Martin, 1997, p. 14. 
 
Figure 2.6 Organization of Ascaris suum motor nervous system in one segment. Each 
segment contains eleven motoneurons and six non-segmental interneurons. The seven 
morphological types of motoneurons are indicated as DI: dorsal inhibitory, VI: ventral 
inhibitory, DE1: dorsal excitatory 1, DE2: dorsal excitatory 2, DE3: dorsal excitatory 3, V1 
and V2: ventral excitatory.  
 
(Stretton, 1976). Anchored to the hypodermis is the obliquely striated contractile substance 
known as the spindle or fibre which has an average length of ca 2 mm (del Castillo et al., 
1989; Rosenbluth, 1965a). The muscle cell forms a large, balloon-like structure called the 
bag or belly around mid-point of the spindle. The muscle bag (Figure 2.7B) measures ca 200 
– 250 m in diameter and contains the single nucleus of the cell. Each muscle cell sends out 
processes called muscle arms which project from the base of the bag and transversely cross 
the muscle field to reach the syncytium over the nerve cord. Most muscle cells have more 
than one muscle arm, the mean number of arms is 2.7 (Stretton, 1976). Each arm branches 
from the nerve cord into thin terminal processes or fingers. The fingers of one arm form tight,  
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Source: Martin, 1997, p. 14. 
 
Figure 2.7 Transverse section of anterior section of Ascaris body showing arrangement of the 
three concentric rings of cuticle, hypodermis, somatic muscle layer, perienteric fluid and gut 
(A) and Ascaris muscle cell showing the muscle bag, spindle, arm, syncytium and nerve cord 
(B).  
 
interwined junctions with those of adjacent arms at the syncytium. The interwound fingers 
extend longitudinally apposed to the nerve cord and are responsible for electrical coupling of 
muscle cells (Debell et al., 1963; Rosenbluth, 1965b). 
2.3 Nicotinic Acetylcholine Receptors (nAChRs) 
Nicotinic acetylcholine receptors (nAChRs) are prototypical Cys-loop ligand-gated 
ion channels that mediate fast synaptic transmission in the neuromuscular and nervous 
system of vertebrates and invertebrates. They are an important target for many anthelmintics 
(Brown et al., 2006). Other members of the Cys-loop superfamily of ligand-gated ion 
channels (LGICs) include ionotropic receptors for 5-hydroxytryptamine (5-HT), -
aminobutyric acid (GABA) and glycine (Connolly & Wafford, 2004). The electric ray  
A B
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Torpedo californica nAChR is the most carefully studied nAChR (Changeux et al., 1996). 
The structure of the nAChR of a related species (Torpedo marmorata) has also been resolved 
at 4.6Å and 4.0Å (Unwin, 2005). nAChRs are composed of five protein subunits arranged 
around a central pore that is permeable to cations in most cases (Changeux, 2012; Karlin, 
2002). Each nAChR subunit consists of an N-terminal, extracellular domain that contains the 
cys-loop (two cysteine residues separated by 13 amimo acids), six loops (A – F) and four 
transmembrane domains (TM1 – TM4) (Figure 2.8). TM2 forms the lining of the ion pore. 
The subunits are differentiated as  and non-, whereby  subunits contain two adjacent 
cysteine residues (linked by a disulfide bond) in loop C which are essential for acetylcholine 
binding, non- subunits lack the adjacent cysteines. nAChRs are further differentiated on the 
basis of their subunit composition as homopentamers, in which all five subunits that make up 
the pentamer are identical, or as heteropentamers, where the subunits are non-identical and  
 
Source: Brown et al., 2006, p. 619. 
 
Figure 2.8 Structure of the nicotinic acetylcholine receptor. Each nAChR consists of five 
subunits arranged around a cationic channel pore. The cys loop, the vicinal cysteines 
characteristic if an  subunit and four transmembrane regions (TM1-4) are shown for one 
subunit  
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contain at least two  subunits (Bouzat, 2012; Taly et al., 2009). The ligand binding domain 
of nAChRs has been carefully elucidated using the acetylcholine binding protein (AChBP) 
from Lymnaea stagnalis (Brejc et al., 2001). AChBP though a structural and functional 
homolog of the N-terminal ligand binding domain of a nAChR subunit, lacks the domains 
required to form a transmembrane ion channel. AChBP forms a stable homopentamer 
comprising of 210 residues. It is most closely related to vertebrate nAChR  subunits. 
Acetylcholine binding involves both an  and an adjacent subunit which could be an  or 
non- depending on nAChR pentamer composition. Loops A – F contribute to the ligand 
binding sites, loops A, B, C from the principal face of the  subunit and loops D, E, F from 
the complementary face of the adjacent subunit (Arias, 1997). 
2.3.1 Caenorhabditis elegans nAChRs 
C. elegans nAChRs are the most widely studied compared to parasitic nematode or 
vertebrate nAChRs. Hence, the free-living nematode, C. elegans, is a powerful tool for 
providing insights into the molecular basis of the pharmacology of nAChRs. There are at 
least 32 nAChR subunits in the model nematode C. elegans, 22 of which are  subunits. 
These subunits are divided into five groups, on the basis of sequence homology, with each 
group named after the first member to be identified in that group (Holden-Dye et al., 2013). 
The five groups are DEG-3, ACR-16, ACR-8, UNC-38 and UNC-29 (Figure 2.9). Subunits 
which display significant homology to nAChRs but do not fall within the five core groups are 
designated ‘Orphan subunits’, many of whose function is unknown (Brown et al., 2006). 
 Almost all the members of the DEG-3, ACR-16, ACR-8 and UNC-38 groups are  
subunits while those in the UNC-29 group are non- subunits (Table 2.1). Notably, some 
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members of the ACR-16 group closely resemble vertebrate homomeric neuronal 7 receptor 
subunits (Mongan et al., 2002). Different nAChR subunit combinations make up different 
nAChR types and on this basis, four major nAChR types have been described namely, 
levamisole-sensitive, nicotine-sensitive, DEG-3/DES-2 and EAT-2 nAChRs. These nAChR 
types also show different expression patterns and play vital roles in a variety of physiological 
functions including feeding, motility, development and reproduction. Levamisole-sensitive 
and nicotine-sensitive receptors are expressed in body wall muscle (Richmond & Jorgensen, 
1999). DEG-3/DES-2 receptors are also expressed in neurons (Treinin et al., 1998). EAT-2 
receptors are expressed in the pharynx, and require a small transmembrane protein, EAT-18, 
for pharyngeal pumping (McKay et al., 2004). Still in C. elegans (and also parasitic 
nematodes), different stoichiometry of nAChR subunits produces further different nAChR 
subtypes (Figure 2.10). 
 Levamisole (levamisole-sensitive) receptors are the most widely explored group of 
receptors in both C. elegans and parasitic nematodes. The nAChR subunit genes lev-1, unc-
29 and unc-38 have been identified as important for levamisole sensitivity. However, when 
these subunits were injected in Xenopus laevis oocytes, expression levels were generally low 
as revealed by the small current responses to the major excitatory neurotransmitter, 
acetylcholine, and the anthelmintic, levamisole (Fleming et al., 1997). Fleming et al., 1997, 
also showed mecamylamine and neosurugatoxin but not -bungarotoxin to inhibit the 
levamisole current responses. Richmond and Jorgensen later showed from in vivo recordings 
from C. elegans body wall muscle cells, evidence for the presence of two nAChR types. 
 These included alevamisole-sensitive receptor, requiring both unc-29 and unc-38 
subunit genes for its activity, and a second receptor type that was activated by both nicotine  
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Source: Brown et al., 2006, p. 620. 
 
Figure 2.9 Tree showing the five core groups of nAChR subunits (indicated by the colored 
regions). Other groups such as the acetylcholine-gated chloride channels and the orphan 
group are also shown. 
 
and acetylcholine. The receptor that was activated by both nicotine and acetylcholine was 
present in unc-29 and unc-38 mutants and showed rapid desensitization. Also, the levamisole 
response in wild-type C. elegans was completely blocked by d-tubocurarine whereas in unc- 
29 mutants, the nicotine response was completely blocked by dihydro--erythroidine which 
caused only a slight block of the levamisole response. The acetylcholine response in wild-
type C. elegans was only about 50% blocked by dihydro--erythroidine. While locomotion in  
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Table 2.1 Summary of the five core groups of nAChR subunits and their expression pattern in 
C. elegans. (Source: Holden-Dye et al., 2013, p. 607.) 
 
Group Subunit Expression 
DEG-3 ACR-17 α ? 
 ACR-18 α Body wall muscle and nervous system 
 ACR-20 α7-like Body wall muscle and nervous system 
 ACR-22 non-α (lcg-11) ? 
 ACR-23 α7-like Body wall muscle and nervous system 
 DES-2 α (ACR-4) Body wall muscle (head) and nervous systems IL2, FLP, PVD, PVC, ALA, and AVG 
 DEG 3 α PVC,, sensory endings of IL2, ALM, and PLM 
 ACR-24 α Role in fast neurotransmission? 
 ACR-5 α Nervous system – head neurons, neurons along body, tail neurons 
ACR-16 ACR-7 α7 like Body wall muscle, pharyngeal muscle, tail neurons 
 ACR-9 non-α Neurons 
 ACR-10 α7 like Body wall muscle and nervous systems? 
 ACR-11 α Muscle 
 ACR-14 non-α DA, VB, AS, DB, DD, HSN, VC4&5, AIY, head and motoneurons, muscle, and intestine 
 ACR-15 α Muscle (head and body wall), AVA, AVB, DVA, RID, PVQ, SMB?, SMD, 15, RIM, SAA, 
  SIA, and SIB, all ventral nerve cord motoneurons except DD 
 ACR-16 α7 like Body wall muscle & subset of neurons, AVA, RIB, RID, SIB, SMD, DM motoneuron 
  head and tail neurons 
 ACR-19 α Neurons? 
 ACR-21 α Ventral nerve cord cholinergic neurons 
 ACR-25 non-α? ? 
 EAT-2 non-α Pharyngeal muscel (pm4&5) 
ACR-8 ACR-8 α All body wall muscle, head & tail neurons, anal and vulval muscles, nerve ring, 
  nerve cord, ventral nerve cord motoneurons 
 ACR-12α Ventral nerve cord neurons, head & tail nervous system 
 LEV-8(ACR-13) α Body wall (strongest in head regiou) and vulval muscles, head neurons, 
  mechanosensory neurons, many ventral nerve cord motoneurons, socket cells 
UNC-38 UNC-38 α Body wall and vulval muscles, nervous system, colocalizes with TAX-6, ACR-8, 
  ACR-12, and UNC-29; dorsal and ventral nerve cord 
 UNC-63 α Body wall & vulval muscle, ventral cord motoneurons, AS, DA, DB, VB, VD, DV, and VC, 
  widespread in neurons 
 ACR-6 α Role in fast neurotransmission 
UNC-29 ACR-2 non α Forms functional channel with UNC-38, muscle & nervous system, ventral cord neurons, 
  e.g., VA, VB, DA, DB (cholinergic motoneurons); PVQ, DVC, IL-1, RMD; tail neurons 
 ACR-3 non-α Body wall muscle and nervous systems, forms functional channels with UNC-38 
 UNC-29 non-α Body wall and head muscles, nervous system, ventral & dorsal cords, nerve  ring 
 LEV-1 (ACR-1) non-α All body wall muscles, some ventral cord neurons 
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Source: From Holden-Dye et al., 2013, p. 608. 
 
Figure 2.10 Proposed stoichiometry of nAChRs in C. elegans and parasitic nematodes, 
showing possible subunit combinations for the various nAChR types.  
 
unc-29 and unc-38 mutants wasimpaired, the response to acetylcholine was maintained, 
suggesting an equal contribution of the nicotine-sensitive, N-AChR and the levamisole- 
sensitive, L-AChR to the acetylcholine response (Richmond & Jorgensen, 1999). In addition 
to lev-1, unc-29 and unc-38, the C. elegans unc-63 subunit gene has been shown to confer 
levamisole sensitivity (Culetto et al., 2004). Subsequently, the L-AChR was described in X. 
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laevis oocyte expression studies to require five nAChR subunits, UNC-29, UNC-38, UNC-
63, LEV-1 and LEV-8 (also known as ACR-13), LEV-1 and UNC-29 are non- subunits 
while UNC-38, UNC-63 and LEV-8 are  subunits. All five subunits, in addition to three 
ancillary proteins (RIC-3, UNC-50 and UNC-74) were required for functional expression of 
the L-AChR (Boulin et al., 2008). The ancillary proteins RIC-3, UNC-50 and UNC-74 are 
respectively involved in the maturation, trafficking and folding of the receptor (Eimer et al., 
2007; Halevi et al., 2002; Haugstetter et al., 2005). Boulin et al., 2008, also showed d-
tubocurarine, methyllycaconitine and hexamethonium to be potent antagonists of the L-
AChR, while -bungarotoxin and dihydro--erythroidine had modest blocking effects, in 
agreement with observations by Richmond & Jorgensen (1999). Another subunit, ACR-8, 
has been identified in C. elegans body wall muscle but its role is uncertain as it neither 
contributes to levamisole-sensitive or insensitive nAChRs (Touroutine et al., 2005).   
Nicotine-sensitive nAChRs or N-AChRs are sensitive to nicotine but insensitive to 
levamisole. Unlike levamisole receptors which are composed of heteropentamers, N-AChRs 
are homopentamers. Five ACR-16 subunits make up a N-AChR in C. elegans (formerly 
called Ce21) which is closely related to vertebrate 7 receptors (Ballivet et al., 1996; 
Raymond et al., 2000). Also, N-AChRs require only RIC-3 for their functional expression in 
X. laevis oocytes. Ballivet et al. (1996), further demonstrated that levamisole not only failed 
to activate the C. elegans ACR-16 receptor but also antagonized acetylcholine responses. 
Additionally, dihydro--erythroidine acted as a potent antagonist of the C. elegans ACR-16 
receptor, as opposed to very weak antagonism on L-AChRs. C. elegans ACR-16 is also 
strongly antagonized by d-tubocurarine but weakly antagonized by methyllycaconitine and 
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-bungarotoxin. Ballivet et al. (1996), showed the C. elegans ACR-16 receptor to desensitize 
rapidly following application of acetylcholine or nicotine. Although nicotine was a more 
potent agonist of the C. elegans ACR-16 receptor than acetylcholine (EC50 12.6 μM for 
nicotine versus 55.4 μM for acetylcholine), the maximum response for nicotine was lower 
than that for acetylcholine, suggesting nicotine is a partial agonist of the C. elegans ACR-16 
receptor. Interestingly, acr-16 mutants showed no obvious behaviorial phenotype but unc-
63:acr-16 or unc-29:acr-16 double mutants showed more severe locomotory deficits than 
either unc-63 or unc-29 mutants (Li et al., 2014; Touroutine et al., 2005).   
Members of the DEG-3 group of nAChRs are preferentially activated by the amino-
acetonitrile derivative, monepantel, causing spastic paralysis of body wall and pharyngeal 
muscles. DEG-3-like nAChRs have been identified only in nematodes. The major subunit 
member is ACR-23 which is expressed mainly in C. elegans body wall muscles and in 
unidentified head and tail neurons (Rufener et al., 2013). Rufener et al. (2013), also 
reconstituted functional receptors made up of C. elegans ACR-23 subunits in Xenopus 
oocytes and showed that these receptors responded to monepantel, in addition to choline, 
nicotine, and acetylcholine, in order of current response magnitude, with choline responses 
strongly potentiated by monepantel. Another subunit member of the DEG-3 group is ACR-20 
which forms homomeric receptors just like ACR-23 (Baur et al., 2015). According to Baur et 
al. (2015), low concentrations (<1 nM) of monepantel produced positive allosteric 
modulatory effects on the C. elegans ACR-20 receptor, while high concentrations (>0.1 M) 
produced direct agonist effects on the receptor. Functional receptors comprising of C. 
elegans DEG-3 and DES-2 subunits have also been reconstituted in X. laevis oocytes where 
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the receptors were activated by choline and acetylcholine, with choline as the more potent 
agonist (Treinin et al., 1998; Yassin et al., 2001). 
EAT-2 nAChRs are not a well-exploited target for anthelmintic drug development. 
These receptors are localized postsynaptically on pharyngeal muscle and require interaction 
with the protein EAT-18 for nicotinic transmission in C. elegans pharynx (McKay et al., 
2004). Hence, EAT-2 receptors are believed to play a role in pharyngeal pumping and 
therefore, feeding. At present, it is not known if EAT-2 is homomeric or requires other 
subunits to form the receptor. 
2.3.2 Parasitic nematode nAChRs 
Parasitic nematode nAChRs are therapeutic targets for many anthelmintics including 
levamisole, pyrantel, oxantel, bephenium and morantel. The nAChR from the pig parasitic 
nematode Ascaris suum (clade III) is the most extensively studied parasitic nematode 
nAChR. Initial patch clamp recordings from Ascaris muscles revealed the presence of at least 
two acetylcholine-activated channel types (Pennington & Martin, 1990). Single channel 
recordings from Ascaris muscle later showed low levamisole concentrations (1 – 10 M) to 
cause channel opening and high levamisole concentrations (30 and 90 M) to cause 
flickering channel block. The channel conductance was in the range of 18 – 50 pS (Robertson 
& Martin, 1993). Pyrantel and oxantel were also shown to act as agonists and open channel 
blockers of these channels (Dale & Martin, 1995; Robertson et al., 1994). Muscle contraction 
studies using different agonists and antagonists revealed the existence of more than one 
nAChR type on Ascaris body wall muscle with different sensitivities to agonists and 
antagonists (Robertson et al., 2002). Three nAChR types on Ascaris muscle having different 
channel conductances and mean open times have been characterized at the single channel 
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level using the patch clamp technique (Qian et al., 2006). These nAChR types have been 
named after their preferred agonist and include the L-type preferentially activated by 
levamisole, the N-type preferentially activated by nicotine and the B-type preferentially 
activated by bephenium (Figure 2.11). The single channel conductance and mean open times 
are respectively, 24 pS and 0.6 ms for the N-type, 35 pS and 0.9 ms for the L-type, and 45 pS 
and 1.3 ms for the B-type. Unlike in C. elegans where the actions of levamisole and nicotine 
 
Source: Qian et al., 2006, p. E2115. 
 
Figure 2.11 Summary diagram of nAChR subtypes on Ascaris suum somatic muscle cell 
membrane. The single channel as well as agonist and antagonist pharmacological properties 
of each subtype are indicated. N-subtype prefers nicotine, L-subtype prefers levamisole and 
B-subtype prefers bephenium. The subtypes show different sensitivities to the competitive 
antagonists paraherquamide (PHQ) and 2-desoxoparaherquamide (2DPHQ).  
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are selective (levamisole-sensitive currents are not activated by nicotine and vice versa), the 
differences in agonist action are subtler in A. suum. For instance, although levamisole 
preferentially activates L-type channels, it also opens N- and B-type channels to a lesser 
extent. Bephenium preferentially activates B-type channels but also opens some L-type but 
not N-type channels. Hence, nAChR types in A. suum are less distinct in terms of agonist 
pharmacology than those in C. elegans. At high concentrations, levamisole activates all three 
nAChR types in A. suum.   
 In addition to the 25 pS, 35 pS and 45 pS single channel conductances, a fourth 
levamisole-activated subtype with a conductance of 40 pS has been revealed in the strongylid 
nematode Oesophagostomum dentatum (clade V), suggesting the presence of four nAChR 
types in O. dentatum (Robertson et al., 1999). Robertson et al. (1999), also showed loss of 
the G35 channel in levamisole-resistant (LEVR) parasites which was present in levamisole-
sensitive (SENS) parasites (Figure 2.12). Therefore, just as in A. suum, the G35 channel is 
the L-type nAChR.  
 
  
Source: Robertson et al., 1999, p. 757. 
 
Figure 2.12 Frequency histograms of single channel conductances for SENS (A) and LEVR 
(B) parasites.  
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 In O. dentatum, different nAChR subunit combinations expressed in Xenopus oocytes 
have revealed the presence of four distinguishable nAChR subtypes based on agonist 
sensitivities (Buxton et al., 2014). These include the pyrantel (Pyr)-nAChR composed of 
UNC-29 and UNC-63 subunits, the pyrantel/tribendimidine (Pyr/Tbd)-nAChR composed of 
UNC-29, UNC-63 and UNC-38 subunits, the acetylcholine (ACh)-nAChR composed of 
UNC-29, UNC-63 and ACR-8 subunits, and the levamisole (Lev)-nAChR composed of 
UNC-29, UNC-63, UNC-38 and ACR-8 subunits (Figure 2.13). Note that the LEV-8 subunit 
has not been detected in any nematode parasite, however, a related subunit (ACR-8) can 
replace LEV-8 to reconstitute L-AChRs in the parasites. In accordance with in vivo studies, 
Buxton et al. (2014), showed the levamisole-nAChR comprising of UNC-29, UNC-63,  
 
 
Source: Modified from Buxton et al., 2014, pp. 5 & 7. 
 
Figure 2.13 Summary of the four O. dentatum nAChR subtypes based on different 
combinations of subunits reconstituted in Xenopus laevis oocytes. The pyrantel (Pyr)-nAChR 
is composed of UNC-29 and UNC-63 subunits, the pyrantel/tribendimidine (Pyr/Tbd)-
nAChR is composed of UNC-29, UNC-63 and UNC-38 subunits, the acetylcholine (ACh)-
nAChR is composed of UNC-29, UNC-63 and ACR-8 subunits, and the levamisole (Lev)-
nAChR is composed of UNC-29, UNC-63, UNC-38 and ACR-8 subunits.  
Pyr-nAChR Pyr/Tbd-nAChR ACh-nAChR Lev-nAChR
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UNC-38 and ACR-8 subunits to have a single channel conductance of 35 pS. These authors 
also demonstrated that varying the subunit stoichiometry of the pyrantel-nAChR comprising 
of UNC-29 and UNC-63 subunits produced changes in its pharmacological properties. When 
the ratio of unc-29:unc-63 injected cRNA was 1:5, the pyrantel and tribendimidine current 
responses were significantly increased, and when it was 5:1, the nicotine and levamisole 
current responses became significantly bigger than the acetylcholine response. 
Two L-AChR subtypes have also been identified in A. suum by varying the 
stoichiometry using different ratios of UNC-38 and UNC-29 subunits (Williamson et al., 
2009). Oocytes injected with unc-38 and unc-29 cRNA at ratios of 5:1 and 1:5 produced 
robust current responses compared to those injected at ratios of 10:1 and 1:10 which 
produced very small current responses. Also, when the unc-38:unc-29 ratio was 5:1, nicotine 
acted as a full agonist and levamisole acted as a partial agonist, whereas when the ratio was 
1:5, levamisole was a full agonist and nicotine a partial agonist. Still with the 5:1 ratio, 
oocytes responded to oxantel but not pyrantel, while with the 1:5 ratio, oocytes responded to 
pyrantel but not oxantel. 
Genes encoding UNC-38, UNC-29, UNC-63 and ACR-8 have been identified in 
Hemonchus contortus, which belongs to Clade V just as O. dentatum and C. elegans. Two 
types of L-AChRs namely Hco-L-AChR1 and Hco-L-AChR2 were identified in H. contortus 
by varying subunit combinations (Boulin et al., 2011). The receptor Hco-L-AChR1 which is 
made up of all four subunits UNC-38, UNC-29, UNC-63 and ACR-8 was more sensitive to 
levamisole than acetylcholine and was weakly sensitive to pyrantel and nicotine. Omitting 
ACR-8 from the combination produced the Hco-L-AChR2 receptor which was more 
sensitive to pyrantel and acetylcholine than levamisole. Recently, four copies of the unc-29 
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L-AChR subunit gene (Hco-UNC-29.1, Hco-UNC-29.2, Hco-UNC-29.3 and Hco-UNC-29.4) 
were identified in H. contortus, and duplication of the unc-29 L-AChR subunit gene was 
shown to be a common feature of the clade V parasitic nematodes (Duguet et al., 2016). 
Substituting each of the four UNC-29 copies in the Hco-L-AChR1 receptor subunit 
composition produced three functional receptor types which differed from each other in 
terms of agonist and antagonist pharmacology. UNC-29.2 failed to reconstitute a functional 
receptor. L-AChR1.1 comprised of UNC-38, UNC-29.1, UNC-63 and ACR-8 subunits and 
was more responsive to levamisole than acetylcholine. Additionally, mecamylamine was a 
potent antagonist of L-AChR1.1. When the UNC-29.1 subunit was replaced with UNC-29.2 
(L-AChR1.2), the oocytes did not produce any detectable current responses. When UNC-
29.1 was replaced with UNC-29.3 (L-AChR1.3), the acetylcholine response was greater than 
the levamisole response and mecamylamine was a less potent antagonist. When UNC-29.1 
was replaced with UNC-29.4 (L-AChR1.4), levamisole and acetylcholine responses were 
about equal and mecamylamine was more potent (Figure 2.14). 
2.3.3 Vertebrate nAChRs 
 Vertebrate nAChRs contain five subunits namely , , ,  and  and are important 
therapeutic targets for various neurodegenerative diseases including Alzheimer’s disease, 
Parkinson’s, disease and schizophrenia, as well targets to treat alcohol and nicotine 
dependence (Dineley et al., 2015; Dwoskin et al., 2009; Posadas et al., 2013). A total of 17 
nAChR subunits have been identified in vertebrates (Millar & Gotti, 2009). This number is 
less than the 32 subunits identified in C. elegans. Vertebrate nAChRs can be divided into two 
groups based on their primary site of expression as muscle and neuronal nAChRs. Muscle 
nAChRs are expressed at the neuromuscular junction and are composed of the subunits 1,  
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Figure 2.14 Pharmacological profile of Hemonchus contortus reconstituted receptors in 
Xenopus oocytes. Hco-unc-29.1, Hco-unc-29.3 and Hco-unc-29.4 were individually 
combined with Hco-unc-63, Hco-unc-38 and Hco-acr-8 and co-expressed with the three 
ancillaries Hco-unc-3.1, Hco-unc-50 and Hco-unc-74. All responses were normalized to 100 
M acetylcholine to generate the acetylcholine and levamisole concentration-response 
curves. Modified from Duguet et al., 2016, pp. 12/26.   
 
1, , and either  and . The five muscle nAChRs co-assemble into only two nAChR 
subtypes, embryonic and adult. Embryonic muscle nAChRs are composed of (1)2, 1,  and 
 subunits whereas adult muscle nAChRs are composed of (1)2, 1,  and . Neuronal 
nAChRs are more diverse than muscle nAChRs and comprise of various homomeric or 
heteromeric combinations of twelve subunits: 2 – 10 and 2 – 4 (Kalamida et al., 2007; 
Millar, 2003). Most vertebrate neuronal nAChRs are heteromeric, containing at least one  
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and one  subunit (most commonly ()2()3). Only 7, 8 and 9 subunits reconstitute 
functional homomeric nAChRs in Xenopus oocytes (Couturier et al., 1990; Elgoyhen et al., 
1994; Gerzanich et al., 1994). Evidence for co-assembly and subunit diversity of vertebrate 
nAChRs has been revealed in the insect Drosophila and C. elegans models. In Drosophila, 
10 nAChR subunits have been identified and 42 possible nAChR subunits have been 
predicted in C. elegans (Bargmann, 1998; Littleton & Ganetzky, 2000). Table 2.2 provides a 
summary of vertebrate nAChR subunit combinations from studies of native nAChRs and 
heterologous expression studies. 
2.4 Medicinal plants 
Broadly, medicinal plants are defined as plants which have similar therapeutic 
properties with conventional pharmaceutical drugs. Humans have used medicinal plants to 
cure or lessen disease symptoms since ancient times. Even today, a large proportion of the 
population in developing nations still rely on phytomedicine for primary health care and 
treatment of diseases in animals (Githiori et al., 2005; Tagboto & Townson, 2001). 
Medicinal plants are frequently preferred because they are perceived to be well-tolerated and 
have fewer side effects compared to conventional pharmaceuticals (Petrovska, 2012). It is 
also important to remember that many drugs used in modern medicine today are modeled 
from medicinal plant products. Use of medicinal plants to treat anthelmintic infections in 
livestock and humans continues to be exploited as an alternative to pharmaceutical products 
(Githiori et al., 2004). Remarkably, use of plants to treat worm infections in animals is no 
longer limited to developing nations. The developed world is experiencing a widespread 
reawakening in phytomedicine. This is driven in part by the limited availability of 
pharmaceutical anthelmintic drugs and the widespread occurrence of multidrug resistance  
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Table 2.2 Assembly and subunit diversity of vertebrate nicotinic acetylcholine receptors. 
(Modified from Millar, 2003, p. 871.) 
 
 
43 
 
(Waller et al., 2001). Although the bioactive compounds in medicinal plants have not been 
fully identified, scientific validation of the anthelmintic activity of several of these plant 
species have been reported (Al-Abd et al., 2013; Githiori et al., 2006). Interaction between 
additional healers and scientists as well as research aiming to identify the bioactive 
compounds in plants with anthelmintic activity should therefore be promoted as this could 
accelerate anthelmintic drug discovery and development.    
2.4.1 Daniellia oliveri 
Daniellia oliveri is a deciduous, medium-sized tree of the family Caesalpinaceae up 
to 25 – 35 m tall. The genus Daniellia comprises 10 species which are all confined to the 
forest areas of West and Central Africa. Only D. oliveri extends to Sudan and Uganda. D. 
oliveri flowers during the dry season from October to March and fruits from January to June. 
Various biological activities for D. oliveri have been reported. Cardiac glycosides present in 
the methanol extract of the bark showed non-competitive antagonism on muscarinic 
receptors on isolated rat bladder smooth muscle (Onwukaeme et al., 1999a). Methanol 
extracts of the leaves and stem bark were showed to possess neuromuscular blocking 
properties on rat skeletal muscle (Onwukaeme et al., 1999b). The smoke of the bark of D. 
oliveri is traditionally used to repel mosquitoes in Guinea Bissau, West Africa, and may 
significantly contribute to reducing prevalence of diseases transmitted by these mosquitoes 
(Palsson & Jaenson, 1999a; Palsson & Jaenson, 1999b). The leaves of D. oliveri are 
traditionally used to treat diarrhea in Northern Nigeria (Ahmadu et al., 2007). Ahmadu et al. 
(2007), showed the n-butanol extract of D. oliveri leaves to protect against castor oil-induced 
diarrhea in mice. The anti-diarrheal effect of this extract was dose-dependent; 200 mg/kg of 
the extract provided 80% while 100 mg/kg and 50 mg/kg provided 60% protection against 
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diarrhea. Various aqueous and ethanol extracts of the leaves, bark and roots showed in vitro 
antibacterial activity against a range of pathogenic bacteria including Staphylococcus aureus. 
The ethanol extract of the leaves also showed significant antifungal activity against 
Tricophyton rubrum (Ahmadu et al., 2004). Fodders supplemented with D. oliveri foliage 
improved performance of buckling goats fed threshed sorghum top basal diet (Isah et al., 
2015; Okunade et al., 2016).  
2.4.2 Psorospermum febrifugum 
Psorospermum febrifugum (family Hypericaceae) is a flowering shrub or tree up to 4 
m high that is widespread in tropical Africa but grows predominantly in the savanna from 
Guinea to West Cameroon. P. febrifugum as the name implies is known for its febrifugal 
action. The bark and roots are used to treat all sorts of skin infections including ‘craw-craw’ 
and other parasitic skin diseases. The bark is used in Bukoba Rural district in Tanzania for 
the traditional treatment of skin infections including body sores and Herpes zoster (Kisangau 
et al., 2007). These authors showed the petroleum ether, dichloromethane and water extract 
of P. febrifugum bark to have antimicrobial activity against Escherichia coli. P. febrifugum is 
rich in antioxidants. Xanthones and emodines have been isolated from P. febrifugum and 
showed to possess antioxidant, anticancer, antiviral and antimicrobial potential (Permana et 
al., 1994; Tsaffack et al., 2009). The leaves, stem bark and root bark of P. febrifugum are 
used for traditional treatment of HIV/AIDS and its asscociated symptoms in some districts in 
Uganda (Lamorde et al., 2010).  
2.4.3 The drug development pipeline 
The demand for new antiparasitic therapeutic agents to complement or replace 
existing ones is on the rise as resistance is likely to compromise every drug over time. Use of 
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existing drugs is also limited by their side effects, poor compliance and limited efficacy 
(Renslo & McKerrow, 2006). Therefore, a drug development pipeline is essential for 
securing the availability of new therapies should existing ones fail. The drug development 
pipeline represents the series of activities involved in the discovery and production of a new 
therapeutic product (Figure 2.15). For NTDs, this usually requires cross-sector partnerships 
with pharmaceutical companies, academic and nonprofit research institutions worldwide 
(Ramamoorthi et al., 2014a; Ramamoorthi et al., 2014b). Unfortunately, development of the 
drugs for NTDs is a low priority to pharmaceutical companies, causing the drug development 
pipeline for these diseases to dry up (Trouiller & Olliaro, 1998; Trouiller & Olliaro, 1999). 
Collaboration between nonprofit private and public research institutions in both developed 
and developing countries should therefore be promoted to significantly accelerate 
development of new drugs (McKerrow, 2005; Trouiller et al., 2002). The very first step in 
pipeline is the identification and validation of targets. This is followed by high-throughput 
screening efforts for identification of hits. Hits are further screened to identify leads which 
show potentials for improvement via development of structure-activity relationships (Nwaka 
& Hudson, 2006). Lead compounds are screened for activity and toxicity, and those with 
pharmacological and toxicity profiles within acceptable limits are considered drug candidates 
and will undergo clinical trials (phases I, II and III) to ascertain their efficacy and safety in 
humans. Lastly, drug candidates that pass all 3 clinical trial phases are submitted to the Food 
and Drug Administration (FDA) for review and approval (Roses, 2008). Since it takes at least 
15 years for a drug to go through the development pipeline to when it becomes available in 
the drug market, research leading to discovery of lead compounds must continue so that  
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Source: Nwaka & Hudson, 2006, p. 944; Roses, 2008, p. 808. 
 
Figure 2.15 Drug candidate and development pipeline. Top: Lead discovery strategy for 
tropical diseases. Bottom: Summary of steps involved in drug discovery and development.  
 
47 
 
compounds will always be available for further development should those in clinical trials or 
under review fail (Figure 2.15). 
2.5 Anthelmintics and anthelmintic resistance 
2.5.1 Anthelmintics 
Anthelmintics are drugs that are used to treat infections caused by parasitic worms 
(helminths) (Holden-Dye & Walker, 2007). There are three major groups of helminths 
namely: nematodes (roundworms), trematodes (flukes) and cestodes (tapeworms) (Castro, 
1996). These groups of helminths are divided into two phyla; nematodes (roundworms) and 
platyhelminths (trematodes and cestodes) (Hotez et al., 2008; Wang et al., 2008). 
Anthelmintics either kill worms or cause their expulsion from the body, without causing any 
significant damage to the host (Martin et al., 1997). Although there is a high prevalence of 
parasitic worms, the progress of anthelmintic drug discovery and development by 
pharmaceutical companies has been slow over the years. One contributing factor is that the 
majority of those suffering from helminth infections live in developing nations who lack the 
resources to support a profitable drug market (Pink et al., 2005). Development of new 
anthelmintics is limited by high costs and modest global markets for antiparasitic drugs and 
chemicals. The cost of development of a new drug is estimated at US $40 million for 
livestock use, and more than US $800 million for human use. The global market for 
antiparasitic drugs and chemicals are estimated at US $12 billion for plant pathogens, $11 
billion for livestock and companion animals, and $0.5 for human health (DiMasi et al., 2003; 
Evans & Chapple, 2002; Martin & Robertson, 2010; Morgan et al., 2011). Many 
anthelmintic drugs used to treat humans were first developed and marketed as veterinary 
drugs (Crump & Omura, 2011; Geary, 2005; Omura, 2008). There are only a few classes of 
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anthelmintics including; benzimidazoles, imidazothiazoles, tetrahydopyrimidines, 
macrocyclic lactones, amino-acetonitrile derivatives, spiroindoles and 
cyclooctadepsipeptides. 
2.5.1.1 Benzimidazoles (BZs).  Thiabendazole was the first benzimidazole 
anthelmintic agent produced. Since the introduction of thiabendazole in 1961, a number of 
benzimidazoles with improved efficacy and extended spectrum of action have been 
developed (McKellar & Scott, 1990). These include mebendazole, albendazole and 
flubendazole (Figure 2.16). The initial mode of action of benzimidazoles was thought to be 
inhibition of various parasite metabolic enzymes including fumarate reductase and malate 
dehydrogenase (Prichard, 1970; Tejada et al., 1987). However, it is now established that 
benzimidazoles selectively bind with high affinity to parasite -tubulin and inhibit 
microtubule polymerization. This results in the destruction of cell structure and consequent 
death of the parasite (Lacey, 1990). 
 
Source: McKellar & Scott, 1990, p. 227. 
 
Figure 2.16 Chemical structures of thiabendazole (A), mebendazole (B), albendazole (C) and 
flubendazole (D).  
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2.5.1.2 Imidazothiazoles.  Imidazothiazoles act as nicotinic acetylcholine receptor 
(nAChR) agonists. They bind to nAChRs on body wall muscles, causing spastic paralysis of 
the worm, and hence, its expulsion from the host (Aceves et al., 1970). Tetramisole (Figure 
2.17), an aminothiazol derivative, was the first member of this class of anthelmintics, and 
constitutes a racemic mixture of 50% L- or S- and D- or R-isomers (Raeymaekers et al., 
1966; Raeymaekers et al., 1967; Thienpont et al., 1966). The L-isomer was later 
demonstrated to be more potent than the racemic mixture or the the D-isomer (Thienpont et 
al., 1969; Van den Bossche & Janssen, 1967). Consequently, the D-isomer was removed 
from the racemic mixture and this led to the development of the L-isomer as levamisole. The 
detailed mode of action of levamisole, the only existing drug in this class, has been carefully 
studied at the single-channel level in nematode body wall muscles (Qian et al., 2006; 
Robertson et al., 1999; Robertson & Martin, 1993). Robertson & Martin (1993), showed 
using the patch-clamp technique that at the single-channel level in A. suum muscles. 
Levamisole (1 – 90 M concentrations) causes activation of cation-selective channels, in 
 
Source: Van den Bossche & Janssen, 1967, p. 1781. 
 
Figure 2.17 Chemical structures of R (+)-tetramisole (A) and S (-)-tetramisole (levamisole) 
(B) 
A B
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addition to voltage-sensitive open channel-block and desensitization. The mean open-times 
for single-channel currents activated by levamisole were 0.80 – 2.85 ms and the conductance 
levels were 19 – 46 pS, with a mean of 32.9  1.23 pS. This corresponded to the levamisole-
sensitive, L-subtype nAChR with a channel conductance of 35 pS, as revealed by Qian et al. 
(2006). Robertson et al. (1999) later revealed the presence of a similar nAChR subtype in 
levamisole-sensitive O. dentatum muscle patches which was absent in the levamisole-
resistant muscle patches. In subsequent oocyte expression studies, the reconstituted O. 
dentatum L-subtype nAChR (UNC-29, UNC-38, UNC-63 and ACR-8) was preferentially 
sensitive to levamisole and also had a single channel conductance of 35 pS (Buxton et al., 
2014). Levamisole not only causes spastic paralysis but it also stimulates egg-laying in wild-
type C. elegans (Trent et al., 1983). 
2.5.1.3 Tetrahydropyrimidines.  Tetrahydropyrimidines share a similar mode of 
action to imidazothiazoles and are commonly grouped together as nicotinic agonists (Aubry 
et al., 1970; Martin, 1997). Examples of this anthelmintic drug class include pyrantel, oxantel 
and morantel (Figure 2.18). Pyrantel is an imidazothiazole-derived tetrahydropyrimidine that 
was discovered in 1966 as an anthelmintic agent with broad spectrum activity against 
roundworms and hookworms in domestic animals (Austin et al., 1966; Howes & Lynch, 
1967). Pyrantel however lacks activity against whipworms (McFarland & Howes, 1972). 
Studies on the mode of action of pyrantel at the single-channel level identified the L-subtype 
nAChR in A. suum as also preferentially activated by pyrantel (Martin et al., 2005). Pyrantel, 
like levamisole, also causes open channel-block (Robertson et al., 1994). Although not 
characterized at the single-channel level, the O. dentatum nAChR receptor subunits UNC-29, 
UNC-38 and UNC-63 reconstitute a pyrantel/tribendimidine- but not levamisole-sensitive  
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Source: Martin, 1997, p. 13. 
 
Figure 2.18 Chemical structures of pyrantel (A), morantel (B) and oxantel (C).   
 
nAChR subtype in X. laevis oocytes (Buxton et al., 2014). The search for an agent with 
activity against whipworms led to the development of oxantel, an m-oxyphenol derivative of 
pyrantel (Howes 1972). Contrary to pyrantel, oxantel preferentially activates the N-subtype  
nAChRs in A. suum (Martin et al., 2004). Oxantel, like levamisole and pyrantel, also causes 
open channel-block in A. suum (Dale & Martin, 1995). Morantel is a methyl ester analog of 
pyrantel which also targets the L-subtype nAChR in A. suum (Bamgbose et al., 1973; 
Cornwell & Blore, 1970). At the single-channel level, morantel causes the activation and 
block of this receptor subtype (Evans & Martin, 1996). Recently, morantel was shown to act 
as an agonist of the nAChR subtype comprising ACR-26/ACR-27 subunits from H. contortus 
or Parascaris equorum expressed in X. laevis oocytes (Courtot et al., 2015). In oocyte 
expression studies, morantel was seen to cause a non-competitive voltage-sensitive open 
channel block of the newly characterized A. suum ACR-16 receptor (Abongwa et al., 2016a). 
2.5.1.4 Macrocyclic lactones (MLs).  Macrocyclic lactones (avermectins and 
milbemycins) are a group of chemical compounds derived from soil microorganisms of the 
genus Streptomyces (Burg et al., 1979; Takiguchi et al., 1980; Takiguchi et al., 1983). MLs 
were introduced in the 1980s as antiparasitic agents with broad spectrum activity against  
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Source: Martin, 1997, p. 19. 
 
Figure 2.19 Chemical structures of ivermectin (A), abamectin (B), milbemycin D (C) and 
moxidectin (D).  
 
nematodes and arthropods (Davies & Green, 1986; McKellar & Benchaoui, 1996). Examples 
of commercially available avermectins are ivermectin, abamectin, doramectin and 
selamectin, while milbemycin oxime and moxidectin, are examples of commercially 
available milbemycins (Figure 2.19). MLs are selective agonists of glutamate-gated chloride 
channels (GluCls) which are present in neurons and pharyngeal muscles of nematodes and 
arthropods, but absent in humans. ML activation of GluCls inhibits movement and 
pharyngeal pumping (Cully et al., 1994; Wolstenholme & Rogers, 2005). In addition to 
GluCl effects, the avermectins also act as antagonists of 4-aminobutyric acid (GABA) and 
nicotinic receptors expressed on somatic muscle cells of parasitic nematodes (Abongwa et 
al., 2016b; Holden-Dye & Walker, 1990; Puttachary et al., 2013). Ivermectin, the first 
member of the avermectins, although originally developed as a veterinary drug, was later 
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approved for use in humans for the control of onchocerciasis and lymphatic filariasis (Crump 
& Omura, 2011; Geary, 2005; Omura, 2008; Ottesen & Campbell, 1994). Also, ivermectin 
was shown to act as an irreversible agonist of recombinant human glycine receptors at higher 
concentrations >0.3 M, but at lower concentrations (30 nM), it acted as a positive allosteric 
modulator (Shan et al., 2001). Ivermectin showed a similar positive allosteric modulation 
effect on the vertebrate neuronal 7 nicotinic acetycholine receptor (Krause et al., 1998).   
2.5.1.5 Amino-acetonitrile derivatives (AADs).  The AADs are a new class of 
synthetic anthelmintics with high broad spectrum activity against nematodes that are resistant 
to the benzimidazoles, imidazothiazoles and macrocyclic lactones (Ducray et al., 2008; 
Kaminsky et al., 2008a; Kaminsky et al., 2008b). Monepantel, also known as AAD 1556, is 
the first member of this class to be developed for the control of a broad range of parasitic 
nematodes in sheep (Figure 2.20) (Kaminsky et al., 2008b). Genetic screens of C. elegans 
identified ACR-23, which belongs to the nematode-specific DEG-3 subfamily of nAChRs, as 
the target of AADs (Kaminsky et al., 2008a). Further studies on the mode of action of the 
AADs have led to the confirmation of ACR-23 as the principal target for monepantel in C. 
elegans, as well as the identification of other DEG-3-like nAChR target genes; H. contortus 
monepantel-1 (Hco-mptl-1, formerly Hc-acr-23), Hco-des-2, Hco-deg-3 and C. elegans acr-
20 (Baur et al., 2015; Lecova et al., 2014; Rufener et al., 2013; Rufener et al., 2009). Baur et 
al., 2015, also demonstrated that at low concentrations (<1 nM), monepantel acts as a 
positive allosteric modulator of H. contortus MPTL-1 and C. elegans ACR-20 receptors, and 
at high concentrations (>0.1 M), it acts as a direct agonist of these receptors. In a different 
study, monepantel by itself did not activate H. contortus DEG-3/DES-2 receptors expressed 
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in X. laevis oocytes, but did cause a potentiation in the receptors’ current responses when co-
applied with choline (Rufener et al., 2010).  
2.5.1.6 Spiroindoles.  Derquantel (2-deoxy-paraherquamide or PNU-141962) is the 
first semi-synthetic member of this new class of anthelmintics (Figure 2.21) (Lee et al., 
2002). Derquantel which is also the first commercial member of the spiroindoles, was 
introduced in 2010 for use in combination with the macrocyclic lactone, abamectin, under the 
trade name STARTECT, for the control of parasitic nematodes in sheep. Derquantel acts as 
an antagonist of nAChRs to cause flaccid paralysis which results in the expulsion of parasites 
from the host (Robertson et al., 2002). The combination of derquantel and abamectin has an 
 
Source: Kaminsky et al., 2008b, p. 935. 
 
Figure 2.20 Chemical Structure of monepantel. 
 
 
Source: Little et et al., 2011, p. 182. 
 
Figure 2.21 Chemical structure of derquantel. 
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excellent broad spectrum efficacy against several parasitic nematodes in sheep, including 
those resistant to benzimidazoles, levamisole and macrocyclic lactones (Geurden et al., 2012; 
Little et al., 2011). The efficacy of the derquantel and abamectin combination has also been 
shown in muscle contraction and electrophysiological studies on A. suum muscle flaps. 
Derquantel or abamectin alone inhibited responses to acetylcholine, and the inhibition was 
greater when a combination of derquantel and abamectin was used, producing a synergistic 
(greater than additive) effect (Puttachary et al., 2013). Also, the derquantel and abamectin 
combination was shown to produce a greater inhibition of acetylcholine- or pyrantel-induced 
current responses from expressed pyrantel/tribendimidine O. dentatum receptors compared to 
derquantel or abamectin alone (Abongwa et al., 2016b). The introduction of combination 
anthelmintics provides a useful tool to increase anthelmintic drug efficacy, overcome 
resistance to other anthelmintic classes and delay resistance development (Anderson et al., 
1988; Bartram et al., 2012).  
2.5.1.7 Cyclooctadepsipeptides.  Cyclooctadepsipeptides were discovered in the 
early 1990s. In 1992, PF1022A, the parent compound, was isolated from the fungus, Mycelia 
sterilia, which grows on the leaves of the plant, Camellia japonica (Sasaki et al., 1992). 
PF1022A is made up of four N-methyl-L-leucine, two D-lactate and two D-phenyllactate 
residues that are arranged as a cyclic octadepsipeptide with an alternating L-D-L 
configuration (Figure 2.22) (Harder et al., 2003). Emodepside, formerly PF1022-221 and 
BAY 44-4400, is a semisynthetic derivative of PF1022A, produced by attaching a 
morpholine ring at the para position of the two D-phenyllactic acids (Harder et al., 2005). 
This modification resulted in improved pharmacokinetic properties. The anthelmintic 
potential of PF1022A and emodepside has been reported in numerous in vitro and in vivo  
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Source: Harder et al., 2003, p. 320. 
 
Figure 2.22 Chemical structure of PF1022A (A) and emodepside (B). 
 
studies (Harder & von Samson-Himmelstjerna, 2001; Kulke et al., 2013a; Kulke et al., 
2013b; Kulke et al., 2014; Zahner et al., 2001a; Zahner et al., 2001b). Interestingly, 
PF1022A and emodepside have a broad spectrum of activity against several nematode 
species including those that are resistant to benzimidazoles, levamisole and ivermectin (von 
Samson-Himmelstjerna et al., 2005). This indicated that the mode of action of the 
cyclooctadepsipeptides is different and that this class of anthelmintics possess ‘resistance-
busting’ properties. 
Studies on the mode of action suggest that emodepside targets the calcium-activated 
potassium channel (SLO-1), there is also evidence for the involvement of the latrophilin 
(LAT-1) receptor (Holden-Dye et al., 2007; Krucken et al., 2012; Martin et al., 2012a). 
Mutagenesis screens in C. elegans revealed a lack of sensitivity of slo-1 null mutants to 
emodepside’s inhibitory effects on locomotion and feeding. Inhibition of locomotion was 
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achieved via the action of emodepside on SLO-1 expressed in body wall muscles or neurons, 
whereas inhibition of feeding was achieved via the action of emodepside on SLO-1 
expressed in neurons but not muscle (Guest et al., 2007). RNAi studies implicated a role for 
LAT-1 in mediating emodepside’s inhibitory effect on pharyngeal pumping in the pharynx 
(Willson et al., 2004). Guest et al. (2007) showed C. elegans lat-1 null mutants had an 
estimated five-fold reduction in sensitivity to emodepside. These studies suggest that the 
inhibitory effect of emodepside on feeding is both SLO-1 and latrophilin-dependent. 
However, emodepside treatment inhibited locomotion in both wild type and lat-1:lat-2 null 
C. elegans, implying that the inhibitory effect of emodepside on locomotion is latrophilin-
independent (Guest et al., 2007). The sensitivity of nematode SLO-1 channels to calcium is 
different from that of insects and humans (Crisford et al., 2015). 
2.5.1.8 Tribendimidine.  Tribendimidine is a symmetrical diamidine derivative of 
amidantel (Figure 2.23). It was developed in the mid 1980s by the National Institute of 
Parasitic diseases in Shanghai, China, as a broad spectrum anthelmintic drug (Ren et al., 
1987). In 2004, tribendimidine was approved by the Chinese Food and Drug Administration 
for treatment of helminth infections in humans (Xiao et al., 2005). It is the only new 
anthelmintic drug that has been approved for human use within the past 3 decades 
(Bergquist, 2016). Tribendimidine has been shown in laboratory and clinical studies to have 
a broad spectrum of activity against several nematode, trematode and cestode species (Keiser 
et al., 2007; Kulke et al., 2012; Steinmann et al., 2008; Wu et al., 2006; Xiao et al., 2009; Xu 
et al., 2014). The activity of tribendimidine against 20 helminth parasites has been 
documented (Xiao et al., 2013). Earlier studies on the mode of action of tribendimidine in the 
nematode model C. elegans demonstrated that tribendimidine acts as an agonist of the L-  
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Source: Kulke et al., 2012, p. 79. 
 
Figure 2.23 Chemical structure of amidantel (A) and tribendimidine (B). 
 
subtype nAChR in this species, similar to levamisole and pyrantel (Hu et al., 2009). Parasitic 
nematodes however, show different nAChR subtype selectivity from C. elegans, and this 
varies across nematode species. Buxton et al. (2014), showed in oocyte expression studies 
that tribendimidine, just like pyrantel, is more selective for the reconstituted 
pyrantel/tribendimidine nAChR subtype comprising of UNC-29, UNC-38 and UNC-63  
subunits from O. dentatum and had little effect on the levamisole-sensitive subtype. In A. 
suum, the action of tribendimidine is pharmacologically similar to that of bephenium rather 
than levamisole, leading to the conclusion that tribendimidine selectively acts on the 
bephenium-sensitive, B-nAChR subtype, not the L-subtype nAChR in Ascaris (Robertson et 
al., 2015). Robertson et al. (2015), further showed tribendimidine to cause a more potent 
inhibition of migration of O. dentatum levamisole-resistant larvae (LEVR) than levamisole-
sensitive larvae (SENS). Thus, confirming their hypothesis that unlike in C. elegans, 
tribendimidine does not act on the L-subtype nAChR in parasitic nematodes.   
A
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2.5.2 Anthelmintic resistance 
In broad terms, anthelmintic resistance is referred to as the decline in the efficacy of 
an anthelmintic drug in a population of parasites that were once susceptible to the drug. The 
repeated and improper use of currently available anthelmintics has led to the development of 
resistance in numerous veterinary parasite species worldwide, with increasing concerns that 
this this may extend to human parasites (Coles et al., 2006; Geerts & Gryseels, 2000; Geerts 
& Gryseels, 2001). Since anthelmintics within each drug class act in a similar manner, 
resistance to one anthelmintic in a given drug class is likely to be accompanied by resistance 
to other anthelmintics of that same class (side resistance). There is also the likelihood for the 
development of cross resistance from anthelmintics of one drug class to those of another, if 
the two drug classes share similar targets (Sangster, 1999). Hence, the widespread occurrence 
of resistance across the majority of anthelmintic drug classes (Tables 2.3 & 2.4). Sadly, the 
onset of anthelmintic resistance development can be rapid, thiabendazole resistance occurred 
3 years after its introduction to the market (Conway, 1964). 
Reports of resistance to anthelmintics in various parts of the world have been well-
documented (Kaplan, 2004; Kaplan & Vidyashankar, 2012; Waller, 1997). In spite of the 
numerous reports of anthelmintic resistance, the mechanisms by which resistance occurs 
remain to be fully elucidated (Table 2.3). Resistance mechanisms include: (i) mutation or 
deletion of one or more amino acids in the target genes, (ii) reduction in the number of 
receptors, (iii) decreased affinity of receptors for drugs, and (iv) absence of bioactivating 
enzymes (Gilleard, 2006; Jabbar et al., 2006; James et al., 2009; Sangster & Gill, 1999; 
Wolstenholme et al., 2004). Management practices can also delay or overcome  
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Table 2.3 Anthelmintic resistance and mechanisms of resistance to the major anthelmintic 
drug classes. (Modified from Kaplan, 2004, p. 478; Sangster & Gill, 1999, p. 141; & 
Wolstenholme et al., 2004, p. 471.) 
 
 
 
anthelmintic resistance (Shalaby, 2013). Anthelmintic resistance can be delayed or overcome 
by: (i) identifying new drug targets with different pharmacological profiles from those of 
existing drugs, (ii) introducing new anthelmintics with different modes of action from those 
of existing anthelmintics, (iii) combination therapy, with members of the combination from 
different drug classes, (iv) rotating drugs with different modes of action between dosing 
seasons, and (v) keeping some parasites in untreated refugia (Coles, 2005; Leathwick et al., 
2009; Shalaby, 2013). A detailed understanding of the biochemical and genetic basis of  
Anthelmintic class Host Year of initial 
approval
Year of first 
published 
report of
resistance
Potential mechanism of 
resistance
Benzimidazoles Mutations in β-tubulin;
Phe200Try, Phe167Try 
or Glu198Ala.Thiabendazole Sheep 1961 1964
Horse 1962 1965
Imidothiazoles-
tetrahydropyrimidines
Changes in nicotinic 
acetylcholine receptors
Levamisole Sheep 1970 1979
Pyrantel Horse 1974 1996
Avermectin-
milbemycins
Reduced sensitivity of 
GluCl/GABA receptors
Ivermectin Sheep 1981 1988
Horse 1983 2002
Moxidectin Sheep 1991 1995
Horse 1995 2003
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Table 2.4 Worldwide reports of anthelmintic resistance. (Modified from Jabbar et al., 2006, 
pp. 2415-2416) 
Species/genus of nematodes Resistant to anthelmintic Country 
O. circumcincta TBZ, LEV, Morantel Australia 
H. contortus TBZ Australia 
H. contortus BZ, Non-BZ, Organophosphorus Anthelmintics Australia 
Haemonchus, Trichostrongylus, 
Ostertagia spp. 
FEN, LEV Australia 
T. colubriformis OXF, LEV Australia 
Haemonchus, Trichostrongylus, 
Ostertagia, Nematodirus 
TBZ, LEV Australia 
Trichostrongylus, Ostertagia spp. TBZ, LEV, ALB, OXF, Morantel Australia 
H. contortus, Trichostrongylus, 
Ostertagia spp. 
TBZ, LEV Australia 
Sheep nematodes TBZ, LEV Australia 
H. contortus, T. colubriformis, O. 
circumcincta 
OXL, LEV, Closantel, Morantel Australia 
H. contortus BZ Belgium 
T. circumcincta TBZ, IVM, LEV Brazil 
O. circumcincta LEV Denmark 
Ostertagia, Trichostrongylus spp. T5BZ, LEV, IVM Denmark 
Goat nematodes BZ France 
H. contortus BZ France 
   
   
H. contortus, Trichostrongylus, 
Ostertagia spp. 
BZ, LEV France 
H. contortus BZ Germany 
Gastrointestinal nematodes TBZ, MBZ, FEN, ALB, OXF, IVM LEV, 
Febantel, Pyrantel Tartrate 
Germany 
Nematodes BZ, LEV, Morantel Greece 
Nematodes BZ Ireland 
H. contortus BZ India 
H. contortus BZ, LEV, IVM, Thiophanate, Morantel, 
Closantel 
India 
H. contortus FEN, LEV, IVM, Closantel, Morantel India 
Gastrointestinal nematodes ALB, LEV, IVM India 
H. contortus FEN, LEV, IVM, Morantel India 
Sheep and goat nematodes BZ Italy 
H. contortus Trichostrongylus spp. BZ, FEN, LEV Kenya 
Gastrointestinal nematodes BZ, LEV, IVM Kenya 
H. contortus Thiophanate, Closantel, ALB, LEV, IVM Kenya 
H. contortus, Trichostrongylus, 
Oesophagostomum spp. 
BZ, LEV, IVM, RAF Kenya 
Goat nematodes TBZ Malaysia 
H. contortus, T, colubriformis BZ, LEV, IVM, Closantel, Moxidectin Malaysia 
Trichostrongylus spp. BZ Netherlands 
H. contortus, C. curticei, Ostertagia, 
Trichostrongylus spp. 
OXF, IVM, LEV Netherlands 
H. contortus, O. circumcincta BZ, LEV, IVM Netherlands 
Sheep nematodes BZ, Non BZ New Zealand 
Cooperia oncophora OXF New Zealand 
H. contortus, Trichostrongylus spp. BZ, LEV, IVM New Zealand 
Sheep nematodes BZ, LEV, IVM New Zealand 
Trichostrongyles BZ North West Cameroon 
Sheep gastrointestinal nematodes BZ, LEV Pakistan 
H. contortus OXF Pakistan 
Sheep gastrointestinal nematodes OXF, LEV Pakistan 
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Table 2.4 (Continued) 
 
Species/genus of nematodes Resistant to anthelmintic Country 
Trichostrongylus spp. BZ Slovakia 
Ostertagia, Trichostrongylus spp. BZ, LEV, TMZ Slovakia 
H. contortus IVM, BZ, CLOST, Rafoxanide South Aftica 
H. contortus, Ostertagia, 
Trichostrongylus spp 
BZ, LEV, IVM, Closantel Southern Latin America, 
Brazil 
H. contortus Trichostrongylus, 
Oesophagostomum 
BZ, LEV, IVM South Latin America, 
Argentina 
H. contortus Trichostrongylus, 
Oesophagostomum 
BZ, LEV Southern Latin America 
H. contortus, Ostertagia spp. BZ, LEV, IVM Southern Latin America, 
Uruguay 
T. circumcincta Netobimin, BZ Spain 
H. contortus TBZ United Kingdom 
O. circumcincta TBZ United Kingdom 
H. contortus FEN, IVM United Kingdom 
H. contortus, O. circumcincta  United Kingdom 
H. contortus, O. circumcincta BZ, IVM United Kingdom 
O. circumcincta BZ United Kingdom 
Sheep nematodes BZ United Kingdom 
Sheep and goat nematodes BZ, LEV, IVM United Kingdom 
Sheep nematodes BZ, LEV, IVM United Kingdom 
H. contortus TBZ United States of America 
H. contortus, O. circumcinta TBZ United States of America 
H. contortus FEN, LEV, IVM, Pyrantel pamoate United States of America 
H. contortus BZ, LEV, FEN, RAF Zimbabwe 
C. – Cooperia; H. – Haemonchus; O. – Ostertagia, T. – Trichostrongylus; T. – Teladorsagia; BZ – Benzimidazole; MBZ – Mebendazole; 
FEN – Fenbendazole; TBZ – Thiabendazole; ALB – Albendazole; OXF = Oxfendazole; Lev = Levamisole; IVM = Ivermectin; RAF = 
Rafoxanide; TMZ = Tetramizole; CLOST = Closantel. 
 
anthelmintic action is, therefore, imperative as this will allow for the development of 
sensitive assays for early detection and, hence, more efficient management of anthelmintic 
resistance. 
2.6 Xenopus laevis oocytes heterologous expression system 
Oocytes of the South African clawed toad, Xenopus laevis, are an efficient and widely 
employed heterologous expression system for protein expression, including ion channels and 
membrane receptors (Broer, 2010; Buckingham et al., 2006; Dascal, 1987; Sigel, 1990). The 
oocytes have 6 growth stages, namely, stages I – VI, which are distinguished based on size 
and level of pigmentation (Dumont, 1972). All 6 developmental stages of the oocytes are 
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contained in the ovaries of the adult female Xenopus. These oocytes, which are usually in 
thousands, can be surgically removed after blocking hormonal stimulation such that the 
oocytes are retained in the ovaries and do not pass into the oviduct (Bossi et al., 2007; 
Theodoulou & Miller, 1995). Stages V and VI Xenopus oocytes are the largest and measure 
1.0 – 1.2 and 1.2 – 1.3 mm in diameter respectively. Stages V and VI Xenopus oocytes are 
typically used as a system for expression and electrophysiological analysis of ion channels 
and membrane receptors, although the smaller stage IV oocytes are used for studying 
currents with very fast kinetics (Bianchi & Driscoll, 2006). The oocytes have two clearly 
distinct poles; the yellow vegetal pole, and the darker animal pole, surrounded by a vitelline 
membrane and a layer of follicle cells containing ion channels which are electrically coupled 
to the oocytes through gap junctions (Figure 2.24). Therefore, the oocytes must be 
defolliculated prior to conducting electrophysiological studies to prevent recording 
endogenous current responses. Additionally, for single channel studies where the patch 
clamp technique is used, the vitelline membrane must be removed prior to recordings. This is 
because interferes with the formation of high resistance gigaseal between the patch electrode 
and the oocyte membrane (Bianchi & Driscoll, 2006; Choe & Sackin, 1997). This gigaseal is 
crucial for improving signal-to-noise ratio during patch clamp recordings. 
 During oogenesis, Xenopus oocytes accumulate massive amounts of enzymes and 
organelles which after fertilization can be used for DNA transcription and RNA translation 
(Dumont, 1972). The introduction of Xenopus oocytes as an expression system can be traced 
as far back as 1971 when John B. Gurdon observed that mRNA injected into Xenopus 
oocytes were translated to the appropriate proteins after a period of incubation (Gurdon et al., 
1971). Nevertheless, it was only in 1982 that Xenopus oocytes came to the spotlight as a 
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Source: Bossi et al., 2007, p. 124 and Bianchi & Driscoll, 2006, p. 3. 
 
Figure 2.24 Structures of Xenopus laevis oocytes showing different stages of development 
(A), annotated anatomical features (B) and cartoon representation of protein expression (C).  
 
system for the expression of membrane proteins such as nicotinic acetylcholine receptors 
(Barnard et al., 1982; Miledi et al., 1982). Subsequently, Xenopus oocytes have been greatly 
utilized for expression of nicotinic acetylcholine receptors, allowing for the characterization 
of these receptors using different electrophysiology techniques such as two-electrode voltage 
clamp and patch clamp (Papke & Smith-Maxwell, 2009; Wagner et al., 2000). The two-
electrode voltage clamp technique is usually employed for studying expressed nicotinic 
acetylcholine receptors as it is is more suitable for clamping large cells like Xenopus oocytes 
(Dascal, 2001; Guan et al., 2013). RNA or DNA is injected into the oocyte cytoplasm or 
nucleus respectively, and the injected oocytes to allow for functional protein expression. 
Cytoplasmic injection of RNA is preferred over nuclear injection of DNA because of the 
technical difficulties associated with locating the nucleus (Miller & Zhou, 2000). 
The ability of Xenopus oocytes to initiate protein synthesis, in addition to their 
abundance, large size and relative ease of manipulation make Xenopus oocytes a popular 
A B C
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heterologous expression system compared to Escherichia coli, yeast, or some eukaryotic cell 
lines (Lin-Moshier & Marchant, 2013; Markovich, 2008). For studies involving parasitic 
nematode ion channels, the Xenopus oocyte has two specific advantages; (i) 
electrophysiology requires a steady supply of viable parasites which is often problematic, and 
(ii) the Xenopus system allows expression of a single type (or subtype) of channels whereas 
in vivo recordings from nematode cells can be confounded by the presence of multiple 
channel types and subtypes. 
There are also limitations of the Xenopus oocyte expression system which should be 
taken into consideration when interpreting results and these include: (i) oocytes are not the 
native cells the proteins are normally expressed in so results may be different from those 
obtained in native cells, (ii) seasonal variations in oocyte quality and alterations in protein 
expression ability, and (iii) oocytes are temperature sensitive; they can only survive at room 
temperature (18 – 22 0C) and will deteriorate at higher temperatures (Stuhmer, 1992). 
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CHAPTER 3. PHARMACOLOGICAL PROFILE OF ASCARIS SUUM ACR-16, A 
NEW HOMOMERIC NICOTINIC ACETYLCHOLINE RECEPTOR WIDELY 
DISTRIBUTED IN ASCARIS TISSUES 
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3.1 Summary 
3.1.1 Background and Purpose 
Control of nematode parasite infections relies largely on anthelmintic drugs, several 
of which act on nicotinic ACh receptors (nAChRs), and there are concerns about the 
development of resistance. There is an urgent need for development of new compounds to 
overcome resistance and novel anthelmintic drug targets. We describe the functional 
expression and pharmacological characterization of a homomeric nAChR, ACR-16, from a 
nematode parasite. 
3.1.2 Experimental Approach 
Using RT-PCR, molecular cloning and two-electrode voltage clamp 
electrophysiology, we localized acr-16 mRNA in Ascaris suum (Asu) and then cloned and 
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expressed acr-16 cRNA in Xenopus oocytes. Sensitivity of these receptors to cholinergic 
anthelmintics and a range of nicotinic agonists was tested. 
3.1.3 Key Results 
Amino acid sequence comparison with vertebrate nAChR subunits revealed ACR-16 
to be most closely related to α7 receptors, but with some striking distinctions. acr-16 mRNA 
was recovered from Asu somatic muscle, pharynx, ovijector, head and intestine. In 
electrophysiological experiments, the existing cholinergic anthelmintic agonists (morantel, 
levamisole, methyridine, thenium, bephenium, tribendimidine and pyrantel) did not activate 
Asu-ACR-16 (except for a small response to oxantel). Other nAChR agonists: nicotine, ACh, 
cytisine, 3-bromocytisine and epibatidine, produced robust current responses which 
desensitized at a rate varying with the agonists. Unlike α7, Asu-ACR-16 was insensitive to α-
bungarotoxin and did not respond to genistein or other α7 positive allosteric modulators. Asu-
ACR-16 had lower calcium permeability than α7 receptors. 
3.1.4 Conclusions and Implications 
We suggest that ACR-16 has diverse tissue-dependent functions in nematode 
parasites and is a suitable drug target for development of novel anthelmintic compounds. 
3.2 Abbreviations 
α-BTX, α-bungarotoxin; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid tetrakis (acetoxymethyl ester); blastP, protein–protein blast; DHβE, dihydro-
β-erythroidine; DMPP, dimethyl-4-phenyllpiperazinium iodide; dTC, d-tubocurarine; GHK, 
Goldman Hodgkin Katz; MLA, methyllycaconitine; nAChR, nicotinic ACh receptor; PAM, 
positive allosteric modulator. 
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3.3 Table of Links 
Table 3.0 Key protein targets and ligands. 
 
 
3.4 Introduction 
Soil-transmitted helminths (gastrointestinal nematode parasites) cause significant 
global health problems in humans and animals. It is estimated that at least one-quarter of the 
world's human population (Brooker, 2010) and most animal species are infected with 
parasitic worms. Nematode parasite infections have a high morbidity and cause debilitating 
conditions such as weight loss, anaemia, compromised immunity, impaired learning ability 
and, in severe cases, death (Hotez et al., 2007). No current vaccine against nematode parasite 
infections of humans is effective (Hewitson and Maizels, 2014), so control of these infections 
relies on chemotherapy. Regrettably, there are a limited number of classes of anthelmintics 
(Martin, 1997; Kaminsky et al., 2008), which, with the repeated large scale use of the drugs, 
has led to the development of resistance in animals (Wolstenholme et al., 2004), and 
concerns about the development of resistance in humans (Taman and Azab, 2014). The 
increasing resistance means that novel drug targets are required to overcome this resistance. 
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Nicotinic ACh receptors (nAChRs) of vertebrates and invertebrates serve a very wide 
range of functions. For example, in excitable cells, they are involved in neuronal and 
neuromuscular transmission and, in non-excitable cells, are involved in modulation, 
development of growth and differentiation (Wessler and Kirkpatrick, 2008). Nematode 
parasite nAChRs are pharmacologically different to their host nAChRs and are validated and 
exploited anthelmintic drug targets (Gopalakrishnan et al., 2007). All nAChRs are five-
subunit ligand-gated ion channels which open in the presence of ACh or choline, and are 
found on muscles, nerves, secretory cells and a wide range of non-excitable tissues in both 
vertebrates and invertebrates. The pharmacology of individual nAChRs depends on key 
amino acid sequences of each nAChR subunit of the pentamer and the composition of the 
subunits that form the receptor. The subunits that make up vertebrate nAChRs are derived 
from at least 17 genes (α1–α10, β1–β4, γ, δ, ϵ) (Karlin, 1993; Millar and Gotti, 2009) and 
from 29 genes in the free-living nematode, Caenorhabditis elegans (Jones et al., 2007). The 
subunits of the pentameric receptor channel may be composed of five identical subunits 
(homomeric) or a mixture of different subunits (heteromeric) arranged around a central ion 
conducting pore (Chen, 2010). 
The older, cholinergic anthelmintics, levamisole and pyrantel, and the more recently 
introduced anthelmintics, tribendimidine and derquantel, activate heterogeneous pentameric 
nAChRs composed of a mixture of UNC-29, UNC-38, ACR-8 or UNC-63 subunits (Buxton 
et al., 2014). The more recently introduced cholinergic anthelmintic, monepantel, activates 
nAChRs composed of a mixture of DEG-3-like subunits, including ACR-23, ACR-20 and 
MPTL-1 (Baur et al., 2015). Resistance to some of these anthelmintics has been observed in 
animal parasites (McMahon et al., 2013; Scott et al., 2013), and although the mechanism(s) 
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of field resistance have not been well characterized, there is evidence that the resistance can 
involve altered subunit sequence or subunit truncation (Fauvin et al., 2010; Neveu et al., 
2010). 
Here, we have cloned and expressed, in Xenopus oocytes, acr-16 cRNA from Ascaris 
suum, a clade III nematode parasite, which is very similar to the significant human parasite, 
A. lumbricoides. This receptor was expressed as a homomeric receptor in Xenopus oocytes, 
and transcripts are found in muscle, intestine, reproductive tract and other tissues of the 
Ascaris body, suggesting diverse physiological functions in addition to neuromuscular 
transmission. Knowing that ACR-16 is a nicotine-sensitive nAChR and that nicotine has in 
the past been used as the drug of choice for treatment of Ascaridia galli infections (Kerr and 
Cavett, 1952), a selective drug targeted against ACR-16 could affect motility, digestion and 
reproduction of parasites and be an effective anthelmintic. 
3.5 Methods 
 3.5.1 Animals 
No vertebrate animals were used directly in the study. Adult female A. suum worms 
were collected from Marshalltown Pork Plant, Marshalltown, IA, USA. Defolliculated 
Xenopus laevis oocytes were obtained from Ecocyte Bioscience (Austin, TX, USA). 
3.5.2 Sequence analysis 
For convenience, the sources of the AChR subunits are indicated, in this article, by 
three letter prefixes. Thus, Ace, Asu, Cel, Hco, Llo, Nam, Sra, Tca and Xle, refer to 
Ancylostoma ceylanicum, Ascaris suum, Caenorhabditis elegans, Haemonchus contortus, 
Loa loa, Necator americanus, Strongyloides ratti, Toxocara canis and Xenopus laevis 
respectively. 
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Database searches around the sequence of Asu-ACR-16 were performed with the 
blast Network Service (NCBI), using the protein–protein blast (blastP) algorithm (Altschul et 
al., 1997). Signal peptide predictions were carried out using the SignalP 4.0 server (Bendtsen 
et al., 2004), and membrane-spanning regions were predicted using TMpred (Hofmann and 
Stoffel, 1993). Distance trees were generated on the full-length deduced amino acid 
sequences aligned with the MUSCLE programme (Edgar, 2004). The alignment was 
analysed using the SEAVIEW suite (Gouy et al., 2010) with the neighbour-joining method 
and bootstrapped with 1000 replicates. The resulting tree was visualized and edited using 
FigTree 1.4 (http://tree.bio.ed.ac.uk/software/figtree/). 
3.5.3 Asu-ACR-16 receptor localization 
Total RNA was extracted with TRIzol (Invitrogen™, Carlsbad, CA, USA) from 
different body tissues of five dissected adult female Asu worms. The tissues were the gut, 
ovijector, head, single muscle cells (RNA extracted via micropipette), bulk somatic muscle, 
single muscle cells of the pharynx (RNA extracted via micropipette) and bulk muscle cells of 
the pharynx. Specific primers were designed for PCR for acr-16 (forward primer 
GACTTGCAACCAGGCAAAGG; reverse primer ACGGGTCGTTATGCCCATTT) and 
gapdh (positive control) (forward primer CTGCTGGACCAATGAAGGGT; reverse primer 
CACTCCACTCACAGCCACTT) using the online Primer-blast tool. With these primer sets, 
the expected product size for acr-16 was 468 and 411 bp for gapdh. The presence or absence 
of acr-16 in the RNA samples was detected using RT-PCR and single-cell RT-PCR 
(QIAGEN OneStep RT-PCR Kit; Valencia, CA, USA) at an annealing temperature of 55°C 
and for 45 PCR cycles. The PCR products from both RT-PCR and single-cell RT-PCR were 
run on a 1% agarose gel, at the end of which the gel was viewed and captured on a UVP 
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BioSpectrum Multi Spectral Imaging System (UVP LLC, Upland, CA, USA). Representative 
bands were sequenced to confirm the identity of acr-16. 
3.5.4 cRNA preparation 
Total RNA samples were extracted with TRIzol (Invitrogen™) from a 1 cm muscle 
flap and dissected whole pharynx of Asu. RT-PCR was used to synthesize first-strand cDNA 
from muscle and pharynx total RNA with both oligo (dT) RACER primer and Random 
Hexamer, and superscript III reverse transcriptase (Invitrogen). To amplify the full-length 
coding sequence of Asu-ACR-16, specific primer pairs were designed on the putative 5′- and 
3′-UTRs mRNA sequence deduced from Asu whole genome shotgun contig 
N°AEUI02000378 (Asu-acr-16-F0 ATCACGCATTACGGTTGATG, Asu-acr-16-F1 
TTGATGTAGTGGCGTCGTGT, Asu-acr-16-R0 ATTAGCGTCCCAAGTGGTTG, Asu-
acr-16-R1 GCATTGATGTTCCCTCACCT) for a first round of PCRs. We used a classical 
nested PCR approach with F0/R0, F0/R1, F1/R0 and F1/R1 respectively to perform four 
separate PCR reactions for the first round to increase the chance of amplification success. 
These four PCR products were subsequently used as templates for a second round of four 
separate PCR reactions using the following specific primers containing HindIII and ApaI 
restriction enzyme sites (Asu-acr-16-F-
Hind3AAAAAGCTTATGAGCGTGCAGCGGGCATT, Asu-acr-16-R-ApaI 
TTTGGGCCCTAGAGTGCTGATGATGTGCTA) to facilitate directional cloning into the 
PTB-207 expression vector. PCR products were then digested with HindIII and ApaI 
restriction enzymes, purified using the NucleoSpin® Gel and PCR Clean-up kit (Macherey-
Nagel Inc. Bethlehem, PA, USA), cloned into PTB-207 as previously described (Boulin et 
al., 2011) and sequenced. A positive clone was selected and linearized with NheI for 
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subsequent in vitro transcription with the mMessage mMachine T7 transcription kit 
(Ambion). The cRNA was precipitated with lithium chloride, resuspended in RNAse-free 
water, aliquoted and stored at −80°C. 
3.5.5 Oocyte microinjection 
The Xenopus oocytes were kept at 19°C for ~3 h prior to injections in incubation 
solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2.2H20, 1 mM MgCl2.6H20, 5 mM 
HEPES, 2.5 mM Na pyruvate, 100 U·mL−1 penicillin and 100 μg·mL−1 streptomycin, 
pH 7.5). Depending on the cRNA mix, 10–25 ng of acr-16 cRNA either alone or in 
combination with 2.5–15 ng of each ancillary (ric-3, unc-50 and unc-74), in a total volume of 
50 nL in RNAse-free water, was injected into the animal pole of the oocytes using a nanoject 
II microinjector (Drummond Scientific, Broomall, PA, USA). The injected oocytes were 
transferred into 96-well culture plates containing 200 μL incubation solution per well; each 
well contained one oocyte. Oocytes were incubated at 19°C for 2–7 days to allow for 
receptor expression; incubation solution was changed daily. Oocytes with membrane 
potentials less than −15 mV were excluded from recording. Oocyte recordings that failed 
(shown by a change in the holding current following wash) before the complete series of 
drug applications were excluded from the analysis. 
3.5.6 Two-electrode voltage clamp electrophysiology (TEVC) in Xenopus oocytes 
Two-electrode voltage clamp electrophysiology was used to record currents produced 
by activation of the expressed Asu-ACR-16 receptor (Buxton et al., 2014). Four hours prior 
to recording, 100 μM BAPTA-AM (final concentration), a cell-permeant calcium chelator, 
was added to the oocyte incubation solution to prevent activation of endogenous calcium-
activated chloride channels during recordings. Recordings from non-injected oocytes served 
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as control experiments. Recordings were made using an Axoclamp 2B amplifier (Warner 
Instruments, Hamden, CT, USA) with the oocytes voltage clamped at −60 mV and data 
acquired on a computer with Clampex 9.2 (Molecular Devices, Sunnyvale, CA, USA). The 
microelectrodes used to impale the oocytes were pulled using a Flaming/Brown horizontal 
electrode puller (Model P-97; Sutter Instruments, Novato, CA, USA) set to pull 
micropipettes that when filled with 3 M KCl had a resistance of 20–30 MΩ. The 
micropipettes tips were carefully broken with a piece of tissue paper in order to achieve a 
resistance of 2–5 MΩ in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2.2H2O 
and 5 mM HEPES, pH 7.3). The low resistance pipettes allowed large currents to be passed 
to maintain adequate voltage clamp. 
3.5.7 Assessment of agonists and antagonists 
Except where indicated, agonists were used at a final concentration of 100 μM, while 
the antagonists were used at a final concentration of 10 μM for rank order potency 
experiments and 1 μM for the dose–response experiments. Effects of the positive allosteric 
modulators (PAMs): ivermectin (10 μM), genistein (3 μM) and PNU120596 (3 μM), were 
tested. Control responses were obtained first with agonists applied for 10 s. Responses were 
again observed after the antagonists or PAMs were applied for 2 min and observed in the 
continued presence of antagonist or PAM. In the case of the antagonist rank order potency 
experiments, a control application of 100 μM ACh was first applied for 10 s, immediately 
followed by a test 10 s application of antagonist in the continued presence of 100 μM ACh 
and then a final 10 s application of 100 μM ACh. Note that, with this approach, the potency 
for each antagonist is likely to be slightly underestimated due to the short time of drug 
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application. In order to minimize desensitization effects, at least 2 min was allowed for drug 
wash off between applications. 
Dose–response studies were conducted in ascending order of concentrations and were 
not presented randomly. This approach minimizes desensitization by high concentrations of 
agonist. The application of the sequence of agonists for determining the potency series was 
random and not predetermined. 
Blinding was not used because it was necessary to allow the appropriate technique 
and study methods to be used to test if the drug was a potential agonist, potential antagonist 
or potential PAM. In all our recordings, we applied an initial 100 μM ACh control, and all 
other responses were normalized to this control 100 μM ACh current. The normalized ACh 
current (100%) was not used for statistical analysis. Log dose–response plots are used for 
display and determination of the EC50, nH and maximum response. 
 3.5.8 Permeability of receptors to calcium 
Calcium permeability experiments were conducted by increasing the external Ca2+ 
concentration from 1 to 10 mM in the recording solution without changing the concentration 
of other cations. Oocytes were challenged with 30 μM ACh in the recording solution, with 
the membrane of the oocytes held at different potentials between −60 and +30 mV. The 
Goldman Hodgkin Katz (GHK) constant field equation was used to calculate the 
permeability ratio, PCa/PNa. Because the oocytes were BAPTA-treated prior to recording, the 
assumptions made in calculating the permeability ratio of the expressed Asu-ACR-16 
receptor were that the internal [Ca2+] is negligible and permeability of Na and K, PNa and PK 
is equal. Ionic activity coefficients used for the calculations were 0.56 for Ca2+ and 0.72 for 
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Na+ and K+. The GHK equation (with ionic activity inserted) used in calculating the PCa/PNa 
was: 
 
where Erev is the reversal potential (potential at which current changes direction), R is the 
universal gas constant (8.314 J·K−1·mol−1), T is room temperature in Kelvin (298 K), F is 
Faraday's constant (96 485 C·mol−1) and P′ = PCa/PNa{1/(1 + eFErev/RT)}. 
3.5.9 Data and statistical analysis 
The data and statistical analysis comply with the recommendations on experimental 
design and analysis in pharmacology (Curtis et al., 2015). The acquired data from 
electrophysiological recordings were analysed with Clampfit 9.2 (Molecular Devices, 
Sunnyvale, CA, USA) and GraphPad Prism 5.0 (Graphpad Software Inc., La Jolla, CA, 
USA). In all recordings, the peak currents in response to applied drugs were measured, and 
except where otherwise indicated, peak current values obtained were normalized to 100 μM 
ACh and expressed as mean ± SEM. Dose–response relationships were analysed by fitting 
log dose–response data points with the Hill equation as previously described (Boulin et al., 
2008), while desensitization kinetics in response to the potent agonists were fitted using a 
single exponential decay fit: 
 
where n is the number of components, A the amplitude, t the time, Ʈ the time constant and C 
the constant y-offset for each i component. 
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The group sizes varied with the type of experiment performed, as described below. 
To optimize our expression and recording conditions, we injected 10 ng of Asu-acr-16 alone 
and with 1.8 ng each of the ancillary factors, ric-3, unc-50 and unc-74 from A.suum, H. 
contortus and X.laevis (n = 21 for Asu-acr-16 alone; n = 15 for Asu-acr-16 + Hco-ric-3, Hco-
unc-50 and Hco-unc-74; n = 15 for Asu-acr-16 + Asu-ric-3, Asu-unc-50 and Asu-unc-74; 
n = 17 for Asu-acr-16 + Hco-ric-3; n = 20 for Asu-acr-16 + Xle-ric-3; and n = 23 for Asu-
acr-16 + Asu-ric-3). We found that Asu-unc-50 and Asu-unc-74 were not required for 
expression and that Asu-acr-16 + Asu-ric-3 produced the large robust currents (290.6 ± 63.7, 
n = 23). We also tested different amounts of Asu-acr-16 and Asu-ric-3 (n = 6 for 25 ng Asu-
acr-16 + 5 ng Asu-ric-3, n = 6 for 10 ng Asu-acr-16 + 5 ng Asu-ric-3, n = 6 for 10 ng Asu-
acr-16 + 10 ng Asu-ric-3 and n = 6 for 15 ng Asu-acr-16 + 15 ng Asu-ric-3) and observed 
that the size of the currents depended on the amount of Asu-acr-16 and Asu-ric-3 injected. 
Thereafter, we injected 25 ng Asu-acr-16 + 5 ng Asu-ric-3 (which produced the 
biggest currents) for all subsequent experiments. For nAChR agonists and cholinergic 
anthelmintics, we tested larger numbers of oocytes (n = 21 for nicotine, n = 21 for cytisine, 
n = 15 for 3-bromocytisine, n = 15 for epibatidine, n = 21 for DMPP, n = 36 for oxantel, 
n = 15 for choline, n = 15 for betaine, n = 15 for lobeline, n = 15 for A844606, n = 21 for 
morantel, n = 21 for levamisole, n = 15 for methyridine, n = 15 for thenium, n = 15 for 
bephenium, n = 15 for tribendimidine and n = 15 for pyrantel) to measure and examine 
variability of responses between oocytes. Once we had confirmed the reproducible nature of 
the responses (the mean and standard errors for each of the nAChR agonist and cholinergic 
anthelmintics shown in Figure 3.3), we reduced our n number to 6 for all other experiments, 
except the antagonist experiment where the n number was 5. 
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Data were analysed statistically as follows. All completed drug application sequences 
on the oocytes were used for analysis without exclusion. If the recording became unstable, 
indicated by a change in the baseline holding current, all of that recording was rejected for 
analysis. Statistical analyses were performed on groups of values using ANOVA to 
determine if the group means are similar and if there was variance inhomogeneity (Bartlett's 
test). Post hoc tests (Tukey's multiple comparison test for Figures 3.2B, 3.3 and 3.6A; 
Dunnett's test to compare with control, for Figure 3.4) were used to determine significance of 
differences between groups. We analysed the effects of PAMs on Asu-ACR-16 using two-
way ANOVA. We defined P < 0.05 as showing statistical significance. 
3.6 Materials 
The drugs used in this study, with the exception of paraherquamide, tribendimidine 
and derquantel were purchased from Sigma-Aldrich (St Louis, MO, USA), Tocris Bioscience 
(Ellisville, MO, USA) or Calbiochem (San Diego, CA, USA). The drugs were solubilized in 
recording solution, DMSO or ethanol. Paraherquamide and derquantel were gifts from Zoetis 
(Kalamazoo, MI, USA) and tribendimidine was a gift of Prof Shu Hua Xiao (National 
Institute of Parasitic Diseases, China). 
3.7 Results 
 3.7.1 Identification of Asu-ACR-16 sequence 
We used the Cel-ACR-16 sequence (Supporting Information Figure S3.0) as a query 
in a blastP search in protein databases from nematodes which allowed the identification of a 
potential complete coding sequence of an ACR-16 homologue in the pig parasite Asu 
(ERG81952.1). RT-PCR experiments using primers designed using this predicted sequence 
79 
 
led to the amplification of a full coding sequence (Figure 3.0A), which was submitted to 
GenBank under the accession number KP756901. 
When we used the Asu-acr-16 transcript sequence as a query, a blastP search resulted 
in the identification of highly conserved (complete or partial) homologous sequences from 
other parasitic nematode species belonging to Clade III (T. canis and L. loa), Clade IV (S. 
ratti) and Clade V (H. contortus, A. ceylanicum and Necator americanus) (Figure 3.0B and 
Supporting Information S3.1). The distance tree presented in Figure 3.0B indicates the 
orthologous relationship of the ACR-16 sequences from parasitic nematodes with the Cel-
ACR-16 sequence and also shows the orthologous relationship to the other nAChR subunits 
of C elegans. The predicted complete sequences corresponding to ACR-16 orthologues in 
parasitic nematodes from Clade III and V were further analysed in a structural alignment. All 
amino acid sequences were found to share typical features of nAChR subunits including a 
predicted signal peptide, four transmembrane domains, a Cys-loop motif and a cysteine 
doublet in the potential agonist site defining them as α-subunits. Of note is that, despite their 
phylogenetic separation, ACR-16 sequences from Clade III and Clade V species were found 
to be highly conserved (i.e. 80% identities between Asu-ACR-16 and Hco-ACR-16), 
suggesting that their pharmacology may also be similar. 
3.7.2 Asu-ACR-16 sequence suggests pharmacological differences to host 
mammalian α7 nAChRs 
Alignment of the Asu-ACR-16 amino acid sequence with that of human-α7 nAChRs 
using the Clustal Omega online alignment tool (Sievers et al., 2011) showed Asu-ACR-16 
and human-α7 receptors share 44.90% identity in their amino acid sequences. Figure 3.0A 
shows the amino acid sequence alignment of Asu-ACR-16, which is compared with that of 
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Figure 3.0 (A) Amino acid sequence alignment of Asu-ACR-16 and human-α7 nAChR 
subunits. The signal peptide (bright green box), ACh-binding loops A–F (pink boxes), cys-
loop (yellow box) and transmembrane regions TM1–TM4 (turquoise boxes) are indicated. 
The vicinal cysteines (black-edged box) that characterize an α-subunit are present in the C-
binding loop. The blue-edged box between TM2 and TM3 represents the region where 
PNU120596 acts on α7 nAChRs. Green arrows are residues important for positive allosteric 
modulation of α7 receptors by ivermectin. Grey (and grey outline) arrows are residues 
important for permeability of α7 receptors to Ca2+. Black (and black outline) arrows are 
residues affecting α7 receptor desensitization. Residues in C-binding loop of α7 nAChRs that 
bind α-BTX are highlighted in grey. (B) Distance tree showing relationships of ACR-16 
homologues in parasitic nematode species with AChR subunit sequences from C. elegans. A 
neighbour joining tree was generated with deduced amino acid sequence from AChR 
subunits representative from the ACR-16, ACR-8, UNC-38, UNC-29 and DEG-3 group as 
defined by Mongan et al., ([1]). Three letter prefixes in AChR subunit names: Ace, Asu, Cel, 
Hco, Llo, Nam, Sra and Tca, refer to A. ceylanicum, A. suum, C. elegans, H. contortus, L. 
loa, N. americanus, S. ratti and T. canis respectively. ACR-16 orthologues are highlighted in 
red. Numbers at each branch indicate percentage bootstrap values (>80%) corresponding to 
1000 replicates. The scale bar represents substitutions per site. The Cel-lgc-30 subunit 
sequence was used as an outgroup. 
 
human-α7 receptors (Raymond et al., 2000; Touroutine et al., 2005). Asu-ACR-16 has the 
characteristic vicinal cysteine residues (Y-x-C-C) found in the C-loop of most nAChR α-
subunits; these C-C residues play an essential role in ACh binding (Kao et al., 1984). 
Significantly, the Y-x-C-C residues of the C-loop of Asu-ACR-16 (Supporting Information 
S3.2) differ from the C-loop of the levamisole receptor α-subunits, Cel-UNC-38 and Cel-
ACR-13, which have a Y-x-x-C-C motif (Mongan et al., 1998); this C-loop difference 
encouraged our view that the Asu-ACR-16 nAChR would differ in its pharmacology from 
that of the levamisole receptors. 
We were further encouraged to investigate the pharmacology of Asu-ACR-16 because 
of other significant differences in amino acid residues which are known to affect activation, 
desensitization and modulation in α7 nAChRs. For example, Figure 3.0A shows four amino 
acids (black and black outline arrows in the TM2 region known as L247, V251, L254 and 
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L255 when mature peptide numbering of α7 subunits is used) that change the desensitization 
of α7 receptors (Revah et al., 1991; Bertrand et al., 1992; Corringer et al., 1999b). Note that 
only the first of these (L247) is conserved in Asu-ACR-16. Consequently, we chose to 
investigate the rate of desensitization of Asu-ACR-16. Other amino acid differences between 
the α7 and the levamisole α-receptor subunits, which we describe subsequently, suggest that 
the Asu-ACR-16 receptor pharmacology will be different. 
3.7.3 Ubiquitous tissue and single-cell expression of ACR-16 in Asu 
We examined the distribution of Asu-ACR-16 in dissected adult female Asu tissues 
using RT-PCR. We found reproducible and clear evidence of expression of Asu-ACR-16 
message in strips of intestine (Figure 3.1A; g, gut), sections of the reproductive tract 
(Figure 3.1A; o, oviduct, uterus), whole dissected pharynx (Figure 3.1A; p), body muscle 
strips (Figure 3.1A; m) and head (Figure 3.1A; h) region. We observed similar expression 
patterns of Asu-ACR-16 message in the gut, oviduct, whole pharynx, body muscle strip and 
head from four other adult female Asu. The expression of Asu-ACR-16 in tissues other than 
nerves and body muscle tissue, like the non-excitable tissues of the intestine and reproductive 
tract (uterus), was not anticipated. But it was reproducible and may be part of an ACh-
mediated paracrine system (Proskocil et al., 2004; Bschleipfer et al., 2007) rather than part of 
a neurotransmitter process. The Asu-ACR-16 ACh receptor may serve multiple roles in 
reproduction, digestion, etc., as well as neuromuscular transmission in the parasite. 
Single-cell RT-PCR was conducted to further investigate the localization of Asu-
ACR-16 in the pharyngeal and somatic muscle cells of A. suum. We used intracellular 
micropipettes to collect cytoplasm from individual somatic and pharyngeal muscle cells for 
PCR analysis. We recovered Asu-ACR-16 message from single body muscle cells but not 
83 
 
from pharyngeal muscle cells (Figure 3.1B). The presence of Asu-ACR-16 positive bands in 
the whole pharynx and absence in single-cell RT-PCR samples suggests that Asu-ACR-16 is 
present in the neurons of the circum-pharyngeal nerve ring but not present on pharyngeal 
muscle cells. In contrast to the pharyngeal muscle cells, we observed that Asu-ACR-16 
expression is widespread in somatic muscle as well as other tissues of the Ascaris body, 
implying tissue-related functions in addition to a neuromuscular function. 
 
 
 
Figure 3.1 Localization of Asu-ACR-16 in different body tissues of the A. suum worm using 
RT-PCR and single-cell RT-PCR (n = 5). (A) RT-PCR analysis of Asu-acr-16 (lanes 2, 4, 6, 
8, 10) and gapdh control (lanes 3, 5, 8, 9, 11) in gut (g), oviduct (o), pharynx (p), somatic 
muscle strip (m) and head region (h). The PCR products size for acr-16 and gapdh is 468 and 
411 bp respectively. (B) Single-cell RT-PCR of Asu-ACR-16 in pharyngeal muscle (2, 4, 6, 
8, 10) and in somatic muscle (1., 3., 5., 7., 9.). RT-PCR of gapdh control in pharyngeal 
muscle (3, 5, 7, 9, 11) and in somatic muscle (2., 4., 6., 8., 10.). 1, FastRuler High Range 
DNA ladder; ntc1, no-template controls for acr-16; ntc2, no-template controls for gapdh. 
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3.7.4 ric-3 is required for functional expression of Asu-ACR-16 
After we cloned Asu-ACR-16, we examined ancillary protein requirements for its 
expression in Xenopus oocytes. Figure 3.2 shows the effects of co-injecting the cRNA for the 
ancillary proteins: ric-3, unc-50 and unc-74 from A.suum; ric-3, unc-50 and unc-74 from 
H.contortus; and ric-3 from X. laevis. We measured oocyte responses to 100 μM ACh. 
Figure 3.2A shows representative traces of inward currents induced by the different 
combinations of ancillary proteins and Asu-acr-16. Figure 3.2B is a bar chart of the 
mean ± SEM of the 100 μM ACh responses. Oocytes injected with Asu-acr-16 cRNA alone 
did not respond to 100 μM ACh (n = 21). The largest currents (Imax = 290.6 ± 63.7 nA, 
n = 23) were seen in oocytes where just ric-3 from A. suum was co-injected with Asu-acr-16: 
these oocytes had larger current responses to 100 μM ACh than oocytes in which all three of 
the ancillaries (ric-3, unc-50 and unc-74 from either H. contortus or A. suum) were injected 
with Asu-acr-16. The currents were also larger than when just Hco-ric-3 was co-injected with 
Asu-acr-16, suggesting that there is a species-selective interaction between Asu-ACR-16 and 
Asu-RIC-3. Interestingly, Xle-ric-3 produced mean currents that lay between those produced 
by Ascaris and Haemonchus ric-3. We concluded that the robust expression of Asu-ACR-16 
in Xenopus oocytes requires ric-3, but not unc-50 and unc-74. 
We also varied the amount of cRNA of Asu-acr-16 (10–25 ng) and cRNA of Asu-ric-
3 (5–15 ng) injected to test the effects on expression. Supporting Information S3A, B shows 
representative current traces and bar charts of mean ± SEM of the current responses. The 
largest response (1062 ± 94.1 nA, n = 6) was obtained from oocytes injected with 25 ng Asu-
acr-16 and 5 ng Asu-ric-3. We observed that the responses were dependent on the amounts of 
Asu-acr-16 and Asc-ric-3 injected and that increased ric-3 did not overcome the effects of 
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Figure 3.2 Effects of the ancillary proteins, RIC-3, UNC-50 and UNC-74, from different 
nematode species, on Asu-ACR-16 expression. (A) Sample traces represented as inward 
currents produced in response to 100 μM ACh. (B) Bar chart (mean ± SEM) showing (left to 
right) current (in nA) generated in response to 100 μM ACh produced. Control (ctrl): Asu-
acr-16 alone (n = 21). Black bar: Asu-acr-16 plus Hco-ric-3, unc-50 and unc-74 (n = 15). 
Vertical line fill: Asu-acr-16 plus Asu ric-3, unc-50 and unc-74 (n = 15). Horizontal line fill: 
Asu-acr-16 plus Hco-ric-3 (n = 17). Checkered fill: Asu-acr-16 plus Xle-ric-3 (n = 20). No 
fill: Asu-acr-16 plus Asu-ric-3 (n = 23). Asu-acr-16 on its own did not respond to ACh, and 
the largest current size was obtained when Asu-acr-16 was co-injected with Asu-ric-3. * 
P < 0.05; significantly different as indicated; Tukey's multiple comparison tests. 
3.7.5 Asu-ACR-16 forms a nicotine-sensitive but levamisole-insensitive nAChR 
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reduced acr-16. All subsequent recordings were carried out on oocytes in which 25 ng Asu-
acr-16 was co-injected with 5 ng Asu-ric-3. 
 3.7.5 Asu-ACR-16 forms a nicotine-sensitive but levamisole-insensitive nAChR 
Figure 3.3 shows the rank order potency series for a selection of nine nicotinic 
agonists and eight cholinergic anthelmintic agonists tested on the expressed Asu-ACR-16 
nAChR. The nicotinic and anthelmintic agonists were tested at 100 μM, except for  
 
Figure 3.3 Effects of nAChR agonists and anthelmintics on Asu-ACR-16. Sample traces and 
bar chart (mean ± SEM) showing rank order potency series for nAChR agonists: nicotine 
(nic), cytisine (cyt), 3-bromocytisine (3-bc), epibatidine (epi), DMPP, choline (cho), betaine 
(bet), lobeline (lobe) and A844606; and cholinergic anthelmintics: oxantel (oxa), morantel 
(mor), levamisole (lev), methyridine (met), thenium (the), bephenium (beph), tribendimidine 
(tbd) and pyrantel (pyr); on Asu-ACR-16. Overall, the rank order potency series for agonists 
and anthelmintics on Asu-ACR-16 when normalized to the control 100 μM ACh current was 
as follows: 100 μM nic (n = 21) ~ 100 μM cyt (n = 21) ~ 100 μM 3-bc (n = 15) ~ 100 μM epi 
(n = 15) > 100 μM DMPP (n = 21) > 100 μM oxa (n = 36 ) >>> 100 μM cho 
(n = 15) = 100 μM bet (n = 15) = 100 μM lobe (n = 15) = 100 μM A844606 (n = 15) = mor 
(n = 21) = 100 μM lev (n = 21) = 100 μM met (n = 15) = 100 μM the (n = 15) = 100 μM 
beph (n = 15) = 30 μM tbd (n = 15) = 100 μM pyr (n = 15). * P < 0.05; significantly different 
as indicated; Tukey's multiple comparison tests. 
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tribendimidine, which was tested at a concentration of 30 μM due to its limited solubility. 
Representative traces of inward currents induced by each nicotinic or anthelmintic agonist 
are shown along with their mean ± SEM normalized values as bar charts. Nicotine, cytisine, 
3-bromocytisine and epibatidine were the most potent (>80% of the control ACh current), 
whereas DMPP was least potent (<20% of the control ACh current). Choline, betaine, 
lobeline and A844606 were not active on the Asu-ACR-16 nAChR. With the exception of 
oxantel, which showed a very weak agonist effect (<10% of the control ACh current), the 
Asu-ACR-16 nAChR was not activated by any of the other anthelmintic drugs tested 
(morantel, levamisole, methyridine, thenium, bephenium, tribendimidine and pyrantel). The 
rank order potency series for agonists and anthelmintics on Asu-ACR-16 when normalized to 
the internal standard control 100 μM ACh current was as follows: nicotine ~ cytisine ~ 3-
bromocytisine ~ epibatidine > DMPP > oxantel >> > choline = betaine 
= lobeline = A844606 = morantel = levamisole = 
methyridine = thenium = bephenium = tribendimidine = pyrantel. Nicotine was among the 
most potent agonists, while none of the cholinomimetic anthelmintics produced any effect, 
except for the small effect of oxantel. This agonist potency series shows that this nAChR is 
distinct from the levamisole receptors of nematodes. 
3.7.6 Asu-ACR-16 desensitization 
Desensitization was a feature of the Asu-ACR-16 receptor responses and was 
characterized by the peak and waning current responses observed during maintained (for 
10 s) agonist applications. We observed receptor desensitization with all potent agonists. The 
time constants for desensitization observed with different agonists are shown in Figure 3.4: 
the mean time constants for desensitization rates ranged between 6.2 and 12.6 s, with the  
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Figure 3.4 Asu-ACR-16 desensitization rate constant fit. Bar chart (mean ± SEM) showing 
Asu-ACR-16 desensitization in response to ACh, 3-bromocytisine (3-bc), cytisine (cyt), 
nicotine (nic) and epibatidine (epi). The rank order for Asu-ACR-16 time constants of 
desensitization was as follows: 100 μM ACh (12.6 ± 2.1 s, n = 6) ~ 100 μM 3-bc 
(11.2 ± 2.8 s, n = 6) ~ 100 μM cyt (7.3 ± 0.7 s, n = 6) ~ 100 μM nic (6.6 ± 1.0 s, 
n = 4) ~ 100 μM epi (6.2 ± 0.8 s, n = 6). Insert: Sample trace with red line signifying 
desensitization fit. * P < 0.05; significantly different as indicated; Tukey's multiple 
comparison tests. 
 
time constant for desensitization depending on the agonist and significantly higher for ACh 
than for epibatidine. However, these time constants were markedly longer than the vertebrate 
α7 receptor, which has desensitization time constants in the 230–1300 ms range (McCormack 
et al., 2010): the slower desensitization rates may be explained in part by the absence of the 
amino acids: V251, L254 and L255 in Asu-ACR-16. 
89 
 
3.7.7 Nicotine as a potent agonist 
Figure 3.5 shows representative recordings and concentration–response relationships 
of inward currents induced by the application of different concentrations of ACh 
(Figure 3.5A), top trace, and nicotine (Figure 3.5A), lower trace. The first application of an 
agonist for each new recording was always 100 μM ACh, which was used as the internal 
standard for normalization. The EC50 for nicotine (4.5 ± 0.2 μM, n = 6) was statistically 
significantly smaller than that for ACh (EC50 of 5.9 ± 0.1 μM, n = 6), which, on this basis, 
nicotine is more potent than ACh. Interestingly, there was no significant difference between 
the maximum response for nicotine (Imax of 82.5 ± 3.4%, n = 6) and that for ACh (Imax of 
82.7 ± 2.4%, n = 6). There was also no significant difference between the Hill slopes, nH, for 
 
Figure 3.5 Nicotine (nic) and ACh concentration–response relationships for Asu-ACR-16 in 
the absence of antagonists. (A) Sample traces for ACh (top trace) and nicotine (lower trace) 
dose–response relationships for Asu-ACR-16. (B) ACh and nic dose–response curves for 
Asu-ACR-16. EC50 values (mean ± SEM, μM) were 5.9 ± 0.1 for ACh, Hill slope 
(nH) = 3.9 ± 0.3, n = 6, and 4.5 ± 0.2 for nic, nH = 3.4 ± 0.2, n = 6. 
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both nicotine and ACh. However, both the nicotine and ACh concentration–response curves 
were very steep, with Hill slopes, NH, of 3.4 ± 0.2, n = 6, for nicotine and 3.9 ± 0.3, n = 6, for 
ACh, showing strong cooperativity consistent with homomeric receptors containing multiple 
ligand binding sites. 
3.7.8 Rank order antagonist potencies: Asu-ACR-16 is not sensitive to α-BTX 
We tested 10 μM concentrations of eight nAChR antagonists of mammalian or 
nematode receptors on the expressed Asu-ACR-16 nAChR. The antagonists were α-
bungarotoxin (α-BTX), dihydro-β-erythroidine (DHβE), d-tubocurarine (dTC), 
hexamethonium, mecamylamine, methyllycaconitine (MLA), derquantel, and 
paraherquamide. The mean % inhibition of the control 100 μM ACh current response 
wasused to determine the rank order potency of the antagonists. α-BTX, an α7 receptor 
selective antagonist, had little effect on the Asu-ACR-16 receptor and was the least potent 
(inhibition, 5.5 ± 0.8% n = 6) antagonist in the rank order series. In this respect, the Asu-
ACR-16 receptor was unlike the mammalian α7 nAChR. Mecamylamine, MLA and dTC 
were the most potent. The rank order of potency (Figure 3.6A) was 
mecamylamine = MLA = dTC > paraherquamide ~ derquantel ~ 
hexamethonium ~ DHβE > α-BTX. 
3.7.9 Non-competitive derquantel antagonism and mixed antagonism of dHβE 
We tested the effects of the nAChR antagonists, derquantel and DHβE on ACh 
(Figure 3.6B1). The concentration–response plots (Figure 3.6B2) show that derquantel acts 
as a non-competitive antagonist, with 1 μM derquantel producing a statistically significant 
reduction in the maximum response, but no significant change in the EC50. Imax and EC50 
values were respectively 82.7 ± 2.4% and 5.9 ± 0.1 μM, n = 6, for ACh and 63.8 ± 2.8% and  
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Figure 3.6 (A) Effects of selected nAChR antagonists on Asu-ACR-16-mediated ACh 
responses. Bar chart showing effects of selected nAChR antagonists on Asu-ACR-16. Results 
were expressed as mean (± SEM) % inhibition of currents elicited by 100 μM ACh, n = 6, for 
all antagonists. dTC, mecamylamine (mec) and MLA completely blocked Asu-ACR-16-
mediated ACh responses, while paraherquamide (para), derquantel (der), hexamethonium 
(hexa) and DHβE only produced a partial block of Asu-ACR-16-mediated ACh responses 
and α-BTX produced an almost insignificant block of Asu-ACR-16-mediated ACh responses. 
Rank order potency series for the nAChR antagonists each tested at a concentration of 10 μM 
was as follows: mecamylamine (n = 6) = MLA (n = 6) ≈ dTC (n = 6) > paraherquamide 
(n = 6) ~ derquantel (n = 6) ~ hexamethonium (hexa) (n = 6) ~ DHβE (n = 6) > α-BTX 
(n = 6). * P < 0.05; significantly different as indicated; Tukey's multiple comparison tests. 
We used ANOVA and Bartlett's test for variance inhomogeneity and found no significant 
difference and Tukey's multiple comparison tests. (B) Dose–response relationships for Asu-
ACR-16 in the presence of antagonists. (B1) Sample traces for ACh concentration–response 
relationships for Asu-ACR-16 in the presence of 1 μM derquantel and 1 μM DHβE. (B2) 
ACh concentration–response plots for Asu-ACR-16 in the presence of 1 μM derquantel and 
1 μM DHβE. Derquantel caused a reduction in the maximum response, but no change in 
EC50, whereas DHβE caused both a reduction in the maximum response and a right shift in 
the EC50. 
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6.2 ± 0.5 μM, n = 6, for derquantel. DHβE produced mixed competitive and non-competitive 
antagonism (Figure 3.6B2) characterized by a significant right shift in the EC50 and a 
statistically significant reduction of the maximum response. EC50 and Imax values were 
respectively 5.9 ± 0.1 μM and 82.7 ± 2.4%, n = 6, for ACh and 29.0 ± 1.0 μM and 
58.0 ± 3.1%, n = 6, for DHβE. These observations suggest that antagonists of this receptor 
act at more than one site that may include the agonist-binding site and/or a different allosteric 
site. 
3.7.10 PAMS of human α7 nAChRs inhibit Asu-ACR-16 responses 
Ion channel receptor opening may be increased (agonists) or decreased (competitive 
antagonists) by drugs binding to the ligand binding site, or the opening can be increased by 
PAMs or decreased by negative allosteric modulators binding to a site other than the ligand 
binding site (allosteric sites). Ivermectin and genistein are α7 receptor type 1 PAMs (Sattelle 
et al., 2009), which increase the response to a fixed concentration of an agonist by increasing 
the amplitude of the current response; PNU120596 is an α7 receptor type 2 PAM (Kalappa 
and Uteshev, 2013) whose action is characterized by both an increased amplitude of response 
and the reduction of desensitization of the current response to a fixed concentration of 
agonist. 
We were interested to see if ivermectin, genistein and PNU120596 were PAMs of the 
Asu-ACR-16. We tested the effects of ivermectin (10 μM), genistein (3 μM) and PNU120596 
(3 μM) separately on responses to 10, 30 and 100 μM ACh (Supporting Information S3.3). 
We did not observe potentiation in any experiment, but we saw modest reductions in the 
amplitudes of the responses. Figure 3.7 shows bar charts of the mean ± SEM [n = 6 
(ivermectin), n = 6 (genistein), n = 6 (PNU120596)] currents of the control and test responses  
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Figure 3.7 Effects of PAMs of human-α7 on Asu-ACR-16-mediated ACh responses. Bar 
charts showing blocking actions of human-α7 PAMs; (A) 10 μM ivermectin (n = 6), (B) 
3 μM genistein (n = 6) and (C) 3 μM PNU120596 (n = 6), on the responses of Asu-ACR-16 
to ACh. The type 1 PAMs, ivermectin and genistein, as well as the type 2 PAM, 
PNU120596, caused a reduction in Asu-ACR-16 responses to 10, 30 and 100 μM ACh, with 
the reduction being more pronounced at 10 than at 30 or 100 μM ACh. 
3.7.11 Calcium permeability of Asu-ACR-16 
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in the presence of the allosteric modulator. Two-way ANOVA showed that ivermectin, 
genistein and PNU120596 had a statistically significant inhibitory effect on Asu-ACR-16 
ACh responses. This inhibitory effect of ivermectin, genistein and PNU120596 was opposite 
to the stimulatory effect on mammalian α7 receptors (Sattelle et al., 2009). 
 3.7.11 Calcium permeability of Asu-ACR-16 
The calcium permeability of nAChRs varies and relates to the channel pore region 
formed by the TM2 domain of the subunit (Corringer et al., 1999a; Tapia et al., 2007). We 
tested the calcium permeability of the Asu-ACR-16 receptor by determining the shift in the 
reversal potential of the current–voltage (I–V) plot following a change in the concentration of 
Ca2+ in the extracellular solution (Supporting Information S3.4). Increasing the concentration 
of Ca2+ from 1 to 10 mM produced an inward rectification of the current through the Asu-
ACR-16 receptor and a small positive shift of the I–V plot of 2.4 ± 2.1 mV (n = 6). A shift of 
2.4 mV indicates relative calcium permeability (PCa/PNa) of 0.4 when calculated from the 
GHK equation. The α7 receptor is much more permeable to calcium than the Asu-ACR-16 
receptor. The PCa/PNa reported for α7 nAChRs is 20, calculated from a 29 ± 3 mV shift under 
similar conditions (Séquéla et al., 1993), which was significantly (two-tailed t-test) bigger 
than the 2.4 mV shift observed for Asu-ACR-16. 
3.8 Discussion 
This study reports for the first time the reconstitution in the Xenopus oocyte 
expression system of a fully functional homomeric nAChR, ACR-16, from a parasitic 
nematode. This finding is of significant importance in anthelmintic drug discovery in that it 
provides an efficient platform for screening anthelmintic compounds. 
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3.8.1 Comparison of pharmacology of Asu-ACR-16 with Cel-ACR-16 
Previous work on the functional reconstitution in Xenopus oocytes and 
pharmacological characterization of ACR-16 has focused on the model nematode, C. elegans 
(Ballivet et al., 1996). In agreement with Ballivet et al. (1996), Asu-ACR-16 was more 
sensitive to nicotine than ACh, but insensitive to levamisole and pyrantel. However, the Hill 
slopes for nicotine (nH = 3.4 ± 0.2, n = 6) and ACh (nH = 3.9 ± 0.3, n = 6) concentration–
response curves for Asu-ACR-16 were slightly steeper than those reported for Cel-ACR-16 
(nH = 2.2 for nicotine and nH = 2.1 for ACh). In any case, the Hill slopes for both Asu-ACR-
16 and Cel-ACR-16 reveal strong cooperativity associated with homomeric receptors. The 
steeper Hill slopes for Asu-ACR-16 may account for its higher sensitivity (as shown by EC50 
values) to nicotine and ACh when compared with those for Cel-ACR-16 (Asu-ACR-16's 
EC50 values were 4.5 ± 0.2 μM, n = 6, for nicotine and 5.9 ± 0.1 μM, n = 6, for ACh. On the 
other hand, for Cel-ACR-16, EC50 values were 12.6 μM for nicotine and 55.4 μM for ACh. 
Despite the high degree of sequence identity (74.75% identity) between Asu-ACR-16 and 
Cel-ACR-16 (Ce21), there exist significant differences in terms of the antagonist 
pharmacology of these two receptors. In accordance with Ballivet et al. (1996), Asu-ACR-16 
was nearly insensitive to α-BTX, but highly sensitive to dTC. In contrast, Asu-ACR-16 was 
highly sensitive to MLA, but moderately sensitive to hexamethonium and DHβE. 
3.8.2 Comparison of pharmacology of Asu-ACR-16 with α7 nAChRs 
Alignment of Asu-ACR-16 with human α7 nAChRs shows similarities but important 
differences in amino acid residues, suggesting differences in their pharmacologies. We 
findsimilarities in agonist sensitivity to ACh, nicotine and epibatidine of Asu-ACR-16 and α7 
receptors (Raymond et al., 2000; Li et al., 2011). However, Asu-ACR-16 was insensitive to 
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the α7-selective agonist, A844606. Asu-ACR-16 was highly sensitive to MLA just like α7 
(Briggs et al., 1995), but in contrast to the sensitivity of α7 receptors to α-BTX (Zhao et al., 
2003), we observed Asu-ACR-16 to be quite insensitive to α-BTX. The PAMs of α7 
(ivermectin, genistein and PNU120596) were inhibitory on Asu-ACR-16. Lastly, we found 
that the relative calcium permeability ratio of Asu-ACR-16 was about 50× smaller than that 
of the α7 receptor (Séquéla et al., 1993). The pharmacology of Asu-ACR-16 receptors is thus 
different to that of α7 nAChRs, indicating that the Asu-ACR-16 receptor has potential as a 
drug target site. 
3.8.3 Comparison of pharmacology of Asu-ACR-16 with levamisole receptors 
Asu-ACR-16 is different from the classical cholinergic levamisole receptor. The 
levamisole receptor subtypes are composed of different mixtures of heterologous subunits 
(UNC-29, UNC-38, ACR-8, LEV-1, ACR-13 and UNC-63) (Martin et al., 2012b), whereas 
Asu-ACR-16 consists of only one subunit (ACR-16). Unlike the levamisole receptors, which 
are sensitive to levamisole but insensitive to nicotine, Asu-ACR-16 is sensitive to nicotine 
but insensitive to levamisole. All three ancillary proteins, RIC-3, UNC-50 and UNC-74, are 
required for robust expression of levamisole-sensitive receptors (Boulin et al., 2008), while 
ACR-16 requires only RIC-3 for optimal expression in Xenopus oocytes (Sattelle et al., 
2009; Bennett et al., 2012). 
Another important difference between Asu-ACR-16 and the levamisole receptor can 
be seen in their antagonist pharmacologies. The levamisole receptor was only slightly 
inhibited by the nAChR antagonist, DHβE (Richmond and Jorgensen, 1999), whereas Asu-
ACR-16 was strongly inhibited by DHβE. MLA and hexamethonium are also less potent on 
levamisole receptors. Because the pharmacology of ACR-16 is different from the levamisole 
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receptors, a selective anthelmintic directed at ACR-16 may have the appropriate properties to 
bypass resistance. 
3.8.4 Differences in α-BTX potency, allosteric modulation and Ca2+ permeability 
Site-directed mutagenesis of nAChR subunits has been exploited as one of the tools 
in understanding the pharmacological differences between nAChR types. In a bid to provide 
reasons for the differences between the pharmacology of α7 receptors and Asu-ACR-16, we 
reviewed and compared the amino acids known to affect receptor pharmacology. In α7 for 
instance, the amino acids critical for α-BTX binding are ERFYECCKEPYPD in the C-loop 
(Balass et al., 1997). The corresponding residues in Asu-ACR-16 are EKFYDCCPEPYPD: 
the RK, ED and KP substitutions may explain why α-BTX is not as potent as an antagonist of 
the Asu-ACR-16 receptor. 
There are seven residues in α7 nAChRs important for positive allosteric modulation 
by ivermectin (Figure 3.0A, dark green arrows). Remarkably, none of these amino acids are 
conserved in Asu-ACR-16, which may explain why a positive allosteric effect of ivermectin 
for Asu-ACR-16 was not detected. Mutations in four of these residues (A225D, Q272, 
T456Y and C459) caused a significant reduction in the potency of ivermectin as a PAM, 
while mutations in the other three (S222M, M253L and S276V) caused ivermectin to act as 
an antagonist (Collins and Millar, 2010). Asu-ACR-16 contains the M253L substitution 
consistent with the observed inhibitory effect of ivermectin. Furthermore, we found that 
PNU120596 was not an allosteric modulator of Asu-ACR-16, in contrast to its action at α7 
receptors. The amino acid residues between TM2 and TM3 in α7 responsible for PNU120596 
positive allosteric modulation (AEIMPATSDS) (Bertrand et al., 2008) are replaced with 
SEISPPTSEA in Asu-ACR-16 (blue-edged box, Figure 3.0A). These differences may 
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account for the lack of positive allosteric modulation by PNU120596 in Asu-ACR-16. The 
amino acid differences in allosteric modulatory sites may allow for the design of selective 
drugs targeted at Asu-ACR-16. 
Three residues, E237, L254 and L255, play key roles in the Ca2+ permeability of α7 
nAChRs (grey and grey outline arrows, Figure 3.0A). In these receptors, mutations E237A, 
L254R/T and L255R/T/G cause a reduction in Ca2+ permeability (Bertrand et al., 1993). 
When compared with Asu-ACR-16, only one (E237) of these three residues is conserved. 
Amino acid differences at one or more positions may account for the reduction in the Ca2+ 
permeability of the Asu-ACR-16 compared with the α7 receptor. 
3.8.5 Ubiquitous distribution of Asu-ACR-16 receptor and its function 
ACR-16 has been identified as one of the proteins required for the excitatory current 
at the neuromuscular junction of C. elegans (Richmond and Jorgensen, 1999; Francis et al., 
2005). In fact, acr-16 null mutants show nearly normal motor behaviour. Severe locomotion 
deficits were, however, seen with acr-16:unc-63 or acr-16:unc-29 double mutants 
(Touroutine et al., 2005; Li et al., 2014), showing that, in combination with other subunits, 
its function was essential. 
The ubiquitous distribution of the Asu-ACR-16 message in tissues like the intestine 
and reproductive tract suggests that this receptor has functions which are not limited to 
regulation of fast neuromuscular transmission. The presence of Asu-ACR-16 in non-excitable 
tissues suggests that Asu-ACR-16 also has slower paracrine/autocrine and homeostatic or 
differentiation functions associated with digestion and reproduction (Kawashima and Fujii, 
2008). A paracrine and endocrine intestinal function for ACh is also supported by the 
presence of an organized distribution of acetylcholinesterase just beneath and adjacent to the 
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intestinal epithelium (Lee, 1996). The wide tissue distribution of Asu-ACR-16 message 
suggests that a selective agonist may have advantages as an anthelmintic. 
 3.8.6 Consideration of Asu-ACR-16 as a drug target 
Our findings show the Asu-ACR-16 receptor is pharmacologically different from 
previously characterized nAChRs and may serve as a potential target for therapeutic drug 
discovery. Given that Asu-ACR-16 shares some similarities with the mammalian α7 nAChR 
in terms of agonist pharmacology, it seems more likely that a drug directed at allosteric 
modulation sites may be more selective because the actions of α7 PAMs on the Asu-ACR-16 
receptor were clearly different from those observed on the mammalian α7 receptor. This is 
particularly of interest because in recent years, PAMs have received considerable attention as 
nAChR-targeted therapeutic agents (Williams et al., 2011). The α7 nAChR has been more 
exploited in this regard because of its implication in cognitive disorders such as Alzheimer's 
disease and schizophrenia, and drugs targeting α7 PAM sites have been suggested to have 
therapeutic potential for these disorders (Bertrand and Gopalakrishnan, 2007). Therefore, 
targeting the corresponding sites in Asu-ACR-16 may give rise to potential therapeutics 
which will not affect the mammalian host. It may therefore be possible to identify a suitable 
novel cholinergic anthelmintic which is ‘resistance busting’ if it were to activate a vital 
cholinergic receptor that was composed of different novel nAChR subunits. 
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3.13 Supporting Information 
 
 
Supporting Figure S3.0 Amino acid sequence alignment of Asu-ACR-16 and Cel-ACR-16 
nAChR subunits. The signal peptide (bright green box), ACh-binding loops A–F (pink 
boxes), cys-loop (yellow box) and transmembrane regions TM1–TM4 (turquoise boxes) are 
indicated. The vicinal cysteines (blackedged box) that characterize an α-subunit are present 
in the C-binding loop. The blue-edged box between TM2 and TM3 represents the region 
where PNU120596 acts on α7. 
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Supporting Figure S3.1 Alignment of ACR-16 sequences from Asu, Toxocara canis, Loa loa, 
Hco, Ancylostoma ceylanicum and C. elegans. Predicted signal peptide sequences are shaded 
in grey. Amino acids conserved between the different ACR-16 sequences are highlighted in 
blue. The Cys-loop, the four transmembrane regions (TM1–TM4) and the primary agonist 
binding site are noted above the sequence. 
  
103 
 
 
 
Supporting Figure S3.2 Effects of varied amounts of Asu-acr-16 and Asu-ric-3 on Asu-ACR-
16 expression. (A) Sample traces represented as inward currents produced in response to 100 
μM ACh. (B) Bar chart (mean ± SEM) showing current sizes produced by 25 ng Asu-acr-16 
and 5 ng Asu-ric-3 (1062 ± 94.1, n = 6), 10 ng Asu-acr-16 and 5 ng Asu-ric-3 (848.8 ± 155.4, 
n = 6), 10 ng Asu-acr-16 and 10 ng Asu-ric-3 (727.3 ± 63.1, n = 6); 15 ng Asu-acr-16 and 15 
ng Asu-ric-3 (602.8 ± 106.8, n = 6) in response to 100 μM ACh. * P < 0.05, Tukey's multiple 
comparison tests. 
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Supporting Figure S3.3 Sample traces showing the effects of PAMs of α7; (A) 10 μM 
ivermectin, (B) 3 μM genistein and (C) 3 μM PNU120596, on Asu-ACR-16-mediated ACh 
responses. 
 
 
Supporting Figure S3.4 Calcium permeability of Asu-ACR-16 with 30 μM ACh currents: 
representative I–V plot for oocytes expressing Asu-ACR-16, showing current change with 
voltage in 1 mM (black line) and 10 mM (red line) Ca2+ recording solutions. I–V relationship 
was plotted using a cubic polynomial equation and interpolated to measure the Erev. The 
mean ± SEM for the positive shift of the I–V plot for six observations was 2.4 ± 2.1mV, and 
this corresponded to a relative calcium permeability ratio of 0.4. Insert: magnified view of 
the I–V fitted line from -10 to 10 mV, showing the Erev in 1 and 10 mM Ca2+. 
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4.1 Abstract 
Currently approved drugs for treatment of onchocerciasis and lymphatic filariasis; 
ivermectin, diethylcarbamazine (DEC) and albendazole, are only effective against the 
microfilariae (mfs), with little or no effect on adult worms (macrofilariae). Effective control 
is therefore hindered by the lack of macrofilaricides, leaving the adult worms, which may 
live for over 15 years to continue to produce mfs and exacerbate the disease symptoms. 
Additionally, the repeated use of ivermectin, DEC and albendazole has generated concerns of 
resistance development. Clearly, there is the need for the development of new drugs that will 
be effective against the adult worms, while more effective microfilaricidal compounds are 
also desirable. To contribute to the search for new antifilarial drugs, we screened extracts and 
chromatographic fractions of the plants; Daniellia oliveri and Psorospermum febrifugum for 
activity against O. ochengi mfs and against both adult O. ochengi and B. pahangi. We found 
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crude extracts of D. oliveri to be effective in killing adult O. ochengi and B. pahangi based 
on the MTT/formazan assay and the Worminator system. Additionally, some extracts of D. 
oliveri and P. febrifugum were also active on O. ochengi microfilariae based on motility 
reduction. Results from our three assay systems identified D. oliveri hexane bark (DOBHEX), 
dichloromethane stem bark (DOBDCM) and dichloromethane leaf (DOLDCM) as active in all 
three assay systems. The activity and lack of cytotoxicity for these extracts encouraged us to 
select them for bioassay-guided fractionation. Importantly, DOBHEX IC50 for adult O. ochengi 
was about 12x smaller than that for the mfs, which is desirable in cases of co-endemicity 
with Loa loa due to severe adverse reactions associated with L. loa mf death. Furthermore, B. 
pahangi activity was retained in some of the Sep-Pak and HPLC fractions, although our 
results also suggest the possibility of compounds acting in synergy which may be present in 2 
or more HPLC fractions. We conclude therefore that D. oliveri has potential as a natural 
plant source for the discovery and development of suitable macrofilaricides and that there is 
some validity in its traditional use.    
4.2 Author Summary 
Human onchocerciasis and lymphatic filariasis are classified by the WHO as 
“Neglected Tropical Diseases” (NTDs), and have the highest disease burdens of the filarial 
infections, affecting over 150 million people worldwide and placing a billion people at risk. 
Current control of these infections is limited to the use of antifilarial drugs which are only 
microfilaricidal. Effective control is therefore hindered by the lack of adulticides 
(macrofilarides), the adult worms can live for over 15 years in humans continuing to 
exacerbate symptoms of the disease and reproduce. Clearly, macrofilarides are needed, while 
more efficacious and safer microfilaricides are also desirable. In this study, we used the 
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MTT/formazan assay and the Worminator system to screen plant extracts and 
chromatographic fractions for activity against O. ochengi microfilariae and adults, the best-
known laboratory model for O. volvulus, and against adult Brugia pahangi as a model for 
human lymphatic filariasis-causing species. 
4.3 Introduction 
Subcutaneous filariasis, otherwise known as onchocerciasis or river blindness, and 
lymphatic filariasis (LF), commonly known as elephantiasis, are debilitating diseases of the 
poor. They are among the diseases currently classified by the World Health Organization as 
“Neglected Tropical Diseases” (NTDs) (Hotez et al., 2007). Onchocerciasis is caused by the 
filarial nematode, Onchocerca volvulus, and transmitted by the bite of the blackfly, Simulium 
damnosum (Winthrop et al., 2011). Approximately 37 million people globally suffer from 
onchocerciasis, the majority of which are in Africa where >100 million people are at high 
risk of infection (Gustavsen et al., 2011). Onchocerciasis is the world’s second leading 
infectious cause of blindness, after trachoma. In Africa, hyper endemic villages can have 
significantly higher infection rates, where >10% of an entire village may be blind (Boatin & 
Richards, 2006). Additionally, onchocerciasis presents a spectrum of other debilitating 
pathologies which include grave and unbearable itching, disfiguring dermatitis, and 
depigmentation (Enk, 2006). LF is caused by the filarial nematode parasites Brugia malayi, 
B. timori, and Wuchereria bancrofti, and is transmitted by a variety of mosquitoes 
(Anopheles spp, Culex spp, Aedes spp, Mansonia spp) depending on the geographical area 
(de Souza et al., 2012). Disease manifestations include painful and profound disfigurement 
of the skin (particularly of the lower portion of the body), lymphedema, elephantiasis and 
scrotal swelling which may eventually lead to permanent disability. LF is the second leading 
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cause of chronic disability worldwide, after mental illness. Over 1.2 billion people are 
threatened by LF, with ≥120 million people infected, and ~40 million people disfigured or 
incapacitated by the disease (Ottesen et al., 1997). Hence, individuals infected with either 
onchocerciasis and/or LF not only suffer physical disability, but also suffer mental, social 
and economic losses, resulting in depression, stigma and poverty (Hotez et al., 2006; Weiss, 
2008). 
Current control of onchocerciasis and LF relies on mass drug administration of 
ivermectin, DEC and albendazole (Gyapong et al., 2005; Liang et al., 2008; Richard-Lenoble 
et al., 2003). However, these drugs are only effective against the juvenile worms 
(microfilariae) or larval stage of the parasites, with limited activity against the adults. This 
leaves the adult worms to continue to produce microfilariae and exacerbate the disease 
symptoms. Effective control of onchocerciasis and LF is therefore hindered by the lack of 
adulticides (macrofilaricides). There also exist other factors such as poor compliance, and 
poor safety, which limit the use of these drugs. Despite ≥15 years of mass treatment with 
ivermectin, in some parts of Africa (e.g North and West Regions of Cameroon) transmission 
of onchocerciasis has still not been interrupted (Katabarwa et al., 2013; Katabarwa et al., 
2011). Additionally, the emergence of ivermectin resistance in parasites of veterinary 
importance has generated concern that resistance will eventually extend to O. volvulus 
(Felippelli et al., 2014; Lustigman & McCarter, 2007). Current treatment also poses life-
threatening side effects in onchocerciasis and LF patients who are co-infected with Loa loa. 
Co-infection with high levels of L. loa microfilariae present can cause serious adverse 
reactions including encephalopathy (brain damage), kidney failure, and even death (Awadzi, 
2003; Boussinesq & Gardon, 1997; Boussinesq et al., 2003; Gardon et al., 1997). These 
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adverse reactions are attributed to the sudden killing of the very large microfilariae 
population. DEC is further contraindicated in onchocerciasis patients due to the likelihood of 
severe reactions involving the skin and eye (Molyneux et al., 2003). Therefore, there is a 
pressing need for new and safer filaricidal compounds for more effective control or 
eradication of onchocerciasis and LF. 
Historically, plants have been important sources of therapeutic compounds 
(Farnsworth, 1990; Farnsworth et al., 1985). For instance, Papaver somniferum (the opium 
poppy) is the source of morphine (Vallejo et al., 2011); Cinchona officinalis is the source for 
the antimalarial medication, quinine; artemisinin which is also used for treatment of malaria 
was isolated from Artemisia annua (sweet wormwood) (Willcox, 2009); and Digitalis lanata 
(foxglove) is the source for digoxin used in treatment of congestive heart failure (Hollman, 
1996). Plants as traditional medicine have been identified to play an important role in the 
remedy of diseases (Martkoplishvili & Kvavadze, 2015). About 70-80% of the population in 
developing countries rely on traditional medicine for their health needs (Wachtel-Galor & 
Benzie, 2011). Nevertheless, use of traditional medicine has evolved over the years and is no 
longer limited to developing countries. Interest in natural therapy has greatly increased in 
developed countries like the United States, with an increased interest in some forms of 
traditional medicine like herbal, dietary or nutritional supplements (Harrison et al., 2004; 
Qato et al., 2008). Literature on the antifilarial activities of plant extracts and 
chromatographic fractions of medicinal plants implies plant natural products may serve as 
sources of lead compounds for the development of new and safe filaricides (Cho-Ngwa et al., 
2010; Ndjonka et al., 2011; Samje et al., 2014). 
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Daniellia oliveri (DO) and Psorospermum febrifugum (PF) are among the plants 
commonly used for the traditional treatment of onchocerciasis and LF in Bambui, North 
West Cameroon. Bambui is a village located in the highlands of the North West Region of 
Cameroon where the vegetation is predominantly of the forest savannah type. This area has 
many fast-flowing streams, providing a good breeding site for blackfly and mosquito species 
and thus transmission of arthropod-borne infections including onchocerciasis and LF. 
D. oliveri (family Caesalpiniaceae) is a deciduous, medium-sized flowery tree that 
can reach up to 25 – 35 m tall. The plant predominantly grows in the forest areas of West and 
Central Africa. The genus Daniellia comprises of 10 species, with only D. oliveri extending 
to Sudan and Uganda. D. oliveri, locally known as ‘kahi’ in Bambui, NW Cameroon is 
traditionally used for the treatment of all worm infections including onchocerciasis and 
lymphatic filariasis and is also used for treating stomach upset. It is administered as a 
decoction of the stem bark, prepared by boiling and drinking one cup twice daily. 
P. febrifugum (family Hypericaceae) is a flowering shrub or tree that can reach 4 m 
tall. The plant is generally widespread in tropical Africa, predominantly in the savanna from 
Guinea to West Cameroon. P. febrifugum is locally known as ‘sawayki’ in Bambui, NW 
Cameroon where it is traditionally used to treat onchocerciasis and rashes of any sort. It is 
prepared and administered just like D. oliveri except that the decoction is also bathed with 
and the oily supernatant applied as body lotion.     
Treatment of onchocerciasis and LF is greatly hampered by the lack of 
macrofilaricides, new and safer microfilaricides to replace or complement currently available 
filaricidal drugs are needed. Despite the claimed efficacy of D. oliveri and P. febrifugum in 
the traditional treatment of onchocerciasis and LF, no scientific evidence for this claim has 
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been demonstrated. The overall aim of our study was to screen extracts and chromatographic 
fractions of D. oliveri and P. febrifugum for activity against adult Onchorcerca sp and Brugia 
sp as a way of contributing to the search for suitable macrofilaricides. We also screened plant 
extracts for microfilaricidal activity. For this study, we used O. ochengi as a model for the 
human equivalent, O. volvulus for screening for Onchocerca activity. B. pahangi was used 
for screening for LF activity because it is a suitable laboratory model organism for B. malayi 
(Bulman et al., 2015). 
4.4 Materials and Methods 
4.4.1 Collection and identification of plants 
Plants were collected from Bambui in Tubah Sub-Division, North West Cameroon 
based on ethnopharmacological information (Figure 4.0A: Daniellia oliveri; Figure 4.0B: 
Psorospermum febrifugum). Voucher specimens of all plants harvested were prepared and 
taken to the National Herbarium, Yaounde, Cameroon for expert identification. The plants 
and parts used for this study and other valuable information can be seen in Table 4.0. 
 
 
Figure 4.0 Pictures of Daniellia oliveri (A) and Psorospermum febrifugum (B). 
A B 
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Table 4.0 Classification and traditional uses of plants screened. 
 
 
4.4.2 Preparation of plants extracts 
The plant parts collected were air-dried in Bambui to eliminate moisture before 
transporting them to the University of Buea. They were further dried in an oven (40 oC) for 2 
days, and ground to fine powder using an electric blender or a grinding mill. The resultant 
powders were weighed and put in labeled receptacles. Powders were then sequentially 
macerated with HPLC grade hexane (HEX), dichloromethane (DCM) and methanol (MeOH), 
with the plant material always fully submerged in solvent. For each solvent, the slurry was 
allowed to stand closed at room temperature for 48 hours to prevent the solvent from 
evaporating and then filtered using Whatmann No. 1 filter paper. Extracts were concentrated 
under reduced pressure on a rotary evaporator (BUCHI Rotavapor R-200, Switzerland). The 
concentrated extracts were transferred into labeled vials and residual solvent evaporated at 
Family Scientific 
Name
Common 
Name
Traditional uses Preparation and 
administration
Plant parts 
used
Code 
adopted
Caesalpiniaceae Daniellia
oliveri
Kahi Treatment of all worm 
infections including river 
blindness, lymphatic 
filariasis, as well as 
stomach upset
Bark boiled and 
decoction drunk one cup 
x2/day
Leaves (L) and 
stem bark (B)
DO
Hypericaceae Psorospermum 
febrifugum
Sawayki Treatment of 
onchocerciasis and rashes 
of any sort
Bark boiled and 
decoction drunk one cup 
x2/day. Decoction also 
bathed with. Oily 
supernatant applied as 
body lotion
Leaves (L) and 
stem bark (B)
PF
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ambient temperature. Once all residual solvent had evaporated, the resultant crude extracts 
were weighed, and their respective percentage (%) yield determined as shown in Table 4.1. 
The % yield for each plant extract was calculated using the formula: 
% 𝑦𝑖𝑒𝑙𝑑 = (𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑑𝑒 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 ÷ 𝐷𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑙𝑎𝑛𝑡 𝑝𝑎𝑟𝑡) × 100 
The vials were then sealed and stored at –20 oC or –80 oC. 
 
Table 4.1 Percent (%) yield of plant extracts. 
 
 
4.4.3 Onchocerca ochengi adult worm assay 
Viable O. ochengi adult worm masses were extracted from cattle skin as previously 
described (Cho-Ngwa et al., 2010). Fresh pieces of umbilical cattle skin containing palpable 
nodules were obtained from the slaughterhouse in Douala, Cameroon and immediately 
transported to the laboratory. The skin was thoroughly washed 2x with soap and distilled 
water, drained and transferred to a sterile laminar flow hood where it was entirely covered 
Plant Dry weight (Wt) 
of plant part (g)
Hexane
(HEX) 
Dichloromethane (DCM) Methanol
(MeOH)
Wt (g) % yield Wt (g) % yield Wt (g) % yield
Daniella 
oliveri
750.0
(leaves)
17 2.3 12 1.6 16.8 2.2
500.0
(stem bark)
4.6 0.9 4.3 0.9 52.3 10.5 
Psorospermum
febrifugum
600.0
(leaves)
3.0 0.5 10.9 1.8 51.4 8.6
300.0
(stem bark)
21.7 7.2 48.1 16.0 120.2 40.1
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with 70% ethanol and allowed to evaporate completely (Figure 4.1: Left). Adult worm 
masses, which are generally pale orange-yellow in appearance, were extracted from the 
nodules by careful dissection with a sterile blade (Figure 4.1: Right). Individual worm masses 
were immediately submerged in sterile 24-well culture plates containing 1 ml of complete 
culture medium (CCM) [RPMI-1640 supplemented with 25 mM HEPES, 2.0 g/L sodium 
bicarbonate, 20 mM L-glutamine, 10% new born calf serum (SIGMA, USA), 200 units/ml 
penicillin, 200 μg/ml streptomycin and 2.5 μg/ml amphotericin B (Sigma, USA)], pH 7.4] 
per well. Worm masses were incubated at 37 oC, 5% CO2 supplemented humidified air 
(HERACell 150, Haraeus, Germany) overnight. Viability of the extracted adult worms was 
ascertained by microscopic examination using an inverted microscope (Euromex, Holland). 
Dead and damaged worms were discarded, and only viable worms were retained for our 
assays. 
For the O. ochengi adult worm assay, a stock solution of 25 mg/ml of the plant 
extracts was prepared by dissolving 25 mg of the plant extract in 1 ml of ≥99.9% dimethyl 
sulfoxide (DMSO). The extracts were tested in triplicate at an initial single concentration of 
500 µg/ml by adding 40 µl of extract stock in 1 ml of CCM to each well of a 24-well plate 
 
 
Figure 4.1 Onchocerca ochengi nodular masses. Left: Inner surface of infected cattle skin 
revealing nodules. Right: Extracted nodular worm masses. 
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already containing one worm in 1 ml CCM. Extracts that showed no activity at this 
concentration were not investigated further. 1% DMSO (the highest concentration of used in 
our assays) served as the negative control, while 10 µM auranofin served as positive control. 
Macrofilariae cultures were incubated at 37 oC, 5% CO2 in humidified air for 5 days (120 
hours), without any change of CCM. After incubation, adult worm viability was assessed 
using the MTT/formazan assay (Comley et al., 1989). Each nodular worm mass was placed 
in a well of a 48-well plate containing 500 µl of 0.5 mg/ml MTT (Sigma-Aldrich) in 
incomplete culture medium (CCM without serum). The plates were then incubated in the 
dark at 37 oC for 30 mins, after which individual worms were blotted on tissue paper and 
transferred to a clean white sheet of paper (Figure 4.2). % inhibition of purple color formazan 
formation relative to the negative control was then visually estimated. Mean % inhibition of 
purple color formazan formation relative to the negative control worm masses correlates with  
 
 
Figure 4.2 Illustration of the MTT/formazan assay for an active extract (Daniellia oliveri 
dichloromethane stem bark extract, DOBDCM). Each extract concentration was tested in 
triplicate. DOBDCM caused a 100% inhibition of purple formazan formation (which correlates 
with worm death) from 500 µg/ml down to 31.3 µg/ml.  
500 µg/ml
250 µg/ml
125 µg/ml
62.5 µg/ml
31.3 µg/ml
15.6 µg/ml
+ve control (10 µM auranofin)
-ve control (DMSO)
DOBDCM
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worm death. Extracts that showed 100% inhibition of formazan were considered active and 
further tested at 6 concentrations from 500 µg/ml to 15.6 µg/ml to determine their IC50 
values. 
4.4.4 Onchocerca ochengi microfilaria (mf) assay 
Extraction of O. ochengi mfs followed the method of Cho-Ngwa et al. (2010) with 
slight modification. Infected cattle skin was obtained, cleaned and sterilized as described in 
section 4.4.3. Using autoclaved thumbtacks, the skin was tightly attached to a wooden board 
whose surface had been covered with 70% ethanol with the outer surface of the skin was 
facing up (Figure 4.3: Left). The outer surface was shaved with a sterile blade, and then 
rinsed twice with distilled water. Excess moisture from the skin was removed with a clean 
dry cloth. The entire skin was covered with 70% ethanol and then evaporated in a laminar 
flow hood. Skin snips approximately 0.5 – 1 mm apart were obtained. Individual skin snips 
were submerged in 20 ml of CCM and incubated at room temperature for 2 hours to allow for 
emergence of mfs. Emerged mfs were concentrated by centrifugation at 400 xg for 10 
minutes. The supernatant was discarded and the pelleted mfs were resuspended in fresh 
CCM, and the highly motile mfs quantified with the aid of an inverted microscope (Euromex, 
Holland) (Figure 4.3: Right). Mfs were distributed into 96-well culture plate to obtain an 
average of 10-15 mfs per well (final volume 100 µl). 
 Fully confluent monkey kidney epithelial cells (LLC-MK2) obtained from American 
Type Culture Collection (ATCC, Virginia, USA) served as a feeder layer for the mf assays. 
The cultures were maintained under the same conditions as described for the adult worm 
assay. Extracts were tested in duplicate at 8 different serially diluted concentrations from 250 
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Figure 4.3 Onchocerca ochengi microfilariae. Left: Outer surface of infected cattle skin for 
extraction of skin snips. Right: Extracted microfilariae observed under the microscope.  
 
µg/ml to 1.95 µg/ml. 100 µl of 2x the concentration of each serial dilution was added to 
corresponding wells of plates already containing 100 µl of mfs to give a total volume of 200 
µl, and a final 1x concentration. 1% DMSO was used as negative control while 10 µg/ml 
ivermectin served as positive control. Mf viability was assessed by microscopic examination 
for mean motility scoring (relative to the positive control) every 24 hours post addition of 
drug for 120 hours. The scale used for motility scoring ranged from 0 – 100% (100% for 
complete inhibition, 75% for only head or tail moving, 50% for entire worm moving 
sluggishly, 25% for little change in motility, 0% for no inhibition). 10 µg/ml ivermectin 
produced 100% inhibition of mf motility by day 5. An extract was considered active if it 
produced 100% inhibition of mf motility ≤250 µg/ml. The serial dilutions also allowed for 
the determination of the IC50 values of the active extracts. 
4.4.5 Brugia pahangi adult worm assay 
The B. pahangi assays were carried out using the Worminator motility tracking 
system described by Marcellino et al. (2012). Adult female B. pahangi were shipped from 
University of Missouri-Columbia (UMC, Columbia, MO) or the NIAID/NIH Filariasis 
Research Reagent Resource Center (FR3) (Athens, GA) in 24-well plates or 50 ml falcon 
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tubes containing media (RPMI-1640 with 25 mM HEPES, 2.0 g/L NaHCO3, 5% heat 
inactivated FBS, and 1X Antibiotic/Antimycotic solution), with 1 worm per well or 80 
worms per falcon tube. Individual worms were carefully transferred into fresh 24-well plates 
containing 500 µl/well fresh media. Worms were observed under an inverted microscope to 
ascertain viability. Damaged or sluggish worms were discarded, and only highly motile 
worms were retained for assays. A stock extract or chromatographic fraction concentration of 
30 mg/ml in DMSO was prepared and tested in quadruplicate at an initial working 
concentration of 300 µg/ml. The negative control wells had 1% DMSO and positive control 
wells had 10 µM auranofin. Worms were cultured in a 5% CO2 incubator at 37 
oC for 72 
hours (3 days) post drug addition. 
The Worminator was used to record videos of each worm plate for approximately 60 
seconds, and mean motility units (MMUs) (number of pixels displayed per second) 
determined for each worm (Marcellino et al., 2012). Videos were recorded at time 0, 4, 24, 
48 & 72 hours post drug exposure. % inhibition of motility was calculated by dividing 
MMUs of test worms by the average MMUs of the controls, multiplying the value by 100, 
and subtracting from 100. Extracts which showed ≥95% inhibition of motility or 
chromatographic fractions which showed ≥75% inhibition of motility were considered active 
and further screened under the same conditions at 6 concentrations (300, 100, 30, 10, 3 and 1 
µg/ml) to determine IC50 values. 
4.4.6 Bioassay-guided fractionation of plant extracts 
Bioassay-guided fractionation was done on the most active plant extracts based on 
IC50 values using Sep-Pak cartridges (Waters corporation, MA, USA), followed by semi-
preparative High Performance Liquid Chromatography (HPLC). 
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Sep-Pak Silica Plus cartridges were used for non-polar (hexane) extracts. Elution was 
achieved with a step gradient of hexane and isopropanol mixture (100:0, 100:0, 90:10, 50:50, 
10:90), and a final elution with 100% chloroform (CHCl3) or dichloromethane (DCM). For 
dichloromethane extracts whose polarity is midway that of hexane and methanol, we carried 
out an additional fractionation using Sep-Pak C-18 Plus cartridges. Here, elution was 
achieved with a step gradient of methanol and water mixture (20:80, 20:80, 40:60, 80:20, 
100:0) For both cartridges, the ratio of extracts to solvent system was always 2:1, which was 
achieved by re-suspending 10 mg of extract in 5 ml of the appropriate solvent system. The 
resulting Sep-Pak fractions generated were separately concentrated using in-house air at a 
maximum temperature of 40 oC. 
Active Sep-Pak fractions were selected for further fractionation using a Hewlett 
Packard 1050 Series HPLC System coupled with a Hewlett Packard/Agilent 1050 Diode 
Array Detector (DAD)/Multiple Wavelength UV Detector (MWD) and silica (straight phase) 
semi-preparative column (SUPELCOSIL LC-SI SEMI-PREP, 25 cm x 10 mm, 5 µm; 
Catalog No. 58365). Elution was performed with a 100 – 0% gradient of 99.6% hexane in 
0.4% isopropanol (solvent A) and a 0 – 100% gradient of 50% hexane in 50% isopropanol 
(solvent B) during 30 mins, with an additional 5 mins collection of the eluent, at a flow rate 
of 4 ml/min to produce 7 subfractions (F1 – F7), collected over 5 min intervals. Detection 
was accomplished in a Hewlett Packard 1050 Series HPLC System coupled with a Hewlett 
Packard/Agilent 1050 Diode Array Detector (DAD)/Multiple Wavelength UV Detector 
(MWD) at 220, 264 and 320 nm. 
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4.4.7 Cytotoxicity on N27 cells using the MTS assay 
Cytotoxicity of active extracts on N27 cells, an immortalized rat mesencephalic 
neuronal cell line was assessed using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay (Cory et al., 
1991). The MTS assay is a colorimetric method for assessing the viability of cells in 
proliferation or cytotoxicity assays, and is based on the ability of the mitochondria of viable 
cells to biologically reduce the pale-yellow MTS compound to a purple formazan product. 
The resulting formazan product formed is quantified by colorimetry, and the quantity of 
formazan formed is directly proportional to the amount of viable cells in culture. 
For our cytotoxicity studies, N27 cells were seeded in 96-well culture plates 5,000 
cells/100 µl of RPMI growth media (RPMI-1640 medium containing 10% fetal bovine 
serum, 2 mM L-glutamine, 50 units penicillin, and 50 µgml streptomycin). Treatment with 
active extracts followed once the cells had achieved 40 – 50% confluence. All treatments 
were performed in sextuplicate. 30 µM H2O2 served as positive control, while the negative 
control had cells and growth media containing 1% DMSO. After plating, cells were 
incubated at 37 oC, 5% CO2 in humidified air (Forma Scientific CO2 water jacketed 
incubator) for 24 hours. At the end of the incubation, 10 µl of MTS reagent (CellTiter 96® 
Aqueous One Solution Reagent, Promega G3580) was added to each well and mixed. The 
plates were then covered with aluminium foil and incubated at 37 oC, 5% CO2 in humidified 
air (Forma Scientific CO2 water jacketed incubator) for 90 mins. The plates were then read at 
490 nm and 670 nm using a SpectraMax M2e reader (Molecular Devices, USA). Cell 
viability was assessed as (Abs490-670nm) for the extracts and H2O2 treated cells relative to the 
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untreated controls. SI values were then calculated by mean IC50 N27 cell/mean IC50 parasite. 
Extracts with SI values >1 are more selective for parasites than N27 cells. 
4.4.8 Data analysis 
Results obtained for biological activity and cytotoxicity assays were analyzed using 
GraphPad Prism 5.0 or 6.0 software (Molecular Devices, USA), and expressed as mean ± 
S.E.M. Statistical analysis for the cytotoxicity assay was done using unpaired student t-test. 
A p-value < 0.05 was considered significant. 
4.4.9 Phytochemical screening 
Concentrated crude extract residues were used to detect the presence of the secondary 
plant metabolites; alkaloids, steroids, flavonoids, saponins, tannins, coumarins and cardiac 
glycosides using standard methods with some modifications (Schiff, 1980). 
4.4.9.1 Test for saponins (Frothing test).  Briefly, saponins were tested by 
dissolving 0.5 g of the crude extract in a test tube containing 3 ml of distilled hot water, 
followed by vigorous shaking for 1 minute. The observation of persistent foaming indicated 
the presence of saponins. 
4.4.9.2 Test for flavonoids (Cyanidin test).  0.5 g of crude extract was dissolved in 
~3 ml methanol plus 2 ml of concentrated hydrochloric acid. ~0.1 g of magnesium turnings 
was then added to the mixture. A brick red coloration with effervescence indicated the 
presence of flavonoids. 
4.4.9.3 Test for steroids (Liebermann-Burchard test).  0.5 g of crude extract was 
dissolved in 5 ml dichloromethane, then 0.5 ml of acetic anhydride was added, followed by 
three drops of concentrated sulphuric acid. Observation of a blue-green coloration indicated 
the presence of steroids. 
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4.4.9.4 Test for tannins (Ferric chloride test).  0.5 g of crude extract was dissolved 
in a boiling tube containing 20 ml distilled water and boiled for an hour. 3 – 4 drops of ferric 
chloride were added and allowed to stand for ~15 minutes. A blue-black coloration indicated 
a positive test for tannins. 
4.4.9.5 Test for Alkaloids (Dragendorff’s test).  The sample (~0.5 g) was dissolved 
in about 3 ml of dichloromethane and then spotted on a thin layer chromatographic plate 
which was developed in 20% hexane in ethylacetate. The presence of alkaloids in the 
developed chromatogram was detected by spraying with freshly prepared Dragendorff’s 
reagent in a fume chamber. A positive reaction on the chromatogram was indicated by an 
orange or darker colored spot against a yellow background, confirming the presence of 
alkaloids. 
4.4.9.6 Test for coumarins.  To 2 ml of the crude extract was added 1 ml of 
ammonium hydroxide. One drop was spotted on filter paper and observed under a UV lamp 
for the presence of blue or green fluorescence, indicating the presence of coumarins. 
4.4.9.7 Test for cardiac glycosides.  Approximately 1 ml of aqueous extract of the 
plants was added to 2 ml of glacial acetic acid plus one drop of ferric chloride. 1 ml of 
concentrated sulfuric acid was then added. The appearance of violet and brownish rings 
below the interface, followed by the formation of a greenish ring in the acetic acid layer 
confirmed the presence of cardiac glycosides. 
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4.5 Results 
4.5.1 Activity of D. oliveri and P. febrifugum extracts on O. ochengi adult worms 
and mfs 
A total of 12 extracts were generated from the leaves and stem bark of the 2 plants (6 
extracts per plant) using solvents of different polarities (hexane, dichloromethane and 
methanol). A summary of the activity of the plant extracts is provided in Table 4.2. 
 
Table 4.2 IC50 values (mean ± S.E.M) of extracts with macro- and/or microfilaricidal activity 
against O. ochengi. 
 
 
 
Extracts
Onchocerca ochengi
IC50 mf
(µg/ml)
IC50 adult worm
(µg/ml)
DOLHEX Inactive Inactive
DOLDCM 16.2 ± 0.0, n = 2 43.3 ± 9.2, n = 3
DOLMeOH Inactive Inactive
DOBHEX 185.2 ± 0.0, n = 2 13.9 ± 1.7, n = 3
DOBDCM 9.7 ± 0.0, n = 2 22.5 ± 0.0, n = 3
DOBMeOH Inactive Inactive
PFLHEX Inactive Inactive
PFLDCM 132.4 ± 0.0, n = 2 Inactive
PFLMeOH 8.8 ± 0.0, n = 2 Inactive
PFBHEX 4.0 ± 0.0, n = 2 Inactive
PFBDCM 7.2 ± 0.0, n = 2 Inactive
PFBMeOH 6.6 ± 0.0, n = 2 Inactive
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Of the 12 extracts screened, 3 were active against adult O. ochengi (Figure 4.4). 
These were the hexane extract of the stem bark, and the dichloromethane extracts of the 
leaves and stem bark of D. oliveri (DOBHEX, DOLDCM and DOBDCM). Of these 3, DOBHEX 
recorded the lowest IC50 of 13.9 ± 1.7 µg/ml (n = 3) for O. ochengi macrofilaricidal activity. 
Remarkably, DOBHEX also recorded the lowest IC100 of 31.3 µg/ml (n = 3). 
 
Figure 4.4 Dose-dependent inhibition of formazan formation (decrease in worm viability) 
after 120 hours of incubation with extracts of Daniellia oliveri. Results are plotted as mean ± 
S.E.M. The order of potency was DOBHEX (IC50 13.9 ± 1.7 µg/ml, n = 3) > DOBDCM (IC50 
22.5 ± 0.0 µg/ml, n = 3) > DOLDCM (IC50 43.3 ± 9.2 µg/ml, n = 3).   
 
 
For the O. ochengi mf assay, 8 of the 12 extracts screened showed a dose-dependent 
microfilaricidal activity (Figure 4.5). These were DOBHEX, DOLDCM, DOBDCM, 
dichloromethane leaf extract of P. febrifugum (PFLDCM), methanol leaf extract of P. 
febrifugum (PFLMeOH), hexane stem bark extract of P. febrifugum (PFBHEX), dichlomethane 
stem bark extract of P. febrifugum (PFBDCM), and methanol stem back extract of P. 
febrifugum (PFBMeOH). The effects of these extracts were also time-dependent. Note, of the  
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Figure 4.5 Dose-dependent inhibition of microfilariae motility after 120 hours of incubation 
with extracts of Daniellia oliveri (A) and Psorospermum febrifugum (B & C). Results are 
plotted as mean ± S.E.M (n = 2). Note that the D. oliveri microfilaricidal extracts (DOBHEX, 
DOLDCM, DOBDCM) were also active against adult worms.    
 
extracts that showed both O. ochengi adult worm and mf activity (DOBHEX, DOLDCM and 
DOBDCM), DOBHEX was more active on adult O. ochengi (IC50 13.9 ± 1.7 µg/ml, n = 3) 
compared to the mfs (IC50 185.2 ± 0.0 µg/ml, n = 2). PFBHEX recorded the lowest IC50 of 4.0 
± 0.0 µg/ml (n = 2) for O. ochengi microfilaricidal activity, and the lowest IC100 of 7.8 µg/ml. 
PFLMeOH had an IC50 and IC100 of respectively 8.8 ± 0.0 µg/ml and 31.3 µg/ml (n = 2) for O. 
ochengi microfilaricidal activity. 
4.5.2 Activity of extracts and chromatographic fractions of D. oliveri and P. 
febrifugum on adult B. pahangi 
Adult B. pahangi were more sensitive to the extracts than O. ochengi. Of the 12 
extracts initially screened for activity against adult B. pahangi at 300 µg/ml, 11 (DOLHEX, 
DOLDCM, DOLMeOH, DOBHEX, DOBDCM, DOBMeOH, PFLHEX, PFLDCM, PFBHEX, PFBDCM and 
PFBMeOH) were active, while only PFLMeOH was inactive (Figure 4.6). The effects were also 
time-dependent, with DOLDCM and DOBDCM causing close to 100% inhibition of motility after 
only 4 and 24 hours of incubation. 
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Figure 4.6 Time-dependent inhibition of adult Brugia pahangi motility following incubation 
with extracts of Daniellia oliveri and Psorospermum febrifugum. Results are plotted as mean 
± S.E.M (n = 4). All 12 extracts tested (except PFLMeOH) caused a 100% inhibition of motility 
after 72 hours of incubation. Remarkably, DOLDCM and DOBDCM caused close to 100% 
inhibition of motility after only 4 and 24 hours of incubation. 
 
Of these 11 active extracts, 3 (DOBHEX, DOLDCM and DOBDCM) were selected for 
further screening for IC50 determination as they were also active on both adult O. ochengi 
and mfs (Figure 4.7). DOLDCM and DOBDCM were equally potent on adult B. pahangi with 
IC50 values of 6.1 ± and 6.3 ± µg/ml respectively (n = 4). These IC50 values were lower than 
the 59.0 ± 1.2 µg/ml (n = 4) recorded for DOBHEX (Table 4.3). 
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Figure 4.7 Dose-dependent inhibition of adult Brugia pahangi motility after 72 hours of 
incubation with extracts of Daniellia oliveri. Results are plotted as mean ± S.E.M (n = 4). 
The order of potency was DOLDCM (IC50 6.1 ± 1.3 µg/ml, n = 4) ~ DOBDCM (IC50 6.3 ± 1.2 
µg/ml, n = 4) > DOBHEX were (IC50 59.0 ± 1.2 µg/ml, n = 4).   
 
Table 4.3 IC50 values (mean ± S.E.M) for all active extracts. 
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Extracts
Onchocerca ochengi Brugia pahangi
IC50 mf
(µg/ml)
IC50 adult worm
(µg/ml)
IC50 adult worm
(µg/ml)
DOLHEX Inactive Inactive < 300
DOLDCM 16.2 ± 0.0, n = 2 43.3 ± 9.2, n = 3 6.1 ± 1.3, n = 4
DOLMeOH Inactive Inactive < 300
DOBHEX 185.2 ± 0.0, n = 2 13.9 ± 1.7, n = 3 59.0 ± 1.2, n = 4
DOBDCM 9.7 ± 0.0, n = 2 22.5 ± 0.0, n = 3 6.3 ± 1.2, n = 4
DOBMeOH Inactive Inactive < 300
PFLHEX Inactive Inactive < 300
PFLDCM 132.4 ± 0.0, n = 2 Inactive < 300
PFLMeOH 8.8 ± 0.0, n = 2 Inactive Inactive
PFBHEX 4.0 ± 0.0, n = 2 Inactive < 300
PFBDCM 7.2 ± 0.0, n = 2 Inactive < 300
PFBMeOH 6.6 ± 0.0, n = 2 Inactive < 300
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Following IC50 determination, DOBHEX, DOLDCM and DOBDCM were subjected to 
solid-phase extraction using Sep-Pak Plus cartridges. 18 Sep-Pak fractions were generated 
from DOBHEX, DOLDCM and DOBDCM (6 fractions per extract), and tested for adult B. pahangi 
activity in quadruplicate at 300 µg/ml for 72 hours (Figure 4.8). 
 
 
Figure 4.8 Time-dependent inhibition of adult Brugia pahangi motility following treatment 
with Daniellia oliveri Sep-Pak fractions. Results are plotted as mean ± S.E.M (n = 4). Active 
fractions from Sep-Pak Silica Plus cartridges are colored green and red, green for Hex/Iso 
90:10 and red for Hex/Iso 50:50 fractions. Active fractions from Sep-Pak C-18 Plus 
cartridges are colored light green (MeOH/H20 80:20) and brown (MeOH/H20 20:80-1). 
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Sep-Pak fractions that showed activity after 72 hours of incubation were selected for 
IC50 determination (Figure 4.9). These were DOBHEX eluted with 90% hexane in 10% 
isopropanol (DOBHEX Hex/Iso 90:10), DOBHEX eluted with 50% hexane in 50% isopropanol 
(DOBHEX Hex/Iso 50:50), DOLDCM eluted with 90% hexane in 10% isopropanol (DOLDCM 
Hex/Iso 90:10) and DOLDCM eluted with 80% methanol in 20% water (DOLDCM MeOH/H2O 
80:20). Of the 2 active DOBHEX Sep-Pak fractions (DOBHEX Hex/Iso 90:10 and DOBHEX 
Hex/Iso 50:50, Figure 4.9A), DOBHEX Hex/Iso 90:10 was selected for HPLC because based 
on IC50, it was more potent (IC50 27.3 ± 1.2 µg/ml, n = 4) than DOBHEX Hex/Iso 50:50 (IC50 
122.2 ± 1.3 µg/ml, n = 4). Likewise, DOLDCM Hex/Iso 90:10 was selected for HPLC as it was 
more potent (IC50 15.2 ± 1.3 µg/ml, n = 4) than DOLDCM MeOH/H2O 80:20 (IC50 33.3 ± 1.3 
µg/ml, n = 4), Figure 4.9B.  
 
 
Figure 4.9 Dose-dependent inhibition of adult B. pahangi motility after 120 hrs of incubation 
with Sep-Pak fractions from D. oliveri stem bark hexane extract (A) and leaf 
dichloromethane extract (B). Results are plotted as mean ± S.E.M (n = 4). DOBHEX Hex/Iso 
90:10 (IC50 27.3 ± 1.2 µg/ml, n = 4) was more potent than DOBHEX Hex/Iso 50:50 (IC50 122.2 
± 1.3 µg/ml, n = 4). DOLDCM Hex/Iso 90:10 (IC50 15.2 ± 1.3 µg/ml, n = 4) was more potent 
than DOLDCM MeOH/H2O 80:20 (IC50 33.3 ± 1.3 µg/ml, n = 4). 
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Seven HPLC subfractions (F1 – F7) from each of the selected Sep-Pak fractions were 
generated and again tested for adult B. pahangi activity at 300 µg/ml (Figures 4.10). Only 
active fractions were selected for IC50 determination and further purification. These were 
DOBHEX Hex/Iso 90:10 F4 (IC50 50.7 ± 1.0 µg/ml, n = 4) and DOLDCM Hex/Iso 90:10 F3 (IC50 
141.5 ± 1.1 µg/ml, n = 4) (Figures 4.11A & 4.11B). 
 
 
Figure 4.10 Time-dependent inhibition of adult Brugia pahangi motility following treatment 
with HPLC fractions from the hexane stem bark Sep-Pak fraction eluted with 90% hexane in 
10% isopropanol (DOBHEX Hex/Iso 90:10) (A & B) and the dichloromethane leaf Sep-Pak 
fraction eluted with 90% hexane in 10% isopropanol (DOLDCM Hex/Iso 90:10) (C & D). 
Results are plotted as mean ± S.E.M (n = 4). Active HPLC fractions were: F4, F6 & F7 from 
the Sep-Pak fraction DOBHEX Hex/Iso 90:10, and F3 from Sep-Pak fraction DOLDCM Hex/Iso 
90:10.   
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Figure 4.11 Dose-dependent inhibition of adult Brugia pahangi motility after 72 hours of 
incubation with HPLC fractions; F4 from the hexane stem bark Sep-Pak fraction eluted with 
90% hexane in 10% isopropanol (A) and F3 from the dichloromethane leaf Sep-Pak fraction 
eluted with 90% hexane in 10% isopropanol (B). Results are plotted as mean ± S.E.M (n = 
4). DOBHEX Hex/Iso 90:10 F4 (IC50 50.7 ± 1.0 µg/ml, n = 4) was more potent than DOLDCM 
Hex/Iso 90:10 F3 (IC50 141.5 ± 1.1 µg/ml, n = 4). 
 
4.5.3 Cytotoxicity of active extracts 
N27 cytotoxicity was established for the active extracts using the MTS assay. The 
N27 IC50 values were compared to the IC50 values for the parasites to determine the 
Selectivity Index (SI). Of all 12 active extracts evaluated at an initial single high 
concentration of 250 µg/ml for toxicity to N27 cells, DOBHEX and PFBDCM showed no 
cytotoxicity when compared to the untreated controls (Figure 4.12A). On the other hand, all 
the other extracts tested showed a significant reduction (p < 0.001) in cell viability compared 
to the untreated control. These extracts were further tested at 8 serially diluted concentrations 
from 500 to 3.91 µg/ml to determine their IC50 values (Figures 4.12B–D). 
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Figure 4.12 Effects of extracts of Daniellia oliveri and Psorospermum febrifugum on N27 
cell viability after 24 hours of incubation with 250 g/ml (n = 6) (A) and 500 down to 3.91 
µg/ml (B – D) of the extracts. Results are plotted as mean ± S.E.M. Mean IC50 ranged from 
35 to >250 g/ml (n = 4). ***p < 0.001 (unpaired student t-test). 
 
IC50 (mean ± S.E.M) values for the extracts on N27 cells are shown in Table 4.4. 
Comparing the IC50 values for N27 cells with that for parasites revealed only PFLDCM to be 
more toxic to N27 cells than to parasites (Table 4.5). All other extracts were more selective 
for parasites than for N27 cells with an SI of >1. The higher the SI value, the more toxic the 
extract is to parasites than cells. Therefore, the higher the SI value, the better or ‘safer’ the 
extract and the more potentially useful for therapeutic drug development. 
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Table 4.4 IC50 (mean ± S.E.M) for extracts of Daniellia oliveri and Psorospermum 
febrifugum on N27 cells. 
 
 
 
 
4.5.4 Phytochemical analysis of active extracts 
The active extracts were screened for the presence of phytochemicals as described in 
the Materials and Methods section. The presence (+) and absence (-) of the different 
phytochemicals screened are shown in Table 4.6. In general, steroids and saponins were 
found to be present in all active extracts, while cuomarins were absent. The 3 promising 
extracts (DOBHEX, DOLDCM and DOBDCM) with activity against both O. ochengi and B. 
pahangi tested positive for one or more of the following phytochemicals: alkaloids, 
flavonoids and cardiac glycosides, but negative for tannins. 
 
Extract IC50
(Mean ± S.E.M, µg/ml)
DOLDCM 222.8 ± 1.1, n = 4
DOBDCM 224.6 ± 1.1, n = 4
PFLDCM 35.1 ± 1.2, n = 4
PFLMeOH
331.1 ± 6.9, n = 4
PFBHEX 47.0 ± 1.8, n = 4
PFBMeOH
98.2 ± 1.4, n = 4
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Table 4.5 Selectivity index (SI) values (Mean IC50 cell/Mean IC50 parasite) for extracts of 
Daniellia oliveri and Psorospermum febrifugum. 
 
 
Extracts Mean IC50
N27 cells
(µg/ml)
Onchocerca ochengi Brugia pahangi
Mf Adult Adult
Mean 
IC50
(µg/ml)
SI
Mean 
IC50 
(µg/ml)
SI
Mean 
IC50 
(µg/ml)
SI
DOLHEX tbd Inactive / Inactive tbd 89.8 /
DOLDCM 222.8 16.2 13.8 43.3 5.1 6.1 36.5
DOLMeOH tbd Inactive / Inactive / 81.9 /
DOBHEX > 250 185.2 > 1.3 13.9 > 18.0 59.0 > 4.2
DOBDCM 224.6 9.7 23.2 22.5 10.0 6.3 35.7
DOBMeOH / Inactive / Inactive / 44.0 /
PFLHEX / Inactive / Inactive / 153.7 /
PFLDCM 35.1 132.4 0.3 Inactive / < 300 /
PFLMeOH 331.1 8.8 37.6 Inactive / Inactive /
PFBHEX 47.0 4 11.8 Inactive / < 300 /
PFBDCM > 250 7.2 > 34.7 Inactive / < 300 /
PFBMeOH 98.2 6.6 14.9 Inactive / < 300 /
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Table 4.6 Phytochemical analysis of all active extracts. 
 
 
4.6 Discussion 
Onchocerciasis and LF are two major NTDs whose control is hindered by the lack of 
suitable drugs that will kill adult worms. The aim of this project was to screen medicinal 
plants for activity against the parasites that cause onchocerciasis and LF in a bid to identify 
new compounds that could serve as leads for macrofilaricidal drug development. Based on 
ethnopharmacological information, D. oliveri and P. febrifugum are plants commonly used 
by the traditional healers of Bambui, NW Cameroon to treat onchocerciasis and LF. 
However, there is no documented scientific evidence to support the claimed efficacy of D. 
oliveri and P. febrifugum in treating onchocerciasis and LF. Our study is the first report of 
scientific evidence for in vitro filaricidal activity of D. oliveri and P. febrifufum. Of 12 crude 
extracts prepared from D. oliveri and P. febrifufum using solvents of different polarities 
Key: (+) = present, (-) = absent
Class of 
compound
Daniellia oliveri extracts Psorospermum febrifugum extracts
DOLDCM DOBHEX DOBDCM PFLDCM PFLMeOH PFBHEX PFBDCM PFBMeOH
Alkaloids - + - + + + + +
Steroids + + + + + + + +
Flavonoids + - + + + + + +
Saponins + + + + + + + +
Tannins - - - + + - - +
Cuomarins - - - - - - - -
Cardiac 
glycosides
+ - + - + + - -
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(hexane, dichloromethane and methanol), all 12 extracts showed a time- and dose-dependent 
activity against O. ochengi mfs, adult O. ochengi or adult B. pahangi. Interestingly, 3 
(DOBHEX, DOLDCM and DOBDCM) of the 12 extracts were active against all life cycle stages of 
O. ochengi and B. pahangi used in this study. Thus, DOBHEX, DOLDCM and DOBDCM have 
potential as sources of lead compounds for broad spectrum filaricidal activity. The low IC50 
values (6 – 185 µg/ml) recorded by DOBHEX, DOLDCM and DOBDCM and their lack of 
cytotoxicity encouraged us to select these extracts for further purification (Table 4.5). 
Sep-Pak fractions of DOBHEX, DOLDCM and DOBDCM which showed activity against B. 
pahangi were further fractionated using semi-preparative HPLC. Seven HPLC fractions 
collected at different time points were generated for each active Sep-Pak fraction. These 
fractions were tested for activity against B. pahangi and IC50’s determined from dose-
response curves. After analysis of the HPLC fractions, we propose that DOBHEX Hex/Iso 
90:10 F4 (IC50 50.7 ± 1.0 µg/ml, n = 4) and DOLDCM Hex/Iso 90:10 F3 (IC50 141.5 ± 1.1 
µg/ml, n = 4) are further purified to identify the active compounds. 
The potency of extracts varied during the course of the fractionation process. For 
example, crude extract DOBHEX recorded an IC50 adult B. pahangi of 59.0 ± 1.2 µg/ml, the 
most potent resulting Sep-Pak fraction was DOBHEX Hex/Iso 90:10 IC50 27.3 ± 1.2 µg/ml, 
while HPLC fraction DOBHEX Hex/Iso 90:10 F4 IC50 50.7 ± 1.0 µg/ml was the most potent. 
However, when we combined all seven HPLC fractions of extract DOBHEX Hex/Iso 90:10, the 
activity was similar to that of the parent Sep-Pak fraction (Figure 4.10B). This led us to 
conclude that active compounds are present in two or more HPLC fractions acting additively 
or in synergy.  
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Our results show that the HPLC fractions DOBHEX Hex/Iso 90:10 F4 and DOLDCM 
Hex/Iso 90:10 F3 have potential as sources of macrofilaricides. Additionally, we recommend 
that various combinations of the HPLC fractions be tested as this may yield combinations 
with enhanced activity. Knowing that phytochemicals have a wide range of pharmacological 
activities, the phytochemicals present in our promising extracts which we report in Table 4.6 
suggest that the bioactive compounds in the extracts may be from these groups of plant 
chemicals (alkaloids, steroids, flavonoids, saponins and cardiac glycosides). The presence of 
one or more of these phytochemicals have been reported in the following plants with 
demonstrated activity against O. ochengi: Margaritaria discoidea, Homalium africanum, 
Craterispermum laurinum, Morinda lucida, Tragia benthami, Piper umbellatum and Annona 
senegalensis (Cho-Ngwa et al., 2010; Cho-Ngwa et al., 2016; Ndjonka et al., 2011). Also, 
the anthelmintic activity for some of these phytochemicals like alkaloids, flavonoids and 
saponins has been published elsewhere (Ayers et al., 2007; Wang et al., 2010a; Wang et al., 
2010b). Overall, our results justify the traditional use of D. oliveri. However, more studies 
focusing on identifying the active compounds are necessary, as well as determining their 
mode of action.     
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5.1 Abstract 
Nematode parasites may be controlled with drugs, but their regular application has 
given rise to concerns about the development of resistance. Drug combinations may be more 
effective than single drugs and delay the onset of resistance. A combination of the nicotinic 
antagonist, derquantel, and the macrocyclic lactone, abamectin, has been found to have 
synergistic anthelmintic effects against gastro-intestinal nematode parasites. We have 
observed in previous contraction and electrophysiological experiments that derquantel is a 
potent selective antagonist of nematode parasite muscle nicotinic receptors; and that 
abamectin is an inhibitor of the same nicotinic receptors. To explore these inhibitory effects 
further, we expressed muscle nicotinic receptors of the nodular worm, Oesophagostomum 
dentatum (Ode-UNC-29:Ode-UNC-63:Ode-UNC-38), in Xenopus oocytes under voltage-
clamp and tested effects of abamectin on pyrantel and acetylcholine responses. The receptors 
were antagonized by 0.03 μM abamectin in a non-competitive manner (reduced Rmax, no 
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change in EC50). This antagonism increased when abamectin was increased to 0.1 μM. 
However, when we increased the concentration of abamectin further to 0.3 μM, 1 μM or 10 
μM, we found that the antagonism decreased and was less than with 0.1 μM abamectin. The 
bi-phasic effects of abamectin suggest that abamectin acts at two allosteric sites: c We also 
tested the effects of 0.1 μM derquantel alone and in combination with 0.3 μM abamectin. We 
found that derquantel on these receptors, like abamectin, acted as a non-competitive 
antagonist, and that the combination of derquantel and abamectin produced greater 
inhibition. These observations confirm the antagonistic effects of abamectin on nematode 
nicotinic receptors in addition to GluCl effects, and illustrate more complex effects of 
macrocyclic lactones that may be exploited in combinations with other anthelmintics. 
5.2 Introduction 
Gastro-intestinal nematode parasite infections of both humans and animals are a 
global public health problem. These infections cause livestock production losses, morbidity, 
and if left uncontrolled, may result in death (Pullan et al., 2014). In the absence of effective 
sanitation and vaccines, control of nematode parasite infections is achieved by the use of 
anthelmintic drugs, many of which act on ligand-gated ion channels (LGICs) (Beech & 
Neveu, 2015; Greenberg, 2014; Wolstenholme, 2011). The nicotinic acetylcholine receptor 
(nAChR) is a prototypic pentameric LGIC. Different subunit combinations or different 
stoichiometry of the same nAChR subunits can give rise to multiple receptor subtypes with 
different pharmacological properties (Buxton et al., 2014; Williamson et al., 2009). There are 
a limited number of anthelmintics which are currently approved for use (Wolstenholme, 
2011). Those that act on nAChRs include: imidazothiazoles (levamisole) (Martin & 
Robertson, 2007), tetrahydropyrimidine derivatives (pyrantel, oxantel, morantel) (Rayes et 
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al., 2001), spiroindoles (derquantel) (Lee et al., 2002), and tribendimidine (Robertson et al., 
2015). The macrocyclic lactones (ivermectin, abamectin, moxidectin) act on glutamate-gated 
chloride channels (GluCls) (Wolstenholme & Rogers, 2005); the benzimidazoles 
(albendazole, mebendazole) act on β-tubulin (Lacey, 1990); and piperazine acts on GABA 
receptors (Martin, 1997). Other more recent drugs include the amino-acetonitrile derivatives 
(monepantel) which act on LGICs receptors comprised of DEG-3/DES-2 nAChR subunits 
(Rufener et al., 2010); and the cyclooctadepsipeptide (emodepside) whose mode of action is 
understood to be on SLO-1 potassium channels (Guest et al., 2007; Martin et al., 2012a) and 
latrophilin receptors (Saeger et al., 2001). 
The increased use of anthelmintics has led to the development of resistance in both 
animal and human nematode parasites (Wolstenholme & Martin, 2014). Resistance to 
anthelmintics presents a serious drawback in the control of nematode parasite infections and 
is an increasing medical concern (Kotze et al., 2014). Combination therapy involving 
anthelmintic drugs of different classes is an important approach that may slow the 
development of anthelmintic drug resistance. The simultaneous development of resistance to 
two drugs is less likely than the development of resistance to one drug alone; hence 
combinations are predicted to slow the development of resistance (Leathwick, 2012). 
Startect® (derquantel and abamectin combination, Figure 5.0) is a more recently introduced 
anthelmintic combination that is marketed for use in sheep, but it has been shown to have 
effects on nematode parasites of other host species such as Ascaris suum of pigs (Puttachary 
et al., 2013). In this study, we investigated the effects of derquantel alone, abamectin alone, 
and a combination of derquantel and abamectin on a nAChR subtype from the nematode 
parasite Oesophagostomum dentatum. This subtype is comprised of Ode-UNC-29:Ode-UNC- 
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Figure 5.0 Structures of derquantel and abamectin. A: Structure of derquantel. B: Structure of 
abamectin. Abamectin is a mixture of avermectin B1a and avermectin B1b. Avermectin B1a 
differs from avermectin B1b by a functional group at the ‘R’ position, and makes up more 
than 80% of abamectin, while avermectin B1b makes up less than 20% of abamectin. 
 
63:Ode-UNC-38 (29-63-38) nAChR subunits. Other pharmacologically characterized 
nAChR subtypes of O. dentatum are Ode-UNC-29:Ode-UNC-63 (pyrantel-sensitive 
nAChR), Ode-UNC-29:Ode-UNC-63:Ode-ACR-8 (acetylcholine-sensitive nAChR), and 
Ode-UNC-29:Ode-UNC-63:Ode-UNC-38:Ode-ACR-8 (levamisole-sensitive nAChR) 
(Buxton et al., 2014). We chose O. dentatum parasite for further investigation because the 
worm is easily maintained and passaged, and it is a Clade V nematode, just like the model 
free-living nematode, Caenorhabditis elegans (Blaxter et al., 1998). O. dentatum is a 
common nodule worm in pigs, very similar to other Oesophagostomum species which infect 
humans, most notably in northern Togo and Ghana (Polderman et al., 1991). The O. 
dentatum nAChR subtype, Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 used in this study is 
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preferentially activated by pyrantel and tribendimidine, and it is antagonized in a non-
competitive manner by derquantel (Buxton et al., 2014). We show here that abamectin is a 
potent antagonist of these nAChRs, and that a combination of derquantel and abamectin has 
greater effects than derquantel or abamectin used alone. These additive effects support the 
continued use of the derquantel and abamectin combination for the control of nematode 
parasites. 
5.3 Materials and Methods 
Experiments described in this study have been conducted according to US national 
and international welfare guidelines. The Office for Responsible Research at Iowa State 
University, IACUC Log #3-2-5134-s specifically approved this study and granted permission 
for the culture of the Oesophagostomum parasites. There was no animal suffering or surgery 
required. 
5.3.1 Cloning of nAChR subunits from O. dentatum and ancillary factors from 
Haemonchus contortus 
O. dentatum nAChR subunits and H. contortus ancillary factors used in this research 
study have been previously cloned and reported (Buxton et al., 2014). 
5.3.2 Expression of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 in Xenopus laevis 
oocytes 
Defolliculated X. laevis oocytes were purchased from Ecocyte Bioscience (Austin, 
TX, USA). Oocyte microinjection was done using a Drummond nanoject II microinjector 
(Drummond Scientific, PA, and USA). 1.8 ng of each subunit cRNA (Ode-unc-29, Ode-unc-
63 and Ode-unc-38) and ancillary factor cRNA (Hco-ric-3, Hco-unc-50 and Hco-unc-74) in a 
total volume of 36 nL in RNAse-free water were microinjected into the animal pole of the 
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oocytes. Once micro-injected, the oocytes were transferred to a sterile 96-well culture plate 
(one oocyte/well) containing 200 μL incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2.2H20, 1 mM MgCl2.6H20, and 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL 
penicillin and 100 μg/mL streptomycin, pH 7.5) in each well. The oocytes were incubated at 
19°C for 2–5 days, with a daily change of incubation solution. 
5.3.3 Two-microelectrode voltage-clamp (TEVC) electrophysiology 
We followed methods we have described in detail before (Buxton et al., 2014). 
Briefly, 100 μM BAPTA-AM was added to the oocytes in incubation media approximately 3 
hours prior to electrophysiological recordings from the oocytes. TEVC recordings were 
carried out by impaling the oocytes with two microelectrodes; a voltage sensing electrode, 
Vm, and a current injecting electrode, Im, were used to inject the current required to hold the 
membrane at the set voltage. The microelectrodes were pulled with a Flaming/Brown 
horizontal electrode puller (Model P-97, Sutter Instruments), filled with 3 M potassium 
chloride and the microelectrode tips carefully broken with a piece of tissue paper to achieve a 
low resistance of 2–5 MΩ in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM 
CaCl2.2H2O and 5 mM HEPES, pH 7.3). Current/voltage signals were amplified by an 
AxoClamp 2B amplifier (Molecular Devices, CA, USA). The amplified signals were 
converted from analog to digital format by a Digidata 1322A digitizer (Molecular Devices, 
CA, USA) and finally acquired on a desktop computer with the Clampex 9.2 data acquisition 
software (Molecular Devices, CA, USA).  
5.3.4 Drugs 
Acetylcholine (ach) and pyrantel (pyr) were purchased from Sigma-Aldrich (St Louis, 
MO, USA), while derquantel (der) and abamectin (aba) were gifts from Zoetis (Kalamazoo, 
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MI). Acetylcholine and pyrantel were dissolved in recording solution. Derquantel and 
abamectin were dissolved in DMSO and added to recording solution at a final concentration 
of ≤ 0.01% DMSO.  
5.3.5 Drug applications 
Acetylcholine which is a natural agonist of many nAChRs served for normalization 
and as a control in our experiments. Each agonist concentration was applied for 10 s, with 
sufficient time allowed for wash off between drug applications. For every oocyte recording, 
100 μM acetylcholine was applied initially and this current response was measured, 
subsequent responses were measured and normalized to this acetylcholine current. To 
generate control agonist concentration-response plots, acetylcholine was applied at different 
concentrations between 0.1–100 μM or pyrantel was applied at different concentrations 
between 0.03–10 μM. Higher concentrations of pyrantel were not tested because pyrantel 
acts as an open channel blocker at high concentrations (Robertson et al., 1994). For the 
antagonist experiments, a control 100 μM acetylcholine was also first applied for 10s, and 
then followed by a 2 min or 10 min challenge with the antagonist (derquantel and/or 
abamectin), and a final application of the agonist (pyrantel) in the continued presence of the 
antagonist. 
5.3.6 Data analysis 
We used Clampfit 9.2 (Molecular Devices, CA, and USA) to measure peak current 
responses and normalized them to the first 100 μM acetylcholine responses. GraphPad Prism 
5.0 software (GraphPad Software Inc., USA) was used to analyze the data, and results were 
expressed as mean ± S.E.M. Concentration-response data points were fitted with the Hill 
equation as previously described: where Rmax is the maximum response % relative to the 
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control 100 μM ach response; the EC50 is the concentration producing the half-maximum 
response and nH is the slope factor or Hill coefficient (Boulin et al., 2008). We used the 
unpaired two-tailed Student’s t-test to test for statistical significance and a p value < 0.05 was 
considered significant. 
The Bliss additive effect dose-response relationship for pyrantel current responses 
was calculated as previously described (Greco et al., 1996) to predict the linear additive 
effects of derquantel and abamectin on the Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 
nAChR. To do so, we determined: the normalized mean current responses to each control 
pyrantel concentration (CR[pyr]); the mean current responses to each concentration of 
pyrantel in the presence of derquantel (derquantel effect) and; the mean current responses to 
each concentration of pyrantel in the presence of abamectin (abamectin effect). We then used 
the fractional inhibition (mean reduction in response/CR[pyr]) produced by derquantel alone, 
Fd, and abamectin alone, Fa, at each pyrantel concentration to determine the additive effect. 
We used Fa(1-Fd) to denote the fractional inhibition produced by abamectin when 
derquantel is already present, and Fd+Fa(1-Fd) to denote the fractional inhibition produced 
by the combination of derquantel and abamectin. Lastly, the normalized additive response 
was calculated as:  
 
The difference between the observed and calculated additive effects for the 
combination of derquantel and abamectin were tested for statistical significance using the 
paired two-tailed Student’s t-test, taking p < 0.05 as significant. 
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5.4 Results 
5.4.1 Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 forms a pyrantel-sensitive nAChR 
Representative traces (inward currents from oocytes expressing Ode-UNC-29:Ode-
UNC-63:Ode-UNC-38) produced in response to different concentrations of acetylcholine and 
pyrantel are shown in Figure 5.1A and Figure 5.1B respectively. Figure 5.1C shows 
acetylcholine and pyrantel concentration-response relationships for Ode-UNC-29:Ode-UNC-
63:Ode-UNC-38. The EC50 and maximum response (Rmax) values for acetylcholine were 13.0 
± 1.6 μM and 114.3 ± 4.3%, n = 4. The EC50 and Rmax values for pyrantel were 0.4 ± 0.0 μM 
and 135.5 ± 7.9%, n = 6 (S5.0 Table). Our results showed the EC50 for pyrantel to be 
significantly smaller (p < 0.001) than the EC50 for acetylcholine, but showed no significant 
difference (p > 0.05) in Rmax between acetylcholine and pyrantel. Based on these EC50 values, 
pyrantel is 32.5 times more potent than acetylcholine on the Ode-UNC-29:Ode-UNC-
63:Ode-UNC-38 nAChR. Also there was a slightly steeper Hill slope (nH) for pyrantel than 
acetylcholine (nH = 1.2 ± 0.1, n = 6 for pyrantel; nH = 1.0 ± 0.1, n = 4 for acetylcholine; p < 
0.05). We used pyrantel rather than acetylcholine for most subsequent experiments because 
of its potency and because it is a more selective agonist than acetylcholine for this nAChR 
subtype (Buxton et al., 2014). 
5.4.2 Effects of abamectin on Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 
We investigated pyrantel concentration-response relationships on Ode-UNC-29:Ode-
UNC-63:Ode-UNC-38 in the presence of 0.03 μM and 0.1 μM abamectin. A representative 
trace is shown in Figure 5.2A. The concentration-response plots, Figure 5.2B, show 
abamectin to be an antagonist of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38. The EC50 and 
Rmax values were: 0.4 ± 0.0 μM and 135.5 ± 7.9%, n = 6 for pyrantel in the absence of 
148 
 
 
 
Figure 5.1 Acetylcholine and pyrantel concentration-response relationships for the Ode-
UNC-29:Ode-UNC-63:Ode-UNC-38 receptor. A: Representative trace (inward currents, 
holding potential -60mV, from oocytes expressing Ode-UNC-29:Ode-UNC-63:Ode-UNC-
38) following 10 seconds applications of different acetylcholine concentrations, from 0.1 μM 
to 100 μM. B: Representative trace (inward currents, holding potential -60mV, from oocytes 
expressing Ode-UNC-29:Ode-UNC-63:Ode-UNC-38) of the 10 seconds application of 
different pyrantel concentrations, from 0.03 μM to 10 μM. An initial 10 seconds application 
of 100 μM acetylcholine served as the control. C: Concentration-response plots for 
acetylcholine (n = 4, black) and pyrantel (n = 6, red). Results were normalized to 100 μM 
acetylcholine current responses and expressed as mean ± S.E.M. 
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Figure 5.2 Pyrantel concentration-response relationships in the presence of 0.03 μM and 0.1 
μM abamectin. A: Representative trace (inward currents, holding potential -60mV, from 
oocytes expressing Ode-UNC-29:Ode-UNC-63:Ode-UNC-38) of the 10 seconds application 
of the control 100 μM acetylcholine, followed by a 10 minutes application of abamectin 
(0.03 μM) and finally, a 10 seconds application of different pyrantel concentrations in the 
continued presence of abamectin. B: Concentration-response plots for pyrantel in the absence 
(n = 6, red) and presence of 0.03 μM abamectin (n = 5, orange) and 0.1 μM abamectin (n = 6, 
dark blue). Results were normalized to 100 μM acetylcholine current responses and 
expressed as mean ± S.E.M. Notice 0.03 μM abamectin caused an inhibition of current 
responses to pyrantel, and this inhibition was greater with 0.1 μM abamectin. 
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abamectin; 0.4 ± 0.0 μM and 107.3 ± 4.7%, n = 5 for pyrantel in the presence of 0.03 μM 
abamectin; and 0.3 ± 0.0 μM and 80.6 ± 8.4%, n = 6 for pyrantel in the presence of 0.1 μM 
abamectin. There was no significant difference (p > 0.05) in the EC50s between pyrantel in 
the absence and presence of 0.03 μM or 0.1 μM abamectin. But, there was a significant 
difference (p < 0.05) in Rmax for pyrantel in the absence and presence of 0.03 μM abamectin, 
and this difference was greater (p < 0.001) in the presence of 0.1 μM abamectin. Hence, 
abamectin did not cause a significant change in EC50, but did cause a significant reduction in 
Rmax, showing that abamectin acts as a non-competitive antagonist of the Ode-UNC-29:Ode-
UNC-63:Ode-UNC-38 nAChR. 
When we increased the concentration of abamectin from 0.1 μM to 0.3 μM, Figure 
5.3A, we noticed that the EC50 for pyrantel in the presence of 0.3 μM abamectin remained 
unchanged: 0.3 ± 0.1 μM, n = 5 (p > 0.05). Although not statistically significant (p > 0.05), 
the mean value for the Rmax for pyrantel in the presence of 0.1 μM abamectin (80.6 ± 8.4, n = 
6) appeared smaller than Rmax in the presence of 0.3 μM abamectin (98.4 ± 6.5, n = 5). This 
suggested that the inhibitory effects of lower concentrations of abamectin can be greater than 
those of higher concentrations. This reversed inhibitory effect was tested and confirmed 
when we increased the concentration of abamectin from 0.3 μM to 1 μM and 10 μM. While 
the EC50 values did not change (0.3 ± 0.1 μM, n = 6 in the presence of 1 μM abamectin, and 
0.4 ± 0.1 μM, n = 5 in the presence of 10 μM abamectin), the Rmax values increased to 108.0 
± 3.5%, n = 6 in the presence of 1 μM abamectin, and 106.0 ± 9.4%, n = 5 in the presence of 
10 μM abamectin. We point out that the effects of abamectin were reversible on washing, 
although the current responses did not return to control responses even after a 10 mins wash.  
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S5.1 Table summarizes the EC50, Rmax, nH and n numbers for these experiments.  
 
Figure 5.3. Effects of increasing concentrations of abamectin (above 0.1 μM) on the pyrantel 
concentration-response plots. A: Concentration-response plots for pyrantel in the absence (n 
= 6, red) and presence of 0.1 μM abamectin (n = 6, dark blue); 0.3 μM abamectin (n = 5, dark 
green); 1 μM abamectin (n = 6, pink); 10 μM abamectin (n = 5, light blue). Results were 
normalized to 100 μM acetylcholine current responses and expressed as mean ± S.E.M. 
Increasing the concentration of abamectin from 0.1 μM to 0.3, 1 and 10 μM rather caused a 
reduction in the inhibition instead of a potentiation. B: Bar chart showing the mean ± S.E.M 
of the maximum current responses (Rmax) for pyrantel and the different abamectin 
concentrations. Rmax for 0.1 μM abamectin (n = 6, dark blue), 0.3 μM abamectin (n = 5, dark 
green), 1 μM abamectin (n = 6, pink) and 10 μM abamectin (n = 5, light blue) were 
significantly lower than Rmax for pyrantel alone (n = 6, red). * p < 0.05, ** p < 0.01 and *** p 
< 0.001, unpaired two-tailed student t-test. C: Model of ligand sites of action. Pyrantel binds 
to the orthosteric sites opening the channel. Low concentrations of abamectin (0.03 and 0.1 
μM) bind to a negative allosteric site (NAM) in the lipid phase of the channel, inhibiting 
opening. Higher concentrations of abamectin (0.3, 1 and 10 μM) bind to a positive allosteric 
site (PAM) increasing opening. D: Abamectin Rmax inhibition (blue curve) and inhibition 
reduction (red curve) dose response plots. The data points for inhibition used data from 0.03 
μM and 0.1 μM abamectin from Figure 5.2. The data points for inhibition reduction used data 
from Figure 5.3B. 
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Interestingly, when the EC50s for pyrantel alone are compared with that for pyrantel in the 
presence of 0.1 μM, 0.3 μM, 1 μM or 10 μM abamectin, there were no significant differences 
in the EC50 values. In contrast however, the Rmax values for pyrantel in the presence of 0.1 
μM, 0.3 μM, 1 μM and 10 μM abamectin were significantly less than the Rmax for pyrantel 
alone, Figure 5.3B. We emphasize again that the Rmax for pyrantel in the presence of 
abamectin concentrations ≥0.3 μM were greater than the Rmax for pyrantel in the presence of 
0.1 μM abamectin, with the difference being statistically significant (p < 0.05) for 1 μM. 
These observations show that abamectin has a bi-phasic effect, suggesting two allosteric sites 
of action: a high affinity site causing antagonism, and a lower affinity site causing a 
reduction in the antagonism, Figures 5.3C and 5.3D. 
5.4.3 Effects of derquantel and abamectin combination on Ode-UNC-29:Ode-
UNC-63:Ode-UNC-38 
For this set of experiments, we tested the combination of 0.3 μM abamectin and 0.1 
μM derquantel. We selected 0.3 μM abamectin because it is the reported concentration in H. 
contortus following the administration of abamectin at its therapeutic dose of 0.2 μM at 12 
hours (Lloberas et al., 2013). 0.1 μM derquantel was selected because the reported 
concentration is 13 μM at 12 hours in the intestine (Jin, 2010) with an uncertain but lower 
concentration being present within the worm. Figures 5.4A and 5.4B show representative 
traces for Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 responses to pyrantel in the presence of 
0.3 μM abamectin alone, and the 0.1 μM derquantel plus 0.3 μM abamectin combination 
respectively. Concentration-response plots for pyrantel in the absence and presence of 0.1 
μM derquantel alone, 0.3 μM abamectin alone, and the 0.1 μM derquantel and 0.3 μM 
abamectin combination are shown in Figure 5.4C. The calculated additive effect of the  
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Figure 5.4 Effects of 0.1 μM derquantel alone, 0.3 μM abamectin alone, and derquantel and 
abamectin combination (0.1 μM derquantel + 0.3 μM abamectin) on the pyrantel 
concentration-response plots. A: Representative trace (inward currents from oocytes 
expressing Ode-UNC-29:Ode-UNC-63:Ode-UNC-38) of the 10 seconds application of the 
control 100 μM acetylcholine, followed by a 10 minutes application of 0.3 μM abamectin 
and finally, a 10 seconds application of different pyrantel concentrations in the continued 
presence of abamectin. B: Representative trace (inward currents from oocytes expressing 
Ode-UNC-29:Ode-UNC-63:Ode-UNC-38) of the 10 seconds application of the control 100 
μM acetylcholine, followed by a 10 minutes application of derquantel and abamectin 
combination and finally, a 10 seconds application of different pyrantel concentrations in the 
continued presence of the derquantel and abamectin combination. C: Concentration-response 
plots for pyrantel in the absence (n = 6, red) and presence of 0.1 μM derquantel (n = 4, light 
purple); 0.3 μM abamectin (n = 5, dark green); 0.1 μM derquantel + 0.3 μM abamectin 
combination (n = 6, olive green). Results were normalized to 100 μM acetylcholine current 
responses and expressed as mean ± S.E.M. Inhibition with 0.1 μM derquantel + 0.3 μM 
abamectin combination was greater than that with 0.1 μM derquantel alone and 0.3 μM 
abamectin alone. The calculated additive effect for the combination of derquantel and 
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abamectin (broken black) was not statistically different (p > 0.05, paired two-tailed student t-
test) from the observed additive effect for the combination of derquantel and abamectin 
(olive green). D: Bar chart showing the mean ± S.E.M of the maximum current responses 
(Rmax) for 0.1 μM derquantel (n = 4, light purple); 0.3 μM abamectin (n = 5, dark green); 0.1 
μM derquantel + 0.3 μM abamectin combination (n = 6, olive green). Rmax for the 
combination of 0.1 μM derquantel + 0.3 μM abamectin was significantly smaller than Rmax 
for 0.1 μM derquantel alone and for 0.3 μM abamectin alone. * p < 0.05 and *** p < 0.001, 
unpaired two-tailed student t-test. 
 
combination of derquantel and abamectin is also shown in Figure 5.4C. The observed effect 
was not greater than the calculated additive effect (p > 0.05) so this combination does not 
show synergism. S5.2 Table shows the EC50 and Rmax values for these experiments. There 
was no significant difference (p > 0.05) between EC50 values for pyrantel in the absence and 
presence of derquantel alone, abamectin alone or the derquantel and abamectin combination. 
However, as before the Rmax values for pyrantel in the presence of 0.1 μM derquantel alone, 
0.3 μM abamectin alone, and 0.1 μM derquantel and 0.3 μM abamectin combination were 
significantly smaller (p < 0.001) than the Rmax for pyrantel in the absence of derquantel 
and/or abamectin. Thus both derquantel and abamectin show non-competitive antagonism on 
the Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 receptor. Figure 5.4D also shows that Rmax 
values for pyrantel in the presence of 0.1 μM derquantel alone and 0.3 μM abamectin alone 
were significantly greater (p < 0.05 and p < 0.001) than Rmax in the presence of 0.1 μM 
derquantel and 0.3 μM abamectin combination. Thus the combination of abamectin and 
derquantel together increases the antagonism but their combination was not significantly 
greater than the calculated additive effect. 
We used pyrantel as the preferred agonist to study the effects of abamectin and 
derquantel on the Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 receptor because it is more 
selective than acetylcholine for this receptor (Buxton et al., 2014). However, we also tested 
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the effects of abamectin and derquantel with acetylcholine as the agonist instead of pyrantel. 
We found, as with pyrantel, that a lower concentration of 0.1 μM abamectin was a more 
potent non-competitive acetylcholine antagonist than 0.3 μM or 1 μM abamectin, S5.0 
Figure. We also found that 0.3 μM derquantel acts as a non-competitive antagonist of 
acetylcholine and that the combination of derquantel and abamectin shows additive 
inhibitory effects without demonstrating synergism, S5.1 Figure. 
5.5 Discussion 
 5.5.1 Abamectin as a non-competitive antagonist of Ode-UNC-29:Ode-UNC-
63:Ode-UNC-38 
Abamectin, a mixture of avermectins B1a and B1b (Figure 5.0), belongs to the 
macrocyclic lactone class of anthelmintics which have been shown to act on GluCls 
(Wolstenholme & Rogers, 2005). In addition to the effect of abamectin on GluCls, 
Puttachary et al (Puttachary et al., 2013) showed, using muscle contraction and current-
clamp electrophysiological techniques, that abamectin acts as a non-competitive antagonist 
of Ascaris suum (Clade III nematode) somatic muscle nAChRs. In this paper we were 
interested to see if abamectin had similar effects on the expressed O. dentatum (Clade V 
nematode) receptor, Ode-UNC-29:Ode-UNC-63:Ode-UNC-38. Interestingly, we found that 
abamectin was also a potent non-competitive antagonist of this receptor (Figure 5.2B).   
5.5.2 Bi-phasic effects of abamectin on Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 
The inverse dose-dependent bi-phasic effects of abamectin on Ode-UNC-29:Ode-
UNC-63:Ode-UNC-38 suggest that abamectin has two allosteric sites of action on this 
receptor: one, a higher affinity negative allosteric modulator (NAM) site causing antagonism; 
and the other, with lower affinity, a positive allosteric modulator (PAM) site, causing a 
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reduction in the antagonism (Figure 5.3D). The NAM and PAM sites of action of abamectin 
on the receptors may be in the outer lipid phase of the membrane (Martin & Kusel, 1992) 
between the TM1 transmembrane domain of one receptor subunit and the TM3 domain of the 
adjacent receptor subunit (Hibbs & Gouaux, 2011). Since the receptor channel is composed 
of heterogeneous subunits, binding between one pair of subunits may stabilize closing 
(negative allosteric modulator) while binding between another pair of subunits may stabilize 
opening (positive allosteric modulator).   
5.5.3 Derquantel and abamectin combination produces greater effects than 
either derquantel or abamectin used alone 
The effects of a combination of derquantel and abamectin on a mixture of in situ A. 
suum somatic nAChR subtypes have been described by Puttachary at al (Puttachary et al., 
2013): when derquantel was used alone, A. suum somatic nAChRs were antagonized in a 
competitive manner (right-shift in EC50, but no change in Rmax); when abamectin was used 
alone, A. suum somatic nAChRs were antagonized in a non-competitive manner (reduction in 
Rmax, but no change in EC50); when derquantel and abamectin were used in combination, 
abamectin potentiated the antagonism of derquantel. In our experiments with Ode-UNC-
29:Ode-UNC-63:Ode-UNC-38, derquantel showed non-competitive (Figure 5.4C) rather 
than competitive antagonism. With the combination of derquantel and abamectin together, 
the Rmax was significantly smaller than for derquantel alone and abamectin alone (Figure 
5.4D). Additionally, the effects of the combination were greater than those of 0.1 μM 
derquantel at pyrantel concentrations ≥ 0.3 μM suggesting that the use of abamectin and 
derquantel in combination is likely to be more effective than either one of the two drugs 
administered alone. 
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5.6 Conclusion 
Our observations reveal that abamectin, in addition to its recognized effects on GluCl 
channels also has effects on an UNC-29: UNC-63: UNC-38 subtype of nematode nAChR 
and that the antagonism is non-competitive with a bi-phasic inverse dose-dependent effect 
characteristic of two sites of action. The higher affinity site, a negative allosteric site, 
produces more closing of the nAChR in contrast to the other lower affinity site, a positive 
allosteric site that produces more opening. The significant observation is that lower 
concentrations of abamectin produced greater inhibition of the nAChR than higher 
concentrations. The combination of derquantel and abamectin as StartectR can produce 
inhibition of nematode worm movement and feeding. Derquantel and abamectin inhibits the 
nAChRs; and in addition, abamectin inhibits movement and feeding by activating GluCls. 
The double action of the combination of derquantel and abamectin has the potential to slow 
resistance development in nematode parasites by acting at a number of different sites of 
action. The emergence of resistance in numerous nematode parasite species makes the 
control of helminth infections with the currently available anthelmintics more difficult but 
the recent introduction and careful use of appropriate anthelmintic combinations may be used 
to reduce the rate of development of anthelmintic resistance. It should also be noted that 
effects of abamectin does not involve a simple mode of action and that there are effects on 
more than one LGIC in addition to the GluCls. 
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5.7 Supporting Information 
 
S5.0 Figure Concentration-response plots for acetylcholine in the absence (n = 4, black) and 
presence of 0.1 μM abamectin (n = 4, dark blue), 0.3 μM abamectin (n = 4, dark green) and 1 
μM abamectin (n = 3, pink). Results were normalized to 100 μM acetylcholine current 
responses and expressed as mean ± S.E.M. The standard errors are smaller than the symbols 
and some are not visible. Notice 0.1 μM abamectin caused an inhibition of current responses 
to acetylcholine, and this inhibition was reduced with 0.3 and 1 μM abamectin. 
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S5.1 Figure. Concentration-response plots for acetylcholine in the absence (n = 4, black) and 
presence of 0.3 μM derquantel (n = 4, light purple); 0.1 μM abamectin (n = 4, dark blue); 0.3 
μM derquantel + 0.1 μM abamectin combination (n = 4, olive green). Results were 
normalized to 100 μM acetylcholine current responses and were expressed as mean ± S.E.M. 
The standard errors are smaller than the symbols and some are not visible. Inhibition with 0.3 
μM derquantel + 0.1 μM abamectin combination was greater than that with 0.3 μM 
derquantel alone and 0.1 μM abamectin alone. The calculated additive effect (*) is also 
plotted. 
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S5.0 Table. EC50, Rmax, nH and n numbers for acetylcholine and pyrantel on Ode-UNC-
29:Ode-UNC-63:Ode-UNC-38. 
 
Drug EC50 
(mean ± S.E.M, μM) 
Rmax  
(mean ± S.E.M, % 100 μM 
acetylcholine response) 
nH n 
Acetylcholine   13.0 ± 1.6  114.3 ± 4.3 1.0 ± 0.1 4 
Pyrantel   0.4 ± 0.0  135.5 ± 7.9 1.2 ± 0.1 6 
 
S5.1 Table. EC50, Rmax, nH and n numbers for pyrantel in the absence and presence of 
abamectin on Ode-UNC-29:Ode-UNC-63:Ode-UNC-38. 
 
Drug EC50 
(mean ± S.E.M, μM) 
Rmax  
(mean ± S.E.M, % 100 μM 
acetylcholine response) 
nH n 
Pyrantel 0.4 ± 0.0 135.5 ± 7.9 1.2 ± 0.1 6 
Pyrantel + 0.03 μM 
abamectin 
0.4 ± 0.0 107.3 ± 4.7 0.9 ± 0.1 5 
Pyrantel + 0.1 μM 
abamectin 
0.3 ± 0.0 80.6 ± 8.4 1.2 ± 0.2 6 
Pyrantel + 0.3 μM 
abamectin 
0.3 ± 0.1 98.4 ± 6.5 1.0 ± 0.1 5 
Pyrantel + 1 μM 
abamectin 
0.3 ± 0.1 108.0 ± 3.5 1.2 ± 0.1 6 
Pyrantel + 10 μM 
abamectin 
0.4 ± 0.1 106.0 ± 9.4 1.5 ± 0.4 5 
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S5.2 Table. EC50, Rmax, nH and n numbers for pyrantel in the absence and presence of 
derquantel, abamectin, and a combination of derquantel and abamectin on Ode-UNC-
29:Ode-UNC-63:Ode-UNC-38. 
 
Drug EC50 
(mean ± S.E.M, μM) 
Rmax  
(mean ± S.E.M, % 100 μM 
acetylcholine response) 
nH n 
Pyrantel 0.4 ± 0.0 135.5 ± 7.9 1.2 ± 0.1 6 
Pyrantel + 0.1 μM 
derquantel 
0.4 ± 0.0 69.4 ± 1.1 1.1 ± 0.1 4 
Pyrantel + 0.3 μM 
abamectin 
0.3 ± 0.1 98.4 ± 6.5 1.0 ± 0.1 5 
Pyrantel + 0.1 μM 
derquantel + 0.3 μM 
abamectin 
0.3 ± 0.1 60.9 ± 2.3 0.9 ± 01 6 
 
S5.3 Table. EC50, Rmax, nH and n numbers for acetylcholine in the absence and presence of 
0.1 μM, 0.3 μM and 10 μM abamectin on Ode-UNC-29:Ode-UNC-63:Ode-UNC-38. 
 
Drug EC50 
(mean ± S.E.M, μM) 
Rmax  
(mean ± S.E.M, % 100 μM 
acetylcholine response) 
nH n 
Acetylcholine 13.0 ± 1.6 114.3 ± 4.3 1.0 ± 0.1 4 
Acetylcholine + 0.1 μM 
abamectin 
14.0 ± 1.1 75.1 ± 2.0 1.3 ± 0.1 4 
Acetylcholine + 0.3 μM 
abamectin 
11.6 ± 1.0 98.5 ± 4.7 1.1 ± 0.0 4 
Acetylcholine + 1 μM 
abamectin 
14.4 ± 1.0 99.6 ± 1.6 1.1 ± 0.1 3 
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S5.4 Table. EC50, Rmax, nH and n numbers for acetylcholine in the absence and presence of 
derquantel, abamectin, and a combination of derquantel and abamectin on Ode-UNC-
29:Ode-UNC-63:Ode-UNC-38. 
 
Drug EC50 
(mean ± S.E.M, μM) 
Rmax  
(mean ± S.E.M, % 100 μM 
acetylcholine response) 
nH n 
Acetylcholine 13.0 ± 1.6 114.3 ± 4.3 1.0 ± 0.1 4 
Acetylcholine + 0.3 μM 
derquantel 
16.6 ± 1.1 32.1 ± 1.9 1.4 ± 0.1 4 
Acetylcholine + 0.1 μM 
abamectin 
14.0 ± 1.1 75.1 ± 2.0 1.3 ± 0.1 4 
Acetylcholine + 0.3 μM 
derquantel + 0.1 μM 
abamectin 
15.8 ± 1.6 17.2 ± 1.6 1.5 ± 0.2 4 
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CHAPTER 6. GENERAL DISCUSSION 
Many of the currently available anthelmintics used to control parasitic nematode 
infections act on nematode ion channels. However, there are a limited number of these 
anthelmintics and their repeated use has led to increasing worldwide reports of anthelmintic 
resistance development. Thus, the increased need for the development of alternative 
strategies to slow down or overcome the resistance problem. This PhD research has 
addressed three strategies by which resistance can be slowed or overcome. These include: (i) 
the identification of a new drug target ACR-16, (ii) identifying new therapeutic compounds 
from plant natural sources, and (iii) understanding interactions of drugs used in combination 
therapy. 
ACR-16 is an 7-like nAChR that forms homomeric receptors in nematodes. Earlier 
studies have focused on the cloning and expression of ACR-16 from the free-living model 
nematode, C. elegans. We have showed for the first time the cloning and expression of ACR-
16 from a parasitic nematode, A. suum. We have demonstrated that although A. suum ACR-
16 shares a high degree of similarity with C. elegans ACR-16, these two receptors have 
significant differences in antagonist pharmacology. We have shown that A. suum ACR-16 is 
different from the carefully studied levamisole receptors. A. suum ACR-16 is insensitive to 
levamisole (and other cholinomimetic anthelmimntics) but very sensitive to nicotine. Based 
on these differences with levamisole receptors, developing drugs that target A. suum ACR-16 
may circumvent resistance. Importantly, A. suum ACR-16 though closely related to 
vertebrate 7 receptors showed striking differences in sensitivity to -BTX, allosteric 
modulation and calcium permeability which could be related to differences in key amino acid 
residues known to affect 7 receptor pharmacology. Therefore, targeting sites in A. suum 
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ACR-16 that are distinct from vertebrate 7 receptors are unlikely to affect the vertebrate 
host. 
We have demonstrated that plant natural products have potential as sources of lead 
compounds for the development of macrofilaricidal drugs. We have showed that there is 
some validity for the traditional uses of D. oliveri and P. febrifugum in the treatment of 
filarial infections and that extracts from the medicinal plants D. oliveri and P. febrifugum are 
useful to medical practice. Our work focused on D. oliveri because extracts of this plant 
showed good activity against adult O. ochengi and B. pahangi, in addition to activity against 
O. ochengi microfilariae. This is interesting because a desirable anthelmintic drug is one that 
has a broad spectrum of action against various parasite species. Therefore, our study has shed 
more light on the discovery of novel therapeutic drugs from traditionally used plants. We 
have also demonstrated that D. oliveri has potential as a natural source for isolating 
macrofilaricidal compounds that would contribute to more effective control or elimination of 
filarial infections. 
Finally, we have identified at least one mechanism in which a combination therapy is 
more effective than single drug approach. We showed that abamectin not only acts on GluCls 
but also has potent effects on pyrantel/tribendimidine nAChRs in O. dentatum. The inhibitory 
effect of abamectin on nAChRs increases the inhibition caused by derquantel (the other 
component of the combination therapy).   
Future Directions 
We would recommend more experiments be done in order to further validate ACR-16 
as a potential drug target for anthelmintic development. First, we would recommend the 
expression of ACR-16 in a mammalian cell line which will provide a platform for high 
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throughput screening. Once this is done, various compounds known to be specific for the 
closely related human 7 receptors should be tested on ACR-16. Doing so will confirm our 
observations in electrophysiology studies that ACR-16’s pharmacology is different from that 
of human 7, thus, confirming ACR-16 is a potential anthelmintic drug target. Since we have 
demonstrated that ACR-16, unlike levamisole receptors desensitizes quickly, we would not 
recommend the use of specific agonists as anthelmintic compounds. An agonist effect would 
not produce long term inhibition of ACR-16 mediated behaviors. Additionally, the 
observation that acr-16 null C. elegans have a close to wild-type phenotype implies that 
antagonists are also unlikely to be effective. We propose that research should focus on the 
discovery of positive allosteric modulators of ACR-16 as the most attractive potential drugs. 
For the filaricidal plant extracts, we intend to pursue the following: (i) active HPLC 
fractions will be further purified to allow for isolation of the compounds that are responsible 
for biological activity, (ii) structure-activity relationship studies will be exploited to increase 
the potency of the identified compounds if necessary, (iii) the mode of action of lead 
compounds will be determined, (iv) various combinations of bioactive compounds will be 
tested for synergistic effects as potential combination therapies, and (v) the efficacy and 
safety of identified compounds will be evaluated in both in vitro and in vivo systems. 
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A1.0 Abstract 
Nicotinic acetylcholine receptors (nAChRs) of parasitic nematodes are required for 
body movement and are targets of important “classical” anthelmintics like levamisole and 
pyrantel, as well as “novel” anthelmintics like tribendimidine and derquantel. Four 
biophysical subtypes of nAChR have been observed electrophysiologically in body muscle of 
the nematode parasite Oesophagostomum dentatum, but their molecular basis was not 
understood. Additionally, loss of one of these subtypes (G 35 pS) was found to be associated 
with levamisole resistance. In the present study, we identified and expressed in Xenopus 
oocytes, four O. dentatum nAChR subunit genes, Ode-unc-38, Ode-unc-63, Ode-unc-29 and 
Ode-acr-8, to explore the origin of the receptor diversity. When different combinations of 
subunits were injected in Xenopus oocytes, we reconstituted and characterized four 
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pharmacologically different types of nAChRs with different sensitivities to the cholinergic 
anthelmintics. Moreover, we demonstrate that the receptor diversity may be affected by the 
stoichiometric arrangement of the subunits. We show, for the first time, different 
combinations of subunits from a parasitic nematode that make up receptors sensitive to 
tribendimidine and derquantel. In addition, we report that the recombinant levamisole-
sensitive receptor made up of Ode-UNC-29, Ode-UNC-63, Ode-UNC-38 and Ode-ACR-8 
subunits has the same single-channel conductance, 35 pS and 2.4 ms mean open-time 
properties, as the levamisole-AChR (G35) subtype previously identified in vivo. These data 
highlight the flexible arrangements of the receptor subunits and their effects on sensitivity 
and resistance to the cholinergic anthelmintics; pyrantel, tribendimidine and/or derquantel 
may still be effective on levamisole-resistant worms. 
A2.0 Author Summary 
Parasitic nematode infections of humans and animals are world-wide. In humans, 
they cause disease and perpetuate a cycle of poverty. In animals, the parasites cause welfare 
problems and production loss. In developing countries, the debilitating effect of nematode 
parasites in school children limits their education, and in adults reduces productivity. These 
two factors, along with the production loss associated with nematode infections of animals 
that affects human nutrition, sustain poverty. Treatment and prophylaxis of these parasites 
requires the use of anthelmintic drugs. Here, we employ the Xenopus oocyte expression 
system to investigate the diversity of anthelmintic receptors in the parasitic nematode 
Oesophagostomum dentatum. We demonstrate effects of the ‘novel’ anthelmintics 
tribendimidine and derquantel on these reconstituted receptors, revealing, for the first time, 
the subunits that make up a tribendimidine- and derquantel-sensitive receptor from a parasitic 
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nematode. We show that the receptor structure and pharmacology can be plastic, and depends 
on subunit composition and stoichiometry. The factors that affect the diversity of the receptor 
may contribute to anthelmintic resistance. Our results demonstrate the presence of 
acetylcholine receptor subtypes that may serve as anthelmintic targets and suggest that 
pyrantel, tribendimidine and/or derquantel may still be effective on levamisole-resistant 
worms. 
A3.0 Introduction 
Human nematode parasite infections are of public health concern in many developing 
countries where over a billion people are infected [1], [2]. Also very important for human 
nutrition are infections of livestock which cause significant production loss [3]. Treatment 
and prophylaxis for these nematode infections requires the use of anthelmintic drugs because 
sanitation is limited and vaccines are not available. Disturbingly, the regular use of 
anthelmintics has now been associated with treatment failures and gives rise to concerns 
about the development of resistance. Resistance has been seen, for example, against 
levamisole and pyrantel in animals [4]. These two ‘classic’ anthelmintics work by selectively 
opening ligand-gated nicotinic acetylcholine (nAChR) ion-channels of nematode muscle to 
produce depolarization, entry of calcium, contraction and spastic paralysis [5]. The nAChR is 
composed of 5 transmembrane subunits which surround the cation permeable channel pore. 
The importance of nAChRs has increased recently because of the introduction of novel 
cholinergic anthelmintics including: the agonist tribendimidine, which has been approved for 
human use in China [6]; the allosteric modulator monepantel [7], [8]; and the antagonist 
derquantel [9]. Tribendimidine is a symmetrical diamidine derivative of amidantel effective 
against Ascaris, hookworms, Strongyloides stercolaris, trematodes and tapeworms [10]. 
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Molecular experiments using the free-living model nematode C. elegans suggest that 
tribendimidine acts as a cholinergic agonist like levamisole and pyrantel [11]. Derquantel is a 
2-desoxo derivative of paraherquamide in the spiroindole drug class effective against various 
species of parasitic nematodes, particularly the trichostrongylid nematodes [12]. Derquantel 
is a selective competitive antagonist of nematode muscle nAChRs especially on the B-
subtype nAChR from Ascaris suum [13]. In contrast to levamisole and pyrantel sensitive-
nAChRs [14], [15], [16], the molecular basis for the action of tribendimidine and derquantel 
in parasitic nematodes are still not known. The chemical structures of the cholinergic 
anthelmintics are different and resistance to one of the cholinergic anthelmintics sometimes 
does not give rise to cross-resistance to other cholinergic anthelmintics [17]. These 
observations imply that the nAChR subtypes in nematode parasites may represent distinct 
pharmacological targets sensitive to different cholinergic anthelmintics. Therefore, in the 
present work, we have investigated mechanistic explanations for the variability and diversity 
of the cholinergic receptors of parasitic nematodes and their therapeutic significance. 
The model nematode, C. elegans, possesses two muscle nAChR types: one sensitive 
to levamisole and one sensitive to nicotine [18]. The levamisole AChR type is composed of 
the five subunits, Cel-UNC-29, Cel-UNC-38, Cel-UNC-63, Cel-LEV-1 and Cel-LEV-8 [18], 
[19], [20], [21], [22]. The nicotine-AChR type is a homopentamer composed of Cel-ACR-16 
subunits [23]. In Ascaris suum, there are three pharmacologically separate nAChR types on 
the body muscle: the N-type that is preferentially activated by nicotine; the L-type that is 
preferentially activated by levamisole and; the B-type that is preferentially activated by 
bephenium [13]. In Oesophagostomum dentatum there are four muscle nAChRs which are 
defined by their single-channel conductances: G 25 pS, G 35 pS, G 40 pS and G 45 pS. The 
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G 35 pS receptor type of O. dentatum is reduced in a levamisole-resistant isolate [24] but not 
in a pyrantel-resistant isolate [25]. Interestingly, the G 35 pS type of O. dentatum has a 
similar channel conductance to the L-type from the distantly related species, A. suum [13]. 
However, the precise molecular mechanisms of levamisole and pyrantel resistance 
occurring in O. dentatum isolates are still unknown because the O. dentatum genes encoding 
muscle nAChR subunits have not yet been identified. In order to determine a mechanistic 
explanation for the variability and pharmacological diversity of the muscle nAChR types in 
parasitic nematodes like Oesophagostomum dentatum, we took advantage of the Xenopus 
oocyte expression system [14], [26], [27]. 
In this study our first objective was to clone the four putative subunit genes Ode-unc-
38, Ode-unc-29 Ode-unc-63 and Ode-acr-8, which are homologues of the C. elegans 
levamisole muscle receptor genes [15], [16] and express them in Xenopus laevis oocytes to 
recapitulate the levamisole-sensitive AChRs of O. dentatum. In a previous study on H. 
contortus which is closely related to O. dentatum, we have reported that co-expression of 
four AChR subunits (Hco-UNC-38, Hco-UNC-63, Hco-UNC-29 and Hco-ACR-8) in 
Xenopus oocytes resulted in the robust expression of a levamisole sensitive nAChR [16]. In 
the present work we have identified and cloned the homologs of the corresponding genes in 
O. dentatum (Ode-unc-38, Ode-unc-63, Ode-unc-29 and Ode-acr8) and express them in 
Xenopus oocytes. Of particular note is the evidence that these receptor subtypes are 
pharmacological targets of the new anthelmintic tribendimidine. Moreover, we demonstrate 
that the nAChR reconstituted with all four subunits is more sensitive to levamisole than 
pyrantel and has a single channel conductance of 35 pS, corresponding to the L-type 
previously observed in vivo in O. dentatum and A. suum. Another receptor type, made of 3 
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subunits, was more sensitive to pyrantel and the new anthelmintic derquantel had a selective 
effect against receptors activated by pyrantel rather than levamisole, providing the first 
insight of its molecular target composition in any parasitic nematode. These results provide a 
basis for understanding the greater diversity of the nAChR repertoire from parasitic 
nematodes and for deciphering the physiological role of nAChR subtypes targeted by distinct 
cholinergic anthelmintics. This study will facilitate more rational use of cholinergic 
agonists/antagonists for the sustainable control of parasitic nematodes impacting both human 
and animal health. 
A4.0 Results 
A4.1 Identification of unc-29, acr-8, unc-38 and unc-63 homologues from O. 
dentatum and phylogenetic comparison to related nematode species 
Taking advantage of the phylogenetic closeness of O. dentatum, C. elegans and H. 
contortus in clade V of the nematode phylum, we used a candidate gene approach to identify 
full-length subunit cDNAs from O. dentatum of unc-63, unc-29 and acr-8 homologues. The 
previously available O. dentatum unc-38-like full-length cDNA sequence (Accession number 
GU256648) allowed the rapid cloning of the Ode-unc-38 subunit cDNA. The UNC-38 and 
UNC-63 subunits being closely related in the UNC-38 “core” group [28], multi-alignment of 
unc-63 and unc-38 cDNA sequences from different nematode species allowed the design of 
degenerate primers that were able to specifically amplify the unc-63 homologue from O. 
dentatum. To identify the unc-29 homologue from O. dentatum, degenerate primers from the 
H. contortus and C. elegans unc-29 sequences were used to amplify a partial 288 bp cDNA 
sequence, providing specific information to get the full-length cDNA by RACE-PCR 
standard procedures. To identify the acr-8 homologue from O. dentatum, a partial cDNA of 
204 
 
861 bp was cloned using primers from H. contortus acr-8, allowing subsequent identification 
of the full-length cDNA encoding Ode-ACR-8 subunit. The four O. dentatum subunit 
transcripts were trans-spliced at their 5′end with the splice leader 1 (SL1). The predicted 
nAChR proteins displayed typical features of LGIC subunits including a secretion signal 
peptide, a cys-loop domain consisting of 2 cysteines separated by 13 amino acid residues and 
four transmembrane domains (TM1-4) (supplemental figure S1A–D). The Ode-UNC-38, 
Ode-UNC-63 and Ode-ACR-8 subunits contained in their N-terminal part the Yx(x)CC motif 
characteristic of the α-type subunits whereas the Ode-UNC-29 subunit sequence lacked these 
vicinal di-cysteines. The different nAChR subunit sequences, accession numbers, 
characteristics and closest levamisole subunit homologues of C. elegans and H. contortus are 
presented in Table 1. Alignment of the deduced amino acid sequences of the four O. 
dentatum nAChR subunits revealed 66 to 92% identity with their respective homologues 
from C. elegans and H. contortus (Table 1 and supplemental Fig. S1A–D), indicating that 
even in closely related species some interspecies polymorphisms could impact the nAChR 
subunit composition and pharmacological properties. The phylogenies shown in Fig. 1 
(maximum likelihood tree) and supplemental Fig. S2 (distance tree) identify a single ortholog 
each for the unc-38, unc-63, acr-8, and unc-29 subunits in O. dentatum. The branching 
topology is consistent, in each case, with a taxonomic position of O. dentatum with 
strongylida and outside the trichstrongyloidea [29]. Interestingly, this topology places the 
speciation of O. dentatum significantly before the previously identified trichostrongylid 
specific unc-29 diversification event [15]. As such, these duplications cannot be shared with 
O. dentatum, although it is not possible to rule out other independent unc-29 duplication 
events in O. dentatum. Clearly, further studies that include analysis of unc-29 homolog  
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Figure 1. Maximum likelihood tree showing relationships of acetylcholine receptor (nAChR) 
subunit cDNA sequences in Oesophagostomum dentatum (Ode, highlighted in red), 
Caenorhabditis elegans (Cel), Haemonchus contortus (Hco) and Teladorsagia circumcincta 
(Tci). The C. elegans acr-16 nAChR subunit sequence was used as an outgroup. Branch 
support was evaluated using the chi2 option of PhyML and values more than 0.9 were 
considered reliable. 
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Table 1. Comparison of O. dentatum AChR subunits with the homologs of C. elegans and H. 
contortus. 
 
 
 
sequences in a wide range of nematode species are required to understand the evolutionary 
impact of such duplication events. 
A4.2 Expression of Ode(29-63), the Pyr-nAChR and stoichiometry effect on 
pharmacological properties 
Our investigation of O. dentatum receptor expression determined the minimum 
number of subunits that is required to reconstitute a functional muscle nAChR. Previous 
expression studies of C. elegans and H. contortus functional nAChRs in Xenopus oocytes 
required the use of ancillary proteins [16], [26]. Hence, the H. contortus ancillary factors 
Hco-ric-3, Hco-unc-50 and Hco-unc-74 were also injected to facilitate the expression of O. 
dentatum functional receptors in Xenopus oocytes. In control experiments we observed that 
oocytes injected with ancillary protein cRNAs did not produce current responses to 100 µM 
acetylcholine or other cholinergic anthelmintics. We then injected different combinations of 
pairs of cRNAs (1∶1) of: Ode-unc-29, Ode-unc-38, Ode-unc-63 and Ode-acr-8. 
Only those oocytes injected with 1∶1 Ode-unc29∶Ode-unc-63 cRNA, regularly 
produced currents of >50 nA in response to 100 µM acetylcholine or cholinergic 
anthelmintics, indicating that the two subunits could form functional receptors (Fig. 2). We  
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Figure 2. Voltage-clamp of oocytes injected with O. dentatum Ode-unc-29 and Ode-unc-63 
nAChR subunits. (A) Diagram of possible subunit arrangements of Ode-unc-29 and Ode-
unc-63. X represents either UNC-63 or UNC-29 subunit. PyR, pyrantel; Tbd, tribendimidine, 
ACh, acetylcholine; Nic, nicotine; Bep, bephenium; The, thenium. (B) Representative traces 
showing the inward currents in oocytes injected with 1∶1 Ode-unc-29 and Ode-unc-63. (C) 
Bar chart (mean ± se) of agonists-elicited currents in the Ode-(29 - 63) Pyr-nAChR, (paired 
t-test, **p<0.01, ***p<0.001). All agonist responses have been normalized to the average 
100 µM ACh currents. (D) Dose-response relationships for Pyr (inverted Δ, n = 6), Tbd (▴, 
n = 5) and ACh (•, n = 6) in the Ode-(29 - 63) Pyr-nAChR, (n = number of oocytes). (E) Bar 
chart (mean ± se) of normalized currents elicited by different agonists in 1∶5 Ode-unc-
29∶Ode-unc-63 injected oocytes. Currents have been normalized to and compared with 100 
µM ACh currents (paired t-test, **p<0.01, ***p<0.001). (F) Bar chart (mean ± se) of 
normalized currents elicited by different agonists in oocytes injected with 5∶1 Ode-unc-
29∶Ode-unc-63. Currents normalized to and compared with 100 µM ACh currents (paired t-
test, *p<0.05, **p<0.01). 
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found that no other paired combination produced currents. Without both subunits in any of 
our subsequent injected mixes, no functional receptor could be reconstituted, demonstrating 
that Ode-UNC-29 and Ode-UNC-63 are essential O. dentatum levamisole receptor subunits. 
Injection of each of these subunits alone did not form receptors that responded to the agonists 
we tested, demonstrating that these subunits do not form homopentamers. 
More than 75% of injected oocytes responded to acetylcholine. For our standard test 
concentrations, except for 100 µM acetylcholine and 100 µM levamisole, we used 30 µM 
drug concentrations of different important anthelmintics to limit effects of open-channel 
block. Interestingly, the novel anthelmintic tribendimidine elicited currents when perfused on 
oocytes expressing Ode-UNC-29 and Ode-UNC-63. The potency series of the agonists 
(anthelmintics) based on the normalized currents, Fig. 2C, was: 30 µM pyrantel >30 µM 
tribendimidine >30 µM nicotine ≈100 µM levamisole ≈100 µM acetylcholine. Neither 30 
µM bephenium, nor 30 µM thenium, were active. Even at 30 µM, pyrantel produced currents 
bigger than 100 µM acetylcholine (Fig. 2C). We refer to this receptor type as: Ode(29–63), 
or the Pyr-nAChR. 
We determined the concentration current-response plot for pyrantel, tribendimidine 
and acetylcholine, Fig. 2D for Ode(29–63). The EC50 values for pyrantel and tribendimidine 
were less than the EC50 for acetylcholine but the Imax values were larger for pyrantel and 
tribendimidine (Table 2). Thus the anthelmintics pyrantel and tribendimidine were much 
more potent and produced a greater maximum response than the natural ligand, acetylcholine 
and levamisole on this type of receptor. To date, this result represents the first 
characterization of a nematode tribendimidine-sensitive nAChR. 
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Table 2. Properties of the four main receptor subtypes obtained from dose-response 
relationships. 
 
 
 
We were interested to see if there was evidence of pharmacological changes 
associated with variation in stoichiometry of the Ode(29-63) receptor. When we injected a 
1∶5 ratio of Ode-unc-29∶Ode-unc-63 cRNA with the same 1∶1∶1 ratio of ancillary proteins, 
the mean amplitudes of the pyrantel and tribendimidine currents were significantly increased 
(pyrantel: 6-fold increase from a mean of 104 nA to 653 nA, p<0.01; tribendimidine: 7-fold 
increase from a mean of 68 nA to a mean of 447 nA, p<0.01). The large increase in the size 
of the currents with increased Ode-unc-63 cRNA suggests that increased UNC-63 favors 
expression of receptors with a stoichiometry of (UNC-63)3∶ (UNC-29)2 [14]. Also, when we 
injected 5∶1 Ode-29∶Ode-63 cRNA, the normalized currents of 30 µM nicotine and 100 µM 
levamisole became significantly bigger than 100 µM acetylcholine (Fig. 2C, E &F) 
suggesting increased expression of (UNC-63)2∶ (UNC-29)3. The increase in currents with the 
1∶5 and 5∶1 Ode-29∶Ode-63 cRNA was not due to variability in currents with different 
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batches of oocytes because we observed the same effects when we injected 1∶1, 1∶5 and 5∶1 
Ode-29∶Ode-63 cRNA in the same batch of oocytes. 
A4.3 Expression of Ode(29-63-38), the Pyr/Tbd-nAChR 
We subsequently added unc-38 and injected Ode-unc-29∶Ode-unc-63∶Ode-unc-38 
cRNAs in the ratio 1∶1∶1, along with the three H. contortus ancillary factors. Oocytes 
injected with this mix responded with larger currents of around 250 nA to 100 µM 
acetylcholine and to all the other agonists tested except bephenium and thenium (Fig. 3A–D). 
Pyrantel was the most potent agonist but with this receptor type, pyrantel and tribendimidine 
produced the same amplitude of current at 30 µM. We termed this receptor the Ode(29–63–
38), or the Pyr/Tbd-nAChR. The potency series of the agonists based on the normalized 
currents was 30 µM pyrantel ≈30 µM tribendimidine >100 µM acetylcholine >30 µM 
nicotine ≈100 µM levamisole (Fig. 3 C). The dose-response curves for pyrantel, 
tribendimidine and acetylcholine are shown in Fig. 3D. The EC50 for pyrantel was less than 
the EC50 for tribendimidine and acetylcholine (Table 2). The Hill slopes for tribendimidine 
and acetylcholine were both close to 1.0 (Table 2), showing little co-operativity between 
agonist concentration and response. Again interestingly, the two anthelmintics, pyrantel and 
tribendimidine were more potent than the natural ligand and the anthelmintic levamisole, but 
with this receptor type, the currents were larger than with the Ode(29–63) receptor. 
A4.4 Expression of Ode(29-63-8), the ACh-nAChR 
When we added Ode-acr-8 and injected Ode-unc-29∶Ode-unc-63∶Ode-acr-8 cRNA in 
the ratio 1∶1∶1 along with the three H. contortus ancillary factors into the oocytes, we 
observed even bigger receptor responses to 100 µM acetylcholine. We also observed 
responses to all the agonists we tested, including bephenium and thenium (Fig. 3E–H), which 
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Figure 3. Voltage-clamp of oocytes injected with different combinations of the four O. 
dentatum nAChR subunits. (A) Depiction of a possible arrangement of O. dentatum UNC-29, 
UNC-63 & UNC-38. ‘X’ represents any of the subunits. PyR, pyrantel; Tbd, tribendimidine, 
ACh, acetylcholine; Nic, nicotine; Bep, bephenium; The, thenium. (B) Representative traces 
of inward currents elicited by the various agonists in oocytes injected with 1∶1∶1 Ode-unc-
29∶Ode-unc-63∶Ode-unc-38. Pyr & Tbd were the most potent agonists on this receptor 
subtype. (C) Bar chart (mean ± se) of currents elicited by the different agonists in the Ode-
(29 - 38 - 63) Pyr/Tbd-nAChR (paired t-test, **p<0.01, ***p<0.001). (D) Dose-response of 
normalized currents vs log concentration for Pyr (inverted Δ, n = 6), Tbd (▴, n = 6) and ACh (•, 
n = 5) in the Pyr/Tbd-nAChR. (E) Diagrammatic representation of the three subunits, unc-29, 
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unc-63 and acr-8 injected into oocytes. ‘X’ could be any of the three subunits. (F) 
Representative traces of inward currents produced by the different agonists in oocytes 
injected with 1∶1∶1 Ode-unc-29∶Ode-unc-63∶Ode-acr-8. (G) Bar chart (mean ± se) of 
normalized currents elicited by the different agonists in the Ode(29-63-8) receptor subtype. 
All currents normalized to 100 µM ACh currents; comparisons made with the ACh currents 
(paired t-test, *p<0.05, **p<0.01, ***p<0.001). (H) Dose-response plot of normalized 
currents vs log. Concentration of Pyr (inverted Δ, n = 6), Tbd (▴, n = 6), ACh (•, n = 6) and Lev 
(▪, n = 6). (I) Representation of a possible arrangement of the four O. dentatum subunits 
injected into Xenopus oocytes. (J) Representative traces of inward currents elicited by the 
different agonists on the Ode(29–63–38–8) or Lev-nAChR. (K) Bar chart (mean ± se) of 
normalized currents elicited by the different agonists on the Lev-nAChR subtype. 
Comparisons were made with 100 µM ACh currents, which was used for the normalization 
(paired t-test, ***p<0.001). (L) Dose-response plot of normalized currents against log of Tbd 
(▴, n = 6), ACh (•, n = 18) and Lev (○, n = 5) concentrations. 
 
suggests that Ode-acr-8 introduces bephenium and thenium binding sites. 100 µM 
acetylcholine produced the largest current responses, always greater than 800 nA and 
sometimes greater than 1 µA. We termed this receptor type: Ode(29–63–8), or the ACh-
nAChR. 
For the Ode(29–63–8) receptor, the potency series of the agonists (anthelmintics) 
based on the normalized currents, was 100 µM acetylcholine >30 µM tribendimidine ≈100 
µM levamisole ≈30 µM pyrantel >30 µM nicotine ≈30 µM thenium ≈30 µM bephenium 
(Fig. 3G). Here, the least potent agonists were nicotine, bephenium and thenium with average 
currents <20% of the acetylcholine currents. The dose-response curves (Fig. 3H) show that at 
the highest concentrations tested, levamisole and tribendimidine current responses were less 
than that of acetylcholine. Despite this, the EC50 values of both tribendimidine and 
levamisole were lower than acetylcholine on this receptor type. The EC50 values are 
summarized in Table 2. The levels of co-operativity (slope) were similar for these three 
agonists, but Imax for acetylcholine (100.0%) was bigger than Imax for tribendimidine 
(75.0±6.2%) and levamisole (73.0±2.4%). 
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Two characteristic features of the response of the Ode(29–63–8) receptor to pyrantel 
suggest the presence of open-channel block which is more pronounced with Ode(29–63–8) 
than with the other types. Firstly, the maintained application of 30 µM pyrantel produced a 
response that declined rapidly despite the concentration being maintained, and secondly, on 
wash-out of pyrantel the response ‘rebounded’ or increased temporally before declining. 
Pronounced open-channel block with pyrantel has been observed at the single-channel level 
[30]. Altogether, these results highlight for the first time the reconstitution of a new 
functional receptor with distinct pharmacological profile made of the UNC-29, UNC-63 and 
ACR-8 subunits. 
A4.5 Expression of Ode(29-63-8-38), the Lev-nAChR 
Finally, we injected all our subunits in a mix of Ode-unc-29∶Ode-unc-63∶Ode-acr-
8∶Ode-unc-38 cRNA in the ratio 1∶1∶1∶1 along with the three H. contortus ancillary factors. 
These subunits reconstituted a receptor type on which 100 µM levamisole produced the 
biggest responses of >1.5 µA, sometimes reaching >4.5 µA, Fig. 3I–L. We termed this 
receptor type: Ode(29–63–8–38) or the Lev-nAChR. The potency series of the agonists based 
on the normalized currents, was 100 µM levamisole >100 µM acetylcholine >30 µM 
tribendimidine >30 µM thenium ≈30 µM bephenium ≈30 µM pyrantel >30 µM nicotine (Fig. 
3K). Here, the least potent agonists were thenium, bephenium, pyrantel and nicotine with 
average currents <25% of the acetylcholine currents. The EC50 for tribendimidine was less 
than the EC50 for levamisole and acetylcholine (Table 2). The dose-response curves were 
rather shallow with Hill slopes less than one for acetylcholine, levamisole and tribendimidine 
(Table 2). We have shown that expression of Ode-UNC-29, Ode-UNC-63 Ode-ACR-8 and 
Ode-UNC-38 produced large currents, and that the receptor, Ode(29–63–8–38), was most 
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sensitive to levamisole. It is clear from the observations above that each of the four subunits: 
Ode-UNC-29, Ode-UNC-63 Ode-ACR-8, and Ode-UNC-38 may combine and be adjacent to 
different subunits as they form different pentameric nAChRs. 
A4.6 Antagonistic effects of derquantel 
We tested the antagonist effects of derquantel on the levamisole and pyrantel 
concentration-response plots of Ode (29-63-38-8) and Ode (39-63-38), Fig. 4A–D. Recall 
that levamisole is more potent as an agonist on Ode(29–63–8–38) and pyrantel is more potent 
on Ode(39-63-38). Fig. 4A shows that derquantel behaves like a potent competitive 
antagonist of levamisole, with 0.1 µM producing a right shift in EC50 dose-ratio of 1.7 (the 
antagonist negative log dissociation constant from the Schild equation, pKB, was 6.8±0.1). 
When we tested the antagonist effects of derquantel on Ode(29–63–8–38) using pyrantel as 
the agonist, we saw mixed non-competitive and competitive antagonism: there was a right-
shift in the EC50 and a reduction to 41% of the maximum response by 0.1 µM derquantel, 
Fig. 4 B. One explanation for these mixed effects of derquantel is that co-expression of 
UNC-29, UNC-63, UNC-38, ACR-8 subunits produces a mixture of receptors: mostly 
Ode(39-63-38-8) receptors that are preferentially activated by levamisole and which are 
competitively antagonized by derquantel and; a smaller number of receptors like Ode(39-63-
38) that are preferentially activated by pyrantel and antagonized non-competitively by 
derquantel. To test this further we examined the antagonist effects of derquantel on pyrantel 
and levamisole activation of Ode (39-63-38). Derquantel antagonized both agonists non-
competitively, Fig. 4 C & D. We interpret these observations to suggest that expression of 
Ode(39-63-38-8) receptors can give rise to expression of a smaller number of other receptors  
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Figure 4. Effects of derquantel on levamisole-activated and pyrantel-activated expressed 
Ode(29-63-8-38), the Lev-nAChR, and on pyrantel-activated and levamisole-activated 
Ode(29-63-38), the PyR/Trbd-nAChR subtypes. Der: derquantel; Lev: levamisole; Pyr: 
pyrantel. (A) Antagonistic effects of varying derquantel concentrations on levamisole 
currents of Ode(29-63-8-38). Levamisole evokes supramaximal normalized currents and 
derquantel competitively inhibited levamisole currents. (B) Derquantel antagonism of 
pyrantel currents of Ode(29-63-8-38). Here, derquantel produced mixed non-competitively 
competitive antagonism. Pyrantel did not activate supramaximal currents. (C) Antagonism of 
pyrantel by derquantel on the Ode(29-63-38), Pyr/Tbd-nAChR. Derquantel is a potent non-
competitive antagonist. (D) Derquantel non-competitively antagonized levamisole responses 
on the Ode(29-63-38) receptor. 
 
including Ode(39-63-38). We comment further on these observations in our discussion. 
Nonetheless, the competitive and non-competitive antagonism of derquantel when levamisole 
is used on the two different receptor subtypes, Fig. 4 A & D, illustrates that derquantel 
effects are subtype selective. 
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A4.7 The receptor types have different calcium permeabilities 
The EC50 concentrations of acetylcholine for the different expressed receptors varied 
(Table 2), suggesting that there are different physiological functions for the different nAChR 
types. One physiological difference may be the permeability to the second messenger, 
calcium. To examine this we measured the relative permeability of calcium in Ode(29–63–
38), Ode(29–63–8) and Ode(29–63–8–38), receptors which produced large enough currents 
to determine reversal potentials. 
We observed two different effects of increasing calcium from 1 mM to 10 mM on the 
acetylcholine currents. One effect was potentiation of the current amplitudes, an effect that 
was voltage-dependent (Fig. 5A, B & C). The voltage-dependent increases in acetylcholine 
currents was prominent in Ode(29–63–8–38), and less in the other two receptor types. The 
potentiating effect of calcium on the acetylcholine currents indicates the presence of positive 
allosteric binding sites on one or more subunits of the pentameric nAChR [31]. The second 
effect was a positive shift to the right of the current-voltage plot indicating that the channels 
are permeable to calcium [32]. A shift in reversal potential of 1.7 mV was recorded for the 
Ode(29–63–8) (Fig. 5A). Using the Goldman Hodgkin Katz constant field equation (Text S1 
Legend), we calculated this change in reversal potential corresponds to a relative calcium 
permeability ratio, PCa/PNa of 0.5. The reversal potential shift for Ode(29–63–38) was 
similar, 1.3 mV, also giving a permeability ratio PCa/PNa of 0.4 (Fig. 5B). For Ode(29–63–8–
38), the shift was 16.0 mV (Fig. 5C), corresponding to a calcium permeability ratio, PCa/PNa, 
of 10.3. The Ode(29–63–8–38) receptor, was therefore much more permeable to extracellular 
calcium and positively allosterically [31] modulated by extracellular calcium than the other 
two receptor types, a physiologically significant observation. 
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Figure 5. Ca2+ permeability of the O. dentatum receptor subtypes with large ACh currents. 
(A) Current-Voltage plot for oocytes injected with Ode(29–63–8), showing the change in 
current with voltage in 1 mM and 10 mM Ca2+ recording solutions. Insert: Magnified view of 
current-voltage plot from −20 mV to +40 mV showing the Erev in 1 mM and 10 mM 
extracellular Ca2+. (B) Current-Voltage plot for oocytes injected with Ode(29–63–38) 
showing the current changes in 1 mM and 10 mM Ca2+ recording solution under different 
voltages. Insert: Magnified view of current-voltage plot from −20 mV to +40 mV showing 
the Erev in 1 mM and 10 mM extracellular Ca
2+. (C) Current-Voltage plot for oocytes injected 
with Ode(29–63–38–8) in 1 mM and 10 mM Ca2+ recording solutions. Insert: Magnified 
view of current-voltage plot from −20 mV to +40 mV showing the Erev in 1 mM and 10 mM 
extracellular Ca2+. The calcium permeability was calculated using the GHK equation (Text 
S1 Legend). 
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A4.8 Ode(29-63-8-38), Lev-nAChR channels have a mean conductance of 35 pS 
Single-channel studies in Oesophagostomum dentatum body muscle have 
demonstrated the presence of different nAChR types with conductances of 25, 35, 40 and 45 
pS, showing the presence of four or more receptor types. We have shown in experiments 
here, that combinations of four nAChR subunits from this parasite can produce four 
pharmacologically different receptor types. We found that the expressed Ode(29–63–38–8) 
Lev-nAChR type was most sensitive to levamisole and had a high permeability to calcium 
and hypothesized that this type may be the G35 type. Accordingly we investigated the single-
channel properties of this type under patch-clamp using 10 µM levamisole as the agonist. In 
control oocytes injected with only the ancillary proteins, we recorded no nAChR-like channel 
currents in 4 oocytes. We found however, that in patches from oocytes expressing the 
Ode(29–63–8–38) type, that more than 90% of patches contained active, recognizable 
nAChR channels with one main conductance level. Fig. 6A shows representative channel 
currents from one of these patches and its current-voltage plots which had a conductance of 
36.6±0.5 pS (mean ± SE). The mean conductance of channel from patches made from five 
different oocytes was 35.1±2.4 pS. We did not test the effects of different cholinergic 
anthelmintics on channel conductance. The reversal potentials of all plots were close to 0 
mV, an indication that the channel was nonselective and permeable to Cs+ (reversal potential 
of 0 mV). 
We measured the mean open times, τ, at the different potentials and observed values 
of 2.4±0.4 ms at +100 mV and 2.9±0.5 ms at −100 mV (Fig. 6B). The mean open times are 
comparable to the mean open times recorded in vivo in O. dentatum with the same 
concentration of levamisole. 
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Figure 6. Single-channel properties of the Lev-nAChR subtype. (A) Representative current-
voltage plot from oocyte-attached patch with 10 µM levamisole. Inserts are representative 
channel openings at +75 mV and −75 mV membrane potentials. Even with 10 µM 
levamisole, we sometimes observed ‘flickering’ channel block events; note the ‘flickering’ 
channel block shown by openings at −75 mV. (B) Bar chart (mean ± se) of the mean open 
times (τ) at the different patch potentials. (C) Bar chart (mean ± se) of the probability of 
channel opening, Po, at the different patch potentials. 
 
 
A4.9 The three ancillary proteins affect expression levels 
We tested the requirements for the ancillary proteins, RIC-3, UNC-50 and UNC-74, 
by removing each of the ancillary proteins in turn when expressing the Ode(29–63–8–38) 
receptor. We found that the requirement for all the ancillary proteins was not essential and 
that each protein, when absent reduced currents produced by the expressed receptors (Fig. 
S3). When all the ancillary factors were removed, we observed no measurable currents in 
response to acetylcholine. Here, we have observed that unlike in C. elegans, robust 
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functional O. dentatum receptors can be reconstituted when one of these three ancillary 
factors is omitted and that the ancillary proteins can affect the balance of the pharmacology 
of the receptors expressed (Fig. S3) 
A5.0 Discussion 
A5.1 The origin of diverse nAChR types in parasitic nematodes 
We have shown previously in the parasitic nematodes, O. dentatum [24] and A. suum 
[13], that there are diverse types of nAChR on body muscle of parasitic nematodes which 
may be activated by cholinergic anthelmintics. In A. suum we found that these types have 
different sensitivities to different cholinergic anthelmintics like levamisole and derquantel. In 
O. dentatum there are four types that can be distinguished by their single-channel 
conductance, with reduced numbers of the G 35 pS type in levamisole resistant isolates. Here 
we explored and tested the hypothesis that the receptor subtypes may be due to different 
combinations of subunits. We found that four main pharmacology types could be produced 
and separated by expressing in Xenopus oocytes different combinations of the α-subunits 
Ode-UNC-38, Ode-UNC-63 and Ode-ACR-8 together with the non-α subunit Ode-UNC-29. 
The types could be separated on the basis of their EC50 and amplitude of response to the 
natural ligand acetylcholine, permeability to calcium and anthelmintic profiles (rank order 
potency and/or concentration-response relationships). We have not tested the possibility that 
post-translational modification may serve as an additional mechanism to produce different 
receptor types. 
A5.2 The different AChR types have different functional properties 
Ode(29–63–38–8), Ode(29–63–8) and Ode(29–63–38) produce the largest current 
responses to acetylcholine. On the basis of the larger size of the currents responses to 
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acetylcholine and the smaller currents of Ode(29–63) mixture, we speculate that the other 
three receptor types have more important physiological roles in the worm. Ode(29–63–38) 
was the most sensitive type to acetylcholine with an EC50 of 3.5±0.2 µM but it had a lower 
calcium permeability, PCa/PNa of 0.5, than Ode(29–63–38–8) that had an acetylcholine EC50 
of 4.2±0.2 µM. However, Ode(29–63–38–8) had greater responses to levamisole and a 
calcium permeability, PCa/PNa of 10.4. Thus the addition of ACR-8 is responsible for 
increasing the calcium permeability and the response to levamisole. Since the Ode(29–63–
38–8) receptor produced the biggest current to levamisole and had a single-channel 
conductance of 35.1±2.4 pS, close to the in vivo G 35 pS type that is reduced with levamisole 
resistance, we suggest that Ode(29–63–38–8) subunit combinations give rise to the in vivo G 
35 pS channel in O. dentatum. There may also be pH regulatory effects on channel activity of 
Ode(29–63–38–8). The presence of histidine (pKa 6.0) in the ACR-8 (Fig. S1D, position 
282) channel pore entrance on TM2 region is predicted to produce a pH sensitive channel 
that is less permeable to cations and calcium at pH 6.0 than 7.5. ACR-8 may provide a 
functional mechanism of reducing depolarization and muscle contraction at low pHs that can 
occur in an anaerobic environment. It would also have been of interest to look at the single-
channel properties of the other receptor types when activated with levamisole to compare 
with the in vivo channel properties. Unfortunately, the smaller size of the levamisole currents 
due to the presence of fewer receptors on the oocytes, made single-channel recording less 
tractable than for Ode(29–63–38–8). 
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A5.3 Different nAChR types and sensitivities to levamisole, pyrantel, 
tribendimidine and derquantel 
The different nAChR types have different sensitivities to cholinergic anthelmintics: 
for example Ode(29–63–38–8) produces the biggest response to levamisole, while Ode(29–
63–38) produces the biggest response to pyrantel. If these two types of receptors exist 
together in the nematode parasite, our observations suggest that combinations of levamisole 
and pyrantel will produce a bigger therapeutic response than either of the two anthelmintics 
given alone and that combination therapy may be advantageous. However, very few reports 
of combining levamisole and pyrantel for treatment are available. In one report [33] using T. 
muris infected mice, combination of levamisole and pyrantel treatment produced antagonism 
but these authors did not determine the EC50 dose for pyrantel pamoate and used a very high 
dose of 300 mg/Kg dose, above the normal therapeutic dose. At this level we anticipate the 
presence of open-channel block limiting the effects of the therapeutic combination [32]. 
We tested the effects of derquantel on the Ode(29–63–38–8), the Lev-nAChR, and on 
Ode(29-63-38), the Pyr/Trbd-nAChR. Interestingly, the mode of action of derquantel varied 
(competitive or non-competitive) with the receptor subtypes when activated by the same 
agonist, levamisole. The difference in the mode of action will relate to the preferred non-
equivalent binding sites of derquantel, of levamisole and of pyrantel on the receptor 
subtypes. The competitive antagonism of levamisole suggests a common binding site for 
derquantel on the Ode(29–63–38–8) receptor; the non-competitive antagonism of pyrantel 
and levamisole by derquantel on Ode(29–63–38) suggests negative allosteric modulation and 
different non-equivalent binding sites for derquantel and the agonists, levamisole and 
derquantel, on this receptor. Interestingly the loss of the ACR-8 subunit, which reduces the 
223 
 
levamisole sensitivity of the Ode(29-63-38) receptor, changes the antagonism of levamisole 
from competitive to non-competitive. Thus ACR-8 may contribute to a high affinity binding 
site of levamisole and a competitive site of derquantel. When ACR-8 was not present 
derquantel behaved non-competitively. We have interpreted the mixed non-competitive 
competitive antagonism of pyrantel by derquantel on Ode(29–63–38–8) to be due to a mixed 
expression of receptor subtypes with mostly the levamisole sensitive Ode(29–63–38–8) 
receptors being present and a smaller proportion of other receptors like Ode(29-63-38) being 
present. This is certainly possible because, as we have shown, the subunits can and do 
combine in different ways to form 4 types of receptor. Although less likely, it may be that: 1) 
expression of Ode(29-63-38-8) produces only one receptor type, 2) levamisole and pyrantel 
bind to separate sites on this receptor, 3) derquantel acts competitively, binding at the 
levamisole site but; 4) derquantel acts as a negative allosteric modulator when pyrantel binds 
to its receptor. Further study is required to elucidate details of binding sites on the different 
receptor types. Despite these possibilities we have seen potent antagonist effects of 
derquantel on both the Ode(29–63–38-8) and the Ode(29–63–38) subtypes suggesting that 
derquantel could still be active against levamisole resistance associated with reduced ACR-8 
expression. 
We were also interested in the effects of the novel cholinergic anthelmintics 
tribendimidine [6] and to compare their effect with the other anthelmintics. We found that 
tribendimidine was a potent cholinergic anthelmintic on the Ode(29–63–38), Ode(29–63–8) 
and Ode(29–63–38–8) types. Thus tribendimidine could remain an effective anthelmintic if 
levamisole resistance in parasites were associated with null mutants or decreased expression 
of acr-8 and/or unc-38. 
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A5.4 Regulation of AChR type expression 
The different functional properties of the nAChR types indicate that each type may 
have different physiological roles to play in the parasite and the proportion of the different 
types present at the membrane surface is likely to be regulated. This regulation could allow 
changes in calcium permeability, desensitization, receptor location, receptor number and 
anthelmintic sensitivity. The control is expected to include dynamic physiological processes 
and developmental process that take place over different time scales. An adaptable and 
diverse receptor population may allow changes, even during exposure to cholinergic 
anthelmintics. We know little about these processes, their time-scales and how they may be 
involved in anthelmintic resistance in parasitic nematodes but some information is available 
from C. elegans. 
In C. elegans there are a number of genes involved in processing and assembly of the 
subunits of AChR; specific examples include Cel-ric-3, Cel-unc-74 and Cel-unc-50 [34], 
[35], [36]. Cel-RIC-3 is a small transmembrane protein, which is a chaperone promoting 
nAChR folding in the endoplasmic reticulum [37]. The gene Cel-unc-74 encodes a 
thioredoxin-related protein required for the expression of levamisole AChR subunits [38]. 
The gene Cel-unc-50 encodes a transmembrane protein in the Golgi apparatus [35]. In Cel-
unc-50 mutants, levamisole nAChR subunits are directed to lysosomes for degradation. We 
found that acetylcholine currents and pharmacological profile of the receptors were sensitive 
to the presence of the accessory proteins, RIC-3, UNC-74 & UNC-50, suggesting the 
possibility that the expression level of these proteins could contribute to anthelmintic 
resistance in parasitic nematodes. 
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A5.5 Species differences 
We show here that four O. dentatum receptor subunits can be used to reconstitute 
different functional levamisole receptor types and that levamisole is a full agonist in one of 
the main types. All of the four main O. dentatum receptor types responded to nicotine, which 
supports our use of the term nAChR. In contrast, in the expressed levamisole-sensitive 
AChRs of C. elegans, levamisole is a partial agonist, requires five subunits (Cel-UNC-
38:Cel-UNC-29:Cel-UNC-63:Cel-LEV-1:Cel-LEV-8) and does not respond to nicotine. The 
C. elegans nicotine-sensitive muscle receptor is a separate homopentamer of ACR-16 [39]. 
We also saw differences between the expressed receptors of O. dentatum and the expressed 
AChR of H. contortus [16]: only two types of AChRs were produced in Xenopus oocytes 
expressing H. contortus subunits. Furthermore, we saw differences and similarities between 
the expressed O. dentatum receptors and the expressed A. suum receptors [14]. Only two 
subunits were used to reconstitute the A. suum AChR, such that varying the amounts of the 
subunit cRNAs injected changed the pharmacology of the expressed receptors. This is similar 
to the Ode(29–63), in that only two subunits were used to reconstitute a Pyr-nAChR and 
varying the amount of injected subunit cRNAs affected the pharmacology of the receptor. 
Whereas no ancillary factors were used to reconstitute the A. suum nAChRs, we observed 
that the three ancillary factors were required to reconstitute the O. dentatum receptors. 
Another observation is that the amounts of cRNA we injected to reconstitute the O. dentatum 
receptors were far less than what was injected to reconstitute the A. suum receptors. These 
demonstrate differences between the expressed receptors of nematodes in the same clade (O. 
dentatum, C. elegans and H. contortus) and/or in different clades (O. dentatum and A. suum). 
In addition we have also demonstrated tribendimidine's effect on all four O. dentatum 
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receptor types and in two of the receptor types, the EC50 values show tribendimidine was 
more potent than the other agonists across the types. We found that pyrantel was the most 
potent agonist of two types of O. dentatum receptors but it is only most potent in one of the 
types of H. contortus. The real and significant differences between the effects of 
pharmacological agents on the model nematode C. elegans and on the parasitic nematode O. 
dentatum, both Clade V nematodes, shows that species variation requires that effects of 
anthelmintics on the relevant nematode parasite are tested as a vital reality check. 
A6.0 Materials and Methods 
A6.1 Ethical Concerns 
All animal care and experimental procedures in this study were in strict accordance 
with guidelines of good animal practice defined by the Center France-Limousin ethical 
committee (France). The vertebrate animals (pig) studies were performed under the specific 
national (French) guidelines set out in the Charte Nationle portant sur l'ethique de 
l'experimentation animal of the Ministere De Lensiengnement Superieur et de la Recherch 
and Ministere De L'Agriculture et de la Peche experimental agreement 6623 approved by the 
Veterinary Services (Direction des Services Vétérinaires) of Indre et Loire (France). 
A6.2 Nematode isolates 
These studies were carried out on the levamisole-sensitive (SENS) isolate of O. 
dentatum as previously described [40]. Large pigs were experimentally infected with 1000 
infective larvae (L3s) and infection was monitored 40 days later by fecal egg counts every 3 
days. The pigs were slaughtered after 80 days at the French National Institute for 
Agricultural Research (Nouzilly) abattoir and adult nematodes (males and females) were 
collected from the large intestine and stored in RNA later (Qiagen®) at −80°C. 
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A6.3 Molecular biology 
Ten adult males from O. dentatum SENS isolate were used for total RNA preparation 
using TRIzol (Invitrogen) according to the manufacturer's instructions. First-strand cDNA 
synthesis on resuspended and DNase-treated total RNA was carried out with the oligo (dT) 
RACER primer and superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) as 
previously described [16]. To identify full-length cDNA sequences of O. dentatum unc-29, 
unc-63 and acr-8 homologues, 5′- and 3′- rapid amplification of complementary ends 
(RACE) polymerase chain reactions (PCR) were performed using the splice leader sequence 
primer (SL1) with internal reverse primers and internal forward specific primers with reverse 
transcription 3′-site adapter primers, respectively. PCR products were cloned into the pGEM-
T vector (Promega). Positive identifications were made by BLAST analysis against all 
Haemonchus contortus entries in the H. contortus information resource data base. Primers 
designed on unc-29 sequence from H. contortus and C. elegans (unc-29-F0 
GGACGAGAAAGATCAAGTTATGCA, unc-29-XR2 
TCATCAAATGGGAAGAAYTCGACG) allowed PCR amplification of a 288 bp fragment 
corresponding to partial O. dentatum unc-29 homologue. New gene specific primer sets were 
designed on this sequence for the 5′- and 3′-RACE-PCR providing the full-length cDNA 
sequence of Ode-unc-29. To identify the unc-63 homologue from O. dentatum, degenerate 
primers were designed based on the Ode-unc-38 mRNA sequence (accession number 
GU256648) and the unc-63 and unc-38 sequences of cDNAs available from multiple 
nematode species (Ode-unc-63-F1 GCGAATCGCGAYGCGAATCGKCT, F2 
AARAGYATGTGYCAAATWGAYGT, R3 ATATCCCAYTCGACRCTGGGATA, R4 
TAYTTCCAATCYTCRATSACCTG). An 861 bp partial coding sequence of Ode-acr-8 
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cDNA was amplified using a sense primer (Hco-acr-8-FT1 
TATGGTTAGAGATGCAATGGTT) and an antisense primer (Hco-acr-8-RE8 
GTGTTTCGATGAAGACAGCTT) from H. contortus Hco-acr-8. The product of this 
reaction was cloned and sequenced, and the data were used to design primers to get the 5′ and 
the 3′ ends of the target transcript. To amplify the full-length coding sequence of Ode-unc-
38, Ode-unc-63, Ode-unc-29 and Ode-acr-8, we used the Phusion DNA polymerase 
(Finnzymes) and gene specific primer pairs containing HindIII or XhoI and ApaI restriction 
enzyme sites (Table S1 in Text S1) to facilitate directional cloning into the pTB-207 
expression vector that is suitable for in vitro transcription. PCR products were then digested 
with XhoI and ApaI restriction enzymes (except Ode-unc-29, digested with HindIII and 
ApaI), purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel), ligated 
into the respective corresponding sites of the pTB-207 expression vector with T4 DNA 
Ligase (New England Biolabs), and resulting constructs were transformed into E. coli DG1 
cells (Eurogentec) [26]. Three clones of each gene were sequenced using the standard 
primers T7 and polyT-V. Each of the reported sequences in supplementary figures S1A–D is 
from one of the nearly identical clones. The mMessage mMachine T7 transcription kit 
(Ambion) was used for in vitro cRNA synthesis from linearized plasmid DNA templates. The 
cRNAs were precipitated by lithium chloride, resuspended in RNAse-free water and stored at 
−80°C. 
A6.4 Sequence analysis and accession numbers 
Database searches, prediction of conserved motifs and phylogenetic analyses for the 
cDNAs were carried out as already described [16]. Maximum likelihood analysis was 
performed on full-length AChR subunit cDNA sequences as follows: sequences were aligned 
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with Geneious 6.1.6 (Biomatters Ltd) using the translation align MAFFT plugin [41] that 
aligns the nucleotide sequences as codons based on amino acid sequences. The resulting 
nucleotide alignment was used to generate phylogenetic trees with the PhyML plugin for 
Geneious [42]. The HK85 substitution matrix was selected in order to optimize the tree 
topology and branch lengths. Branch support was evaluated using the chi2 option of PhyML. 
The accession numbers for cDNA and protein sequences mentioned in this article are C. 
elegans: UNC-29 NM_059998, UNC-38 NM_059071, UNC-63 NM_059132, ACR-8 
JF416644; H. contortus: Hco-unc-29.1 GU060980, Hco-unc-38 GU060984, Hco-unc-63a 
GU060985, Hco-acr-8 EU006785, Hco-unc-50 HQ116822, Hco-unc-74 HQ116821, Hco-
ric-3.1 HQ116823; O. dentatum: Ode-unc-29 JX429919, Ode-unc-38 JX429920, Ode-unc-63 
HQ162136, Ode-acr-8 JX429921. 
A6.5 Voltage-clamp studies in oocytes 
Xenopus laevis ovaries were obtained from NASCO (Fort Atkinson, Wisconsin, 
USA) and defolliculated using 1–2 mg/ml collagenase type II and Ca2+-free OR2 (mM: NaCl 
100, KCl 2.5, HEPES 5, pH 7.5 with NaOH). Alternatively, defolliculated oocytes were 
purchased from Ecocyte Bioscience (Austin, Texas, USA). Oocytes (animal pole) were 
microinjected with ∼36 nL of a cRNA injection mix containing 50 ng/µL of each subunit 
cRNA, as described in [26]. Equal amounts of the H. contortus ancillary factors ric-3, unc-50 
and unc-74 were added to each mix. Microinjected oocytes were incubated at 19°C for 2–5 
days. The oocytes were incubated in 200 µL of 100 µM BAPTA-AM for ∼3 hours prior to 
recordings, unless stated otherwise. In control experiments, we recorded from un-injected 
oocytes. Recording and incubation solutions used are reported in [26]. Incubation solution 
was supplemented with Na pyruvate 2.5 mM, penicillin 100 U/mL and streptomycin 100 
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µg/ml. All drugs applied, except tribendimidine and derquantel, were purchased from Sigma 
Aldrich (St Louis, MO, USA). Oocytes were voltage-clamped at −60 mV with an Axoclamp 
2B amplifier; all data were acquired on a desktop computer with Clampex 9.2. 
A6.6 Single-channel studies 
Oocyte-attached (outside-out) patch-clamp procedure was used to obtain all 
recordings at room temperature (20°C–25°C). Oocytes were prepared for the recordings by 
removal of the vitelline membrane with forceps after placing in hypertonic solution, as 
already described [43]. The oocytes were transferred to the recording chamber and bathed in 
a high Cs solution with no added Ca2+ (composition in mM: CsCl 140, MgCl2 2, HEPES 10, 
EGTA 1, pH 7.3) to reduce K+ currents and lower opening of Ca2+-activated Cl− channels. 
Patch electrodes were pulled from thin-walled capillary glass tubing (Warner Instruments, 
Hamden, CT), coated close to the tip with sylgard and fire-polished. The electrodes were 
filled with a high pipette solution {composition in mM: CsCl 35, CsAc 105, CaCl2 1, HEPES 
10} containing 10 µM levamisole. Axopatch 200B amplifier (Axon Instruments, Union City, 
CA) was used to amplify currents which were sampled at 25 kHz with Digidata 1320A 
(Axon Instruments) and filtered at 1.5 kHz (3-pole Bessel). The linear least squares 
regression was used to estimate the conductances of the channels since the slopes were linear 
and did not show rectification. 
A6.7 Data analysis 
Acquired data were analyzed with Clampfit 9.2 (Molecular Devices, Sunnyvale, CA, 
USA) and Graphpad Prism 5.0 software (San Diego, CA, USA). The peak of currents in 
BAPTA-soaked oocytes was measured. The response to 100 µM ACh was normalized to 
100% and the responses to the other agonists normalized to that of ACh. For all dose-
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response relationships, the mean ± s.e of the responses is plotted. Dose-response data points 
were fitted with the Hill equation as described previously [26]. To calculate the pKB values, 
the graphs were fitted with the Gaddum/Schild EC50 shift and the bottom of the curves were 
set to zero. 
A7.0 Supporting Information 
A7.1 Supplementary figures 
 
 
 
Supplementary Figure S1. A–D. Amino acid alignments of the four O. dentatum nAChR subunits with the H. 
contortus and C. elegans homologues. The sequences were aligned with the MUSCLE algorithm [44] and 
processed further with GeneDoc. Shaded in grey are the predicted signal peptides and in blue are the amino 
acids conserved between all three species. Noted above the aligned sequences are the cys-loop, Yx(x)CC motif 
and transmembrane domains. Noted with red arrows (S1 A–C) are the amino acids, on either side of the 
transmembrane region (TM2) that are predicted to contribute to the permeability of the channel to calcium [45], 
[46]. Green arrow in S1 D shows a histidine which implies pH sensitivity around pH 6.5 to channel 
permeability. 
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Supplementary Figure S2. Distance tree showing relationships of nicotinic acetylcholine receptors 
(nAChR) subunit sequences in Oesophagostomum dentatum (Ode, highlighted in red), 
Caenorhabditis elegans (Cel), Haemonchus contortus (Hco) and Teladorsagia circumcincta (Tci). 
Numbers at each branch indicate percentage boostrap values corresponding to 1000 replicates. The 
scale bar represents substitutions per site. The C. elegans acr-16 nAChR subunit was used as an 
outgroup. Distance analyses were performed on full-length cDNA sequences. Multiple alignment was 
performed using Muscle program with standard parameters [47]. Relationships between sequences 
were determined using the neighbor-joining method and the HKY substitution model [48]. One 
thousand bootstrap replicates were performed to test the support of nodes. 
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Supplementary Figure S3. Effect of the ancillary proteins on receptor reconstitution. (A) Bar chart 
(mean ± se) of agonist-elicited currents in the Ode(29–63–38–8) or Lev-nAChR subtype. This 
receptor subtype was used to test the effect of sequentially removing the ancillary proteins on the 
reconstitution. All responses were normalized to control 100 µM ACh (unfilled bar) currents in 
oocytes expressing this receptor subtype with all the ancillary proteins (A). (B) Effect of removing 
unc-74 from the mix on the Ode(29–63–38–8)/Lev-nAChR subtype. Note the relative change in ACh 
and Lev responses. (C) Effect of removing ric-3 on the Ode(29–63–38–8) : Lev-nAChR subtype. The 
ACh current responses were reduced to <50% of the control. (D) Effect of removing unc-50 on the 
Ode(29–63–38–8) or Lev-nAChR subtype. Note the dramatic decrease in currents elicited by all 
agonists. 
 
A7.2 Supplementary Results 
A7.2.1 Supplementary results S1.  UNC-74 is a gene that encodes a transmembrane 
thioredoxin that can affect expression of nAChRs [26]. When we expressed the Ode(29–63–
8–38) receptor with RIC-3 and UNC-50 but without UNC-74, the oocytes responded with 
acetylcholine currents that were only slightly reduced (mean 9%, S2-B). However, the order 
of the agonist potency series changed from 100 µM acetylcholine > 100 µM levamisole to 
100 µM acetylcholine ≈ 100 µM levamisole (S2-A, B). We tested the agonist potency series 
of all the anthelmintic agonists and found that their normalized responses were significantly 
different (p< 0.0001, F-test). Thus, UNC-74 was not an absolute requirement for expression 
of Ode(29–63–8–38) but affected the pharmacological profile of the expressed receptors 
suggesting that it changed the balance of the receptor subtypes types present. RIC-3 is an 
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endoplasmic reticulum resident protein that acts as a nAChR chaperone. RIC-3 enhances 
functional expression of some nAChRs, whilst inhibiting expression of other nAChRs 
[49,50,51]. RIC-3 stabilizes receptor intermediates and promotes maturation of receptors 
through subunit-specific interactions with nAChR subunits [52]. When we removed just RIC-
3 from the mix, the acetylcholine and levamisole currents were reduced to < 60 % of control 
(S2-A, C). When we compared the acetylcholine-normalized responses of all the agonists we 
found that they were significantly different (p< 0.0001, F-test) suggesting that the balance of 
the receptor types present had changed.   
The most striking decrease in current amplitude was obtained when just UNC-50 was 
removed. The acetylcholine current amplitudes obtained were < 20 % of control (S2-D). 
UNC-50 is a Golgi resident protein that is required to prevent some nAChR types from being 
trafficked to and degraded by the lysosomal system [53]. In the absence of UNC-50, it is 
reasonable to postulate that only a few synthesized receptors make it to the cell membrane. 
When we compared the acetylcholine-normalized responses of all the anthelmintic agonists 
to the control, we again found that they were significantly different (p< 0.0001, F-test), 
suggesting that the balance of the receptor types expressed was changed. 
A7.3 Supplementary text 
 A7.3.1 Text S1 Materials and Methods: Ca2+-permeability measurements.  For 
these set of experiments, we increased external Ca2+ in the recording solution from 1 mM to 
10 mM without changing the concentration of the other ions. We used the GHK equation to 
calculate the permeability ratio, PCa/PNa. Due to BAPTA treatment before recordings, we 
assumed the internal [Ca2+] to be negligible; we also assumed permeability to Na and K, 
PNa and PK, are equal. Ionic activities were used for the calculations (activity coefficients: 
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0.56 for Ca2+ and 0.72 for Na+ and K+). Below is the GHK equation used to calculate the 
calcium permeability ratio, with the activity coefficients for Na+, K+ and Ca2+ inserted: 
Erev = RT/F 
In{(PNa*0.72[Na]o+PK*0.72[K]o+4P’*0.56[Ca]o)/{PNa*0.72[Na]i+PK*0.72[K]i)}. 
Where R is the universal gas constant (8.314 JK-1mol-1); F is Faraday’s constant (96485 
Cmol-1); T is the temperature (room temperature, 298 K); and P’ = 
PCa/PNa{1/(1+eFErev/RT)}.  
 
A7.3.2 Table S1.0 Primers used for the PCR and cloning of O. dentatum AChR subunits 
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B1.0 Abstract 
‘The best way to predict the future is to create it.’ When we look at drugs that are 
used to control parasites, we see that new knowledge has been created (discovered) about 
their modes of action. This knowledge will allow us to predict combinations of drugs which 
can be used together rationally to increase the spectrum of action and to slow the 
development of anthelmintic resistance. In this paper we comment on some recent 
observations of ours on the modes of action of emodepside, diethylcarbamazine and 
tribendimidine. Emodepside increases the activation of a SLO-1 K+ current inhibiting 
movement, and diethylcarbamazine has a synergistic effect on the effect of emodepside on 
the SLO-1 K+ current, increasing the size of the response. The combination may be 
considered for further testing for therapeutic use. Tribendimidine is a selective cholinergic 
nematode B-subtype nAChR agonist, producing muscle depolarization and contraction. It has 
different subtype selectivity to levamisole and may be effective in the presence of some types 
of levamisole resistance. The new information about the modes of action may aid the design 
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of rational drug combinations designed to slow the development of resistance or increase the 
spectrum of action. 
B1.1 Keywords 
Anthelmintic; mode of action; tribendimidine; emodepside; diethylcarbamazine 
B2.0 Introduction 
‘The best way to predict the future is to create it.’ This quote is usually ascribed to 
Abraham Lincoln and leads to some interesting thoughts when applied to different research 
fields including our own field of study, that is, anthelmintics. What are we creating and what 
can we see for the future for anti-parasitic drugs? We are creating new techniques for the 
screening of anthelmintic drugs, we are creating new methods for studying the modes of 
actions of anthelmintics and we are creating new ways for detecting anthelmintic resistance 
(Gilleard and Beech, 2007 and Lanusse et al., 2014). We are also creating better awareness of 
the ‘neglected tropical diseases’ (Hotez et al., 2008) of humans which include ascariasis, 
hookworm and trichuriasis and better awareness of the link between human and animal 
medicine, the ‘One Health’ concept. Our western economic system has also produced a more 
favorable economic environment for the development of animal anthelmintics, than 
anthelmintics for humans. Currently, we limit the damage done by nematode parasites of 
animals with pasture management, and improved targeted metaphylactic and therapeutic use 
of anthelmintics; for humans, clean water and sanitation are limiting factors (like clean 
pasture for animals) while mass drug administration (MDA) has similarities to the regular 
metaphylactic use of anthelmintics for animals. Vaccinations against parasites for both 
humans and animals are very desirable but so far they have limited efficacy. 
239 
 
The advances and creations listed above lead to a number of logical predictions for 
the future use and development of anthelmintics. We are confident that the development and 
better understanding of anthelmintic properties will continue, at a steady but modest pace, 
driven by economic, human and animal needs. We think that the economic pressures 
associated with animal medicine will remain greater than for human medicine and focused on 
the development of novel ‘resistance-busting’ anthelmintics. Success in research can be 
limited by funding as was said by the father of modern drug development, Paul Ehrlich, Fig. 
1 (1854–1915), who recognized success required the four Gs: Gluck, Geduld, Geshcick und 
Geld (luck, patience, skill and money, (Perutz, 1988). The ‘money’ for animal anthelmintics 
comes from the market for anti-parasitic drugs and chemicals for small animals and livestock 
which was estimated at $11 billion (Evans and Chapple, 2002). This contrasts with the 
market for human anthelmintics which is only $0.5 billion despite some 2 billion humans 
being infected in developing countries, around 25 cents per person annually! Given that the 
out of pocket costs of new human drugs may be $403 million (at year 2000 valuations 
(DiMasi et al., 2003) or more, we can see that the commercial development of human 
anthelmintic drugs is not favorable. It seems more likely that the economics of animal health 
will drive the development and advance of the knowledge base of animal anthelmintics and 
that these developments will be applied and adapted for human use (ivermectin and perhaps 
emodepside) unless private charities, governments and foundations overcome the financial 
limitations. In addition to the gradual development of resistance-busting anthelmintics we 
see: developments in our understanding of the modes of action of anthelmintics; we see more 
logical combinations of anthelmintics to slow down or counter the development of resistance 
and; also new methods for detecting anthelmintic resistance. 
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Fig. 1. Paul Erlich in his Frankfurt office, circa 1900, the father of modern chemotherapy, who worked on 
trypanosome diseases and popularized the concept of the ‘magic bullet’ (magische Kugel, the perfect therapeutic 
agent). 
 
Our lab has focused on understanding of the modes of action of anthelmintics and in 
this paper we illustrate some of our recent observations and developments in our 
understanding of the actions of emodepside, diethylcarbamazine and tribendimidine. The 
mode of action of these anthelmintics involves effects on membrane ion-channels and has 
required us to use electrophysiological techniques for their study (Martin et al., 1996b). We 
think that better knowledge of the mode of action of these compounds will allow rational 
combination with other anthelmintics to increase potency, spectra and allow a slowing of the 
speed of development of resistance in animal and human parasites. This paper is based on a 
lecture given to the World Association for the Advancement of Veterinary Parasitology 
(WAAVP) in Liverpool, 2015 and covers: (1) emodepside, an anthelmintic used for small 
animals, which has the potential for being used for human use to control filarial parasites; (2) 
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diethylcarbamazine, a long serving anthelmintic still used for the control of filariasis in 
humans and; (3) tribendimidine, a recent anthelmintic developed by China for human use. 
B3.0 Emodepside 
Emodepside is a cyclooctadepsipeptide developed by Bayer, Fig. 2, which is related 
to its parent compound, PF1022A (Martin et al., 1996a) which has broad-spectrum 
anthelmintic activity. Emodepside has an inhibitory effect on locomotion that allowed (Guest 
et al., 2007) to use a C. elegans mutagenesis screen to find that slo-1 (a Ca2+-dependent K+ 
channel) mutant alleles were resistant to the inhibitory effects of emodepside. (Crisford et al., 
2011) also described transgenic experiments in which C. elegans SLO-1a channels were 
swapped for KCNMA1, the human orthologue of SLO-1 channels. These studies found that 
the sensitivity to emodepside in the rescues depended upon the origin of the SLO-1 channel: 
the human KCNMA1 channel was 10–100 times less sensitive to emodepside than the 
rescues expressing C. elegans SLO-1a channel. These experiments suggested that SLO-
1Ca2+-dependent K+ channels of nematodes are a major part of the target site of emodepside. 
Expression of C. elegans SLO-1a channels in Xenopus oocytes have revealed that 
emodepside can directly open these channels ( Kulke et al., 2014) and that emodepside action 
on this splice variant of the channel does not require the presence of additional receptors like 
the latrophilin receptors for an emodepside effect (Willson et al., 2004). It does not however, 
rule out a contribution of latrophilin receptors to the overall mode of action of emodepside in 
parasites as indicated by the interaction of Lat-1 and emodepside (Saeger et al., 2001). 
SLO-1 K+ channels have large (∼200 pS) single-channel conductances and are also 
known as ‘big’ potassium (BK) channels. These channels serve to clamp the membrane 
potential near the potassium reversal potential and inhibit electrical excitability. The SLO-1 
K+ channel, has a different function to the high conductance Ca2+-dependent Cl− channel  
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Fig. 2. Summary diagrams of emodepside structure, Slo-1 subunit and a model of the mode action of 
emodepside on nematode body muscle. A: Emodepside. B: Line diagram of structure of one SLO-1 subunit; 
each SLO-1 K+ channel is made up of 4 of these subunits. C. Putative mode of action of emodepside on SLO-
1K+ channels in the muscle: act directly (1) or indirectly by stimulating latrophilin-like receptors (2) and 
signaling cascades that may involve NO, protein Kinase C and/or calcium. It is unlikely that emodepside acts at 
the extracellular surface of the SLO-1 K+ channel because of the slow time course of its action. It is very 
lipophilic and could act in the lipid membrane phase on the SLO-1 K+ channel or move into the cytoplasm and 
act intracellularly. A SLO-1 K+ channel (C) is shown composed of 4 subunits along with the ‘RCK’ 
cytoplasmic regulatory region of the channel. (Martin et al., 2012). 
 
(Thorn and Martin, 1987) which is associated with the transport of carboxylic acids from 
anaerobic metabolism of glucose (Valkanov and Martin, 1995). Subunits homologous to the 
vertebrate SLO-1 K+ channels are found in C. elegans and Ascaris suum ( Buxton et al., 
2011). The SLO-1 K+ channels are composed of 4 α-subunits; α-subunits have seven (S0–S6) 
transmembrane regions, a P-loop between S5 and S6, a large intracellular domain (S7-S-10) 
and a well conserved ‘calcium bowl’ between domains S9 and S10, Fig. 2. In addition, the 
regulator of the K+ channel conductance (RCK) domains (S7, S8) contains high and low 
affinity calcium binding sites. The SLO-1 α-subunits show alternative splicing, producing 
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channels with different calcium sensitivities; in C. elegans there are up to 15 splice variants 
(including SLO-1a, SLO-1b and SLO-1c ( Kulke et al., 2014 and Wang et al., 2001)). Each 
α-subunit of the channel has at least two high affinity calcium binding sites and one low 
affinity calcium/magnesium binding site. The channel also combines with secondary, 
regulatory β-subunits in vertebrates (Knaus et al., 1994) but these subunits have not yet been 
identified in C. elegans. However, Drosophila, which also lacks β subunits, has Slob 
proteins, which appear to carry out similar functions to the vertebrate β-subunits and these 
may be present in nematodes ( Claridge-Chang et al., 2001). 
The suggested function of the SLO-1 K+ channels is that they adjust the resting 
membrane potential of electrically excitable cells and adjust the level of excitability, up or 
down, and so affect the response to other inputs. The opening of the SLO-1 K+ channel, Fig. 
2, is regulated by at least ten factors including: (1) membrane potential; (2) calcium; (3) 
magnesium; (4) NO; (5) CO; (6) arachidonic acid; (7) propagandist; (8) phosphorylation by 
cAMP-dependent protein kinase A; (9) phosphorylation by diacylgycerol/Ca2+-dependent 
protein kinase C; and (10) phosphorylation by cGMP-dependent protein kinase G (Salkoff et 
al., 2006). The kinases allow SLO-1 to be coupled to multiple and quite diverse signaling 
cascades permitting different ways of adjusting the excitability of the cells. The different 
nematode neuropeptides could affect cAMP and cGMP levels (e.g., AF1, AP2, and PF1 and 
PF2) could then affect SLO-1 channels (Muhlfeld et al., 2009, Verma et al., 2007 and Verma 
et al., 2009). A selective agonist for the PF1 and/or a selective antagonist of the AF1 receptor 
would activate a SLO-1 K+-like current and increase the efficacy of emodepside. The 
neuropeptides AF1, AF10 and PF2 also bind with low affinity to the latrophilin-like receptor, 
HC110-R of Haemonchus contortus, suggesting that emodepside could also have an indirect 
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mode of action on SLO-1 K+ channels through these latrophilin-like receptors (Fig. 2) that 
are neuropeptide receptors (Muhlfeld et al., 2009). 
We found (Buxton et al., 2011 and Martin et al., 2012 that Asu-slo-1 is an 
evolutionarily conserved homologue of the slo-1 genes, expressed in adult A. suum body 
muscle flaps. Using a two-micro-electrode current-clamp and voltage-clamp technique, Fig. 
3A, we found in the nematode parasite A. suum, that emodepside activates SLO-1-like K+ 
channels to produce hyperpolarization under current-clamp, Fig. 3B1, and an outward current 
when under voltage-clamp, Fig. 3B2. We also found that emodepside increased voltage-
activated K+ currents, Fig. 3C and D, in a time dependent manner. Emodepside, Fig. 3C, 
unlike PF1 did not decrease calcium currents and so emodepside does not work by releasing 
PF1 as has been hypothesized. We found that the effects of emodepside on the voltage-
activated K+ channels is Ca2+-dependent and were inhibited by 5 mM 4-aminopyridine, Fig. 
4A. The membrane hyperpolarization and increase in voltage-activated K+ current produced 
by emodepside, Fig. 3B, are very slow in onset and increase over a period of more than 
10 min (Buxton et al., 2011); the slow onset effect of emodepside might be due to its very 
lipophilic nature and a membrane partitioning effect. It may also be because the effects of 
emodepside are indirect and produced by activation of a slow signaling cascade. Fig. 4B and 
C shows that the effects of emodepside are potentiated by sodium nitroprusside (a NO 
donor), antagonized by iNOS inhibitors (NNLA), and inhibited by 1 μM staurosporine, an 
inhibitor of protein kinase (Buxton et al., 2011). Interestingly, these signaling molecules are 
known as activators of SLO-1 in other cells ( Bolotina et al., 1994b, Holden-Dye et al., 2007, 
C shows that the effects of emodepside are potentiated by sodium nitroprusside (a NO 
donor), antagonized by iNOS inhibitors (NNLA), and inhibited by 1 μM staurosporine, an  
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Fig. 3. Electrophysiological techniques (two micropipette current-clamp and voltage-clamps) for recording from 
Ascaris suum. A: A. suum muscle bag showing the current (I) and voltage (V) micropipettes in the bag, and the 
perfusion needle (P). B1: Representative current-clamp trace showing the slow hyperpolarizing membrane 
potential during and after 10 min application of 1 μM emodepside. B2: Outward current response to 1 μM 
emodepside at higher time resolution. Holding potential −35 mV. Notice that emodepside produces a gradually 
increasing current after a delay of some 30 seconds. The response does not plateau in the time period of this 
recording. C: Voltage-clamp traces of control K+ current and the time-dependent effects of 1 μM emodepside on 
the K+ currents, all to a step potential of 0 mV from a holding potential of −35 mV. D: Bar chart (mean ± S.E.) 
of 1 μM emodepside effect on steady state(LK) currents. Comparison was made between the control 0 mV step 
current at 30−40 ms and the corresponding current increased by emodepside at 10, 20 and 30 min. Emodepside 
increased LK currents at 10 min (p < 0.01, n = 4, paired t-test), 20 min (p < 0.01, n = 4, paired t-test) and 30 min 
(p < 0.05, n = 4, paired t-test). (Martin et al., 2012). 
 
inhibitor of protein kinase (Buxton et al., 2011). Interestingly, these signaling molecules are 
known as activators of SLO-1 in other cells ( Bolotina et al., 1994b, Holden-Dye et al., 2007, 
Mistry and Garland, 1998 and Wang et al., 1999) and therefore encourage the view that 
emodepside could act through either or both of these signaling cascades and the signaling 
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Fig. 4. Effect of 1 μM emodepside on membrane potential. A: Comparison was made between membrane 
potential before and during emodepside application. 1 μM emodepside caused a significant membrane 
hyperpolarization (p < 0.001, n = 10, paired t-test) which was reduced in the presence of 5 mM 4-aminopyridine 
(p < 0.01, n = 8, unpaired t-test). 10 μM emodepside caused an increased hyperpolarization in comparison to 
1 μM emodepside (p < 0.05, unpaired t-test). B: Bar chart (mean ± s.e) of NO influence on emodepside-induced 
hyperpolarization. In the presence of 1 mM SNP, 1 μM emodepside caused an increased hyperpolarization 
(p < 0.01, n = 4, paired t-test). 100 μM NNLA decreased the hyperpolarization caused by 1 μM emodepside 
(p < 0.01, unpaired t-test). C: Bar chart (mean ± s.e) of effect of protein kinase modulators on emodepside-
induced hyperpolarization. 10 μM PMA had no significant effects on the hyperpolarization caused by 1 μM 
emodepside. However, 1 μM staurosporine decreased the hyperpolarization caused by 1 μM emodepside 
(p < 0.05, unpaired t-test). (Martin et al., 2012). 
 
cascades may be in series or parallel, Fig. 2C. A number of studies on the mammalian 
orthologues of SLO-1 show that they are directly and alternately regulated by complex, 
multiple signaling cascades, involving NO and diacylglycerol or PKC activation (Ghatta et 
al., 2006 and Salkoff et al., 2006). It is pointed out that NO signaling pathways in mammals 
may not be conserved in all species of nematode. 
Thus emodepside appears to selectively activate the SLO-1 K+ current that is present 
in nematodes but has less effect on the SLO-1 K+ currents of vertebrates. This can explain 
the selective toxicity of the drug. The existence and mechanisms of resistance to emodepside 
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in nematode parasites remain to be studied but could involve several different mechanisms 
including changes in the splice forms of the SLO-1 K+ channel or its regulation by different 
signaling cascades. However, such resistance, depending on the specific mechanism, might 
be countered (Verma et al., 2007 and Verma et al., 2009) by a selective agonist for the 
FMRFamide PF1 receptor and/or a selective antagonist of the FMRFamide AF1 receptor 
which would activate a SLO-1 K+-like current and increase the efficacy of emodepside. An 
increased knowledge of the physiology of target site of emodepside provides a new way of 
designing drug combinations. The complex nature of SLO-1 K+ regulation suggests that if 
there were resistance to emodepside it would be complex in nature and therefore likely to be 
polygenic involving multiple mechanisms. 
B4.0 Diethylcarbamazine 
Diethylcarbamazine, Fig. 5A, is an antifilarial drug that has been used since 1947 
against lymphatic filariasis and loiasis. It is still an important and effective antifilarial drug 
but its mode of action is not fully described. Diethylcarbamazine has been suggested to have 
an indirect, host mediated mode of action: it appears to alter host arachidonic acid, nitric 
oxide metabolic pathways and inhibits NF-κB, which together in an unknown way leads to 
immobilization and sequestration of the microfilariae (Maizels and Denham, 
1992 and Peixoto and Silva, 2014). Diethylcarbamazine activity against B. malayi 
microfilariae is abolished in inducible nitric oxide synthase knockout mice (iNOS−/−), 
suggesting that diethylcarbamazine activity is dependent on host inducible nitric oxide 
synthase (iNOS) and nitric oxide (McGarry et al., 2005). 
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Fig 5. The combined effect of emodepside and diethylcarbamazine is greater than the effect of 
emodepside alone on A. suum membrane potential. A: Chemical structure of diethylcarbamazine. B: 
Representative current-clamp traces showing the membrane potential before, during 1 μM 
emodepside application (top trace) and during application of 1 μM emodepside plus 100 μM 
diethylcarbamazine (lower trace). The time delay between the end of the application of 100 μM 
diethylcarbamazine and 1 μM emodepside plus 100 μM diethylcarbamazine was 10 min. The change 
in membrane potential between the beginning of the 100 μM diethylcarbamazine and application of 1 
μM emodepside plus 100 μM diethylcarbamazine was a hyperpolarization of 1.5 mV. C: Bar chart 
(mean ± i.e.) of diethylcarbamazine effect on emodepside-induced hyperpolarization. 100 μM 
diethylcarbamazine increased the hyperpolarization caused by 1 μM emodepside (p < 0.01, n = 5, 
unpaired t-test. (Buxton et al., 2014a). 
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We were interested to determine how diethylcarbamazine would affect calcium-
dependent SLO-1 K+ currents in isolated A. suum muscle flap preparations, and how 
diethylcarbamazine interacts with emodepside. The interest was prompted by observations in 
vertebrates (Bolotina et al., 1994a) which show that nitric oxide activates SLO-1 K+ channels 
and observations on A. suum indicating the presence of nitric oxide synthase and of SLO-1 
K+ channels which show positive modulation by a nitric oxide pathway (Buxton et al., 2011). 
We hypothesized that diethylcarbamazine, with effects on arachidonic acid and nitric oxide 
pathways, would increase activation of SLO-1 K+ currents in A. suum muscle and potentiate 
effects of emodepside on membrane potential (Buxton et al., 2014a). We conducted current-
clamp and voltage-clamp electrophysiological experiments, using A. suum body muscle in 
the presence of sufficient calcium to allow activation of the SLO-1 K+ currents. We found 
that indeed diethylcarbamazine, by itself, can increase activation of SLO-1 K+ currents and 
potentiate the hyperpolarizing effects of emodepside. This to us was very interesting since it 
showed that diethylcarbamazine has a direct effect on the nematode parasite and its effects 
are not exclusively mediated via the host as has been suggest by earlier experiments. It seems 
likely that the effects of diethylcarbamazine may involve effects on NO or arachidonic acid 
metabolites both in the host and in the parasite. Although the mechanism of action of 
diethylcarbamazine remains to be further defined, the synergistic effect of emodepside and 
diethylcarbamazine suggests that the combination of the two drugs could be considered for 
therapeutic use for the treatment of filarial nematode infections. 
B5.0 Tribendimidine 
Tribendimidine, Fig. 6, is a symmetrical diamidine derivative, of amidantel which 
was developed in China for use in humans in the mid-1980s. It is a broad-spectrum  
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Fig. 6. A: Chemical structure of tribendimidine. B: Diagram of the two-micropipette current-clamp technique 
used to record the membrane potential (v) and to inject 40 nA hyperpolarizing 500 ms current pulses (i) at 0.3 
Hz. p is the microperfusion pipette used to apply and wash off the drugs. C: Application of 3 μM acetylcholine 
and then 0.1, 1 and 10 μM tribendimidine to the same preparation. 1 μM tribendimidine produces a bigger 
depolarization response (upward movement) and conductance increase (reduction in the voltage responses to 
current injection, producing a narrowing of the width of the trace) than 3 μM acetylcholine (Robertson et al., 
2015). 
 
anthelmintic effective against soil-transmitted helminthiasis including hookworm, pinworms, 
roundworms, Strongyloides and flatworms (Xiao et al., 2005 and Xu et al., 2014) of humans. 
Molecular studies (Hu et al., 2009) on C. elegans using null-mutants of the levamisole 
receptor subunits strongly suggested that tribendimidine is a cholinergic agonist that is 
selective for the same nematode muscle nAChR as levamisole. When we looked at these 
studies we found that there are no direct electrophysiological observations in nematode 
parasites that had been made to test this hypothesis and we were aware that sometimes 
251 
 
observations on the model Clade V nematode were not always the same in parasitic 
nematodes, particularly for the parasites from a different Clade. We were also interested in 
trying to explain why tribendimidine is effective against some nematode parasites when 
levamisole is not. 
We tested the effects of tribendimidine on the electrophysiology, Fig. 6, and 
contraction of A. suum muscle (Robertson et al., 2015) and found that tribendimidine 
produces a dose-dependent depolarization associated with an increase in the conductance of 
the muscle membrane as the nicotinic receptors (nAChRs) open, Fig. 6. We found that 
tribendimidine was more potent than acetylcholine and had an EC50 of 0.8 μM. We also 
tested the effects of the nicotinic antagonist mecamylamine, a potent antagonist of muscle 
nAChRs of parasitic nematodes and found that 3 μM was potent against tribendimidine; the 
antagonist effects of mecamylamine confirmed the cholinergic action of tribendimidine on 
the nAChRs of the parasite A. suum. 
We characterized the pharmacological profile of tribendimidine using our Ascaris 
muscle contraction assay systems (Qian et al., 2006 and Robertson et al., 2002) with 
tribendimidine as the agonist and methyllycaconitine, paraherquamide and derquantel as 
antagonists to calculate the potency, pA2, of the antagonists and the subtype of the selectivity 
of tribendimidine. We found that tribendimidine was more selective for the B-subytpe 
(bephenium preferring) nAChRs than the L-subtype (levamisole preferring) or the N-subtype 
(nicotine preferring). These observations showed the selectivity for the different groups of 
nAChRs present on the Ascaris muscle was not the same as levamisole and it was possible 
that levamisole-resistant parasites would remain sensitive to tribendimidine. To test this we 
used, Oesophagostomum dentatum L3 larval migration inhibition assays with levamisole-
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sensitive isolates and levamisole-resistant isolates and tested the effects of tribendimidine on 
motility. Levamisole was less effective (p < 0.001, F-test) in inhibiting migration of 
levamisole-resistant larvae than the migration of levamisole-sensitive larvae. We tested the 
effects of tribendimidine to the limits of its solubility, ∼30 μM, and found that 
tribendimidine was actually more potent on the levamisole-resistant isolate than on the 
levamisole-sensitive isolates (p < 0.001, F-test). The larger effect of tribendimidine on the 
levamisole-resistant, than the levamisole-sensitive isolates at lower tribendimidine 
concentrations, supports the view that levamisole and tribendimidine do not activate identical 
nAChR receptor subtypes. The higher efficacy of tribendimidine on the levamisole resistant 
O. dentatum isolate might indicate a case of negative cross resistance (Miltsch et al., 2013) 
We have been able to express, in Xenopus oocytes a range of different nAChR 
receptor subtypes derived from anthelmintic sensitive Oesophagostomum dentatum clones of 
their nAChR receptor subunits (Buxton et al., 2014b). Fig. 7 shows a diagram of the subunit 
composition of two nAChR subtypes expressed in oocytes, one composed of Ode-UNC-
29:Ode-UNC-63:Ode-UNC-38, the other composed of Ode-UNC-29:Ode-UNC-63:Ode- 
UNC-38:Ode-ACR-8 subunits. The Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 receptor was 
more sensitive to tribendimidine and pyrantel but not to levamisole or nicotine. We can see 
that the receptor subunit arrangements affect their pharmacology and that not all cholinergic 
anthelmintics have the same selectivity. 
Our understanding to date is that there are a range of pharmacologically different 
nAChR subtypes present in parasitic nematodes and the pharmacology of the receptor 
subtypes varies with the subunit composition of the receptor which varies with the tissue and 
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Fig. 7. Tribendimidine as an agonistof Ode-(29 – 8 – 38 – 63) and Ode-(29-63-38) receptors expressed in 
oocytes, currents recorded under voltage-clamp at −60 mV (Buxton et al., 2014b) A: Tribendimidine and 
pyrantel at 100 μM is more potent than levamisole on the Ode(29 – 38 – 63) receptor. B: Levamisole at 100 μM 
is more potent than acetylcholine tribendimidine, pyrantel and nicotine on the expressed Ode(29 – 8 – 38 – 63) 
receptor. Note that derquantel produces competitive antagonism of the effects of levamisole but a non-
competitive antagonism of pyrantel, suggesting that the mode of action of levamisole and pyrantel are not 
identical. 
 
 
species of the nematode parasite. There will therefore be cholinergic anthelmintics that act on 
different nAChR subtypes and it is therefore possible that there will not always be cross-
resistance between the cholinergic anthelmintics. 
B6.0 Discussion 
Diethylcarbamazine is used mostly for treatment of filariasis in humans but has 
effects against hookworm and ascariasis, intestinal nematode parasites (Meyrowitsch and 
Simonsen, 2001). In addition to the treatment of filariasis, diethylcarbamazine, as a single 
dose treatment, has modest effects on intestinal nematode parasite infections including 
ascariasis and trichuriasis but is more effective when combined with ivermectin or 
albendazole (Belizario et al., 2003). We have seen in our experiments that emodepside 
increases a Slo-1 K+ current in the parasite and that diethylcarbamazine can potentiate the 
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effect of emodepside. Both of these compounds have been used separately as single 
anthelmintics but we do not have data on their therapeutic effect when used in combination. 
This information is desirable to obtain and if therapeutic combination of emodepside and 
diethylcarbamazine is safe and more potent than either compound in isolation, such 
synergism could slow the development of resistance and extend the spectrum of action of the 
therapy. 
Levamisole and tribendimidine have different selectivities for nAChR subtypes. In 
Ascaris tribendimidine is more selective for the B-subtype rather than the L-subtype of 
nAChR. Tribendimidine is more potent on expressed O. dentatum receptor subtypes 
composed of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 subunits, than on subtypes composed 
of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38:Ode-ACR-8 subunits (Buxton et al., 2014b). 
The difference in selectivity suggests that tribendimidine has the potential to be effective 
against nematode parasites that are not sensitive to levamisole, including those parasites that 
have developed resistance. A careful combination of different cholinergic anthelmintics has 
the potential to extend the spectrum of action of the drug treatment. Tribendimidine has an 
interesting and promising pharmacology and has the potential for single-dose MDA with its 
broad-spectrum of action. Although tribendimidine appears safe and has broad-spectrum 
activity, a large-scale clinical study is advocated to further verify human safety. 
B7.0 Conclusion 
We have been excited by our discovery of further details of the modes of action of the 
different anthelmintics that we work on and believe that the information will be useful for 
defining mechanisms of resistance to the anthelmintic drugs that we have studied. We also 
think that the improved understanding of their mechanisms of action will lead to better use of 
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these compounds and logical design of synergistic combinations. We do not look back, but 
forward, to the future. 
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C1.0 Abstract 
Soil-transmitted helminth infections in humans and livestock cause significant 
debility, reduced productivity and economic losses globally. There are a limited number of 
effective anthelmintic drugs available for treating helminths infections, and their frequent use 
has led to the development of resistance in many parasite species. There is an urgent need for 
novel therapeutic drugs for treating these parasites. We have chosen the ACR-16 nicotinic 
acetylcholine receptor of Ascaris suum (Asu-ACR-16), as a drug target and have developed 
three-dimensional models of this transmembrane protein receptor to facilitate the search for 
new bioactive compounds. Using the human α7 nAChR chimeras and Torpedo marmorata 
nAChR for homology modeling, we defined orthosteric and allosteric binding sites on the 
Asu-ACR-16 receptor for virtual screening. We identified four ligands that bind to sites on 
257 
 
Asu-ACR-16 and tested their activity using electrophysiological recording from Asu-ACR-
16 receptors expressed in Xenopus oocytes. The four ligands were acetylcholine inhibitors 
(SB-277011-A, IC50, 3.12 ± 1.29 μM; (+)-butaclamol Cl, IC50, 9.85 ± 2.37 μM; fmoc-1, IC50, 
10.00 ± 1.38 μM; fmoc-2, IC50, 16.67 ± 1.95 μM) that behaved like negative allosteric 
modulators. Our work illustrates a structure-based in silico screening method for seeking 
anthelmintic hits, which can then be tested electrophysiologically for further characterization. 
  C1.1 Keywords 
Asu-ACR-16; Structure-based drug discovery; Homology modeling; Orthosteric site; 
Allosteric modulator; Xenopus expression    
C1.2 Abbreviations 
ECD, extracellular domain; TID, transmembrane and intracellular domain; (+), 
principal subunit; (−), complementary subunit; NAM, negative allosteric modulator; nAChR, 
nicotinic acetylcholine receptor; AChBP, acetylcholine-binding protein 
C2.0 Introduction 
Soil-transmitted gastrointestinal nematodes, namely roundworms, whipworms and 
hookworms, infect approximately two billion people worldwide and pose a significant health 
challenge to humans and animals (de Silva et al., 2003 and Bethony et al., 2006). The 
infections with the soil-transmitted helminths can cause malnutrition, iron-deficiency anemia 
and impaired cognitive performance (Crompton, 2000 and Hotez et al., 2007). Currently, 
there are no effective vaccines available (Hewitson and Maizels, 2014), and sanitation is not 
adequate in many countries. The World Health Organization (WHO) recommends four 
anthelmintics for treatment and prophylaxis of soil-transmitted nematode infections: 
albendazole, mebendazole, levamisole and pyrantel (Keiser and Utzinger, 2008). The 
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repeated use of a limited number of anthelmintic drugs has led to an increase in drug 
resistance in animals and there are similar concerns for humans. It is therefore important to 
identify novel therapeutic compounds that selectively target receptors of parasitic nematodes 
so that we maintain effective therapeutics. 
The nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion 
channels that mediate synaptic transmission at neuromuscular junctions of vertebrates and 
invertebrates (Changeux and Edelstein, 1998). The neurotransmitter, acetylcholine, activates 
nAChRs by binding to orthosteric binding sites on the extracellular domain of the receptor 
and triggers the opening of the channel pore in the transmembrane domain. The opening of 
the nicotinic receptors leads to an influx of sodium and calcium depending on the receptor 
subtypes, as well as an output of potassium ions, followed by membrane depolarization and 
muscle contraction. 
Nicotinic anthelmintics are selective agonists of nematode muscle nAChRs which 
cause spastic paralysis of the parasites (Martin and Robertson, 2010 and Buxton et al., 2014). 
There are three different pharmacological subtypes of nAChRs present on muscle of Ascaris 
suum. The anthelmintics, levamisole and pyrantel are selective agonists of L-subtypes of 
nAChRs in A. suum (Martin et al., 2012). Bephenium selectively activates B-subtypes of 
nAChRs. Nicotine and oxantel selectively activate N-subtypes of nAChRs in A. suum (Qian 
et al., 2006). The anthelmintic monepantel activates nAChRs which are composed of DEG-3-
like subunits (Haemonchus. contortus MPTL-1, Caenorhabditis. elegans ACR-20 and 
H. contortus ACR-23 subunits (Rufener et al., 2010 and Buxton et al., 2014). We have 
selected the N-subtype of nAChR that is composed of ACR-16 subunits (Ballivet et al., 
1996 and Polli et al., 2015) for a drug target, because it is pharmacologically different to the 
259 
 
other nicotinic receptor subtypes (Raymond et al., 2000), for further study. Asu-ACR-16 
transcript has been found in A. suum muscle and may be involved in locomotion. 
The ACR-16 nicotinic acetylcholine receptor of A. suum (Asu-ACR-16) is a 
homomeric receptor made up of five identical α subunits. Homomeric nAChRs have five 
identical orthosteric binding sites where agonists and competitive antagonists bind at the 
interface of two adjacent subunits. The orthosteric site is in the extracellular domain and is 
formed by the loops A, B & C of the principal subunit and by the loops D, E & F on the 
complementary subunit (Galzi et al., 1991 and Arias, 2000). In addition, three allosteric 
binding sites close to the orthosteric binding sites in the extracellular domain have been 
observed in the α7 nAChR-AChBP chimera (Spurny et al., 2015). In the transmembrane 
domain, an intrasubunit allosteric binding site has been found in Rattus. norvegicus α7 
nAChR (Young et al., 2008), while an intersubunit allosteric binding site has been found in 
C. elegans glutamate-gated chloride channel (GluCl) (Hibbs and Gouaux, 2011). These well-
studied binding sites in nAChRs or other Cys-loop receptors provided our framework for 
characterizing putative orthosteric and allosteric sites in Asu-ACR-16. 
Because of the lack of a crystal structure for Asu-ACR-16, we used homology 
modeling to predict the protein structure, based on the observations that proteins with similar 
sequences usually have similar structures (Cavasotto and Phatak, 2009). In this study, we 
used homology modeling to predict the three-dimensional structure of Asu-ACR-16, based 
on the observed experimental structures of the human α7 nAChR chimeras and the Torpedo 
marmorata nAChR as templates. Virtual screening was performed for the ACR-16 
orthosteric binding sites, using the predicted structure to identify the potential candidates of 
agonists and competitive antagonists. Allosteric binding sites were also used to examine the 
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binding properties of the virtual screening hits. Subsequently, we tested the pharmacological 
profiles of virtual screening hits on Asu-ACR-16 receptors expressed in Xenopus laevis 
oocytes, using a two-electrode voltage clamp to test the activity of the hits on the receptors. 
C3.0 Materials and methods 
C3.1 Identification of template structures 
We selected the extracellular domain of Asu-ACR-16 (ECD-Asu-ACR-16) because it 
forms a homologomer that allows homology modeling. In addition, many of the agonists that 
activate Asu-ACR-16, acetylcholine, nicotine, cytisine, epibatidine (Abongwa et al., 2016), 
are also known to bind to the orthosteric binding sites of extracellular domain of Lymnaea 
stagnalis AChBP or A. california AChBP (Celie et al., 2004, Li et al., 2011, Rucktooa et al., 
2012 and Olsen et al., 2014a). In addition to the orthosteric binding site, three separate 
allosteric binding sites in the extracellular domain of α7 nAChR are now recognized 
(Bertrand et al., 2008, Pan et al., 2012 and Spurny et al., 2015), increasing the possibility of 
identifying allosteric modulators. 
The amino acid sequence of Asu-ACR-16 (Fig. 1) was obtained from the 
UniProtKB/SwissProt database with the accession number F1KYJ9 (Wang et al., 2011). 
Structural templates were identified by using BLASTP on NCBI network service (Altschul 
et al., 1997) and PSI-BLAST on the ProtMod server (Rychlewski et al., 2000) by searching 
in the Protein Data Bank (Berman et al., 2000). Three crystal structures of human α7 nAChR 
chimeras with different co–crystal ligands in orthosteric binding site were used: epibatidine 
bound (PDB code: 3SQ6; Li et al., 2011), no ligand (PDB code: 3SQ9; Li et al., 2011), and 
α-bungarotoxin bound (PDB code: 4HQP; Huang et al., 2013). These structures were 
selected as the templates for three different bound-forms of the ECD-Asu-ACR-16. The three  
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Fig. 1. (A) Sequence and numbering of the ECD-Asu-ACR-16 and its alignment with the template, human α7 
nAChR chimera subunit. Completely conserved residues (red background) and partially conserved residues 
(yellow background) are indicated. Secondary structures are shown schematically above the sequences. α1 
represents α helix. β1-7 represent β sheet. η1 represents α helix. The Cysteine loop and loops A - F are labeled by 
dark green bars. Residues in the orthosteric binding site are indicated by arrows (principal subunit, pink; 
complementary subunit, orange). Residues in three allosteric binding pockets are highlighted by arrows 
(principal subunit of agonist sub-pocket, turquoise; complementary subunit of agonist sub-pocket, green; 
principal subunit of vestibule pocket, dark green; complementary subunit of vestibule pocket, gold; principal 
subunit of top pocket, purple). (B) Sequence and numbering of the TID-Asu-ACR-16 and its alignment with the 
template TID-Tma-AChR subunit A. Completely conserved residues (red background) and partially conserved 
residues (yellow background) are indicated. Four transmembrane α helixes (M1, M2, M3 and M4) are shown 
schematically above the sequences. Residues in the allosteric binding pocket are indicated by arrows (principal 
subunit, pink; complementary subunit, orange). (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
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Fig. 2. (A) Ribbon diagram of the antagonist-bound model of ECD-Asu-ACR-16 viewed from the synaptic cleft, showing 
the location of the orthosteric binding site and agonist sub-pocket. For clarity, only the front two subunits are highlighted 
(principal subunit, light pink; complementary subunit, yellow). The residues that contribute to the orthosteric binding site 
(principal side, pink; complementary side, orange) and the agonist sub-pocket (principal side, turquoise; complementary 
side, green) are represented by sticks and highlighted inside the red dotted circle. (B) Ribbon diagram of the antagonist-
bound model of TID-Asu-ACR-16 viewed above the membrane, showing the location of two transmembrane allosteric 
binding sites. For clarity, only the front two subunits are highlighted (principal subunit, light pink; complementary subunit, 
yellow). The residues that contribute to the intersubunit site (principal side, pink; complementary side, orange) and 
intrasubunit site (principal side, purpleblue) are represented by sticks and highlighted inside the red dotted circle. (C) 
Ribbon diagram of the antagonist-bound model of full-length Asu-ACR-16 viewed parallel to the membrane plane, showing 
the location of the orthosteric binding site and the agonist sub-pocket in the extracellular domain, the intersubunit and 
intrasubunit binding sites in the transmembrane domain. For clarity, only the front two subunits are highlighted (principal 
subunit, light pink; complementary subunit, yellow). The residues that contribute to the ligand binding sites are represented 
by sticks (orthosteric site: (+), pink; (−), orange; agonist sub-pocket: (+), turquoise; (−), green; intersubunit transmembrane 
site: (+), pink; (−), orange; intrasubunit transmembrane site: purpleblue) and highlighted inside the red dotted circle. (D) 
Detailed view of the orthosteric binding site and agonist sub-pocket in the antagonist-bound model of ECD-Asu-ACR-16. 
The principal subunit is colored light pink, whereas the complementary subunit is colored yellow. The residues that 
contribute to the orthosteric binding site (principal side, pink; complementary side, orange) and the agonist sub-pocket 
(principal side, turquoise; complementary side, green) are represented by sticks and highlighted inside the red dotted circle. 
Carbon is in either turquoise or green. Nitrogen is in blue. Oxygen is in red. (E) Detailed view of the transmembrane 
allosteric binding sites in the antagonist-bound model of TID-Asu-ACR-16. The principal subunit is colored light pink, 
whereas the complementary subunit is colored yellow. The residues that contribute to intersubunit site (principal side, pink; 
complementary side, orange) and intrasubunit site (principal side, purpleblue) are represented by sticks and highlighted 
inside the red dotted circle. Carbon is in either pink or orange or purpleblue. Nitrogen is in blue. Oxygen is in red. Sulfur is 
in yellow. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this 
article.) 
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models were: the agonist-bound form ECD-Asu-ACR-16; the apo form ECD-Asu-ACR-16 
and; the antagonist-bound form ECD-Asu-ACR-16 (Fig. 2A). 
We modeled the transmembrane and intracellular domains of Asu-ACR-16 (TID-
Asu-ACR-16, Fig. 2B) because of the presence of an intrasubunit allosteric binding site that 
is found in α7 nAChR and an intersubunit allosteric binding site that is demonstrated in a 
Cys-loop receptor, GluCl crystal structure in complex with ivermectin (Young et al., 2008, 
Bertrand et al., 2008 and Hibbs and Gouaux, 2011). Ivermectin is a known allosteric 
modulator of α7 nAChRs (Krause et al., 1998). The T. marmorata nAChR (PDB code: 2BG9 
chain A; Unwin, 2005) is the only pentameric nAChR structure with the transmembrane 
domains and partial intracellular domains determined. Therefore, the transmembrane and 
intracellular domains of T. marmorata nAChR (TID-Tma-nAChR) were selected as the 
template for our TID-Asu-ACR-16 model. 
The sequence of the ECD-Asu-ACR-16 and the human α7 nAChR chimera 
(SwissProt ID: P36544; Peng et al., 1994) were aligned using CLUSTALW multiple 
alignment (Thompson et al., 1994). The sequence of the TID-Asu-ACR-16 and TID-Tma-
nAChR (SwissProt ID: P02711; Devillers-Thiery et al., 1983 and Devillers-Thiery et al., 
1984) were aligned using CLUSTALW. 
C3.2 Homology modeling of Asu-ACR-16 
We used Modeller (Eswar et al., 2007) to build a three-dimensional model of ECD-
Asu-ACR-16 and used JACKAL 
(http://wiki.c2b2.columbia.edu/honiglab_public/index.php/Software:Jackal) to build the 
model of TID-Asu-ACR-16 for each of the five subunits. These five subunits were then 
assembled to generate the pentamer using COOT software (Emsley and Cowtan, 2004). The 
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model geometry was first refined manually, and then optimized by PHENIX software 
(Adams et al., 2010). Each of the TID-Asu-ACR-16 subunits were then merged into the 
ECD-Asu-ACR-16 model by using COOT to edit and alter the Cα coordinates of residues 
around the outer membrane regions. The final optimized pentameric model was then 
visualized using the program PyMol (The PyMOL Molecular Graphics System, Version 
1.7.4, Schrödinger, and LLC., Figs. 2C & S1). 
C3.3 Structure-based virtual screening 
Smiles strings of ligands were downloaded from the lead-like subset of commercially 
available compounds in the ZINC Database (Irwin et al., 2012) and were converted initially 
to PDB formats using the PHENIX-eLBOW program (Moriarty et al., 2009). The ligand and 
receptor input files were then prepared in PDBQT format for AutoDock Vina by using the 
AutoDock Tools package (Morris et al., 2009). For initial screening, a docking area was 
defined visually around the orthosteric binding site of ECD-Asu-ACR-16 (Fig. 2D S2A & 
S2B) by a grid box of 40 Å × 40 Å × 40 Å using 0.375 Å grid point spacing in AutoGrid. 
The conformations of ligands in the binding sites of the receptor were searched with GALS 
(Genetic Algorithm with Local Search; Morris et al., 1998). The binding free energies 
between the ligands and receptor were calculated by the combination of the knowledge-based 
and empirical scoring function in AutoDock Vina (Trott and Olson, 2010). The best nine 
binding modes of the ligand based on the binding affinities on the three bound-forms of 
ECD-Asu-ACR-16 models were implemented by AutoDock 20 runs for each ligand. Each 
docked ligand was then ranked by its highest binding affinity to the orthosteric binding site 
of the apo, agonist-bound, or antagonist-bound model. From the 60,000 screened molecules, 
we selected the top 9 ligands (0.015%) with the highest predicted affinities that had 
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appropriate binding modes within the ligand-binding pockets for further study. We rejected 
those compounds without a cationic nitrogen in their structure and that were known to be: 
acutely toxic, or carcinogenic, or respiratory depressants, caused dermatitis or conjunctivitis 
or to be significant environmental hazards as recorded on the compound Safety Data Sheets 
available from Sigma Aldrich (http://www.sigmaaldrich.com/safety-center.html). 
The four virtual screen hits (Table 1) out of the top 9 selected ligands (44%) were 
also specifically docked into five allosteric binding pockets: the agonist sub-pocket (Fig. S2C 
& S2D); the vestibule pocket (Fig. S2E & S2F); the top pocket (Fig. S2G & S2H); the 
intersubunit and; the intrasubunit transmembrane sites (Fig. 2E S2I S2J). The docking area 
was defined visually around each allosteric binding pockets of Asu-ACR-16 by a grid box of 
40 Å × 40 Å × 40 Å using 0.375 Å grid point spacing in AutoGrid. The docking was 
performed by AutoDock Vina (Fig. 3). 
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Fig. 3. Binding modes of four virtual screening hits in the orthosteric binding site, the agonist sub-pocket, the intersubunit and 
intrasubunit transmembrane allosteric binding pockets of the antagonist-bound model of Asu-ACR-16: (A), (B), (C), (D) 
fomc-2; (E), (F), (G), (H) SB-277011-A; (I), (J), (K) fomc-1; (L), (M), (N), (O) (+)-butaclamol Cl. Hits docked into the binding 
pockets are represented by sticks (carbon in yellow; ring in white; nitrogen in blue; oxygen in red). (A), (E), (I) and (L) show 
the four hits bound in the orthosteric binding site of the antagonist-bound model of ECD-Asu-ACR-16. The front two subunits 
are highlighted (principal subunit, light pink; complementary subunit, yellow). The residues in the orthosteric binding site are 
labeled (principal side, pink; complementary side, orange) to show the location of the orthosteric binding site. (B), (F), (J) and 
(M) show the four hits bound in the agonist sub-pocket of the antagonist-bound model of ECD-Asu-ACR-16. The front two 
subunits are highlighted. The residues in the agonist sub-pocket are labeled (principal side, turquoise; complementary side, 
green) to show the location of the agonist sub-pocket. (C), (G) and (N) show the four hits bound in the intersubunit 
transmembrane site of the antagonist-bound model of TID-Asu-ACR-16. The front two subunits are highlighted. The residues 
in the intersubunit transmembrane site are labeled (principal side, pink; complementary side, orange) to show the location of 
the intersubunit transmembrane binding site. (D), (H), (K) and (O) show the four hits bound in the intrasubunit transmembrane 
site of the antagonist-bound model of TID-Asu-ACR-16. The residues in the intrasubunit transmembrane site are labeled 
(purpleblue) to show the location of the intersubunit transmembrane binding site. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article.) 
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C3.4 In vitro synthesis of cRNA and microinjection into Xenopus laevis oocytes 
We used TRIzol (Invitrogen™) to extract the total RNA samples from a 1 cm muscle 
flap and dissected the whole pharynx of A. suum. The first-strand of cDNA was synthesized 
with oligo RACER primer, Random Hexamer and superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA) from total RNA in the muscle and pharynx by reverse 
transcription polymerase chain reaction (RT-PCR). Full-length Asu-acr-16 cDNA was 
amplified with the forward primer TTGATGTAGTGGCGTCGTGT, 
ATCACGCATTACGGTTGATG and the reverse primer GCATTGATGTTCCCTCACCT, 
ATTAGCGTCCCAAGTGGTTG (Boulin et al., 2011). The XhoI and ApaI restriction 
enzymes were used to digest the amplified product, which was then cloned into pTB207 
expression vector (Boulin et al., 2008) and linearized by NheI. We used the mMessage 
mMachine T7 kit (Ambion) to in vitro transcribe the linearized cDNA to cRNA, which was 
then precipitated with lithium chloride, re-suspended in RNase-free water, aliquoted and 
stored at −80 °C. 
The ancillary protein RIC-3 is required for the expression of ACR-16 in Xenopus 
oocytes (Halevi et al., 2003). A 50 nL cRNA mixture was prepared with 25 ng Asu-acr-16 
cRNA, 5 ng Asu-ric-3 cRNA (SwissProt ID: F1L1D9; Wang et al., 2011) dissolved in 
RNAse-free water. The nanoject II microinjector (Drummond Scientific, PA, USA) was used 
to injected the cRNA mixture into the animal pole of the de-folliculated X. laevis oocyte 
(Ecocyte Bioscience, Austin, TX, USA). 
The injected oocytes were separated into 96-well culture plates and incubated in the 
incubation solution (pH 7.5), which is composed of 100 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL penicillin, 
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100 μg/mL streptomycin and changed daily. The injected oocytes were stored at 19 °C for 4–
8 days to allow the receptor to be expressed. 
C3.5 Two-electrode voltage-clamp oocyte recording 
We used two-electrode voltage-clamp electrophysiology to record the inward current 
generated by the activated Asu-ACR-16 receptors expressed in X. laevis oocytes. 100 μM 
BAPTA-AM (final concentration) was added into the oocyte incubation solution 4 h prior to 
recording, to prevent the current produced by the endogenous calcium-activated chloride 
channels during recording. An Axoclamp 2B amplifier (Molecular Devices, CA, USA) was 
used for recording and oocytes were held at −60 mV. A PC computer with software Clampex 
9.2 (Molecular Devices, CA, USA) was used to acquire the recording data. The 
microelectrodes used to measure current in oocytes were pulled on a Flaming/Brown 
horizontal electrode puller (Model P-97, Sutter Instruments), filled with 3M KCl and had 
resistances of 20–30 MΩ. The microelectrode tips were broken back carefully with 
Kimwipes (Wilmington, NC, USA) to reduce the resistance to 2–5 MΩ. The recording 
solution was: 100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and 5 mM HEPES, pH 7.3 
(Buxton et al., 2014). Oocytes were placed into a tiny groove of the narrow oocyte recording 
chamber. The Digidata 1322A (Molecular Devices, CA, USA) was used to control the 
switches that controlled the perfusion of the chamber at a speed of 4–6 ml/min. 
100 μM acetylcholine was applied initially for 10 s as a control to check the viability 
of the oocytes and Asu-ACR-16 expression for all the recordings. Recording solution was 
then used to wash out the drug from the oocytes for 2–3 min before next application of drug 
perfusion. 
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C3.6 Drugs 
Table 1 lists the compounds used, their chemical properties and structures. Fmoc-4-
(naphthalen-2-yl)-piperidine-4-carboxylic acid (fmoc-2), SB-277011-A hydrochloride 
hydrate (SB-277011-A), fmoc-4-(naphthalen-1-yl)-piperidine-4-carboxylic acid (fmoc-1) and 
(+)-butaclamol hydrochloride (+)-butaclamol Cl), acetylcholine chloride (ach), 
methyllycaconitine citrate salt (mla) were purchased from Sigma–Aldrich (St Louis, MO, 
USA). Levamisole hydrochloride (levamisole) was purchased from MP Biomedicals (Santa 
Ana, CA, USA). With the exception of ach and mla which were dissolved in the recording 
solution, the rest of chemicals were dissolved in dimethyl sulfoxide (DMSO) to make stock 
solutions. Stock solutions of 100 mM were prepared, except for SB-277011-A where a stock 
solution of 10 mM was prepared due to the solubility; stock solutions were frozen until 
required. Working solutions were then prepared by dilution on the day of the experiment. 
C3.7 Pharmacological characterization of molecules selected by virtual screening 
To characterize the four hits (Table 1) selected by our virtual screening, each drug 
was applied for 10 s to the oocytes expressing Asu-ACR-16 to test if the drugs were agonists. 
They were then tested as antagonists against ach. 
To characterize the antagonistic properties of the four hits, the following protocol was 
used: a) 10 s of 100 μM ach alone; b) then 10 s of 100 μM ach + hit and then; c) 10 s of 
100 μM ach alone. This test procedure was repeated with increasing concentrations of the 
four hits (Fig. 4A–D), to determine the inhibitory dose–response relationships and IC50 by 
fitting Hill equations to the inhibitory dose–response curves using GraphPad Prism 5.0 
(Graphpad Software Inc., CA, USA). As a further study of the antagonism, each of the four 
hits was applied before and during 10 s test applications of increasing concentrations of ach 
(Fig. S4). 
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Fig. 4. Effects of four virtual screening hits on Asu-ACR-16 mediated ach responses. Sample traces for: (A) 
fmoc-2, (B) SB-277011, (C) (+)-butaclamol Cl, (D) fmoc-1 concentration-inhibition relationships on Asu-ACR-
16. Mla in (D), which stands for methyllycaconitine citrate salt, was used as an antagonist control of Asu-ACR-
16. All four hits did not induce the current response by themselves, while produced the concentration-depended 
inhibition of ach current response. (E) is the magnified figure of part of (D) as an example to show the four 
parameters needed to measure the inhibition percentage. Imax control was the peak current of the control 30 s 
application of 100 μM ach. Imax was the peak current of the 100 μM ach that preceded the 10 s co-application of 
ach and antagonist. Iant was the minimal current during the co-application of 100 μM ach and antagonist. Iant 
control was the current at the same time point from the beginning of the 30 s application as Iant during the control 
30 s application of 100 μM ach. 
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C3.8 Data analysis 
The data from electrophysiological recordings were analyzed using Clampfit 9.2 
(Molecular Devices, CA, and USA) and GraphPad Prism 5.0 (Graphpad Software Inc., CA, 
USA). In all recordings, the peak currents in response to applied drugs were measured, which 
were later normalized to the control 100 μM ach response, and expressed as mean ± S.E.M. 
The mean % inhibition of currents elicited by 100 μM ach ± S.E.M. was used to determine 
the inhibition percentage, which was quantified using the following equation: 
 
where Imax control was the peak current of the control 30 s application of 100 μM ach, Imax was 
the peak current of the 100 μM ach that preceded the 10 s co-application of ach and 
antagonist. Iant was the minimal current during the co-application of 100 μM ach and 
antagonist. Iant control was the current at the same point from the beginning of the 30 s 
application as Iant during the control 30 s application of 100 μM ach (Fig. 4E). Concentration-
response relationships or concentration-inhibition (%) relationships were analyzed by fitting 
data points into the Hill equation, with at least four replicates of each experiment set. 
C3.9 Drug treatment of C. elegans 
The wild-type C. elegans strain N2 were obtained from the Caenorhabditis Genetics 
Center (University of Minnesota, MN, USA). We grew C. elegans at 20 °C on nematode 
growth media (NGM, 3 g/l NaCl, 17 g/l agar, 2.5 g/l peptone, 1 mM CaCl2, 5 mg/l 
cholesterol, 1 mM MgSO4, 25 mM KPO4 buffer) agar plates, seeded with Escherichia. coli 
OP50 lawn under standard conditions (Brenner, 1974). Ten larvae at L4 stage with active 
thrashing movement (defined as “normal”) were transferred from NGM plates into M9 buffer 
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(3 g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l NaCl, 1 mM MgSO4) in 24-wall plates for each 
treatment. We counted the number of worms with normal motility in M9 buffer with diluted 
drugs from the stock solutions (≤1% DMSO) at 0, 5, 10, 15 and 20 min. Five replicates were 
applied for each treatment. Motility between negative control (1% DMSO, final 
concentration) and drug treated worms were compared at each time point using student t-test. 
C4.0 Results 
C4.1 Sequence alignment of Asu-ACR-16 and template homologue proteins 
The full-length protein sequence of Asu-ACR-16 (504 residues) was retrieved from 
the SwissProt database, of which the ECD-Asu-ACR-16 accounts for 234 residues. The first 
25 resides of Asu-ACR-16 were excluded from alignment with the full length human nAChR 
α7 chimera (204 residues) because of the shorter length of the template protein sequence. The 
human α7 nAChR chimera shows 37.6% sequence identity and 72.9% sequence similarity 
with the ECD-Asu-ACR-16, based on the alignment generated by CLUSTALW (Fig. 1A, job 
ID: 65782ad6ad6d). The TID-Tma-nAChR subunit A shows 22.0% sequence identity and 
45.4% sequence similarity with TID-Asu-ACR-16, aligned by CLUSTALW (Fig. 1B, job 
ID: 644888f4f30e). The residues involved in the putative orthosteric and the allosteric 
binding sites are highlighted in amino acids sequence of Asu-ACR-16. 
C4.2 Models of the Asu-ACR-16 pentamer 
The model of the antagonist-bound form of the ECD-Asu-ACR-16 subunit starts from 
an N-terminal α helix followed by seven β strands that comprise an immunoglobulin fold. 
Loop A (Val114 – Ala122), loop B (Lys169 – Lys179), loop C (Phe213 – Pro220) from the 
principal subunit, and loop D (Ala78 – Ala83), loop E (Ile143 – Pro144), loop F (Gly185 – 
Met204) from the complementary subunit are involved in forming the orthosteric binding 
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site. A disulphide bond between Cys152 and Cys166 contributes to the characteristic 
component of Cys-loop receptors. The C-terminal continues into the transmembrane domain 
(Fig. S1A). 
The transmembrane domains of the Asu-ACR-16 model are made of four α-helices 
(M1, M2, M3 and M4). M1 links to the β7 sheet of the extracellular domain and extends 
down into the membrane and is followed by the M2 and the M3 helixes as the membrane-
spanning portions. The MA cytoplasmic loop (helix) connects between M3 and M4. The 
region between M3 and MA is not modeled due to the poorly defined intracellular domain of 
the template structure. The C-terminal follows the M4 helix and faces toward the 
extracellular surface (Fig. S1B). 
The pentameric model of Asu-ACR-16 has a five-fold symmetric around the channel 
pore. The average pairwise Root Mean Square Deviation (RMSD) fit of the Cα coordinates of 
the antagonist-bound ECD-Asu-ACR-16 pentameric model and human α7 nAChR chimera 
pentamer (PDB code: 4HQP) was 0.9 Å, which indicates a strong structural conservation 
between the model and the template structures (Fig. S1C). The Cα-RMSD between the TID-
Asu-ACR-16 pentamer and the TID-Tma-AChR pentamer was 1.5 Å, which shows the TID 
fit is still good but not as good as the ECD fit. The membrane-spanning domains are arranged 
symmetrically. The M2 helix lines the channel pore, while M1, M3 and M4 do not contribute 
to the channel pore and are arranged peripherally (Fig. S1D). 
Since no binding site data of Asu-ACR-16 is available to date, we used the published 
orthosteric binding site and allosteric binding sites in nAChRs or other Cys-loop receptors to 
predict the putative binding sites in Asu-ACR-16 (Galzi et al., 1991, Arias, 2000, Young 
et al., 2008, Hibbs and Gouaux, 2011 and Spurny et al., 2015). The orthosteric binding site is 
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at the interface between the principal site and the complementary site in two adjacent 
subunits of the ECD-Asu-ACR-16 pentamer (Fig. 2S2A & S2B). The principal subunit (+) 
has vicinal cysteines (Cys216, Cys217) that contributes to the loop C of the binding site. The 
complementary subunit (−) does not use vicinal cysteines as part of the binding pocket and 
the residues are more variable when nAChRs are compared. The agonist sub-pocket, which 
we argue is a less significant allosteric binding site in ECD-Asu-ACR-16, is located right 
below the orthosteric binding site in the extracellular domain (Fig. 2S2C & S2D). The 
vestibule pocket (Fig. S2E & S2F) and the top pocket (Fig. S2G & S2H) were not high 
affinity binding sites for the ligands and are not discussed further in this manuscript. The 
intersubunit allosteric binding sites in TID-Asu-ACR-16 are at the interface region between 
M2(+), M3(+), M1(−) and M2(−) (Fig. 2S2I & S2J). The intrasubunit allosteric binding sites 
are at the center of the four transmembrane helixes (M1, M2, M3 and M4) in each of the five 
subunits. 
C4.3 Binding properties of virtual screening hits 
We carried out virtual screening of the ZINC ligand-database by using the three 
different bound forms of the ECD-Asu-ACR-16 models. Four molecules were selected as 
hits based on their high binding affinities and appropriate binding modes within the ligand-
binding sites. The 9-fluorenylmethoxycarbonyl group (FMOC) was observed in twelve out of 
top forty hits ranked by binding affinities and exists in the two out of four hits, which 
suggests that FMOC could be necessary for the ligand recognition by the receptor. The 
FMOC group has a low predicted bioavailability due to the biphenyl scaffold, which limits 
aqueous solubility and may affect distribution to the A. suum parasite. Table 1 lists the 
physicochemical characteristics of four hits. They have relatively high molecular weights and 
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are more hydrophobic compared to known Asu-ACR-16 agonists. However, they do follow 
the Lipinski's rule of five, which suggests that these molecules may be orally actively ( 
Lipinski et al., 2001 and Lipinski, 2004). 
The atomic structure predicts the partition-coefficients (XlogP) of the four hits to be 
between 4.27 and 6.04 (Table 1). The XlogPs suggest that the four hits are 10,000–1,000,000 
times more concentrated in the lipophilic phase of the lipid bilayer than the aqueous phase of 
the extracellular domain (Cheng et al., 2007). The four hydrophobic hits are, therefore, more 
likely to bind into the transmembrane allosteric binding pockets rather than to the 
extracellular ligand binding sites. The four hits which bind in the transmembrane allosteric 
binding pockets are therefore predicted to be allosteric modulators of the Asu-ACR-16 
receptor that alter the activity of the agonists or competitive antagonists that bind to 
orthosteric binding site. SB-277011-A is known to be a potent and selective dopamine D3 
receptor antagonist with high oral availability (Stemp et al., 2000). (+)-butaclamol Cl is a 
non-selective dopamine receptor antagonist and a potent antipsychotic agent (Chrzanowski 
et al., 1985). No paper reporting on the activities of fmoc-2 and fmoc-1 has been published to 
date. 
The four hits (Table 1) were tested for docking into the orthosteric binding sites of the 
three forms of ECD-Asu-ACR-16 models and the five allosteric binding pockets in the 
antagonist-bound form of full-length Asu-ACR-16 models. All four hits bound to the 
orthosteric binding sites of three ECD-Asu-ACR-16 models, but only bound to the three 
allosteric binding sites out of five: the intersubunit and intrasubunit transmembrane pockets 
and the agonist sub-pocket (Fig. 3) with high binding affinities. 
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In the intersubunit transmembrane site of TID-Asu-ACR-16 model, M243 (M1, (−)), 
L247 (M1, (−)) make hydrophobic interactions with naphthalene of fmoc-2. T312 (M3, (+)), 
S284 (M2, (+)) form hydrogen bonds with carboxylic acids of fmoc-2. F279 (M2, (−)), I282 
(M2, (−)) and make hydrophobic contacts with fluorene of fmoc-2. F279 (M2, (−)), P244 
(M1, (−)) make hydrophobic interactions with tetrahydroisoquinoline of SB-277011-A. N240 
(M1, (−)) forms a hydrogen bond with carboxamide of SB-277011-A. P288 (M2, (+)) has 
hydrophobic interactions with quinoline of SB-277011-A. L247 (M1, (−)), F279 (M2, (−)) 
and makes hydrophobic contacts with dibenzocycloheptene of (+)-butaclamol Cl. 
Ach, the natural agonist of Asu-ACR-16 was docked into the ligand binding sites of 
three forms of Asu-ACR-16 models for comparison. As expected, ach bound to the 
orthosteric binding site of the agonist-bound Asu-ACR-16 with an affinity (−4.3 kcal/mol), 
which was higher than the affinities at the other binding sites. The binding pose of ach 
docked in the orthosteric binding site of the agonist-bound Asu-ACR-16 model was in 
agreement with the binding pose of ach in the L. stagnalis AChBP cocrystal structure (PDB 
code: 3WIP; Olsen et al., 2014b). The quaternary ammonium of ach faces the basal side of 
the binding cavity and make cation-π interaction with five aromatic residues from the Asu-
ACR-16 ((+): Y89, W143, Y185, Y192; (−): W53), while the carbonyl oxygen of ach faces 
toward the apical side of the binding cavity. The binding affinities of the selected four 
compounds were higher than −8.0 kcal/mol in the three different bound forms of Asu-ACR-
16, while the binding affinities of ach were lower than −4.5 kcal/mol in three states of Asu-
ACR-16 (Table 2). 
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C4.4 Pharmacological properties of virtual screening hits 
We tested the effects of the putative allosteric modulators on Asu-ACR-16 receptors 
expressed in Xenopus oocyte using two-electrode voltage clamp to observe the currents that 
flow through Asu-ACR-16 receptors. Representative traces showing the inhibitory dose–
response relationships are shown in Fig. 4. Their IC50 (Fig. 5A and B) and maximum 
inhibition (Fig. S3) were determined as described in the methods (Table 3). The most potent 
antagonist among them was SB-277011-A, which had an IC50 of 3.12 ± 1.29 μM and 
maximum inhibition effect of 96.07 ± 10.66% (n = 4). 
The ach concentration-response plots in the presence of 3 μM of each putative 
allosteric modulator (Fig. S4 & Fig. 5C), show the reduced maximum current responses with 
little shift in EC50 of ach (Fig. 5Dand E & Table 4), and that the hits were non-competitive 
antagonists and negative allosteric modulators. 
At 10 μM, SB-277011-A, showed evidence of a mixed competitive and non-
competitive antagonism (Fig. S5), characterized by a reduced maximum current response and 
a right-shift in the EC50 of ach (Fig. 5D and E). Thus, 10 μM SB-277011-A appears to act at 
more than one binding site which may include the orthosteric binding sites and additional 
allosteric binding sites. 
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Fig. 5. (A) Effects of four virtual screening hits on Asu-ACR-16 mediated ach responses. Fmoc-2, fmoc-1, (+)-butaclamol 
Cl and SB-277011-A concentration-inhibition curves for Asu-ACR-16. Results were expressed as mean % inhibition of 
currents elicited by 100 μM ach ± S.E.M. (B) Bar chart representing the IC50 (mean ± S.E.M, μM) of each plots in (A). The 
rank order series of inhibition based on IC50 for four hits is: SB-277011-A (3.12 ± 1.29 μM, n = 4) < (+)-butaclamol Cl 
(9.85 ± 2.37 μM, n = 4) ≈ fmoc-1 (10.00 ± 1.38 μM, n = 4) < fmoc-2 (16.67 ± 1.95 μM, n = 4). * represents p < 0.05 
(unpaired t-test). (C) Ach concentration-response plots for Asu-ACR-16 in the absence of hits as a control (ach) and in the 
continual presence of four hits identified in (A). Ach concentration-response curves for Asu-ACR-16 in the presence of 
3 μM of four hits: fmoc-1, fmoc-2, SB-27011-A and (+)-butaclamol Cl. (D) Bar chart (mean ± S.E.M, %) representing the 
reduced maximum current response of ach concentration-response curves in (C). The series of reduced maximum response 
of each hits compared to that of ach by unpaired t-test is: 10 μM SB-27011-A (5.51 ± 1.38%, n = 4), 3 μM (+)-butaclamol 
Cl (17.22 ± 1.94%, n = 4), 3 μM SB-27011-A (23.25 ± 1.80%, n = 5), 3 μM fmoc-2 (49.92 ± 3.27%, n = 4), 3 μM fmoc-1 
(61.25 ± 3.08%, n = 4) and ach (97.45 ± 1.19%, n = 4). * represents p < 0.05, ** represents p < 0.01, *** represents 
p < 0.001. All four hits significantly inhibited the maximum current response induced by ach. (E) Bar chart (mean ± S.E.M, 
μM) displaying the EC50 of ach concentration-response curves in (C). The series of variable EC50 of each hits compared to 
that of ach by unpaired t-test is: 10 μM SB-27011-A (29.40 ± 2.27 μM, n = 4), 3 μM fmoc-1 (8.62 ± 1.04 μM, n = 4), 3 μM 
fmoc-2 (8.01 ± 0.18 μM, n = 4), 3 μM SB-27011-A (7.17 ± 0.33 μM, n = 5), ach (5.92 ± 0.29 μM, n = 4) and 3 μM (+)-
butaclamol Cl (3.94 ± 0.66 μM, n = 4). The EC50 of all four hits obviously shift away from the control when applied. 
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C4.5 SB-277011-A reversibly inhibits locomotion in C. elegans 
We tested the effects of each allosteric modulator on the locomotion of C. elegans L4 
larvae. The number of normal worms with thrashing-like movement dropped by 60% in 
5 min after exposed to 30 μM SB-277011-A (p < 0.01, n = 5, t-test). Paralysis-like movement 
was observed in the rest of the worms. Interestingly, the number of worms with motility that 
appeared normal recovered to 50% (p < 0.05, n = 5, t-test) in 10 min, 85% in 15 min 
(p > 0.05, n = 5, t-test) and returned to near negative control values after 20 min (Fig. S6). 
The recovery may relate to the desensitization properties of the ACR-16 receptor. The 
reversible inhibition of motility in worms was also observed in 100 μM (+)-butaclamol Cl, 
but no significant difference between the number of normal treated worms and negative 
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control was observed at any time point. No visual effects of 100 μM fmoc-2 or 100 μM 
fmoc-1 were found on the locomotion of worms. 
C5.0 Discussion 
C5.1 Asu-ACR-16 models 
We have built up three-dimensional models of full-length structures of Asu-ACR-
16 at the atomic level for the first time. We used homology modeling based on X-ray crystal 
structures of human α7 nAChR chimeras and the electron microscopic structure of the 
T. marmorata nAChR as templates for different domains. The quality of our homology 
models are dependent on the sequence identity of the templates (human α7 nAChR chimeras 
and T. marmorata nAChR) and the target sequence (Asu-ACR-16) and the resolutions of 
template structures (Hillisch et al., 2004 and Cavasotto and Phatak, 2009). Our three ECD-
Asu-ACR-16 models are likely to be reliable for virtual screening because they have high 
sequence identities (37.6% identity and 72.9% similarity) with high resolution (<4 Å) 
templates. More errors might be expected in the TID-Asu-ACR-16 model, because of the 
missing loop between M3 and MA in the template structure which reduces sequence identity 
with the target protein. The missing loop does not include an allosteric binding site, so we 
can assume that the TID-Tma-nAChR structure is similar to the TID-Asu-ACR-16 structure 
(Bertrand et al., 2008). The overall secondary structures of our models are also consistent 
with published nAChRs structures (Finer-Moore and Stroud, 1984, Miyazawa et al., 
2003 and Unwin, 2005). 
We developed the apo, the agonist-bound and the antagonist-bound models of the 
ECD-Asu-ACR-16 on the assumption that these three states of the Asu-ACR-16 receptor 
most closely represent the receptor conformations in the presence and absence of agonists or 
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antagonists. To produce a realistic dynamic model would require more extensive work 
(Cavasotto and Orry, 2007 and Spyrakis et al., 2011) and is beyond the scope of this study. 
C5.2 Virtual screening 
Our structure-based virtual screening approach identified four novel and potent 
negative allosteric modulators of Asu-ACR-16, which were validated by our 
electrophysiological studies. The putative ligands were initially selected based on the virtual 
screening using the orthosteric binding site of the receptor. It was possible that these ligands 
could have been agonists or competitive antagonists that bind within the orthosteric binding 
site. In contrast, the pharmacological characterization of the four virtual screening hits shows 
that they behave as negative allosteric modulators and bind to allosteric sites. This outcome 
may be due to the hydrophobic properties of the four compounds that impedes their 
interactions with the orthosteric site in the extracellular domain of the receptor. The high 
lipid solubility of these compounds increases their concentration in the membrane lipid 
phase, in the region of the transmembrane allosteric sites. 
The binding affinities calculated in the scoring function of AutoDock Vina software 
usually increase with the number of non-hydrogen atoms, which may be due to the neglect of 
desolvation in the scoring function (Shoichet et al., 1999, Kuntz et al., 1999 and Park et al., 
2006). This leads to a bias of virtual screening methods towards big molecules which are 
more hydrophobic, concentrated in the lipid bilayer, and less likely to interact with the 
binding sites in the extracellular domains (Hopkins et al., 2004). It is also pointed out that the 
simplified force fields used to estimate the binding free energies are unable to evaluate the 
conformational entropies and other contributions to the free energies (Cosconati et al., 2010). 
Thus, the success rate of identifying bioactive hits (44%) would be enhanced if we are able to 
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include these additional parameters into a scoring function for virtual screening. Another 
approach, which we did not follow here, to enhance the success rate of identifying bio-active 
hits, is to use the known agonists or antagonists as scaffolds. This would facilitate the 
identification of low molecular-weight and more hydrophilic agonists or antagonists, and 
allow further study of the quantitative structure-activity relationships (Sun, 2008). 
C5.3 Four negative allosteric modulators of Asu-ACR-16 
We evaluated the potency of inhibition for the four negative allosteric modulators in 
our electrophysiology studies on Xenopus oocytes: SB-277011-A (IC50 
3.12 ± 1.29 μM) < (+)-butaclamol Cl (IC50 9.85 ± 2.37 μM) ≈ fmoc-1 (IC50 
10.00 ± 1.38 μM) < fmoc-2 (IC50 16.67 ± 1.95 μM). This rank of inhibition agrees with the 
level of effects of the four modulators in the motility of C. elegans. The most potent 
modulator SB-277011-A was shown to decrease the motility of C. elegans larvae for a 
duration of about 10 min, yet less effective on adult C. elegans. Desensitization of the ACR-
16 or other nAChRs in C. elegans body muscle may be a reason for the reduced effects of 
SB-277011-A on worms (Hernando et al., 2012). Treating the acr-16-null mutant of 
C. elegans with SB-277011-A can help us to investigate the mode of action of SB-277011-A 
on C. elegans as genetic models to understand SB-277011-A action on the parasitic 
nematode A. suum (Ward, 2015). 
C5.4 Allosteric binding sites may offer a better opportunity for drugs that can 
discriminate between the parasite Asu-ACR-16 and mammalian host α7 nAChR 
Asu-ACR-16 shows 42.5% sequence identity and 71.2% sequence similarity with the 
human α7 nAChR (SwissProt ID: P36544) based on the alignment generated by 
CLUSTALW (Fig. S7, CLUSTALW job ID: cfed4f821eaf). The residues constituting the 
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orthosteric binding site (pink and orange arrows in Fig. S7) are highly conserved between 
Asu-ACR-16 and human α7 nAChR, which shows 66.7% identity and 100% similarity 
(Fig. S8). In contrast, the residues of the four allosteric binding sites have much greater 
differences (variance) between the nematode parasite and the equivalent sites on the α7 
receptor (identities: 62.5%, 45.5%, 66.7%, 62.5% and 40.0% and; similarities: 87.5%, 
81.8%, 83.3, 93.8% and 100%). The sequence divergence in the allosteric binding sites 
between Asu-ACR-16 and host human α7 nAChR indicates that drugs targeted at these sites 
may be more selective than drugs targeted at orthosteric binding sites. Virtual screening 
specifically targeting the allosteric binding sites is predicted to offer a better opportunity for 
development of drugs with much greater receptor subtype selectivity (Nussinov and Tsai, 
2013 and Iturriaga-Vasquez et al., 2015). 
C5.5 Conclusion 
We have developed a structure-based in silico screening approach to search for the 
bioactive hits that target at a parasitic nematode receptor. This approach allowed us to 
identify four negative allosteric modulators that were validated using our 
electrophysiological studies. These four compounds may be useful leads for anthelminthic 
drug discovery. We point out however, that we have not yet made the structural models for 
the host human α7 nAChR or other receptors, which would help to distinguish compounds 
that are active only on the nematode receptors, thereby reducing potential toxicity. It would 
also be desirable to perform virtual screening for toxicity on a range of host receptors, some 
structures of which have already been determined and others need to be modeled. 
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C8.0 Supplementary data 
 
Supplementary Figure S1. (A) Ribbon representation of the ECD-Asu-ACR-16 monomer. Secondary elements 
are indicated. Loop A, B, C in the principal subunit and loop D, E, F in the complementary subunit which 
mainly contribute to the orthosteric binding site are labeled by dark green. In the complete structure, the C-
terminal would enter the membrane at the bottom and link to M1 helix in the transmembrane domain. (B) 
Ribbon representation of the full-length Asu-ACR-16 monomer, as viewed parallel to the membrane plane. 
Four α helixes (M1, M2, M3 and M4) that contribute to transmembrane domain and one MA helix that makes 
up the intracellular domain are indicated. The functionally important M1-M2, M2-M3 and MA-M4 loops are 
labeled. (C) Superposition of antagonist-bound model of ECD-Asu-ACR-16 pentamer (purple blue) and 
template human α7 nAChR chimera (red; PDB code: 4HQP, ligands removed for clarity) viewed from the 
synaptic cleft. Five homomeric α-subunits are labeled. The interfaces between two vicinal α-subunits are 
marked by dotted lines. Five orthosteric binding sites are at each interface between the principal side (+) and the 
complementary side (−) from two vicinal subunits. (D) Superposition of TID-Asu-ACR-16 pentamer (purple 
blue) and template TID-Tma-AChR (red; PDB code: 2BG9) viewed above the membrane. Five homomeric α-
subunits are labeled. The interfaces between two vicinal α-subunits are marked by dotted lines. Five allosteric 
binding sites are at each interface among the M2, M3 in the principal side (+) and the M1 in the complementary 
side (−) from two vicinal subunits. 
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Supplementary Figure S2. (A) Detailed view of the orthosteric binding site in the antagonist-bound model of 
ECD-Asu-ACR-16. Principal subunit is colored light pink, whereas the complementary subunit is colored 
yellow. The residues that contribute to the orthosteric binding site are represented by sticks (principal side (+), 
pink; complementary side (−), orange) and highlighted inside the red dotted circle. Carbon is in either pink or 
orange. Nitrogen is in blue. Oxygen is in red. Sulfur is in yellow. (B) Detailed view of the residues involving in 
the orthosteric binding site in the antagonist-bound model of ECD-Asu-ACR-16. Functionally important amino 
acids which interact with the ligands bound in this region are labeled. (C) Detailed view of the agonist sub-
pocket relative to the location of the orthosteric binding site in the antagonist-bound model of ECD-Asu-ACR-
16. Principal subunit is colored light pink, whereas the complementary subunit is colored yellow. The residues 
that contribute to the agonist sub-pocket are represented by sticks (principal side (+), turquoise; complementary 
side (−), green) and highlighted inside the red dotted circle at the bottom. Carbon is in either turquoise or green. 
Nitrogen is in blue. Oxygen is in red. (D) Detailed view of the residues involving in the agonist sub-pocket in 
the antagonist-bound model of ECD-Asu-ACR-16. Functionally important amino acids which interact with the 
allosteric modulators bound in this region are labeled. (E) Detailed view of the vestibule pocket relative to the 
location of the orthosteric binding site in the antagonist-bound model of ECD-Asu-ACR-16. Principal subunit is 
colored light pink, whereas the complementary subunit is colored yellow. The residues that contribute to the 
vestibule pocket are represented by sticks (principal side (+), dark green; complementary side (−), gold) and 
highlighted inside the red dotted circle on the left. Carbon is in either dark green or gold. Nitrogen is in blue. 
Oxygen is in red. (F) Detailed view of the residues involving in the vestibule pocket in the antagonist-bound 
model of ECD-Asu-ACR-16. Functionally important amino acids which interact with the allosteric modulators 
bound in this region are labeled. (G) Detailed view of the top pocket relative to the location of the orthosteric 
binding site in the antagonist-bound model of ECD-Asu-ACR-16. Principal subunit is colored light pink, 
whereas the complementary subunit is colored yellow. The residues that contribute to the vestibule pocket are 
represented by sticks (principal side (+), purple) and highlighted inside the red dotted circle at the top. Carbon is 
in purple. Nitrogen is in blue. Oxygen is in red. (H) Detailed view of the residues involving in the top pocket in 
the antagonist-bound model of ECD-Asu-ACR-16. Functionally important amino acids which interact with the 
allosteric modulators bound in this region are labeled. (I) Detailed view of the two transmembrane allosteric 
binding sites in the antagonist-bound model of TID-Asu-ACR-16. Principal subunit is colored light pink, 
whereas the complementary subunit is colored yellow. The residues that contribute to the intersubunit site 
(principal side, pink; complementary side, orange) and intrasubunit site (principal side, purpleblue) are 
represented by sticks and highlighted inside the red dotted circle. Carbon is in either pink or orange or 
purpleblue. Nitrogen is in blue. Oxygen is in red. Sulfur is in yellow. (J) Detailed view of the residues involving 
in the two transmembrane allosteric binding sites in the antagonist-bound model of TID-Asu-ACR-16. 
Functionally important amino acids which interact with the allosteric modulators bound in this region are 
labeled. 
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Supplementary Figure S3. Bar chart showing effects of the four hits on Asu-ACR-16. Results are expressed as 
maximum inhibition (mean ± S.E.M, %) of each plots in (Fig. 5A). The rank order series of inhibition based on 
maximum inhibition percentage for four hits is: SB-277011-A (96.07 ± 10.66%, n = 4) ≈ fmoc-1 
(82.49 ± 4.74%, n = 4) ≈ fmoc-2 (80.34 ± 10.32%, n = 4) ≈ (+)-butaclamol Cl (79.53 ± 12.41%, n = 4) using 
unpaired t-test. 
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Supplementary Figure S4. Sample traces showing the effects of four hits on the acetylcholine concentration-
response relationships for Asu-ACR-16. Sample trace of acetylcholine concentration-response relationships in 
the absence of hits is depicted in (A) as a control. 3 μM of each of four hits are applied: (B) fmoc-2, (D) SB-
277011, (F) fmoc-1, (H) (+)-butaclamol Cl, to compare the EC50 shifts and the maximum response reduction 
for four hits. 1 μM SB-277011-A (C), 1 μM (+)-butaclamol Cl (G) and 10 μM SB-277011-A (E) were tested to 
study the concentration effects on the mode of inhibition. 
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Figure S5. Ach concentration-response curves for Asu-ACR-16 in the absence of hits as a control (ach) and in 
the continual presence of 1 μM, 3 μM, 10 μM SB-277011-A, 1 μM, 3 μM (+)-butaclamol Cl. 
 
 
Supplementary Figure S6. Plot of average number of L4 C. elegans larvae with normal motility (A) vs. time 
(min) in the absence of drug (1% DMSO, control), presence of 30 μM SB-277011-A and 30 μM levamisole. 
Ten worms were used for each treatment, which was replicated by five times. Comparisons of locomotion were 
made between control and treated worms at each time point. *p < 0.05, **p < 0.01, ***p < 0.001. The recovery 
of normal motility was observed only in the larvae treated with 30 μM SB-277011-A within 20 min, but not in 
the larvae treated with 30 μM levamisole within 24 h. 
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Supplementary Figure S7. Sequence and numbering of the full-length Asu-ACR-16 and its alignment with the 
human α7 nAChR subunit. Completely conserved residues (red background) and partially conserved residues 
(yellow background) are indicated. Secondary structures are shown schematically above the sequences. α1 
represents α helix. β1-7 represent β strand. η1 represents 310 helix. The Cysteine loop labeled by green bars. 
Four transmembrane α helixes (M1, M2, M3 and M4) are labeled by blue coils. Residues in the orthosteric 
binding site are indicated by arrows (principal subunit, pink; complementary subunit, orange). Residues in four 
allosteric binding sites are highlighted by arrows (principal subunit of agonist sub-pocket, turquoise; 
complementary subunit of agonist sub-pocket, green; principal subunit of vestibule pocket, dark green; 
complementary subunit of vestibule pocket, gold; principal subunit of top pocket, purple; principal subunit of 
intersubunit transmembrane site: bright pink; complementary subunit of intersubunit site: brown; principal 
subunit of intrasubunit site: purpleblue). 
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Supplementary Figure S8. Comparison of residues in the orthosteric binding site and five allosteric binding sites 
between Asu-ACR-16 and human α7 nAChR. 
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D1.0 Abstract 
Nematode parasite infections pose a significant threat in human and veterinary 
medicine. At least a third of the world’s population is at risk from nematode parasite 
infections. These infections not only cause health problems, but also cause loss of livestock 
production and hence, economic losses. Anthelmintic drugs are the mainstay by which 
control of nematode parasite infections is achieved. Many of the currently available 
anthelmintics act on nicotinic acetylcholine receptors (nAChRs). However, the detailed mode 
of action (MOA) of these anthelmintics is not clearly understood. Elucidation of the MOA of 
anthelmintics is highly desirable; an in-depth knowledge of the MOA will better inform on 
mechanisms of resistance development and on ways to slow down or overcome resistance. 
The cholinomimetic anthelmintic, morantel, has a complex MOA involving the activation 
and block of levamisole-sensitive single nAChR channels (L-type nAChR or L-nAChR). 
More recently, morantel has been demonstrated to activate Haemonchus contortus and 
Parascaris equorum ACR-26/ACR-27 nAChRs expressed in Xenopus laevis oocytes. 
Previous studies in our laboratory, however, have shown morantel does not activate the 
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nicotine-sensitive nAChR (N-type nAChR or N-nAChR), Ascaris suum ACR-16 (Asu-ACR-
16). In this study, we used two-electrode voltage-clamp (TEVC) electrophysiology to 
investigate the inhibitory effects of morantel, on expressed Asu-ACR-16 nAChRs in X. laevis 
oocytes. Our results show that morantel acts as a non-competitive antagonist on Asu-ACR-
16. This non-competitive antagonism by morantel was further demonstrated to be voltage-
sensitive. We conclude based on our findings that morantel is a non-competitive voltage-
sensitive open channel blocker of Asu-ACR-16.  
D1.1 Keywords 
Ascaris suum ACR-16nAChRElectrophysiologyMorantelOpen channel block 
D1.2 Abbreviations 
 
D2.0 Introduction 
Nematode parasite infections are a significant threat in both human and veterinary 
medicine, affecting about one-third of the human population and causing significant animal 
production losses (Bethony et al. 2006; de Silva et al. 2003; Hotez et al. 2006, 2008). The 
major control strategy for nematode parasite infections involves use of anthelmintic drugs, 
which are selectively toxic to the parasites (Brooker et al. 2006). Although the mode of 
action (MOA) of many anthelmintics is not fully understood, some of their sites of action and 
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biochemical mechanisms are well known. Many of the currently available anthelmintics 
target nicotinic acetylcholine receptors (nAChRs), which are involved in neuromuscular 
coordination (Martin et al. 1997; Wolstenholme 2011). Other anthelmintics exhibit their 
pharmacological effect by interfering with the parasite cell integrity, feeding, or some 
protective mechanisms against the host which may cause starvation, paralysis and expulsion, 
or digestion of the parasite (Holden-Dye and Walker 2007, 2014; Lustigman et al. 2014; 
Morel et al. 2014). 
Nematode muscle nAChRs are of significant interest because they are targets for 
many anthelmintics. nAChRs are pentameric ligand-gated ion channels which mediate rapid 
synaptic transmission at the neuromuscular and nerve–nerve junctions of vertebrates and 
invertebrates (Karlin 2002; Zouridakis et al. 2009). The cholinergic anthelmintic agonist, 
morantel, is a classic example of an anthelmintic that acts on nematode muscle nAChRs 
(Martin 1997). The published MOA of morantel is that it selectively opens nAChRs present 
on nematode parasite muscle cells to cause muscle contraction and hence, spastic paralysis 
and expulsion of the parasite (Martin et al. 1996). However, the agonist effect of morantel 
has been demonstrated in the levamisole-sensitive nAChRs (L-nAChRs) which are 
insensitive to nicotine and are heteropentameric, comprising more than one subunit type 
(Rayes et al. 2007). Morantel has also been shown to cause block of L-nAChRs in addition to 
its agonist effect on these receptor types (Evans and Martin 1996). At the single-channel 
level, L-nAChRs have a conductance (G) of 35 pS in A. suum (Qian et al. 2006), a Clade III 
nematode. A similar channel conductance was observed in Oesophagostomum dentatum 
(Buxton et al. 2014), a Clade V nematode. 
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More recently, morantel was shown to activate the nAChRs, Haemonchus contortus 
ACR-26/ACR-27 (Hco-26/27) and Parascaris equorum ACR-26/ACR-27 (Peq-26/27) 
expressed in Xenopus laevis oocytes, and the sensitivity of Caenorhabditis elegans to 
morantel was increased when these receptors were expressed in body wall muscles (Courtot 
et al. 2015). The nicotine-sensitive nAChRs (N-nAChRs) which are insensitive to levamisole 
and are homopentameric, comprising of one subunit type, are not activated by morantel 
(Raymond et al. 2000). In agreement with this observation, previous studies in our laboratory 
involving the pharmacological characterization of the N-nAChR, A. suum ACR-16 (Asu-
ACR-16), showed ACR-16 to be insensitive to morantel, in addition to other cholinergic 
anthelmintic agonists including levamisole, methyridine, thenium, bephenium, 
tribendimidine, and pyrantel (Abongwa et al. 2016a). In an effort to further elucidate the 
MOA of morantel, we used the two-electrode voltage-clamp electrophysiology technique to 
characterize morantel’s antagonistic effects on Asu-ACR-16 expressed in X. laevis oocytes. 
D3.0 Materials and methods 
D3.1 cRNA preparation 
Preparation of the Asu-acr-16 and Asu-ric-3 cRNA used in this study has been 
previously reported (Abongwa et al. 2016a). 
D3.2 Expression of Asu-ACR-16 in Xenopus laevis oocytes 
Expression of Asu-ACR-16 in X. laevis oocytes has been described previously 
(Abongwa et al. 2016a). Briefly, defolliculated X. laevis oocytes obtained from Ecocyte 
Bioscience (Austin, Texas, USA) were injected with 25 ng Asu-acr-16 cRNA in combination 
with 5 ng of the required ancillary factor, Asu-ric-3 cRNA, in a total volume of 50 nL. Once 
injected, individual oocytes were transferred to a 96-well culture plate containing 200 μL of 
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incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2·2H2O, 1 mM MgCl2·6H2O, 
5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin, pH 
7.5). Oocytes were then incubated at 19 °C for 5–7 days, with incubation solution changed 
daily, to allow for protein functional expression.  
D3.3 Two-electrode voltage-clamp (TEVC) electrophysiology 
At least 2 h prior to recording, 100 μM BAPTA-AM was added to the incubation 
solution to prevent activation of endogenous calcium-activated chloride channels. Current 
responses to drug applications were recorded using TEVC electrophysiology (Abongwa et al. 
2016b; Robertson et al. 2008). An Axoclamp 2B amplifier (Warner Instruments, USA) was 
used to record currents from oocytes voltage-clamped at −90, −60, or −30 mV. The data were 
acquired on a computer with Clampex 9.2 software (Molecular Devices, CA, USA). 
Microelectrodes (standard wall borosilicate glass with filament, o.d. 1.5 mm, i.d. 0.86 mm) 
(G150F-6, Warner Instruments, USA) for impaling oocytes were pulled using a 
Flaming/Brown horizontal electrode puller (Model P-97, Sutter Instruments). The 
microelectrodes were then filled with 3 M KCl, and the tips carefully broken with a piece of 
tissue paper to achieve a resistance of 2–5 MΩ in recording solution (100 mM NaCl, 2.5 mM 
KCl, 1 mM CaCl2·2H2O, and 5 mM HEPES, pH 7.3).  
D3.4 Drugs 
The drugs used for this study, acetylcholine (ach) and morantel (mor), were 
purchased from Sigma-Aldrich (St Louis, MO, USA). BAPTA-AM, an intracellular calcium 
chelator, was also purchased from Sigma-Aldrich (St Louis, MO, USA). Acetylcholine and 
morantel stock solutions were prepared in recording solution and dimethyl sulfoxide 
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(DMSO), respectively. The final working DMSO concentration did not exceed 0.1% in all 
experiments. 
D3.5 Drug applications 
Oocytes were perfused with drugs by a system controlled by eight valves (VC-8 valve 
controller) (Warner Instruments, USA) at a flow rate of 4 ml/min. Except otherwise 
indicated, each concentration of acetylcholine in the absence or presence of morantel was 
applied for 10 s, followed by a 2-min wash with recording solution in between drug 
applications. The oocytes were voltage-clamped at −60 mV, except for the voltage sensitivity 
experiments where the oocytes were voltage-clamped at −90, −60, and −30 mV. 
Acetylcholine concentration–response relationships in the absence of morantel were 
generated by applying acetylcholine at concentrations of 0.1–300 μM, at semilog intervals. 
Morantel antagonism was estimated by first applying 100 μM acetylcholine for 30 s as a 
control, followed by a 2-min wash with recording solution. Thereafter, a test 100 μM 
acetylcholine was applied for 10 s, followed by a 10-s co-application of 100 μM 
acetylcholine in the presence of either 0.3, 1, 3, 10, 30 or 100 μM morantel, and then a final 
10-s application of 100 μM acetylcholine. For subsequent experiments, morantel was used at 
1 and 3 μM. Acetylcholine concentration–response relationships in the presence of 1 and 
3 μM morantel were generated by first applying a control 100 μM acetylcholine for 10 s, 
followed by a 2-min application of morantel, and 10-s applications of 3, 10, 30, 100 and 
300 μM acetylcholine in the continued presence of morantel. Voltage sensitivity experiments 
were conducted by holding the membrane potential at −90, −60, or −30 mV, and applying a 
control 100 μM acetylcholine for 10 s, followed by a 10-s application of 100 μM 
acetylcholine in the presence of 3 μM morantel, at each holding potential. 
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D3.6 Data analysis 
Data acquired from the TEVC electrophysiological recordings were analyzed with 
Clampfit 9.2 (Molecular Devices, CA, USA) and GraphPad Prism 5.0 software (GraphPad 
Software Inc., CA, USA). Unless otherwise indicated, peak currents in response to applied 
drugs were measured and normalized to the 100 μM acetylcholine control response and 
expressed as mean ± S.E.M. The concentration–response relationships were analyzed by 
fitting data points with the Hill equation as previously described (Martin et al. 2004). Initial 
experiments to measure morantel inhibition of acetylcholine responses used a brief (10 s) 
application of morantel during a longer (30 s) application of acetylcholine (Fig. 2a). In these 
experiments, inhibition was calculated by measuring the smallest current during the morantel 
application and the largest current induced by acetylcholine after morantel wash-off began. 
Percent inhibition was calculated as: (acetylcholine current − morantel current)/acetylcholine 
current × 100. In subsequent experiments where morantel was present for sustained period of 
time, the peak currents in the presence of morantel were used and normalized to 
acetylcholine currents in the absence of the drug (Figs. 3a, 4a). The voltage-sensitive block 
effects of morantel were estimated as 1/τ, where τ was the mean of a single exponential decay 
fit to the acetylcholine-induced currents in the presence of morantel:  
 
where n = number of components, A = amplitude, t = time, τ = time constant, and 
C = constant y-offset for each i component. 
Statistical comparisons were done using unpaired Student’s t test or one-way 
ANOVA. A p value < 0.05 was considered significant. 
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D4.0 Results 
D4.1 Asu-ACR-16 is activated by acetylcholine in a concentration-dependent 
manner 
Figure 1a, b, respectively, show the sample traces (inward currents) and 
concentration–response relationship for acetylcholine. Asu-ACR-16 was not activated by 0.1, 
0.3, and 1 µM acetylcholine, but was activated by acetylcholine concentrations ≥3 µM. As 
previously observed, current responses increased with increasing acetylcholine 
concentrations, demonstrating activation of the Asu-ACR-16 nAChR by acetylcholine is 
concentration dependent (Abongwa et al. 2016a; Zheng et al. 2016). The EC50 for 
acetylcholine was 6.1 ± 0.2 µM, Rmax 99.4 ± 0.6%, and Hill slope (nH) 3.4 ± 0.1 (n = 5). 
D4.2 Morantel is a non-competitive antagonist of the Asu-ACR-16 nAChR 
We tested the antagonistic effects of morantel on the Asu-ACR-16 nAChR by varying 
the concentration of morantel from 0.3 to 100 µM, while repeatedly applying a constant 
acetylcholine concentration of 100 µM. The morantel inhibition plot is shown in Fig. 2, with 
sample traces (a) shown above the plot (b). Inhibition of Asu-ACR-16 acetylcholine 
responses was seen to increase with increasing morantel concentration. Morantel was a 
potent antagonist of Asu-ACR-16 as reflected by its observed IC50 value of 5.6 ± 1.8 µM 
(n = 4), nH 0.9 ± 0.1 (n = 4). 
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Fig. 1 Acetylcholine concentration–response relationship for A. suum ACR-16. a Sample 
traces showing inward currents in response to 0.1–100 µM acetylcholine. b Acetylcholine 
concentration–response plot for A. suum ACR-16. EC50 for acetylcholine was 6.1 ± 0.2 µM, 
Rmax 99.4 ± 0.6%, and Hill slope (nH) 3.4 ± 0.1 (n = 5). 
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Fig. 2 Inhibition of A. suum ACR-16 responses to 100 µM acetylcholine by 0.3–100 µM morantel. a Sample 
traces (inward currents) showing a concentration-dependent inhibition of acetylcholine responses by morantel. 
b Concentration–response plot showing percent inhibition of 100 µM acetylcholine by 0.3–100 µM morantel. 
IC50 morantel was 5.6 ± 1.8 µM (n = 4), nH 0.9 ± 0.1 (n = 4) 
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To elucidate the type of antagonism produced by morantel, we first applied 0.3, 1, 3, 
10, 30, 100, and 300 μM acetylcholine in the absence of morantel, which served as the 
control. This was followed by a different set of experiments where we applied 3, 10, 30, 100, 
and 300 μM acetylcholine in the presence of 1 and 3 μM morantel. Sample traces for these 
recordings are shown in Fig. 3a. The concentration–response relationships for acetylcholine 
in the absence and presence of 1 and 3 μM morantel are shown in Fig. 3b. The EC50 and Rmax 
values were 4.5 ± 0.1 µM and 98.2 ± 0.1% (n = 3) for acetylcholine, 4.5 ± 0.3 µM and 
82.6 ± 3.0% (n = 4) in 1 μM morantel, and 4.0 ± 0.5 µM and 39.4 ± 1.6% (n = 4) in 3 μM 
morantel. Morantel showed a concentration-dependent significant reduction of Rmax (p < 0.01 
for 1 μM morantel; p < 0.001 for 3 μM morantel), with no change in EC50 (p > 0.05), which 
are characteristics of non-competitive antagonism. These results indicate that morantel is a 
non-competitive antagonist of the Asu-ACR-16 nAChR. 
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Fig. 3 Concentration–response relationships for acetylcholine in the absence and presence of morantel. a Sample 
traces showing inward currents in response to acetylcholine in the presence of 1 µM morantel. b Concentration–
response plots for acetylcholine alone (black curve), acetylcholine in the presence of 1 µM morantel (green 
curve), and acetylcholine in the presence of 3 µM morantel (blue curve). EC50 and Rmax values were 4.5 ± 0.1 µM 
and 98.2 ± 0.1% (n = 3) for acetylcholine, 4.5 ± 0.3 µM and 82.6 ± 3.0% (n = 4) in 1 μM morantel, and 
4.0 ± 0.5 µM and 39.4 ± 1.6% (n = 4) in 3 μM morantel. 
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D4.3 Morantel acts as an open channel blocker to produce antagonism 
Voltage sensitivity experiments were performed to further elucidate the mechanism of 
morantel’s non-competitive antagonism. Figure 4a shows sample traces of the effect of 
morantel on acetylcholine responses at different holding potentials. Figure 4b shows a plot of 
1/τ against membrane potential (−90, −60 and −30 mV). One-way ANOVA revealed a 
significant effect of voltage on morantel’s blocking actions (p < 0.05); showing morantel’s 
blocking action is voltage-sensitive. In whole-cell recordings, 1/τ is representative of the 
mean open time of the channel. The reduction in 1/τ (and therefore mean open-time of the 
channel) as the holding potential becomes more negative is consistent with the drug acting as 
an open channel blocker.  
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Fig. 4 Voltage sensitivity of morantel’s inhibitory effects on A. suum ACR-16 responses to acetylcholine. a 
Sample traces (inward currents) showing acetylcholine responses in the absence and presence of 3 μM morantel 
at different holding membrane potentials (−90, −60, −30 mV). b 1/τ versus holding potential (mV) showing line 
of best fit by linear regression. Notice morantel’s inhibitory effects were higher at more negative membrane 
potentials, indicating morantel’s blocking action is voltage-sensitive. 
 
D5.0 Discussion 
The goal of this study was to provide an understanding of the MOA of morantel on 
the recently characterized Asu-ACR-16 nAChR. Like C. elegans ACR-16 (Cel-ACR-16), 
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Asu-ACR-16 is a member of the N-type nAChRs that are preferentially activated by nicotine 
(Abongwa et al. 2016a; Ballivet et al. 1996). It is noteworthy that the characterization of the 
N-type nAChRs is not as extensive as the L-type channels preferentially activated by 
levamisole. Furthermore, N-type nAChRs are not activated by the currently used cholinergic 
anthelmintic agonists (Abongwa et al. 2016a; Raymond et al. 2000). As such, the N-type 
nAChRs are not well exploited for anthelmintic drug discovery, compared to the L-type. 
Raymond et al. (2000) showed morantel did not activate C. elegans ACR-16 or chicken α7 
receptors expressed in X. laevis oocytes, voltage-clamped at −100 mV. Rather, morantel 
inhibited current responses to 1 mM acetylcholine in a dose-dependent manner, with pIC50 
values of, respectively, 5.7 and 5.6 for C. elegans ACR-16 and chicken α7, which 
approximates to IC50 values of 2 µM for C. elegans ACR-16 and 2.5 µM for chicken α7 
(Raymond et al. 2000) versus our observed IC50 of 5.6 ± 1.8 µM for expressed Asu-ACR-16 
in oocytes voltage-clamped at −60 mV. Notice the IC50 values for C. elegans ACR-16 and 
chicken α7 are lower than that for Asu-ACR-16, and this is likely due to more negative 
holding potential (−100 mV) used in oocytes expressing C. elegans ACR-16 or chicken α7, 
whereas in our experiments, oocytes expressing Asu-ACR-16 were held at −60 mV. 
By taking advantage of the X. laevis oocyte expression system, we have demonstrated 
using TEVC electrophysiology that morantel acts as a non-competitive antagonist of the Asu-
ACR-16 nAChR and that the mechanism by which morantel produces its inhibitory effects is 
consistent with open channel block. This provides new information for the MOA of morantel 
on the N-type nAChR, Asu-ACR-16, in addition to its known agonistic and blocking effects 
on levamisole receptors (Evans and Martin 1996; Rayes et al. 2007). In our study, however, 
we found morantel to be more potent on the expressed Asu-ACR-16 (IC50 5.6 ± 1.8 µM, 
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n = 4) compared to the IC50 of 10 µM observed in A. suum muscle cells at the single-channel 
level (Evans and Martin 1996). The Hill slope for morantel concentration–response curve in 
our study (nH 0.9 ± 0.1, n = 4) was also less than that reported by Evans and Martin (nH 1.6). 
The conductance of A. suum muscle nAChRs (32–40 pS, depending on the polarity of the 
holding potential) reported by Evans and Martin (1996) indicate that they were investigating 
L-type channels, as described by Qian et al. (2006) rather than the N-type investigated in this 
study. It is also possible that the study by Evans and Martin (1996) included examples of 
channels formed by ACR-26/ACR-27 subunits (Courtot et al. 2015) that have not been 
characterized at the single-channel level to date. According to Raymond et al. (2000), 
morantel IC50 and nH values for C. elegans ACR-16 (2 µM and −0.9) and chicken α7 (2.5 µM 
and −1.1) were also less than those reported by Evans and Martin (1996) for A. suum muscle 
nAChRs (10 µM and 1.6), implying morantel is also more potent on expressed C. elegans 
ACR-16 and chicken α7 receptors than in A. suum muscle cells. Therefore, morantel appears 
to have different effects on the nicotine and levamisole receptor types. 
Multiple sites of action for an anthelmintic are desirable (Martin et al. 1998). 
Morantel is believed to cause spastic paralysis of the nematode by its action as an L-nAChR 
agonist. L-nAChRs are involved in muscle contraction; however, ACR-16 may have a 
paracrine function given its wide distribution in A. suum body tissues (Abongwa et al. 
2016a). Hence, ACR-16 may not have a distinct role in fast signal transduction at the 
neuromuscular junction of nematodes, and just as in C. elegans, inhibition of Asu-ACR16 
may have no obvious effect on motility (Touroutine et al. 2005). Therefore, although the 
inhibition of ACR-16 may be deleterious to the parasite, this anthelmintic effect is uncertain. 
Regardless, it may not be desirable to use morantel with compounds that act as agonists of 
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ACR-16. That notwithstanding, a detailed knowledge of drug effects on multiple receptors 
will inform the selection of compounds to be used in combination therapy, an approach that 
is increasing in popularity due to its potential for slowing the development of drug resistance, 
in addition to the obvious potential increase in spectrum of action. 
D6.0 Author’s contribution 
MA, RJM and APR conceived and designed the research study. MA and KEB 
performed the research. MA, KEB and APR analyzed the data. RJM and APR contributed to 
reagents/materials/analysis tools. MA, RJM and APR wrote the paper. 
D7.0 Funding 
This research was funded by the National Institute of Allergy and Infectious Diseases 
of the National Institutes of Health under Award Number R01AI047194 to RJM, 
R21AI121831-01 to APR and the Schlumberger Foundation to MA.  
D8.0 Compliance with ethical standards 
D8.1 Conflict of interest 
The authors declare that they have no conflict of interest. 
D8.2 Ethical approval 
No vertebrate animals were directly used in this study. Adult female A. suum worms 
and defolliculated Xenopus laevis oocytes used in this study were obtained from 
Marshalltown Pork Plant, Marshalltown, Iowa, and Ecocyte Bioscience (Austin, TX, USA), 
respectively. 
 
312 
 
APPENDIX E. LIST OF ALL CONFERENCE ABSTRACTS, AWARDS AND 
FUNDING 
 
CONFERENCE ABSTRACTS 
Melanie Abongwa, Fidelis Cho-Ngwa, Godfred Ayimele, Moses Samje, Smith B. 
Babiaka, Judy Sakanari, Eman Mostafa, Adrian J. Wolstenholme, Richard J. Martin, Alan P. 
Robertson. "Activity of crude extracts and chromatographic fractions of Daniellia oliveri and 
Psorospermum febrifugum against adult Brugia pahangi". American Society of Tropical 
Medicine and Hygiene (ASTMH) 65th Annual Meeting, held at Atlanta Marriott Marquis and 
Hilton Atlanta, Atlanta, Georgia, USA, November 13-17, 2016. 
Melanie Abongwa, Fidelis Cho-Ngwa, Godfred Ayimele, Moses Samje, Smith B. 
Babiaka, Ann Perera, Eman Mostafa, Adrian J. Wolstenholme, Richard J. Martin, Alan P. 
Robertson. "Filaricidal activities of extracts of Daniellia oliveri and Psorospermum 
febrifugum". International Symposium on Anthelmintics: From Discovery to Resistance II, 
held at the Marina Village Center, San Diego, California, USA, February 9-12, 2016. 
Richard J. Martin, Fudan Zheng, Alan P. Robertson, Melanie Abongwa and Edward 
W. Yu. "The Ascaris suum nicotinic receptor, ACR-16, as a drug target: four novel negative 
allosteric modulators from virtual screening". International Symposium on Anthelmintics: 
From Discovery to Resistance II, held at the Marina Village Center, San Diego, California, 
USA, February 9-12, 2016. 
Sasa Trailovic, Djorje Marianovic, James G. Tipton, Melanie Abongwa, Fudan 
Zheng, Shivani Choudhary, Richard J. Martin and Alan P. Robertson. "Effects of monepantel 
on nicotinic acetylcholine receptors from Ascaris suum and Oesophagostomum dentatum". 
International Symposium on Anthelmintics: From Discovery to Resistance II, held at the 
Marina Village Center, San Diego, California, USA, February 9-12, 2016. 
Mark McHugh, Saurabh Verma, Shivani Choudhary, Melanie Abongwa, Sudhanva 
Kashyap, JoAnne Powell- Coffman, Alan Robertson, Richard Martin. "Differential 
expression of four nicotinic acetylcholine receptor subunits (nAChRs) in Ascaris suum 
tissues". International Symposium on Anthelmintics: From Discovery to Resistance II, held 
at the Marina Village Center, San Diego, California, USA, February 9-12, 2016. 
Melanie Abongwa, Fidelis Cho-Ngwa, Godfred Ayimele, Moses Samje, Smith B. 
Babiaka, Ann Perera, Adrian J. Wolstenholme, Richard J. Martin, Alan P. Robertson. In vitro 
antifilarial activities and metabolomic profiling of extracts of Daniellia oliveri and 
Psorospermum febrifugum. American Society of Tropical Medicine and Hygiene (ASTMH) 
64th Annual Meeting, held at Philadelphia Marriott Downtown, Philadelphia, Pennsylvania, 
USA, October 25-29, 2015. 
313 
 
Melanie Abongwa, Alan P. Robertson, Richard J. Martin. "Not just GluCls 
(Glutamate-gated Chloride channels): Abamectin has potent effects on nicotinic 
acetylcholine receptors of nematode parasites". 25th International Conference of the World 
Association for the Advancement of Veterinary Parasitology (WAAVP), held at The Arena 
and Convention Centre, Liverpool, UK, August 16-20, 2015. 
Melanie Abongwa, Fidelis Cho-Ngwa, Godfred A. Ayimele, Moses Samje, Smith B. 
Babiaka, Ann Perera, Richard J. Martin, Alan P. Robertson. "Anthelmintic activity and 
metabolomic profiling of extracts of Daniellia oliveri and Psorospermum febrifugum". 25th 
International Conference of the World Association for the Advancement of Veterinary 
Parasitology (WAAVP), held at The Arena and Convention Centre, Liverpool, UK, August 
16-20, 2015. 
Melanie Abongwa, Fudan Zheng, Samuel K Buxton, Elise Courtot, Claude Charvet, 
Cédric Neveu, Ciaran J McCoy, Saurabh Verma, Alan P Robertson and Richard J Martin. 
"Asu-ACR-16: a homomeric nAChR widely distributed in Ascaris tissues". 25th International 
Conference of the World Association for the Advancement of Veterinary Parasitology 
(WAAVP), held at The Arena and Convention Centre, Liverpool, UK, August 16-20, 2015. 
Melanie Abongwa, Fidelis Cho-Ngwa, Godfred A. Ayimele, Moses Samje, Smith B. 
Babiaka, Richard J. Martin, Alan P. Robertson. "In vitro filaricidal activity, cytotoxicity and 
phytochemical analysis of crude extracts of Daniellia oliveri and Psorospermum 
febrifugum". Society of Toxicology (SOT) 54th Annual Meeting & ToxExpoTM, San Diego 
Convention Center, San Diego, California, USA, March 21-26, 2015. 
Claude L Charvet, Samuel K Buxton, Cédric Neveu, Jacques Cabaret, Nicolas 
Peineau, Melanie Abongwa, Elise Courtot, Alan P Robertson, Richard J Martin. "Nematode 
nicotinic acetylcholine receptor diversity: expression of tribendimidine- & derquantel-
sensitive receptors in Xenopus oocytes". Joint Meeting of the 16th Drug Design & 
Development Seminar (DDDS 2015) and WG4 of COST Action CM1307, held at the Robert 
Koch Institute, Berlin, Germany, March 16-18, 2015. 
R. J. Martin, M. Abongwa, A. P. Robertson. "Not just GluCls (Glutamate-gated 
Chloride channels): abamectin has potent effects on nicotinic acetylcholine receptors of 
nematode parasites". Proceedings of the 59th Annual Meeting of the American Association of 
Veterinary Parasitologists (AAVP), held at The Curtis Hotel, Denver, Colorado, USA, July 
26-29, 2014. pp81. Published as an Oral Communication in Journal of Veterinary 
Pharmacology and Therapeutics (2015), 38: 42-43.  
Alan Robertson, Melanie Abongwa, Samuel Buxton, Elise Courtot, Claude Charvet, 
Cedric Neveu, Richard Martin. "Characterization of a homomeric nicotinic acetylcholine 
receptor, Ascaris suum ACR-16, in Xenopus laevis oocytes". Proceedings of the 59th Annual 
Meeting of the American Association of Veterinary Parasitologists (AAVP), held at The 
Curtis Hotel, Denver, Colorado, USA, July 26-29, 2014. p. 82. 
314 
 
Shivani Choudhary, Melanie Abongwa, Samuel K. Buxton, Ciaran J. McCoy, Alan 
P. Robertson, Saurabh Verma, Richard J. Martin. "Ascaris suum ACR-21 forms a homomeric 
nicotinic acetylcholine receptor with novel pharmacology". Proceedings of the 59th Annual 
Meeting of the American Association of Veterinary Parasitologists (AAVP), held at The 
Curtis Hotel, Denver, Colorado, USA, July 26-29, 2014. p. 54. 
Charvet, C., Buxton, S. K., Neveu, C., Cabaret, J., Cortet, J., Peineau, N., Abongwa, 
M., Robertson, A. P., Martin, R. J. (2014). "Nicotinic acetylcholine receptors: expression in 
oocytes and functional diversity in parasitic nematodes". Presented at NemaTours: Bringing 
worms together, Tours, FRA (2014-07-17 - 2014-07-18). 
[http://prodinra.inra.fr/record/276369]. 
M. Abongwa, S. K. Buxton, S. Verma, A. P. Robertson and R. J. Martin. 
"Pharmacological and electrophysiological characterization of Ascaris suum homopentameric 
nicotinic acetylcholine receptors in Xenopus laevis oocytes". Society of Toxicology (SOT) 
53rd Annual Meeting & ToxExpoTM, Phoenix Convention Center, Phoenix, Arizona, USA, 
March 23-27, 2014. 
M. Abongwa, S. K. Buxton, C. L. Charvet, C. Neveu, A. P. Robertson and R. J. 
Martin "Characterization of the Ascaris suum homomeric nicotinic acetylcholine receptor, 
ACR-16, in Xenopus laevis oocytes". International Symposium on Anthelmintics: From 
Discovery to Resistance, held at the Fort Mason Conference Center, San Francisco, 
California, USA, February 5-7, 2014. p. 27. 
R. J. Martin, M. Abongwa, S. K. Buxton and A. P. Robertson "Effects of 
paraherquamide, derquantel, and the macrocyclic lactone, abamectin, on native and 
expressed receptors of nematode parasites". International Symposium on Anthelmintics: 
From Discovery to Resistance, held at the Fort Mason Conference Center, San Francisco, 
California, USA, February 5-7, 2014. 7A. 
Alan P Robertson Melanie Abongwa, Samuel K Buxton, Sreekanth Puttachary, 
Nathan Romine, Saurabh Verma, Adrian J Wolstenholme, and Richard J Martin "Cholinergic 
receptors on the Ascaris suum pharynx". International Symposium on Anthelmintics: From 
Discovery to Resistance, held at the Fort Mason Conference Center, San Francisco, 
California, USA, February 5-7, 2014. 6D. 
M. Abongwa, S. K. Buxton, S. Verma, A. P. Robertson and R. J. Martin 
"Pharmacological and electrophysiological characterization of Ascaris suum homopentameric 
nicotinic acetylcholine receptors in Xenopus laevis oocytes". Central States Regional Chapter 
Of The Society of Toxicology (CS-SOT) Annual Fall Meeting, held at the Gateway Center 
and Hotel, Ames, Iowa, USA, October 10-11, 2013. p. 33. 
 
315 
 
AWARDS 
2017 (i) Iowa State University Graduate College, Research Excellence Award, Spring 2017. 
(ii) Iowa State University Interdepartmental Toxicology High Impact Publication Award for 
the academic year 2016 – 2017 (Publication: Melanie Abongwa, Samuel K Buxton, Elise 
Courtot, Claude L Charvet, Cédric Neveu, Ciaran J McCoy, Saurabh Verma, Alan P 
Robertson and Richard J Martin (2016) "Pharmacological profile of Asu-ACR-16, a new 
homomeric nAChR widely distributed in Ascaris tissues" British Journal of Pharmacology 
173(16): 2463-77. doi: 10.1111/bph.13524). 
2016 (i) Schlumberger Foundation Faculty for the Future PhD Fellowship Renewal for the 
academic year 2016 – 2017 (Amount Awarded: $36,000). 
(ii) Iowa State University Graduate and Professional Student Senate (GPSS) Research 
Award. 
(iii) Iowa State University Graduate and Professional Student Senate (GPSS) Professional 
Advancement Grant (PAG) Award. 
2015 (i) Schlumberger Foundation Faculty for the Future PhD Fellowship Renewal for the 
academic year 2015 – 2016 (Amount Awarded: $43,000). 
(ii) American Society of Tropical Medicine and Hygiene (ASTMH) Young Investigator 
Award – 1st Place Winner for Poster and Oral Presentations. 
(iii) Society of Toxicology (SOT) – Drug Discovery Toxicology Specialty Section (DDTSS) 
Emil A. Pfitzer Award – 3rd Place Student Poster Contest. 
(iv) Burroughs Wellcome Fund Collaborative Research Travel Award – University of 
California San Francisco, January 10 – February 14, 2016. 
(v) Iowa State University College of Veterinary Medicine (CVM) Travel Award. 
(vi) Iowa State University Graduate and Professional Student Senate (GPSS) Professional 
Advancement Grant (PAG) Award.  
2014 (i) Schlumberger Foundation Faculty for the Future PhD Fellowship for the academic year 
2014 – 2015 (Amount Awarded: $22,684).  
(ii) Toxicologists of African Origin (TAO) Graduate Student Travel Award to attend the 
Society of Toxicology (SOT) 53rd Annual Meeting in Phoenix, Arizona, USA. 
2012: Three-year Miller Fellowship, Iowa State University, Ames, USA. 
 
316 
 
FUNDING 
2016-2017  Schlumberger Foundation Faculty for the Future Program. Amount Awarded 
$36,000. 
2015-2016  Schlumberger Foundation Faculty for the Future Program. Amount Awarded 
$43,000.  
2014-2015  Schlumberger Foundation Faculty for the Future Program. Amount Awarded 
$22,684. 
2015  Burroughs Wellcome Fund Collaborative Research Travel Award. Amount 
Awarded $1,500. 
TOTAL  $103,184 
 
